Edited by Ja´nos Fischer and C. Robin Ganellin Analogue-based Drug Discovery II
Related Titles Faller, B., Urban, L. (...
165 downloads
1829 Views
7MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Edited by Ja´nos Fischer and C. Robin Ganellin Analogue-based Drug Discovery II
Related Titles Faller, B., Urban, L. (eds.)
Hit and Lead Profiling Identification and Optimization of Drug-like Molecules 2009 ISBN: 978-3-527-32331-9
Chorghade, M. S. (ed.)
Drug Discovery and Development 2 Volume Set 2007 ISBN: 978-0-471-39846-2
Johnson, D. S., Li, J. J. (eds.)
The Art of Drug Synthesis 2007 ISBN: 978-0-471-75215-8
IUPAC / Fischer, János / Ganellin, C. Robin (eds.)
Analogue-based Drug Discovery 2006 ISBN-13: 978-3-527-31257-3
Lednicer, Daniel
New Drug Discovery and Development 2006 ISBN-13: 978-0-470-00750-1
Edited by János Fischer and C. Robin Ganellin
Analogue-based Drug Discovery II
The Editors Prof. Dr. János Fischer Richter Plc Gyömröi ut 30 1103 Budapest Hungary Prof. Dr. C. Robin Ganellin University College London Department of Chemistry 20 Gordon Street London WC1H OAJ United Kingdom
Supported by The International Union of Pure and Applied Chemistry (IUPAC) Chemistry and Human Health Devision PO Box 13757 Research Triangle Park, NC 27709-3757 USA
All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate. Library of Congress Card No.: applied for British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library. Bibliographic information published by the Deutsche Nationalbibliothek The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at http://dnb.d-nb.de. # 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law. Cover Design Adam Design, Weinheim Typesetting Thomson Digital, Noida, India Printing and Binding Strauss GmbH, Mörlenbach Printed in the Federal Republic of Germany Printed on acid-free paper ISBN: 978-3-527-32549-8
V
Contents Preface XV Introduction XVII Abbreviations XXI
1
Part I
General Aspects
1
Optimizing Drug Therapy by Analogues 3 János Fischer, C. Robin Ganellin, John Proudfoot, and Erika M. Alapi Introduction 3 Pharmacodynamic Characteristics 4 Potency 4 Improving the Ratio of Main Activity and Adverse Effects 5 Improving Selectivity Through Receptor Subtypes 6 Improving Selectivity Through Unrelated Receptors 7 Improving Selectivity by Tissue Distribution 7 Improving Selectivity of Nonreceptor-Mediated Effects 10 Improving the Physicochemical Properties with Analogues 10 Analogues to Reduce the Resistance to Anti-Infective Drugs 11 Antibiotics 11 Antifungal Drugs 12 Antiviral Drugs 12 Analogue Research in Resistance to Drug Therapies in Cancer Treatment 15 Pharmacokinetic Characteristics 15 Improving Oral Bioavailability 15 Improving Absorption 16 Improving Metabolic Stability 16 Drugs with a Long Duration of Action 17 Ultrashort-Acting Drugs 18 Decreasing Interindividual Pharmacokinetic Differences 20 Decreasing Systemic Activity 21
1.1 1.2 1.2.1 1.2.2 1.2.2.1 1.2.2.2 1.2.2.3 1.2.2.4 1.2.3 1.2.4 1.2.4.1 1.2.4.2 1.2.4.3 1.2.5 1.3 1.3.1 1.3.1.1 1.3.1.2 1.3.2 1.3.3 1.3.4 1.3.5
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
VI
Contents
1.4 1.4.1 1.4.2 1.5
Drug Interactions 22 Decreasing Drug Interactions 22 Increasing Drug Interactions 23 Summary 23 References 24
2
Standalone Drugs 29 János Fischer, C. Robin Ganellin, Arun Ganesan, and John Proudfoot Acetaminophen (Paracetamol) 30 Acetylsalicylic Acid (Aspirin) 33 Aripiprazole 35 First Generation ‘‘Typical’’ Antipsychotic Drugs (Other Names: Neuroleptics, Conventional Antipsychotics) 36 Second-Generation ‘‘Atypical’’ Antipsychotic Drugs 37 A New Approach: Aripiprazole, a Dopamine Partial Agonist 38 Bupropion 39 Ezetimibe 42 Lamotrigine 46 Metformin 47 Topiramate 49 Valproate 51 Summary 52 References 53
2.1 2.2 2.3 2.3.1 2.3.2 2.3.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10
3
3.1 3.2 3.3 3.4 3.5 3.6 3.7
4 4.1 4.2 4.3 4.4 4.5 4.6 4.7
Application of Molecular Modeling in Analogue-Based Drug Discovery 61 György G. Ferenczy Introduction 61 Cilazapril: An ACE Inhibitor 62 Atorvastatin: A HMG-CoA Reductase Inhibitor 66 PDE4 Inhibitors 70 GPIIb/IIIa Antagonists 73 HIV Protease Inhibitors 74 Epilogue 79 References 79 Issues for the Patenting of Analogues 83 Stephen C. Smith Introduction 83 Patents: Some Fundamentals 84 Patentability 85 Important Elements of the International Patent System Priority 87 Novelty 88 Inventive Step: Nonobviousness 90
86
Contents
4.8 4.9 4.10 4.11 4.12 4.12.1 4.12.2 4.12.3 4.12.4 4.12.5 4.12.6 4.12.7 4.12.8 4.12.9 4.12.10 4.13
Utility: Industrial Application 93 Selection Inventions 93 Enantiomers 94 Prodrugs and Active Metabolites 95 The Patenting Process from the Inventors Standpoint 97 Inventorship 98 The Priority Patent Application 98 Prior Art Disclosure 98 Patent Specification Review 99 ‘‘Best Mode’’ of Carrying Out the Invention 99 Foreign Patent Applications 99 Patent Application Publication 100 Patent Examination 100 Opposition to Grant 101 Patent Litigation 102 Pitfalls for the Unwary: Granted Versus Published Patents, Scientific Publications 102 References 105
Part II
Analogue Classes
5
Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes 109 Jens-Uwe Peters and Patrizio Mattei Introduction 109 In Vitro Assays and Animal Models for the Assessment of DPP-IV Inhibitors 110 Substrate-Based DPP-IV Inhibitors 110 Sitagliptin and Analogues 119 Xanthines and Analogues 122 Pharmacological Comparison of DPP-IV Inhibitors 125 Concluding Remarks 127 References 128
5.1 5.2 5.3 5.4 5.5 5.6 5.7
6 6.1 6.2 6.2.1 6.2.2 6.2.3 6.2.4 6.3 6.3.1 6.3.2
107
Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction 135 Nils Griebenow, Helmut Haning, and Erwin Bischoff Introduction 135 Pharmacology of Phosphodiesterases 136 The Phosphodiesterase Family 136 Pharmacological Effects of cGMP 137 PDE5: Regulation, Activation, and Structure 138 PDE5 Inhibitors and Erectile Dysfunction 143 Pyrimidinone PDE5 Inhibitors 147 Xanthines and cGMP Analogues 147 PDE5 Inhibitors Incorporating the Purinone Nucleus 150
VII
VIII
Contents
6.3.2.1 6.3.2.2 6.3.3 6.3.3.1 6.3.3.2 6.3.4 6.3.5 6.3.6 6.3.7 6.4 6.4.1 6.5
Zaprinast 150 Purinones 150 Pyrazolopyrimidinone PDE5 Inhibitors 151 Pyrazolo[3,4-d]Pyrimidin-4-One PDE5 Inhibitors 151 1,6-Dihydro-7H-Pyrazolo[4,3-d]Pyrimidin-4-One PDE5 Inhibitors 152 Imidazotriazinone PDE5 Inhibitors 154 Imidazoquinazolinones 155 Pyrazolopyridopyrimidines 156 Miscellaneous Heterocylic-Fused Pyrimidinone PDE5 Inhibitors 156 Nonpyrimidone PDE5 Inhibitors 160 Hexahydropyrazino-Pyrido-Indole-1,4-Diones 160 Conclusions 162 References 162
7
Rifamycins, Antibacterial Antibiotics and Their New Applications 173 Enrico Selva and Giancarlo Lancini Discovery of the Pioneer Drug 173 Clinically Used Rifamycins 173 Mode of Action of Rifamycins and Structural Requirements for Activity 174 Modulation of Chemotherapeutic Properties 177 Profiles of Rifamycins Targeted at Tuberculosis Treatment 177 Rifampicin (INN), Rifampin (USAN) 178 Rifapentine 180 Rifabutin 181 Rifamycins Beyond Tuberculosis 181 Rifamycin SV and Rifamide 182 Rifaximin 182 Trials for Other Therapeutic Indications 183 Summary 183 References 184
7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 7.10 7.11 7.12 7.13
8 8.1 8.2 8.2.1 8.2.1.1 8.2.2 8.2.3 8.2.3.1 8.2.3.2 8.3 8.3.1
Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs 189 András Nemes Introduction 189 Vincamine and Derivatives: Cerebrovascular and Neuroprotective Agents 190 Medicinal Chemistry of Vincamine Derivatives 190 Structure–Activity Relationships 192 Synthesis of Vincamine Derivatives 193 Pharmacological Properties of Vincamine Derivatives 193 Mechanism of Action 193 Clinical Pharmacology 194 Antitumor Dimeric Vinca Alkaloids 195 Medicinal Chemistry of Dimeric Vinca Alkaloid Derivatives 195
Contents
8.3.1.1 8.3.2 8.3.3 8.3.3.1 8.3.3.2 8.4 8.4.1 8.4.1.1 8.4.2 8.4.3 8.4.3.1 8.4.3.2 8.5
Structure–Activity Relationships 196 Synthesis of Dimeric Vinca Alkaloid Derivatives 198 Pharmacological Properties of Dimeric Vinca Alkaloid Derivatives Mechanism of Action 199 Clinical Pharmacology 199 Antitumor Camptothecin Derivatives 201 Medicinal Chemistry of Camptothecin Derivatives 201 Structure–Activity Relationships 202 Synthesis of Camptothecin Derivatives 203 Pharmacological Properties of Camptothecin Derivatives 204 Mechanism of Action 204 Clinical Pharmacology 205 Summary and Conclusions 207 References 207
9
Anthracyclines, Optimizing Anticancer Analogues 217 Federico-Maria Arcamone Introduction: Biosynthetic Antitumor Anthracyclines 217 Analogues with Modification of the Aminosugar Moiety 219 Analogues with Modifications in the Anthraquinone Moiety 223 Analogues Modified on Ring A of the Aglycone 226 Disaccharide Analogues 229 Other Compounds 232 Summary and Final Remarks 233 References 234
9.1 9.2 9.3 9.4 9.5 9.6 9.7
10 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 10.9
11
11.1 11.2
Paclitaxel and Epothilone Analogues, Anticancer Drugs 243 Paul W. Erhardt and Mohammad El-Dakdouki Introduction 243 Discovery and Development of Paclitaxel 243 Clinical Success and Shortcomings of Paclitaxel 245 ABDD Leading to Docetaxel 247 Additional Structural Analogues 249 The Pursuit of Microtubule-Stabilizing Pharmacological Analogues 250 The Epothilones 252 ABDD and Development Leading to Ixabepilone 258 Conclusions 260 References 263 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression 269 Wayne E. Childers Jr. and David P. Rotella Introduction 269 Neurochemistry and Mechanism of Action 270
199
IX
X
Contents
11.3 11.3.1 11.3.2 11.3.3 11.3.4 11.3.5 11.4 11.4.1 11.4.2 11.4.3 11.4.4 11.4.5 11.5 11.6
Preclinical Pharmacology 271 Sertraline 271 Escitalopram 272 Fluvoxamine 273 Fluoxetine 274 Paroxetine 275 Medicinal Chemistry 276 Sertraline 276 Escitalopram 278 Fluvoxamine 279 Fluoxetine 281 Paroxetine 284 Comparison of SSRIs and Other Uses 285 Summary 288 References 288
12
Muscarinic Receptor Antagonists in the Treatment of COPD 297 Matthias Grauert, Michael P. Pieper, and Paola Casarosa Introduction 297 Muscarinic Receptor Subtypes 298 Structures of Muscarinic Agonists and Antagonists 299 Muscarinic Agonists 299 Antimuscarinics 300 Discovery of Quaternary Antimuscarinics 303 Once-Daily Quaternary Antimuscarinics: Tiotropium Bromide as the Gold Standard 305 Preclinical Pharmacology: Comparison of Ipratropium and Tiotropium 309 Bronchoconstriction in Conscious Guinea Pigs According to the Method of Kallos and Pagel 310 Bronchoconstriction in Anaesthetized Dogs 310 Clinical Pharmacology 311 Antimuscarinics in Clinical Development for the Treatment of COPD 313 Summary 313 References 314
12.1 12.2 12.3 12.3.1 12.3.2 12.3.3 12.3.4 12.4 12.4.1 12.4.2 12.5 12.6 12.7
13 13.1 13.2 13.3 13.4
b-Adrenoceptor Agonists and Asthma 319 Giovanni Gaviraghi Introduction 319 First-Generation b2-Agonists: The Short-Acting Bronchodilators Second-Generation b2-Agonists: Further Derivatives of Salbutamol 321 Third-Generation b2-Agonists: The Long-Acting Bronchodilators 321
319
Contents
13.5 13.6
Combination Therapy with LABA and Corticosteroids 326 Future Directions: Once-a-Day Therapy and Bifunctional Muscarinic Antagonist–b2-Agonist (MABA) 327 References 329
Part III
Case Histories
14
Liraglutide, a GLP-1 Analogue to Treat Diabetes 335 Lotte B. Knudsen Introduction 335 Discussion 338 Physiology of Native GLP-1 338 Development of Liraglutide: A GLP-1 Analogue 339 The Pharmacology of Liraglutide 346 Clinical Evidence with Liraglutide 349 Summary 350 References 351
14.1 14.2 14.2.1 14.2.2 14.2.3 14.2.4 14.3
15 15.1 15.2 15.3 15.4 15.5 15.6 15.7
16 16.1 16.1.1 16.2 16.2.1 16.2.2 16.3 16.4 16.4.1 16.5 16.6 16.7 16.8 16.9 16.9.1
333
Eplerenone: Selective Aldosterone Antagonist 359 Jaroslav Kalvoda and Marc de Gasparo Introduction 359 Development of a Specific and Selective Aldosterone Antagonist 360 Eplerenone: Selectivity and Specificity 367 Preclinical Development of Eplerenone: From Animal to Man 373 Further Development of Eplerenone 375 Conclusions 376 Epilogue 376 References 377 Clevudine, to Treat Hepatitis B Viral Infection 383 Ashoke Sharon, Ashok K. Jha, and Chung K. Chu Current Status of Anti-HBV Agents 383 Nucleoside Reverse Transcriptase Inhibitors 386 Chemical Evolution of Clevudine 387 Development of Synthetic Routes 387 Structure–Activity Relationships 388 Metabolism and Mechanism of Action 390 Pharmacokinetics 392 Woodchuck Studies 393 Clinical Studies 394 Drug Resistance 396 Toxicity and Tolerability 398 Dosage and Administration 399 Combination Therapy 399 Combination of Clevudine with Other Agents 399
XI
XII
Contents
16.9.2 16.10
Combination of Clevudine with Vaccine 400 Summary 400 References 401
17
Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 409 Jerome Guillemont, Luc Geeraert, Jan Heeres, and Paul J. Lewi Introduction 409 Chemistry 412 Synthesis of TMC278 and Close Analogues 412 Modulation of the Central Heterocycle Core 418 C-5 Substitution of the Pyrimidine Core 419 Structure–Activity Relationships 420 Introduction of G Spacer Between the Aryl Ring and the Cyano Group 421 Modulation of Substituents at C-2 and C-6 on the Left Wing and of the Linker Between Left Wing and Pyrimidine Core 423 Subsitution at C-5 Position of the Pyrimidine Heterocycle 424 Modification of the Central Heterocycle Core 426 TMC278: Physicochemical Properties 429 Modeling of TMC278 and Crystal Structure 430 Pharmacokinetic and Phase II Studies of TMC278 431 Conclusions 434 References 434
17.1 17.2 17.2.1 17.2.2 17.2.3 17.3 17.3.1 17.3.2 17.3.3 17.3.4 17.4 17.5 17.6 17.7
18
18.1 18.2 18.2.1 18.3 18.3.1 18.3.2 18.3.3 18.3.3.1 18.3.3.2 18.3.3.3 18.4 18.4.1 18.4.2 18.4.3 18.5 18.6
Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV 443 Suvit Thaisrivongs, Joseph W. Strohbach, and Steve R. Turner Human Immunodeficiency Virus 443 HIV Protease 443 HIV PIs 444 Approaches to Identifying and Developing PI Leads 446 Focused Screening 446 Broad Screening for Nonpeptidic Leads 447 Structure-Based Drug Design 448 PNU-96988, A First-Generation Clinical Candidate 449 PNU-103017, A Second-Generation Clinical Candidate 450 Tipranavir, The Third Generation 453 Characteristics of Tipranavir 454 In Vitro Activity 454 Pharmacokinetics 455 Highlights of Clinical Data 456 Fragment-Based Lead Development? 457 Summary 458 References 459
Contents
19 19.1 19.2 19.3 19.4 19.4.1 19.4.2 19.4.3 19.5 19.6 19.7
20
20.1 20.2 20.3
21
21.1 21.2 21.3 21.4 21.4.1 21.4.2 21.4.3 21.4.4 21.5 21.6 21.7 21.8 21.8.1 21.8.1.1 21.8.1.2 21.8.1.3 21.8.2
Lapatinib, an Anticancer Kinase Inhibitor 465 Karen Lackey Introduction 465 Aims 467 Chemical Evolution and Proof-of-Mechanistic Approach Using Small Molecules 469 Final Set of Analogues that Led to the Discovery of Lapatinib 6-Furanyl Quinazoline Series 474 6-Thiazolylquinazoline Series 479 Alkynylpyrimidine Series 480 Final Selection Criteria and Data 482 Early Clinical Results 487 Prospects for Kinase Inhibitors 489 References 490 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia 493 Jagabandhu Das and Joel C. Barrish 493 Introduction 493 Discussion 494 Clinical Findings and Summary 502 References 503 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder 507 Magid Abou-Gharbia and Wayne E. Childers Jr. Introduction 507 Major Depressive Disorder 510 MDD Pharmacotherapy 511 The Discovery of Venlafaxine 511 Identification of an Early Lead (WY-44362) 511 Structure–Activity Relationship Studies 512 In Vivo Animal Models of Preclinical Efficacy 514 Selection of WY-45030 for Clinical Trials 514 Clinical Efficacy of Effexor1 515 An Extended Release Formulation – Effexor XR1 516 Discovery of a Second-Generation SNRI – O-Desmethylvanlafaxine 516 Effexor and Pristiq – Additional Considerations 518 Effexor 518 Onset of Action 518 Treatment of Some Anxiety Disorders 519 Painful Somatic Symptoms 519 Pristiq 519
474
XIII
XIV
Contents
21.8.2.1 21.8.2.2 21.9
Anxiety and Painful Symptoms 519 Symptoms Associated with Menopause Conclusions 520 References 520 Index
525
519
XV
Preface The positive response to the first volume stimulated the editors to continue beyond the well-received book. Three very important facts supported this feeling. All copies of the book ‘‘Analogue-Based Drug Discovery’’ were sold within 18 months after its publication in February 2006. 2) The Journal of Medicinal Chemistry in its very positive review recommended the book for teaching of medicinal chemistry. 3) Last, but not the least Wiley-VCH, and, personally, Dr. Frank O. Weinreich welcomed the idea of the continuation.
1)
We started to collect new topics at the beginning of 2008. We have continued to study the general aspects of ‘‘Analogue-Based Drug Discovery’’ with the help of the chapters that describe how analogues optimize drug therapy. In a separate chapter on standalone drugs, we demonstrate that in the case of a minor number of drugs, the pioneer drug could not (or not yet) be optimized. These standalone drugs can always challenge the medicinal chemistry researchers because, as existing drugs, they can serve as starting points for researchers. We are grateful again to the IUPAC (International Union of Pure and Applied Chemistry), which supported this activity in projects. The Subcommittee for Medicinal Chemistry and Drug Development and the Division of Chemistry and Human Health provided the opportunity to the editors to discuss this work with other experts of medicinal chemistry. We are grateful for the participation of all the contributors. Many authors of the book played an important role as inventors who discovered valuable drugs, and their chapters carry a high credibility either as an analogue class study or as a case history of a drug. We are very much obliged to the helpful reviewing work done by many colleagues, whose names are as follows: Karl-H. Baringhaus, Jozsef Bódi, Derek Buckle, Mark Bunnage, Duane Burnett, Neal Castagnoli, Jonathan B. Chaires, Mukund Chorghade, Erik De Clercq, Duncan Curley, György Domány, Joelle Dubois, Andrew Fensome, Tom Heightman, Bastian Hengerer, Duy H. Hua, Robert Jones, Dale
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
XVI
Preface
Kempf, Karsten Krohn, K.H. Lee, John Lowe III, Frank C. Odds, Eckhard Ottow, Tom Perun, István Polgár, Dominick Quagliato, Waldemar Priebe, Graham Robertson, Romano Silvestri, László Szabó, Károly Tihanyi, Edwin B. Villhauer, Niels Vrang, Richard White, Michael Williams, and Puwen Zhang. All these colleagues contributed to the quality of this second volume. We express special thanks to reviewers Derek Buckle, John Lowe III, Bruce E. Maryanoff, Lester A. Mitscher, and Dominick Quagliato, who each corrected the language, and Eckhard Ottow, who corrected the structures, of a whole chapter. Some authors, besides the editors, also served as reviewers. Our thanks are due to these authors and reviewers as follows: Giovanni Gaviraghi, John Proudfoot, and David Rotella. J.F. thanks the Alexander von Humboldt Foundation (Bonn) for a fellowship in 2008 and 2009. We hope that the second volume will also be well received and that it will contribute in some way to help the experts in drug discovery and students of medicinal chemistry. October 2009 Budapest and London
János Fischer and C. Robin Ganellin
XVII
Introduction Janos Fischer and C. Robin Ganellin Analogy plays a very important role in scientific research and especially in applied research. This is certainly true for the medicinal chemist searching for new drugs to treat diseases. The chemical structure and the similarities and differences in chemical and biological properties between compounds help guide the researcher in deciding where to position a new molecule in comparison to what is already known about other compounds. Medicinal chemistry is a relatively young science that spanned the whole of the twentieth century. In the first half of the century, new drug research was dominated by organic chemistry, and researchers sought improved drugs among structurally similar compounds. Full analogues (see below) dominated this kind of research. The latter half of the century saw a much greater contribution from biochemistry and pharmacology, and many pioneer drugs were discovered. This opened the way for researchers to seek to improve upon these drugs by investigating analogues. The first volume of Analogue-Based Drug Discovery focused on an important segment of medicinal chemistry, where an existing drug was selected as a lead compound and the research had, as a goal, to improve upon the lead by synthesizing and testing analogues. The chemical structure and main biological activity of such an analogue were often similar to the lead drug. Thus, the researchers generally sought a structural and pharmacological analogue (more simply called a full analogue) or if the pharmacophores were the same, a direct analogue. Usually, the aim was to achieve an improved biological activity profile, with a greater potency. The first volume included a description of many well-established analogue classes of drug that are indispensable nowadays for the treatment of peptic ulcer disease, gastroesophageal reflux disease, prevention of cardiovascular diseases (e.g., antihypertensives, cholesterol-lowering agents, calcium antagonists, and beta-adrenergic receptor blocking agents), pain (e.g., opioid analgesics), and many other diseases. The last two decades, however, have witnessed great changes in the chemical and biological methods for generating a lead compound. Combinatorial chemistry affords many more compounds than traditional synthetic methods and these are tested very rapidly by high-throughput screening (HTS) to deliver new hit and lead molecules. This procedure often paves the way for new types of structures for drug research thereby decreasing the importance of having chemical similarity. At the Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
XVIII
Introduction
same time, this provides a better opportunity for novelty and therefore for patenting. This also gives rise to a greater need to compare the biological properties of these new lead compounds in order to arrive at the best pharmacological analogue. Analogue-based drug discovery (ABDD) is not a simple research method, but it is a way of thinking that, in addition to organic synthesis, uses most of the procedures that are now available to medicinal chemists, such as i. ii. iii. iv. v.
investigation of structure–activity relationships, molecular modeling, structure-based drug discovery, fragment-based drug discovery, early recognition of drug distribution properties and avoidance of potential toxicities.
Analogue-based drug discovery has the merit that the therapeutic target is already validated, but it carries the hazard of potentially losing out to competitors who may start from the same approach at about the same time. This second volume of Analogue-Based Drug Discovery has a broader scope than the first volume. The book not only contains descriptions of full analogues but also includes several pharmacological analogues. The book is divided into three parts: 1) 2) 3)
General Aspects of Analogue-Based Drug Discovery Analogue Classes Case Histories
General Aspects
The opening chapter summarizes various possibilities exemplifying how the properties of a drug may be modified to give a new drug analogue that improves patient drug therapy. There are 12 principles exemplified and within some of these principles there are several methods; hence this chapter gives a broad overview. A small number of the pioneer drugs remain without successful analogues; we describe these by the term standalone drugs. Among the most frequently used 100 drugs, 9 such standalone drugs can be identified. Their history and present situation may be used to initiate a new research activity to make their analogues. In addition to the traditional structure–activity relationship (SAR) studies, molecular modeling is the most important method that can help the medicinal chemist to find a new drug analogue. The chapter discusses several useful examples of molecular modeling in analogue research. Patenting activity is one of the basic tasks of drug research. Patents mostly concern a group of direct analogues; therefore, the first claim of a patent contains a general structure that describes this group of compounds. The chapter gives an overview of some of the issues that can affect the commercial protection of the discoveries made by medicinal chemists.
Case Histories
Analogue Classes
The discovery of dipeptidyl peptidase IV inhibitors has opened a promising chapter for the treatment of type 2 diabetes. The pioneer drug sitagliptin has been followed by several analogues in order to obtain more potent and longer acting derivatives. Serendipitous clinical observation afforded the pioneer drug sildenafil. Several analogues have been found that have optimized its properties (e.g., selectivity, duration of action). Rifamycins are antibacterial antibiotics derived from fermentation. Analoguebased drug research afforded more potent derivatives. One of the derivatives, the poorly absorbed rifaximin, has a promising application for the treatment of irritable bowel syndrome. Three analogue classes of monoterpenoid indole alkaloids are discussed: (i) vincamine derivatives, (ii) dimeric vinca alkaloid analogues, and (iii) camptothecin analogues. The successful natural product direct analogues are applied for the treatment of cerebral insufficiencies and cancer. The natural product doxorubicin is an anthracycline antibiotic used to treat a wide range of cancers, but it has a cardiotoxic adverse effect. The research into direct analogues had a goal to obtain drugs with a better therapeutic index. Paclitaxel and epothilone analogues are also examples of how natural product drugs can be used to initiate analogue-based drug research to afford new drug analogues with better properties as anticancer agents. The selective serotonin reuptake inhibitors (SSRIs) are pharmacological analogues that revolutionized antidepressant therapy. The structurally different SSRIs have different profiles for inhibiting uptake of the neurotransmitters: serotonin, dopamine, and norepinephrine. The modification of naturally occurring tropane alkaloids afforded the quaternary ammonium salts ipratropium and tiotropium, which are important drugs used for treating chronic obstructive pulmonary disease. Tiotropium, as a result of analogue-based drug discovery, has a longer duration of action that enables a once-daily dosing. The natural product adrenaline (epinephrine) was the starting point for drug research into b-adrenoreceptor agonists. From isoprenaline (isoproterenol) through the selectively acting salbutamol, and on to salmeterol, analogue research resulted in selective, more potent, and longer acting analogues with different PK profiles, which are important drugs in asthma therapy.
Case Histories
Eight case histories are described by their inventors. Liraglutide is a new antidiabetic drug, an analogue of the natural product glucagonlike peptide 1. Among the acylated GLP-1 analogues liraglutide has been developed for a once-daily treatment.
XIX
XX
Introduction
Eplerenone is a spironolactone analogue for treating hypertension that has a greater selectivity for the mineralocorticoid receptor and reduced sexual side effects. Clevudine is a new drug for the treatment of the chronic hepatitis B virus (HBV) infection, which belongs to the class of nucleoside reverse transcriptase inhibitors. Tipranavir is a new anti-HIV agent that is a protease inhibitor. The discovery of tipranavir used structure-based and fragment-based drug design and its long discovery process started from warfarin, which is a weak HIV-1 protease inhibitor. Dasatinib can be regarded as a pharmacological analogue of imatinib. Dasatinib is more potent and it can be used in imatinib-resistant cases for the treatment of chronic myelogenous leukemia (CML). Lapatinib can be regarded as a pharmacological analogue of erlotinib. It is a tyrosine kinase inhibitor and was first approved for the treatment of solid tumors such as in breast cancer. Venlafaxine is the first marketed serotonin/norepinephrine reuptake inhibitor (SNRI) and is used for the treatment of deep depression. Its active metabolite is desvenlafaxine, which has some advantageous properties; for example, it has a more favorable metabolic profile compared to venlafaxine. Rilpivirine is a new HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI), an analogue of etravirine. Rilpivirine is highly potent also against strains that are resistant to the first-generation NNRTI drugs. The first volume of Analogue-Based Drug Discovery discussed mostly well-established drugs. This second volume also opens the door to new drug discoveries and the editors hope that, like the first volume, all of the drugs discussed in this book will have a bright future.
XXI
Abbreviations ABC ABDD ABPM ACAT ACE ACTH ADMET AFC AIDS ALT ALL AMP cAMP ANDA a-APA APV AR ATP AUC AZT BBB Bcr-Abl BG b.i.d. BOC CBF CC50 b-CCE CGI CHB CK CL CLR
ATP binding cassette analogue-based drug discovery ambulatory blood pressure monitoring acyl-CoA:cholesterol acyltransferase angiotensin-converting enzyme adrenocorticotropic hormone absorption, distribution, metabolism, excretion and toxicity 7-amino-4-trifluoromethylcoumarin acquired immunodeficiency syndrome alanine aminotransferase acute lymphoblastic leukemia amprenavir cyclic 30 ,50 -adenosine monophosphate Abbreviated New Drug Application a-anilinophenylacetamide amprenavir androgen receptor adenosine triphosphate area under the curve azidothymidine blood-brain-barrier Breakpoint cluster region - Abelson blood glucose twice a day (from Latin bis in die) t-butoxycarbonyl cerebral blood flow 50% cytotoxic concentration ethyl b-carboline-3-carboxylate Clinical Global Impressions Scale chronic hepatitis B creatine kinase clearance renal clearance
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
XXII
Abbreviations
CLT CLV CLV-TP CML CMRglc CNS COBP COPD COX-1 COX-2 CPI/r CPT CRC CYP DA 10-DAB DAPY DATA dCK DNA cDNA cccDNA mtDNA DOC DOCA DPP-4 DSM-III EBV EC50 ED EFS EGFR EMEA EPA EPO EPS Erk ETC FAAH FBDD FDA L-FEAU FEV L-FMAU
total clearance clevudine clevudine triphosphate chronic myelogenogenous leukemia cerebral metabolic rate of glucose central nervous system chronic obstructive broncho-pneumopathies chronic obstructive pulmonary disease cyclooxygenase-1 cyclooxygenase-2 comparator protease inhibitor boosted with ritonavir camptothecin colorectal cancer cytochrome P450 isoenzyme dopamine 10-deacetyl-baccatin diarylpyrimidine diaryltriazine deoxycytidine kinase desoxyribonucleic acid complementary deoxyribonucleic acid covalently closed circular DNA mitochondrial DNA deoxycorticosterone deoxycorticosterone acetate dipeptidyl peptidase 4 Diagnostic and Statistical Manual of Mental Disorders, third edition Epstein-Barr virus effective concentration 50 erectile dysfunction electric field stimulation epidermal growth factor receptor European Medicines Agency Environmental Protection Agency European Patent Office exprapyramidal side effect extracellularly regulated kinase emtricitabine fatty acid amide hydrolase fragment-based drug design Food and Drug Administration 1-(20 -deoxy-20 -fluoro-b-L-arabinofuranosyl)-5-ethyluridine forced expiratory volume L-20 -fluoro-5-methyl-b-L-arabinofuranosyluracil
Abbreviations
GABAA GAD GI GIP GLP-1 cGMP GPIIb/IIIa HA HAART HA/ACTH HAM-A HAM-D HbA1c HBV HBcAg HBeAg HbsAg HCC HCV HDV hERG HFB HIAA HIV HIV PR HMG-CoA 5-HT 5-HTP HTS IBMX IC50 pIC50 ICS IDR IDV i.m. IND INN IOPY i.p. i.v. Ki LABA Lck hLck
gamma-aminobutyric acid A generalized anxiety disorder growth inhibition glucose-dependent insulinotropic polypeptide glucagon-like peptide-1 cyclic 30 ,50 -guanosine monophosphate glycoprotein IIb/IIIa heavy atom Highly Active Antiretroviral Therapy histamine-induced adrenocorticotropic hormone Hamilton Anxiety Taring Scale Hamilton Depression Rating Scale glycosylated haemoglobin hepatitis B virus hepatitis B core antigen hepatitis B e antigen hepatitis B surface antigen hepatocellular carcinoma hepatitis C virus hepatitis delta virus human ether-a-go-go-related gene human foreskin fibroblast 5-hydroxy-indole acetic acid human immunodeficiency virus HIV protease 3-hydroxy-3-methylglutaryl coenzyme A 5-hydroxytryptamine (serotonin) 5-hydroxytryptophan high-throughput screening isobutylmethylxanthine inhibitory concentration 50 log IC50 inhaled corticosteroids idarubicin indinavir intramuscular Investigational New Drug International Nonproprietary Name iodophenoxypyridone intraperitoneal intravenous inhibitory constant long-acting b2-agonist lymphocyte specific kinase human Lck
XXIII
XXIV
Abbreviations
mLck LDL-C LE LPV LVEF MADRS MAOI M1 MAP rMD MDD MDR MED MES MIC MR MRP MTD NAPQI NCE NCI NDA NE NMR NNRTI NO NPs NPC1L1 NRIs NRTI NSAIDs NSCLC OADs OC OCD OGTT PCA PCF PCT PDEs PDGFR PEP PGE1 PGE2 P-gp
murine Lck low-density lipoprotein-cholesterol ligand efficiency lopinavir left ventricular ejection fraction Montgomery-Asberg Depression Rating Scale monoamine oxidase inhibitor muscarinic receptor M1 subtype mitogen-activated protein restrained molecular dynamics major depressive disorder multidrug resistance minimal effective dose maximal electroshock seizure minimal inhibitory concentration mineralocorticoid receptor multidrug resistance-associated protein maximum tolerated dose N-acetyl-p-benzoquinone imine New Chemical Entity National Cancer Institute New Drug Application norepinephrine nuclear magnetic resonance nonnucleoside reverse transcriptase inhibitor nitric oxide natural products Niemann-Pick C1-Like-1 norepinephrine reuptake inhibitors nucleoside reverse transcriptase inhibitor nonsteroidal anti-inflammatory drugs non-small cell lung cancer oral antidiabetic drugs ovarian cancer obsessive-compulsive disorder oral glucose tolerance test p-chloroamphetamine plant cell fermentation Patent Cooperation Treaty phosphodiesterases platelet derived growth factor receptor prolyl endopeptidase prostaglandin E1 prostaglandin E2 permeability glyocoprotein
Abbreviations
Ph (+) PK PKG POMS PPCE PR QSAR q.d. or QD RBA RGD RNA RNApol mRNA RT RTV SAR SBDD s.c. SCID SCLC SEDDS SEF SI SIV SMC SNRI SQV Src SRI SSRIs TCR TDF TGFa TI TIBO t.i.d. TK TMPK TPV TPV/r TPT TRIPs TTP UDP
Philadelphia chromosome positive pharmakokinetic protein kinase G profile of mood state postproline cleaving enzyme progesterone receptor quantitative structure-activity relationship once a day (from Latin quaque die) relative binding affinity arginine-glycine-aspartic acid ribonucleic acid RNA polymerase messenger RNA reverse transcriptase ritonavir structure-activity relationship structure-based drug design subcutaneous severe combined immunodeficient small-cell lung cancer self-emulsifying drug delivery system sodium excreting factor selectivity index simian immunodeficiency virus smooth muscle cell serotonin/norepinephrine reuptake inhibitor saquinavir sarcoma serotonin reuptake inhibitor selective serotonin reuptake inhibitors T-cell antigen receptor tenofovir disoproxil fumarate tansforming growth factor-a tumor inhibition 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk]benzodiazepin-2 (1H)-one three times daily thymidine kinase thymidylate kinase tipranavir tipranavir/ritonavir combination topotecan Trade-related Aspects of Intellectual Property Rights time to progression uridine diphosphate
XXV
XXVI
Abbreviations
UGT USAN VEGFR VMS VSMC VSS WBC WHcAg WHsAg WHV WTO
uridine diphosphate glucuronyl transferase United States Adopted Names vascular endothelial growth factor receptor vasomotor symptoms vascular smooth muscle cell steady-state volume white blood cell woodchick hepatitis virus core antigen woodchuck hepatitis virus surface antigen woodchuck hepatitis virus World Trade Organization
Part I General Aspects
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j3
1 Optimizing Drug Therapy by Analogues Janos Fischer, C. Robin Ganellin, John Proudfoot, and Erika M. Alapi The medicinal chemist has a complex task to discover a useful new drug molecule. Among the different ways to accomplish this, the use of analogue research has been the most successful over the years, and most of the improvements in drugs have been obtained this way. This chapter will summarize the main aspects and demonstrate how analogues in a class of drugs are used to optimize drug therapy.
1.1 Introduction
The term analogue (from the Greek analogos) means proportionate, but in everyday terms we use it to indicate similarities between things. In medicinal chemistry, an analogue drug [1] has a chemical and/or pharmacological relationship with another drug. Structural analogues are drugs that have a similar chemical structure but quite different pharmacological properties, whereas pharmacological analogues are drugs that have a similar pharmacological activity without any discernible chemical or structural relationship. About half the drugs are analogues in both respects, and we therefore call them full analogues that are structural and pharmacological analogues. One special class of full analogues is considered to be direct analogues if they have identical pharmacophores – that is, they can be described by a general structure that includes most of the chemical skeleton. There are only a few drugs for which no successful analogues have been discovered, these we have termed standalone drugs [2]. Because of the experimental nature of structure–activity relationships (SARs), the term analogue is descriptive and not exact, nevertheless it is a useful tool in classifying the 6000 different drugs used nowadays. An analogue class is a group of drugs that displays similar in vitro and in vivo pharmacological properties; therefore, they are either pharmacological or full analogues. The first drug in the class (often termed first in class) used as a lead for the development of analogues can be considered a pioneer drug. A pioneer drug is therefore the first marketed drug in an analogue class. After the discovery of a pioneer
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 1 Optimizing Drug Therapy by Analogues
4
drug, there are almost always efforts to improve upon it with analogues in order to obtain new drugs with better therapeutic properties. A drug can be characterized by several chemical and pharmacological properties. Even a minor structural change can sometimes modify all these properties. In order to illustrate key concepts in the optimization of drug therapy by analogues, it is necessary to simplify this question and we will always focus on a dominant property in a given analogue class.
1.2 Pharmacodynamic Characteristics
Pharmacodynamics refers to the study of drug actions in living organisms and includes the dominant activity along with possible adverse effects. 1.2.1 Potency
The potency of a drug refers to the amount of drug required to achieve a defined biological activity. The smaller the dose required, the more potent the drug. The discovery of the histamine H2-receptor antagonist cimetidine in 1971 was a pioneer invention in the treatment and prevention of peptic ulcer and gastroesophagitis. Cimetidine is used in a daily dose of 800 mg. The application of analogue-based drug research provided ranitidine (1976), roxatidine (1979), famotidine (1979), and nizatidine (1980), which are more potent drugs and are effective at a lower dosage. Table 1.1 shows daily doses in comparison to cimetidine. Famotidine is the most potent member of the analogue class (Figure 1.1) [3]. Statins are HMG-CoA reductase inhibitors (Figure 1.2). Based on their in vitro effects, rosuvastatin is the most potent analogue and is followed in rank order by atorvastatin, simvastatin, and pravastatin [4] (Table 1.2). The same rank order of potency has been observed in clinical trials.
Table 1.1 Comparison of approximately equivalent daily doses of H2-receptor antagonists.
Drug cimetidine nizatidine ranitidine roxatidine famotidine a)
Daily dose (mg) 800 300 300 150 40
Administered as acetate hydrochloride.
Molecular weight (Da) 252 331 314 385a) 337
1.2 Pharmacodynamic Characteristics
j5
CH3
N H
NH
NH
N
S NC
CH3
H3C
CH3
N
O
NH
S
NH
N O 2N
cimetidine
ranitidine
N
S O
NH
N
O
N
S
N
H2N
NH2 O
NH2
O CH3
O
roxatidine
famotidine
CH3 H3C
N
N
NH
S
S
NH
CH3
O 2N
nizatidine Figure 1.1 Structures of H2-receptor antagonists.
1.2.2 Improving the Ratio of Main Activity and Adverse Effects
There are no drugs without some adverse effects. One important goal of analoguebased discovery approaches is to design improved drugs with a better ratio of efficacy to adverse effects.
Table 1.2 Inhibitory effects of various statins in vitro.
Drug pravastatin simvastatin atorvastatin rosuvastatin
CH3
IC50 (nM)
Molecular weight (Da)
44.1 11.2 8.2 5.4
424 419 559 482
O S
NH2
j 1 Optimizing Drug Therapy by Analogues
6
HO
O
HO
O
O O H3C
OH
O O
H3C
OH
O
H3C
H
CH3
CH3
CH3
H3C
H
CH3
HO pravastatin
simvastatin
HO
HO
OH
OH O
O
OH
OH F
F CH3
CH3 N CH3
CH3 N
N H3C O
S
N O
NH O
CH3
rosuvastatin
atorvastatin
Figure 1.2 Structures of HMG-CoA reductase inhibitors.
1.2.2.1 Improving Selectivity Through Receptor Subtypes The opportunity for improvement is clear if the mechanism of the adverse effect is known and one such example is found in the case of the adrenergic b-receptor blockers (Figure 1.3). The pioneer drug of b-receptor blockers is propranolol, invented in 1962. Subsequently, it was discovered that b-receptors occur as subtypes, for example, b1 (in the heart) and b2 (mediating smooth muscle relaxation). Propranolol blocks both b1- and b2-receptors. However, blocking b2-receptors in bronchitis and asthma can be harmful, and analogue research successfully focused on producing selective b1-blockers. The first b1-selective blocker practolol was invented in 1964, but it was withdrawn from the market due to an unusual side effect, an oculomucocutaneous reaction that can lead to blindness. This is fortunately not a class effect, and many other selective blockers were developed and used in cardiology, such as atenolol, betaxolol, metoprolol, celiprolol, nebivolol, and bisoprolol [5] as b1-selective blockers.
1.2 Pharmacodynamic Characteristics OH
OH O
NH
CH3 CH3
O H3C
CH3
NH
O
CH3
NH
practolol
propranolol
OH
OH O H3C
j7
NH
CH3 CH3
O
O
CH3
H2N
metoprolol
atenolol
OH
O
OH
CH3
NH
O
CH3
NH
O
NH
O
CH3
CH3 CH3
O O H3C
H3C
H3C
N
O
OH O
O H3C
betaxolol
bisoprolol
CH3
NH
CH3 CH3 CH3
NH
O
celiprolol
H
OH
OH NH
O H
H
F
F
nebivolol
Figure 1.3 Structures of adrenergic b-receptor blockers.
1.2.2.2 Improving Selectivity Through Unrelated Receptors Treatment with cimetidine for antiulcer therapy, the pioneer H2-receptor histamine antagonist drug, resulted in a low incidence of gynecomastia as an unwanted side effect. This was traced to a low level of antiandrogenic activity. Thus, cimetidine was shown to competitively inhibit the binding of 3 ½Hdihydrotestosterone to its cytoplasmic receptor and to decrease its specific nuclear uptake in rat ventral prostate slices [6]. Subsequent H2-receptor antagonist analogues were an improvement since they generally did not show this effect. 1.2.2.3 Improving Selectivity by Tissue Distribution Antihistamines, useful in allaying the symptoms of allergic responses such as rhinitis and itching eyes when the pollen count is high, have been in general use for over 60 years. Their use has, however, been somewhat limited by a high incidence of drowsiness or sedation. Early attempts to separate the sedative effects from the antihistaminic action were not very successful, and it took many years until it was realized that these activities were connected. In particular, the work of Schwartz and
j 1 Optimizing Drug Therapy by Analogues
8
F
HO
N
OH
NH
O
Cl
haloperidol
azacyclonol
Figure 1.4 Structures of haloperidol and azacyclonol.
his colleagues in Paris demonstrated that histamine is a neurotransmitter in histaminergic nerves in the central nervous system (CNS) [7]. Histamine, acting on the histamine H1-receptor in the brain, was shown to be a stimulant of wakefulness; blocking these receptors leads to a loss of alertness resulting in drowsiness. Some attempts were made to synthesize compounds that were selective for the peripheral versus the central H1-receptors. Although such claims were made, they were not substantiated and, indeed, the use of molecular biology has demonstrated that there is no difference between the central and peripheral histamine H1receptors. There are some differences in the H1-receptors between species but not within a species. It follows that if it is not possible to separate the activity between peripheral and central histamine H1-receptors, then it is necessary to limit the access of antihistamine drugs to the CNS. The first compound to establish itself on this basis was terfenadine, but it was not originally developed as an antihistamine. Terfenadine was developed for CNS actions (dopamine antagonism) and calcium ion-channel blocking [8]. It was chemically related (as a combination of analogues) to haloperidol and azacyclonol (Figure 1.4) but found to be restricted to peripheral systems and to act as an antihistamine; indeed, it became the first member of a new class of drugs identified as nonsedative antihistamines and was very successful. This was followed by astemizole and then by other drugs that were synthesized as analogues of previously established active but sedating antihistamines (see Table 1.3 and Figure 1.5 for some examples). Astemizole arose from a research program at Janssen Pharmaceutica reportedly aimed at antihistamines having a long duration of action and a low risk of provoking central and anticholinergic effects [9]. Some of the above-mentioned products were later withdrawn because of an unwelcome side effect on heart caused by the blockade of the hERG (human ether-a-go-go-related gene) potassium ion channel that gives rise to cardiac arrhythmias. This led to a search for new analogues. The reasons why the compounds have low concentrations in the brain are complex and not fully understood. Some important factors that determine low brain con-
1.2 Pharmacodynamic Characteristics
j9
OH Cl
O
N
N
N N OH O
O H3C OH
O H3C
R
H3C H3C
CH3
cetirizine
ebastine
R = Me, terfenadine R = COOH, fexofenadine Cl CH3
N
N O
N HO
N
O
O
loratadine
acrivastine
CH3
F
F
N
N
N
N NH
N N
H3C
N
N HN
O O
mizolastine Figure 1.5 Structures of H1-antihistamines.
CH3
astemizole
j 1 Optimizing Drug Therapy by Analogues
10
Table 1.3 H1-antihistamines that have low incidence of sedative effects.
Drug
Type
Launch
terfenadine astemizole cetirizine [10] acrivastine [11] loratadine [12] ebastine [13] fexofenadine mizolastine
pioneer, chance discovery pharmacological analogue metabolite of hydroxizine analogue of triprolidine analogue of azatidine analogue of diphenylpyraline and terfenadine metabolite of terfenadine analogue of astemizole and temelastine
1981 (withdrawn, 1997) 1983 (withdrawn, 1999) 1987 1988 1988 1990 1996 1998
centrations are (i) high binding to brain tissue proteins, (ii) poor penetration of the blood–brain barrier, and (iii) high binding to the P-glycoprotein (Pgp) efflux pump. 1.2.2.4 Improving Selectivity of Nonreceptor-Mediated Effects In many cases, the mechanisms causing side effects are not known. Platinum compounds (Figure 1.6) play a major role in oncology. Cisplatin may cause regression and control of various tumors, such as testicular, ovarian, head, neck, and colon carcinoma. However, among its side effects, renal damage can be observed. Analogues have overcome this problem; thus, for carboplatin, the nephrotoxicity is much lower [14], and oxaliplatin is devoid of nephrotoxicity [15].
O H3N H3N
Cl Pt Cl
H3N H3N
O
O Pt
Pt O O
cisplatin
O
H2 N
carboplatin
N H2
O O
oxaliplatin
Figure 1.6 Structures of platinum compounds.
1.2.3 Improving the Physicochemical Properties with Analogues
Benzylpenicillin (penicillin G) (Figure 1.7), which is acid-sensitive, is rapidly destroyed by gastric fluid at pH 2. The pioneer penicillin drug was administered by intramuscular injection to avoid this problem, but this was not convenient for the patients. Through analogues, where an electron-withdrawing substituent was introduced in the side chain, the acid sensitivity of the b-lactam ring was reduced. A range
1.2 Pharmacodynamic Characteristics
j11
NH2
NH
S
O
CH3
N
O
CH3
O
NH O R
O
OH
S N
CH3 CH3
O
OH
ampicillin, R = H amoxicillin, R = OH
benzylpenicillin
CH3
O N
H3C
NH
R1 R
O O
S N O
O
CH3
NH
S
CH3 OH
H3C
O
O
N O O
R = H, R1 = H, oxacillin R = H, R1 = Cl, cloxacillin
methicillin
R = F, R1 = Cl, flucloxacillin R = Cl, R1 = Cl, dicloxacillin Figure 1.7 Benzylpenicillin and analogues.
of such analogues proved to be resistant to acid hydrolysis and they could be given orally (e.g., ampicillin [16]). 1.2.4 Analogues to Reduce the Resistance to Anti-Infective Drugs 1.2.4.1 Antibiotics Resistance to antibiotics has become an increasing problem all over the world, and the need to find new agents continues [17]. The widespread use of penicillin G led to an alarming increase of penicillinresistant Staphylococcus aureus infections in 1960. A solution to the problem was the design of penicillinase-resistant penicillins. The first such analogue was methicillin [18]; however, it was acid-sensitive and it was inactive against Gramnegative bacteria. Methicillin is no longer used clinically because better analogues (Figure 1.7) have been discovered, such as oxacillin [19], cloxacillin [20], flucloxacillin [21], and dicloxacillin [21] that were stable to b-lactamase enzyme of S. aureus and had acid stability.
CH3 CH3 OH
j 1 Optimizing Drug Therapy by Analogues
12
OH CH3
OH N N
N N
N
N
N N
F
N
N
F
F fluconazole
F
N
F voriconazole
Figure 1.8 Structures of fluconazole and voriconazole.
1.2.4.2 Antifungal Drugs A very important subclass of antifungal drugs is the azoles. Until the 1980s, while these drugs were used only topically, no resistance was detected. Since the introduction of the systemically active azoles, resistance has emerged. Even in the case of fluconazole, which is the most potent member of this analogue class, a resistance was observed in Candida infections. In this case, voriconazole, an analogue of fluconazole (Figure 1.8), has been used with a good result [22]. 1.2.4.3 Antiviral Drugs Although the first generation of anti-AIDS drugs provided key medicines for the treatment of the disease, the emergence of HIV-1 strains resistant to various drug classes prompted efforts to discover analogues with broader activity profiles. Successful analogue design approaches have led to improved pharmacological profiles that include suppression of viral resistance for two of the three classes where multiple drugs have reached the market, the nonnucleoside reverse transcriptase inhibitors (NNRTIs) and the protease inhibitors. For the nucleoside reverse transcriptase inhibitor class, the marketed drugs were generally discovered while generating analogues of zidovudine (stavudine, didanosine, tenofovir disoproxil, abacavir, and lamivudine) (Figure 1.9) with improved therapeutic index, and benefits with regard to resistance profiles were empirically uncovered [23]. Etravirine [24] (Figure 1.10), the most recent NNRTI to reach the market, is a pharmacological analogue of the first-generation NNRTIs and displays activity against a broad panel of drug-resistant reverse transcriptase (RT) mutants. Structurally, it bears no resemblance to any of the first-generation inhibitors and it emerged by iterative design starting with the earlier alpha-APA class over a period of many years. Optimization was guided throughout by structural information. Molecular conformational flexibility is apparently a key attribute that allows the molecule to effectively bind in multiple modes to the conformationally mobile NNRTI binding site of numerous clinically relevant RTmutants. The close structural analogue, rilpivirine [25], is in phase III trials.
1.2 Pharmacodynamic Characteristics
O
O CH3
HN O
CH3
HN N
O
N
O
O OH
N3
OH stavudine
zidovudine
NH2
O N
HN
N
N
N
N
O
N
O
P
N
O
O
CH3
O O
HO
H3C tenofovir disoproxil
didanosine
NH2 HN N
N
N
O
N
N
N
O S HO HO
abacavir
lamivudine
Figure 1.9 Structures of zidovudine and analogues.
O
O
O
O
H2N
j13
O CH3
CH3 CH3
j 1 Optimizing Drug Therapy by Analogues
14
CH3
CH3 O
N
NH
N
Br CH3
NC
NH
CN
NC
N
NH N
CH3
CN
NH2
rilpivirine
etravirine Figure 1.10 Structures of etravirine and rilpivirine.
Among the HIV-1 protease inhibitors, analogue approaches specifically attempting to improve resistance profiles have also given drugs that have reached the market. Cocrystal structure information of ritonavir (Figure 1.11), a first-generation protease inhibitor, bound to HIV-1 protease, was used to design lopinavir [26]. Removal of the isopropylthiazole group of ritonavir that interacts with valine-82 led to decreased sensitivity to the protease mutants selected by ritonavir. This modification, along with the modification of the other thiazole ring in ritonavir, also substantially improved the CYP inhibition profile of lopinavir. The design of amprenavir [27] and darunavir [28] (Figure 1.12) emphasized the importance of interactions between the inhibitors and the conserved elements of the
O
N
NH
NH
NH
S
N
O
NH
O
CH3
NH
O
CH3
CH3
H3C
OH
CH3
O
O
CH3
S
H3C
O
HO
N
ritonavir
H3C
N
NH
O CH3
lopinavir
Figure 1.11 Structures of ritonavir and lopinavir.
O O
O
O NH
N OH
O
H
O
O
S O
CH3
O H
NH2
N H
N
Figure 1.12 Structures of amprenavir and darunavir.
S
OH NH 2
CH3
amprenavir
O
O
darunavir
1.3 Pharmacokinetic Characteristics
N
N Cl
N H3C
O
NH
S
N
N
NH
NH
N
NH
N
N
N
N
O
CH3
CH3
CH3
dasatinib
imatinib
CF3 N
O N
N
H3C
NH
j15
NH
N
N CH3
nilotinib Figure 1.13 Structures of imatinib, dasatinib, and nilotinib.
protein backbone of the wild-type enzyme as a means to attaining excellent potency against mutant strains resistant to the first-generation inhibitors. 1.2.5 Analogue Research in Resistance to Drug Therapies in Cancer Treatment
Imatinib (Figure 1.13) is the pioneer drug for the treatment of chronic myologenous leukemia (CML). However, a significant number of patients develop resistance to imatinib. New analogues, such as dasatinib [29] and nilotinib [30], have been introduced recently, and it is hoped that these analogues will be effective also in imatinib-resistant cases.
1.3 Pharmacokinetic Characteristics
Pharmacokinetics is the study of the metabolism of drugs with particular emphasis on the time required for absorption, duration of action, distribution in the body, and method of excretion. Through analogue design, the pharmacokinetic parameters (ADME) of a pioneer drug or a drug class can be optimized. 1.3.1 Improving Oral Bioavailability
A good oral bioavailability is necessary in most cases because the oral application of a drug is preferred to an injection therapy.
OH
j 1 Optimizing Drug Therapy by Analogues
16
HO
O
NH2 HO
CH3
O
N NH
N
NH O
O
OH
enalaprilat
O
O
OH
lisinopril
Figure 1.14 Structures of enalaprilat and lisinopril.
1.3.1.1 Improving Absorption The angiotensin-converting enzyme (ACE) inhibitor enalaprilat (Figure 1.14) is not orally absorbed but is available for intravenous administration when oral therapy is not appropriate, for example, in hypertensive emergencies. The ethyl ester prodrug, enalapril has an excellent oral bioavailability but requires hydrolysis by esterases. The analogue-based drug research afforded the lysylproline analogue, lisinopril [31], which has an acceptable bioavailability and it does not require metabolic activation. 1.3.1.2 Improving Metabolic Stability The pioneer antifungal miconazole (Figure 1.15) and its analogue tioconazole [32] are clinically effective drugs, when administered by the topical route, against fungal infections of vagina and skin. Unfortunately, tioconazole and other imidazole derivatives of that time showed only poor efficacy in animal models of fungal infection when given by either the intravenous or the oral routes. Pharmacokinetic studies indicated that these agents were very susceptible to metabolic inactivation, resulting in low oral bioavailability and low plasma levels. They were also very lipophilic and highly bound to plasma proteins, which resulted in very low circulating levels of the unbound, active form. The first orally active antifungal drug was ketoconazole [33], which was discovered at Janssen Pharmaceutica. Ketoconazole was metabolically less susceptible than earlier imidazole derivatives, resulting in good oral bioavailability; however, it was metabolized such that less than 1% of unchanged drug was excreted through urine. In addition, although ketoconazole was less lipophilic than the earlier derivatives, leading to high blood levels, it remained highly protein-bound with less than 1% in unbound form. Introducing a polar hydroxyl group and a more polar 1,2,4-triazole ring led to UK47265. It was 100 times more potent than ketoconazole when dosed via either the oral or the intravenous routes; however, its in vitro activity against fungi was modest. Unfortunately, UK-47265 proved to be hepatotoxic in mice and dogs and teratogenic in rats; therefore, it was not developed further. Researchers at Pfizer continued to
1.3 Pharmacokinetic Characteristics
j17
O CH3 N N
Cl
Cl O
Cl Cl
Cl
O
O
O
Cl
N
Cl O
N
Cl N
N
N
N
ketoconazole
miconazole
tioconazole F
Cl
F
Cl OH N
N
N
OH
N
N
N
N
N
N
N N
UK-47265
N
fluconazole
Figure 1.15 Structures of miconazole and analogues.
study further analogues, and the 2,4-difluoro derivative (fluconazole, UK-49858) showed high efficacy without any safety problem. Fluconazole [34] has a plasma half time of 5.1 h and 75% of the drug is excreted unchanged through urine. 1.3.2 Drugs with a Long Duration of Action
Captopril [35] was the first orally active ACE inhibitor (angiotensin-converting enzyme) to reach the marketplace. It is rapidly absorbed with a bioavailability of about 75%. Peak drug concentrations in plasma occur within 1 h of dosing, and the drug is then cleared rapidly (t1/2 about 2 h); therefore, a dosage regimen of two- to
Cl S
j 1 Optimizing Drug Therapy by Analogues
18
Table 1.4 Elimination half-life values of ACE inhibitors [31].
Drug captopril benazepril cilazapril enalapril fosinopril lisinopril perindopril ramipril trandolapril
Elimination half-life (h) 2 11 10 11 12 12 >24 8–14 16–24
three times daily is necessary. Since food reduces the oral bioavailability of captopril, the drug should be given 1 h before meals. Hypertension usually requires a lifelong treatment; therefore, the long-acting analogues of captopril are advantageous (Table 1.4, Figure 1.16). The long-acting once-daily dosing has practical benefits by improving patient compliance. The clinical advantage of full 24-h control of blood pressure is important to prevent cardiovascular events (e.g., myocardial infarction and stroke). The oral bioavailability of the long-acting ACE inhibitors is only slightly reduced by food. The case of the calcium channel antagonists, dihydropyridines, shows a similar picture. The pioneer drug nifedipine has a short duration of action. The long-acting analogues, such as felodipine, lacidipine, and amlodipine are more convenient for the lifelong treatment of hypertension (Table 1.5, Figure 1.17). Table 1.5 Elimination half-life values of calcium antagonist dihydropyridines [36].
Drug nifedipine felodipine lacidipine amlodipine
Elimination half-life (h) 2–4 10–15 7–18 30–50
1.3.3 Ultrashort-Acting Drugs
Esmolol [37] (Figure 1.18) is a b1-selective blocker with a very short duration of action. It is administered intravenously and used when b-blockade of short duration is desired in patients in whom adverse effects of bradycardia, heart failure, or hypotension may necessitate its rapid withdrawal. It is used in emergency situations during critical care medication.
1.3 Pharmacokinetic Characteristics
HS
H3C
O
O
N
N
H3C O
NH OH
O
O HO
captopril H3C
O
j19
O
benazepril
O
CH3
O
O
H3C
N
N
N
NH
NH
O
O
OH
O
H3C O
NH2
O
P O
OH
O
H3C
H3C
N
NH
O
O
OH
O CH3
O
OH
O
ramipril
CH3 N
NH O
N
NH
perindopril
O
O
CH3
O
H3C
O
fosinopril
lisinopril
O
O N
N
NH
O
CH3
H3C
O
O
H3C
OH
cilazapril
enalapril
HO
O
O
trandolapril Figure 1.16 Structures of ACE inhibitors.
OH
O
OH
j 1 Optimizing Drug Therapy by Analogues
20
Cl NO2 MeOOC
H3C
COOMe
N H
Cl MeOOC
CH3
H3C
nifedipine
COOEt
N H
CH3
felodipine
HO Cl
O EtOOC
H3C
COOEt
N H
MeOOC
CH3
lacidipine
COOEt
H3C
N H
O
NH2
amlodipine
Figure 1.17 Structures of nifedipine and analogues.
This special analogue type is called a soft drug. It is active only as an ester that loses its activity after metabolic hydrolysis. Esmolols distribution half-life is 2 min and its elimination half-life is 9 min. The same principle is used in the case of loteprednol etabonate (Figure 1.19), which is a glucocorticoid soft drug that has a good local activity after it is topically administered to the eye. Since it is rapidly deactivated after reaching the general circulation, it does not display systemic side effects. 1.3.4 Decreasing Interindividual Pharmacokinetic Differences
Interindividual pharmacokinetic differences result when a significant number of patients require a higher or multiple doses of a drug to achieve symptom relief and healing. Omeprazole [38] is the pioneer proton pump inhibitor that shows an interindividual variability in pharmacokinetics. Analogue-based drug discovery afforded pantoprazole (Figure 1.20), which possesses linear, highly predictable pharmacokinetics. It has a lower variability in pharmacokinetics compared to omeprazole,
1.3 Pharmacokinetic Characteristics
j21
OH O
NH
O
H3C
CH3
H3C O
Figure 1.18 Structure of esmolol.
HO
O
O
Cl
CH3
O
O
H
CH3 H
CH3
O H
O Figure 1.19 Structure of loteprednol etabonate.
particularly with respect to bioavailability. The pharmacokinetics of pantoprazolesodium [39] is almost the same in patients with gastrointestinal diseases and those with renal failure, and in the elderly, so that no dose adjustment is required. The drawback of omeprazole could also be overcome by using its (S)-enantiomer (esomeprazole) whose bioavailability is about double that of the racemate.
CH3 H3C
N
O
H3C
S N
O
O
O CH3
N H
esomeprazole
H3C
CH3 N
O
S N
O
N H
pantoprazole
Figure 1.20 Structures of proton pump inhibitors.
1.3.5 Decreasing Systemic Activity
In the intranasal and inhalation application of corticosteroids in the treatment of asthma and rhinitis, it is important to decrease the systemic availability of these drugs to avoid their adverse effects, such as adrenocortical insufficiency and osteoporosis. Analogue research afforded budenoside and fluticasone with low oral (systemic) bioavailability (Table 1.6, Figure 1.21).
F
O F
j 1 Optimizing Drug Therapy by Analogues
22
Table 1.6 Oral bioavailability of inhaled corticosteroids [40].
Drug
Oral (systemic) bioavailability (%)
beclomethasone budenoside fluticasone
15–20 10 <2
OH
O
O CH3
HO CH3 H
F CH3
O
HO
O
H
F
O
O
CH3
O O CH3
H
H3C
H
S
H
O F fluticasone furoate
budesonide
OH O CH3
HO CH3
CH3
H
Cl
OH
H
O beclomethasone Figure 1.21 Structures of corticosteroids.
1.4 Drug Interactions 1.4.1 Decreasing Drug Interactions
Cimetidine inhibits CYPs (e.g., CYP1A2, CYP2C9, and CYP2D6), an important class of drug-metabolizing enzymes. This interaction inhibits the metabolism of certain
1.5 Summary
drugs such as propranolol, warfarin, diazepam, and theophylline, thus producing effects equivalent to an overdose of these medicines. It is therefore advisable to avoid coadministration. These effects are avoided by analogues such as ranitidine and famotidine [41]. 1.4.2 Increasing Drug Interactions
Because of the potency of inhibition of cytochrome P-450 by ritonavir, it was found that combination of other HIV-1 protease inhibitors with ritonavir led to increased plasma levels of these drugs. Analogue research starting from ritonavir afforded the more potent lopinavir (Figure 1.11). However, lopinavirs plasma halflife is low. In a combination of ritonavir and lopinavir, known as Kaletra, ritonavir inhibits the P-450-mediated metabolism of lopinavir and therefore the combination is remarkably effective [42]. This CYP3A4 inhibition by ritonavir has been exploited to increase the exposure of other anti-AIDS drugs that are metabolized by this particular CYP.
1.5 Summary
The chapter gives an overview of the possibilities of analogue research, illustrated with examples. Drug therapy can be optimized with the help of analogue research in the following 12 ways: . .
. . . .
. . . . . .
Increasing potency Improving the ratio of the main activity and the adverse effects: –Improving selectivity through receptor subtypes –Improving selectivity through unrelated receptors –Improving selectivity by tissue distribution –Improving selectivity of nonreceptor-mediated effects Improving the physicochemical properties with the help of analogues Decreasing resistance to anti-infective drugs Decreasing resistance to anticancer agents Improving oral bioavailability –Improving absorption –Improving metabolic stability Long-acting drugs for chronic diseases Ultrashort-acting drugs in emergency cases Decreasing interindividual pharmacokinetic differences Decreasing systemic activities Decreasing drug interactions with the help of analogues Synergistic interactions between analogues
j23
j 1 Optimizing Drug Therapy by Analogues
24
Acknowledgments
We thank Derek Buckle, John Lowe III, and Thomas J. Perun for carefully reading and reviewing the manuscript. J.F. thanks the Alexander von Humboldt-Stiftung (Bonn) for a fellowship in 2008 and 2009.
References 1 Fischer, J. and Ganellin, C.R. (eds) (2006)
2
3
4
5
6
7
8
9
Analogue-based Drug Discovery, Wiley-VCH Verlag GmbH, Weinheim, p. XXIII. Fischer, J. (2006–2008) IUPAC Project Standalone Drugs, www.iupac.org. Yanagisawa, I., Hirata, Y., and Ishii, Y. (1987) Studies on histamine H2 receptor antagonists. 2. Synthesis and pharmacological activities of N-sulfamoyl and N-sulfonyl amidine derivatives. J. Med. Chem., 30, 1787–1793. Stein, E.A. (2001) New statins and new doses of old statins. Curr. Atheroscler. Rep., 3, 14–18. Harting, J., Becker, K.H., Bergmann, R., Bourgois, R., Enenkel, H.J., Fuchs, A., Jonas, R., Lettenbaur, H., Minck, K.O., Schelling, P., and Schulze, E. (1986) Pharmacodynamic profile of the selective b1-adrenoceptor antagonist bisoprolol. Arzneim.-Forsch. Drug Res., 36 (1), 200–208. Winters, S.J., Banks, J.L., and Loriaux, D.L. (1979) Cimetidine is an antiandrogen in the rat. Gastroenterology, 76, 504–508. Schwartz, J.-C., Barbin, G., Duchemin, A.-M., Garbarg, M., Llorens, C., Pollard, H., Quach, T.T., and Rose, C. (1982) Pharmacology of Histamine Receptors (eds C.R. Ganellin and M.E. Parsons), Wright PSG, Bristol. Carr, A.A. and Meyer, D.R. (1982) Synthesis of terfenadine. Arzneim.-Forsch. Drug Res., 32, 1157. Janssens, F., Torremans, J., Janssen, R.A., Stokbroekx, M., Luyckx, M., and Janssen, Paul A.J. (1985) New antihistaminic N-heterocyclic 4-piperidinamines. 1. Synthesis and antihistaminic activity of N-(4-piperidinyl)-1H-benzimidazol-2amines. J. Med. Chem., 28, 1925.
10 Pechadre, J.C., Vernay, D., Trolese, F.F.,
11
12
13
14
15
16
17
18
Bloom, M., Dupont, P., and Rihoux, J.P. (1988) Comparison of the central and peripheral effects of cetirizine and terfenadine. Eur. J. Clin. Pharmacol., 35, 255. Barnett, A., Lorio, L.C., Kreutner, W., Tosszi, S., Ahn, H.S., and Gulbekian, A. (1984) Evaluation of the CNS properties of SCH29851, a potential non-sedating antihistamine. Agents Actions, 14, 590. Leighton, H.J., Batz, R.F., and Findlay, J.W.A. (1986) BW 825C: a potent antihistamine with low sedation potential. Pharmacologist, 25, 163. Ratner, P., Falques, M., Chuecos, F., Esbri, R., Gispert, J., Peris, F., Luria, X., and Rosales, M.J. (2005) Meta-analysis of the efficacy of ebastine 20 mg compared to loratidine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. Allergy Immunol., 138 (4), 312–318. Thatcher, N. and Lind, M. (1990) Carboplatin in small cell lung cancer. Semin. Oncol., 17 (1 Suppl. 2), 40–48. Haioun, C. and Mondor, C.H. (2005) Oxaliplatin in lymphoma. Haematol. Rep., 1 (8), 106–107. Doyle, F.P., Nayler, J.H.C., Smith, H., and Stove, E.R. (1961) Some novel acid-stable penicillins. Nature, 191, 1091–1092. von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., and H€abich, D. (2006) Antibacterial products in medicinal chemistry: exodus or revival? Angew. Chem. Int. Ed., 45, 5072–5129. Doyle, F.P., Hardy, K., Nayler, J.H.C., Soulal, M.J., Stove, E.R., and Waddington, H.R.J. (1962) Derivatives of 6aminopenicillanic acid. Part III. 2, 6Dialkoxybenzoyl derivatives. J. Chem. Soc., 1453–1458.
References 19 Doyle, F.P., Long, A.A., Nayler, J.H.C., and
20
21
22
23
24
25
Stove, E.R. (1961) New penicillins stable towards both acid and penicillinase. Nature, 192, 1183. Doyle, F.P., Hanson, J.C., Long, A.A.W., Nayler, J.H.C., and Stove, E.R. (1963) Derivatives of 6-aminopenicillanic acid. Part VI. Penicillins from 3- and 5phenylisoxazole-4-carboxylic acids and their alkyl and halogen derivatives. J. Chem. Soc., 5838. Naylor, J.H.C. (1960) (Beecham) British Patent 905,778; Naylor, J.H.C. (1962) (Beecham) British Patent 978,299. Gothard, P. and Rogers, T.R. (2004) Voriconazole for serious fungal infections. Int. J. Clin. Pract., 58 (1), 74–80. Sluis-Cremer, N. and Ross, T. (2006) HIV-1 reverse transcriptase inhibitors: drug resistance and drug development. Curr. Pharm. Des., 12 (15), 1809–1810. Das, K., Clark, A.D., Jr., Lewi, J.J., Heeres, J., De Jonge, M.R., Koymans, L.M., Vinkers, H.M., Daeyaert, F., Ludovici, D.W., Kukla, M.J., De Corte, B., Kavash, R.W., Ho, C.Y., Lichtenstein, M.A., Andries, K., Pauwels, R., De Bethune, M.P., Boyer, P.L., Clark, P., Hughes, S.H., Janssen, P.A.J., and Arnold, E. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem., 47, 2550–2560. Janssen, P.A.J., Lewi, P., Arnold, E., Daeyaert, F., De Jonge, M., Heeres, J., Koymans, L., Vinkers, M., Guillemont, J., Pasquier, E., Kukla, M., Ludovici, D., Koen, A., De Bethune, M.P., Pauwels, R., Das, K., Clark, A.D., Jr., Volovik Frenkel, Y., Hughes, S.H., Medaer, B., De Knaep, F., Bohets, H., De Clerck, F., Lampo, A., Williams, P., and Stoffels, P. (2005) In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[(1E)-2-cyanoethenyl]2,6-dimethylphenyl]amino]-2pyrimidinyl]-aminobenzonitrile
26
27
28
29
30
31
32
(R278474, rilpivirine). J. Med. Chem., 48, 1901–1909. Sham, H.L., Kempf, D.J., Molla, A., Marsh, K.C., Kumar, G.N., Chen, C.-M., Kati, W., Stewart, K., Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Vasavanonda, S., McDonald, E., Saldivar, A., Wideburg, N., Chen, X., Niu, P., Park, C., Jayanti, V., Grabowski, B., Granneman, G.R., Sun, E., Japour, A.J., Leonard, J.M., Plattner, J.J., and Norbeck, D.W. (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother., 42, 3218–3224. Kim, E.E., Baker, C.T., Dwyer, M.D., Murcko, M.A., Rao, B.G., Tung, R.D., and Navia, M.A. (1995) Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc., 117, 1181–1182. Ghosh, A.K., Kincaid, J.F., Cho, W., Walters, D.E., Krishan, K., Hussain, K.A., Koo, Y., Cho, H., Rudall, C., Holland, L., and Buthod, J. (1998) Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino] sulfonamide isostere. Bioorg. Med. Chem. Lett., 8, 687–690. Shah, N.P., Tran, C., Le, F.Y., Chen, P., Norris, D., and Sawyers, C.L. (2005) Overriding imatinib resistance with novel Abl kinase inhibitor. Science, 305, 399–401. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., OBrien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J.D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L., and Ottmann, O.G. (2006) Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive ALL. N. Engl. J. Med., 354, 2542–2551. Alf€oldi, S. and Fischer, J. (2006) Optimizing antihypertensive therapy by angiotensin-converting enzyme inhibitors, in Analogue-Based Drug Discovery (eds J. Fischer and C.R. Ganellin), Wiley-VCH Verlag GmbH, Weinheim. Jevons, S., Gymer, G.E., Brammer, K.W., Cox, D.A., and Leeming, M.R.G. (1979)
j25
j 1 Optimizing Drug Therapy by Analogues
26
33
34
35
36
37
Antifungal activity of tioconazole (UK20,349), a new imidazole derivative. Antimicrob. Agents Chemother., 15, 597–602. Thienpont, D., Van Cutsem, J., Van Gerven, F., Heeres, J., and Janssen, P.A.J. (1979) Ketoconazole: a new broad spectrum orally active antimycotic. Experientia, 35, 606–607. Richardson, K., Cooper, K., Marriott, M.S., Tarbit, M.H., Troke, P.F., and Whittle, P.J. (1990) Discovery of fluconazole, a novel antifungal agent. Rev. Infect. Dis., 12 (Suppl. 3), S267–S271. Ondetti, M.A., Rubin, B., and Cushman, D.W. (1977) Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science, 196, 441–444. Gaviraghi, G. (2006) Case study of lacidipine in the research of new calcium antagonists, in Analogue-Based Drug Discovery (eds J. Fischer and C.R. Ganellin), Wiley-VCH Verlag GmbH, Weinheim. Erhardt, P.W. (1993) Esmolol. Chron. Drug Discov., 3, 191–206.
38 Larsson, H., Carlsson, E., Junggren, U.,
39
40
41
42
Olbe, L., Sj€ostrand, S.E., Ska:7pt :61ptnberg, I., and Sundell, G. (1983) Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology, 85, 900–907. Huber, R., Kohl, B., Sachs, G., SennBilfinger, J., Simon, W.A., and Sturm, E. (1995) Review article: the continuing development of proton-pump inhibitors with particular reference to pantoprazole. Aliment. Pharmacol. Ther., 9, 363–378. Miller, D.D., Brueggemeier, R.W., and Dalton, J.T. (2002) Adrenocorticoids, in Foyes Principles of Medicinal Chemistry, 5th edn (eds D.A. Williams and T.L. Lemke), Lippincott Williams & Wilkins, Philadelphia. Hoogerwerf, W.A. and Pasricha, P.J. (2006) Pharmacotherapy of gastric acidity, peptic ulcers, and gastrooesophageal reflux disease, in Goodman & Gilmans The Pharmacological Basis of Therapeutics, 11th edn (eds L.L. Brunton, J.S. Lazo, and K.L. Parker), McGraw-Hill, New York. Silverman, R.B. (2004) The Organic Chemistry of Drug Design and Drug Action, 2nd edn, Elsevier/Academic Press, p. 273.
Erika M. Alapi
Richter Plc., Gyömro˝i út 19/21, 1103 Budapest, Hungary Erika M. Alapi was born in Pasztó, Hungary, in 1974. She received her MSc degree in chemistry at the Faculty of Science of E€otv€os Lorand University in Budapest. She is working as a medicinal chemist in the field of CNS and preparing her PhD thesis Optimizing Therapy by Analogues under the supervision of Professor Janos Fischer at Gedeon Richter Pharmaceutical Plc. She contributed to Analogue-Based Drug Discovery I as a coauthor.
References
Janos Fischer
Professor, Richter Plc., Gyömro˝i út 19/21, 1103 Budapest, Hungary Janos Fischer is a Senior Research Scientist at Richter Plc., Budapest, Hungary. He received his MSc and PhD degrees in organic chemistry from the Eotvos University of Budapest under Professor A. Kucsman. Between 1976 and 1978, he was a Humboldt Fellow at the University of Bonn under Professor W. Steglich. He has worked at Richter Plc. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest is analoguebased drug discovery. He is the author of some 100 patents and scientific publications. In 2004, he was elected as a Titular member of the Chemistry and Human Health Division of IUPAC. He received an honorary professorship at the Technical University of Budapest.
C. Robin Ganellin
Professor, University College London, Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK C. Robin Ganellin studied chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the coinventors of the revolutionary drug, cimetidine (also known as Tagamet). In 1986, he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Professor Emeritus of Medicinal Chemistry. Professor Ganellin is coinventor of over 160 patents and has authored over 260 scientific publications. He was President of the Medicinal Chemistry Section of the IUPAC and is Chairman of the IUPAC Subcommittee on Medicinal Chemistry and Drug Development.
j27
j 1 Optimizing Drug Therapy by Analogues
28
John Proudfoot
Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877-0368, USA John Proudfoot is a Medicinal Chemist with over 20 years of experience in drug design, ranging from fragment-based lead identification to late-stage lead optimization. He received his doctorate from the University College Dublin in Ireland, working with Professor Dervilla Donnelly. After postdoctoral studies under Professor Carl Djerassi at Stanford University and under Professor John Cashman at the University of California, San Francisco, he joined Boehringer Ingelheim Pharma in 1987. He is a coinventor of 28 issued US patents, including the one for the marketed drug, nevirapine, the first nonnucleoside HIV-1 reverse transcriptase inhibitor to receive regulatory approval.
j29
2 Standalone Drugs Janos Fischer, C. Robin Ganellin, Arun Ganesan, and John Proudfoot
In volume I of Analogue-Based Drug Discovery we focused on analogue drugs with a double similarity, that is, those that are similar to another drug from both chemical and pharmacological viewpoints. These were referred to as structural and pharmacological analogues or, alternatively, full analogues. One special class of these analogues is considered to be direct analogues if they have identical pharmacophores – that is, they can be described by a general structure that includes most of the chemical skeleton. The book also discussed some examples of structural analogues, in which the similarity is limited to their chemical structures since they possess different pharmacological properties. We also proposed the term pharmacological analogues for drugs that have completely different chemical structures but similar pharmacological properties. Analogues are based on following a lead compound, and if this compound were a drug that opened up a new therapeutic treatment then we use the term pioneer drug. Such a drug is often referred to as first in class. One can subdivide pioneer drugs into those that have analogues and those that do not. Thus, the latter group provides a special subclass called standalone drugs,1) which are pioneer drugs with no effective analogues. An analysis of the Top 100 most important drugs based on the sales data of IMS is revealing. In 2006, the global sales of drugs amounted to US$ 638 billion. The sales of the Top 100 drugs were about 51% of the global sales, that is, US$ 326 billion. Table 2.1 shows that 84.4% of sales of the Top 100 drugs derive from small-molecule drugs, whereas the sales of macromolecular drugs and biological entities amount to 9.2% and the sales of vitamins and a hormone are 6.4%. The importance of small-molecule drugs remains very high in spite of the increasing role of macromolecular drugs (proteins) and biological entities (monoclonal antibodies).
1) In 2006, a new project of IUPACs Subcommittee on Medicinal Chemistry and Drug Development (Division VII, Chemistry and Human Health) was started to study the role and the importance of standalone drug. The project was chaired by Janos Fischer with the coauthors of this chapter as project members. Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 2 Standalone Drugs
30
Table 2.1 Drug types of the Top 100 drugs.
Drug types Small-molecule drugs Macromolecules and biological entities Vitamins and hormone
Sales (2006) US$ (billion)
Ratio (%)
Numbers
275 30 21
84.4 9.2 6.4
80 10 10
Table 2.2 Types of small-molecule drugs among the Top 100 drugs.
Small-molecule drug type Pioneer drugs Full analogues Pharmacological analogues Structural analogues Standalone drugs
Number 10 51 8 2 9
Table 2.2 analyzes the small-molecule drugs among the Top 100 drugs according to their analogue status. It is remarkable how many (51) of full analogues are among the Top 100 drugs. The analogue drugs belong to 42 different analogue classes of drug action, as defined by the main pharmacological effect, for example, ACE inhibitors, a1-blockers, AT1 antagonists, b-lactamase inhibitors, and so on, and there are only 10 pioneer drugs (first in class) among the Top 100 drugs from the analogue classes. This situation derived from the fact that the pioneer drugs were improved through making analogues and then continuous optimization has afforded additional analogue drugs that are even better. The nine standalone drugs from among the Top 100 drugs (2006), acetaminophen, acetylsalicylic acid, aripiprazole, bupropion, ezetimibe, lamotrigine, metformin, topiramate, and valproate semisodium, will be discussed one by one.
2.1 Acetaminophen (Paracetamol)
Based on their structures and biological activity acetanilide, phenacetin, and paracetamol (Figure 2.1) are direct analogues; however, they also have a close metabolic relationship since paracetamol is the active metabolite of both acetanilide and phenacetin. Acetanilide (1) was discovered as an antipyretic drug after it was mistakenly used instead of naphthalene in an antiworming regimen in 1886 [1]. It was marketed under the name Antifebrin in 1886 by the company Kalle, then from 1908 by
2.1 Acetaminophen (Paracetamol)
HN
O
HN
O
O
acetanilide
phenacetin
HN
O
OH
paracetamol
Figure 2.1 Paracetamol and its former analogues.
Hoescht Dyeworks. Acetanilide was cheaper and easier to prepare than other antipyretics and it remained in use for many decades. In 1887, the Bayer Company introduced the 4-ethoxy derivative, phenacetin, as a less toxic analogue of acetanilide. It was a highly successful product and established the Bayer Company as a leading pharmaceutical manufacturer. Phenacetin was widely used for about 90 years until mounting concerns over carcinogenicity and kidney-damaging properties in chronic treatment [2] led to restrictions on its use in most countries. It is, however, even nowadays available in some combinations in some countries. Paracetamol (acetaminophen) was identified as an active antipyretic and analgesic agent in a clinical trial in 1893 by Joseph von Mering [3] in cooperation with the Bayer Company. However, he believed mistakenly that it produced methemoglobinemia as an adverse effect and the compound was ignored for a half century. This situation changed when Lester and Greenberg [4], and subsequently Flinn and Brodie [5], confirmed that paracetamol is the active metabolite of phenacetin and Brodie and Axelrod found that paracetamol is the main metabolite of acetanilide [6]. At the same time, Flinn and Brodie found that, even at high oral doses, paracetamol is not attended by the formation of methemoglobin. In 1953, paracetamol was marketed by the Sterling-Winthrop Company and, especially after the withdrawal of phenacetin, assumed an important role as an antipyretic and mild analgesic drug. It is used in monotherapy and in several combination preparations, which are available on the market as OTC products. In 2007, according to the IMS data, the value of paracetamol sales was greater than US$ 7.5 billion and it ranked fourth among drugs. Paracetamol has no anti-inflammatory activity and its analgesic effect is comparable to aspirin. In patients who are sensitive to aspirin, the use of paracetamol is indicated. Despite its extensive use, the mechanism of action of paracetamol remained unknown. It can be supposed that it has a primarily CNS activity. In a recent study, Hoegestaett et al. showed that paracetamol undergoes a primary deacetylation step in the liver, brain, and spinal cord that is followed by N-acylation of the resulting 4-aminophenol with arachidonic acid by FAAH to form AM404 (Figure 2.2) in the CNS [7]. The biological significance of this route was confirmed by Ottani et al.
j31
j 2 Standalone Drugs
32
OH
O N H
Figure 2.2 N-Arachidonoyl-phenolamine (AM404).
who showed that the effect of paracetamol in pain models is prevented by cannabinoid receptor antagonists [8]. According to Hinz et al., paracetamol is a selective cyclooxygenase-2 (COX-2) inhibitor in man [9]; however, paracetamol has no significant anti-inflammatory activity. With normal use, therapeutic levels of paracetamol are considered to be safe for humans [10]; however, an overdose can cause severe liver toxicity. Paracetamol is metabolized primarily by O-glucuronidation and O-sulfation. However, a small amount is metabolized via a third metabolic pathway, in which oxidation by microsomal cytochrome P-450 gives a toxic metabolite NAPQI (N-acetyl-p-benzoquinone imine). This toxic metabolite is normally rapidly neutralized by glutathione by formation of a nontoxic adduct (Figure 2.3). The problem occurs when glutathione stores are diminished; NAPQI is no longer detoxified and covalently binds to lipid bilayer of hepatocytes, resulting in hepatotoxicity. Paracetamol toxicity is the leading cause of hospital admission for acute liver failure in the United States of America accounting for approximately 40% of all liver transplants [11]. Several direct analogues of paracetamol are summarized by Vermeulen and coworkers [12]. For example, N-methyl-paracetamol caused no hepatic necrosis in mice, rats, or hamsters in doses that caused massive hepatic necrosis in the same animals when paracetamol was administered [13]. No development is reported on these analogues. In 2007, new paracetamol analogues were described by Bazan and coworkers, in which a benzothiazolonyl moiety is linked to the p-acylaminophenol fragment [14]. In 2008, Imming and coworkers described N-(1H-indazol-5-yl)acetamide and N-(4-hydroxybenzyl)acetamide, which displayed analgesic activities comparable to paracetamol [15]. All of these analogues (Figure 2.4) try to avoid the formation of NAPQI. More time is needed to evaluate these efforts to optimize paracetamol.
HN
O
cytochrome
N
O
P450
HN
O
G-SH S-G
OH
O NAPQI
Figure 2.3 Formation of N-acetyl-p-benzoquinone imine.
glutathione
OH
2.2 Acetylsalicylic Acid (Aspirin)
O O S N N
O
HN
OH
O
O
N N H
OH Bazan (2006)
Nelson (1978)
O
HN
Imming (2008)
Figure 2.4 Some direct analogues of paracetamol (experimental phase).
2.2 Acetylsalicylic Acid (Aspirin)
Willow bark [16] and leaves have been used as antipyretic and anti-inflammatory analgesics in ancient civilizations. In 1828, Buchner isolated salicin from boiled willow bark (Figure 2.5) and in 1833 pharmacist Merck in Darmstadt used highly purified salicin as an antipyretic agent for half the price of quinine; however, salicin was poorly palatable because of its bitter taste and its structure at that time was not yet known. In 1839, Piria obtained salicylic acid from salicin by an oxidative cleavage [17]. In 1876, Maclagan [18] found that salicin and salicylic acid are equally efficacious in treating acute rheumatism, which is understandable, since salicin is a prodrug of salicylic acid. Salicylic acid became a cheap chemical through the Kolbe synthesis [19] and in 1876 it was introduced as an analgesic antirheumatic drug at the Charite in Berlin [20]. Despite the undoubted benefits of salicylic acid in the treatment of pain, fever, and inflammatory disorders, there were several side effects at high doses of 4–6 g per day, for example, stomach irritation, often associated with nausea and vomiting, and hearing disorders (tinnitus). In 1897, Eichengr€ un and Hoffmann at Bayer discovered acetylsalicylic acid (aspirin), which was not only as effective as sodium salicylate but also better tolerated. Since the beginning of the last century, aspirin has been the most widely used drug in the world.
OH HO HO
O
O
OH O
OH
O
HO
HO
OH
O O
salicin
salicylic acid
Figure 2.5 History of acetylsalicylic acid.
acetylsalicylic acid
j33
j 2 Standalone Drugs
34
More than 60 years passed before the widely used nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, indometacin, flurbiprofen, diclofenac, naproxen, ketoprofen, piroxicam, and sulindac (Figure 2.6), were discovered. These drugs were all discovered between 1961 and 1969 without the knowledge of their biochemical mechanism of action. In 1971, Vane discovered the mechanism by which aspirin and NSAIDs exert their anti-inflammatory, analgesic, and antipyretic actions. He proved that aspirin and NSAIDs inhibit prostaglandin synthesis [21]. It was already known that PGE1 was
Cl
O N
COOH O
COOH ibuprofen (1961)
indometacin (1961)
COOH Cl H N
COOH
Cl
F
diclofenac (1965)
flurbiprofen (1964)
COOH
COOH
O O naproxen (1967)
ketoprofen (1967) O S
O
O S
N
H N
N
OH O
F COOH
piroxicam (1968)
sulindac (1969)
Figure 2.6 Nonsteroidal anti-inflammatory drugs.
2.3 Aripiprazole
O
HO
NH2 O
HO
O
O
O
OH
HO
F
HO F salicylamide
salsalate
diflunisal
Figure 2.7 Salicylic acid analogues.
a potent pyretic agent [22] and prostaglandins had also been detected in inflammatory exudates [23]. The cyclooxygenase-1 (COX-1) enzyme, which catalyzes the prostaglandin formation, was isolated in 1976 [24]. Aspirin selectively acetylates the hydroxy group of one-serine residue (Ser 530) located 70 amino acids from the C-terminus of COX-1 [25]. In 1991, the COX-2 enzyme was discovered, which produces prostaglandins, mostly PGE2, during inflammatory reactions [26]. At low concentrations, aspirin acetylates COX-1 rapidly (within minutes) and selectively. At high concentrations, over longer time periods, aspirin will also nonspecifically acetylate a variety of proteins and also COX-2 at its serine residue (Ser 516). The pharmacology of aspirin is unique because its activity derives from a reactive acetate and salicylate [27]. There is a significant difference between salicylic acid and aspirin concerning the COX-1 inhibition. In contrast to aspirin, salicylic acid prevents binding of arachidonic acid by competitive inhibition. The nonaspirin NSAIDs (Figure 2.6) also inhibit competitively the COX enzymes, which is an important distinction from aspirin effects. Another important activity of aspirin is the inhibition of thromboxane formation by blocking prostaglandin biosynthesis in platelets [28]. Aspirin is the only antiplatelet agent in clinical use with this mechanism of action. There is no successful aspirin analogue on the market. Salicylamide, salsalate, and diflunisal (Figure 2.7) are existing drugs, which are all salicylic acid analogues. Salicylamide is without anti-inflammatory activity and diflunisal has no antipyretic effect. There have been several attempts to improve aspirin by prodrug approaches, which are reviewed in a recent article by Gilmer and coworkers [29].
2.3 Aripiprazole
Schizophrenia, which affects 1–2% of the global population, is a serious brain disorder characterized by abnormal mental functions and disturbed behavior [30]. The positive symptoms include disorganized thoughts, delusions, and hallucinations, whereas the negative symptoms are characterized by social withdrawal, lack of motivation, and disturbances in basic cognitive functions. Depression and bipolar disorder are highly comorbid in schizophrenia and these are the reasons for a higher risk of suicide in this disorder.
j35
j 2 Standalone Drugs
36
H3C
N
CH3 N CH3
CH3 CH3
N
N
S
S
promethazine antihistamine 1949 (launch)
Cl
chlorpromazine antipsychotic 1952 (launch)
Figure 2.8 Promethazine and chlorpromazine.
2.3.1 First Generation Typical Antipsychotic Drugs (Other Names: Neuroleptics, Conventional Antipsychotics)
Chlorpromazine, the first antipsychotic drug, was obtained from the antihistaminic and sedative promethazine. Charpentier et al. [31] synthesized and Courvoisier et al. investigated many analogues in order to enhance the sedative effect of promethazine [32] (Figure 2.8). Chlorpromazine was marketed by Rhône-Poulenc in 1952. Chlorpromazine initiated an analogue-based drug research, and several direct analogues were discovered and introduced as antipsychotic drugs without the knowledge of their mechanism of action. In vivo pharmacological models, such as conditioned avoidance response test, were typically used to drive these discovery efforts. A completely different approach in the Janssen Laboratories in 1958 afforded more potent drugs. The sedative effect of an analgesic pethidine derivative (R1187) was reminiscent of the sedation produced by chlorpromazine and, after exploring hundreds of derivatives, haloperidol was discovered. Haloperidol was 50–100 times potent than chlorpromazine, with a better side-effect profile (Figure 2.9) [33]. Chlorpromazine and haloperidol and their analogues helped many patients, but treatment with these first-generation antipsychotic drugs was associated with the development of extrapyramidal side effects (EPS), for example, dystonias, akathisias,
O
O
OH Cl
O
O
N
N F R1187 pethidine derivative analgesic effect Figure 2.9 Pethidine derivative and haloperidol.
haloperidol antipsychotic 1959 (launch)
2.3 Aripiprazole
and tardive dyskinesia (TD) in about 20% of patients and, as further adverse effects, elevated prolactin levels, and weight gain are observed. About 30% of patients do not respond to the first-generation antipsychotic drugs. 2.3.2 Second-Generation Atypical Antipsychotic Drugs
The pioneer drug clozapine was discovered in 1960 by the Wander company in Switzerland. The SAR of these tricyclic antidepressants afforded amoxapine and its 7-hydroxy metabolite had an antipsychotic activity. In the case of clozapine, the beneficial effect of the chloro substituent in position 8 and not in position 2 as in some classical tricyclic antidepressants, such as in amoxapine (Figure 2.10), was a key step in the discovery process. Clozapine was poised to revolutionize the treatment of schizophrenia because it had no EPS adverse effect in humans [34]. Clozapine was introduced in 1972 in some European countries, but agranulocytosis, a severe adverse effect, nearly terminated the use of this drug. Careful blood monitoring could decrease this severe adverse effect and clozapine has found an important place in the treatment of schizophrenia. More atypical antipsychotic drugs, such as olanzapine and quetiapine, were discovered by structural modification of clozapine, whereas haloperidol is similar to risperidone, ziprasidone, and sertindole in structure. It was proposed in 1954 that schizophrenia resulted from overactive serotonin neurotransmission [35] whereas, according to the dopamine hypothesis of schizophrenia, a functional hyperactivity of dopamine in the neuronal systems of the brain has a major contribution to the disease [36]. Dopamine receptors were first classified into D1 and D2 subtypes [37]. Typical and atypical antipsychotic drugs (Figure 2.11) are antagonists at D2 receptors; however, the atypical antipsychotics display an increased affinity for serotonin 5-HT2A/2C receptors. The atypical antipsychotic drugs have only a limited effect in the treatment of refractory schizophrenia. Metabolic adverse effects (obesity, diabetes) have been found in the case of clozapine and olanzapine. A prolongation of QT-interval has been observed after the use of quetiapine, ziprasidone, and sertindole.
H N
H N N
N N C
A
2 Cl
Cl 8
N A
amoxapine antidepressant
C N H
O
clozapine antipsychotic 1972 (launch)
Figure 2.10 Amoxapine and clozapine.
j37
j 2 Standalone Drugs
38
O OH
CH3 N
N
N
N
N
N
N H
S
olanzapine
CH3
S
F
quetiapine S
O
N
N
O
N
N
N
N
O N
CH3 Cl
N H
Cl
risperidone
ziprasidone
N
O HN
N
F
N sertindole
Figure 2.11 Atypical antipsychotic drugs.
2.3.3 A New Approach: Aripiprazole, a Dopamine Partial Agonist
All the typical and atypical antipsychotic drugs inhibit dopamine neurotransmission by blocking the postsynaptic dopamine receptors. Unfortunately, dopamine antagonism is also responsible for the most serious side effects of these agents, for example, extrapyramidal syndrome, tardive dyskinesia, and hyperprolactinemia. Carlsson proposed that compounds stabilizing the dopaminergic system without inducing hypodopaminergia would be advantageous in the treatment of schizophrenia [38]. Researchers at Otsuka (Japan) serendipitously found among 2(1H)-quinolone derivatives new compounds with neuroleptic-like activity. The best compound was OPC-4392 (Figure 2.12), which was found to be a dopamine autoreceptor agonist and a weak postsynaptic dopamine D2 antagonist [39]. In clinical investigations, OPC-4392 proved to be active in the treatment of the negative symptoms, but it was not sufficiently potent for the treatment of positive symptoms. A more potent postsynaptic dopamine D2 antagonist was needed. Among the direct analogues of OPC-4392 (lead), aripiprazole was found to fulfill these criteria. In the apomorphine-induced stereotypy in mice, OPC-4392 had an ED50 of
2.4 Bupropion
O
N H
O
H3C
N N
CH3
OPC-4392
O
N H
O
Cl
N N
Cl
aripiprazole Figure 2.12 OPC-4392 and aripiprazole.
41 mmol/kg p.o., whereas aripiprazole showed the highest potency with an ED50 of 0.6 mmol/kg p.o. [40]. Aripiprazole proved to be a presynaptic partial agonist of dopamine D2/3 receptors. The introduction [41] of aripiprazole in 2002 was the first breakthrough in antipsychotic treatment since the discovery of clozapine and analogues. However, unmet medical needs still remain to find a more effective drug for the treatment of refractory patients, to improve treatment of negative symptoms and cognitive dysfunction [42].
2.4 Bupropion
Bupropion, also known as Amfebutamone, is an antidepressant that is also used as an anticigarette smoking treatment. Soroko et al. [43], from the Wellcome Research Laboratories (Research Triangle Park, NC, USA), describe how they sought a compound that would be active in antidepressant screening models but differ chemically and pharmacologically from the well-known tricyclic antidepressants (such as amitriptyline and imipramine), and would not be sympathomimetic, cholinolytic, or an inhibitor of monoamine oxidase. Mehta, who synthesized bupropion in the 1960s, describes [44] that they used as a screen the tetrabenazine-induced sedation [45] in mouse and rat models since most clinically useful antidepressants prevent this. As he stated [44] optimally a compound should prevent tetrabenazine-induced sedation without itself being a stimulant at antidepressant doses. Several observations from their earlier studies [46] of compounds related to bupropions chemical structure (Figure 2.13) were used in the overall design of bupropion. They were as follows: 1)
The tert-alkyl group on the nitrogen atom was found to be less susceptible to N-dealkylation than other alkyl groups.
j39
j 2 Standalone Drugs
40
O H N H3C
Cl
CH3 H3C CH 3
Figure 2.13 Bupropion.
2)
The substituent in the meta position on the phenyl ring would mitigate the possibility of para-hydroxylation and consequent elimination of the drug as a glucuronide. 3) Alkoxy and alkyl substituents on the phenyl ring should be avoided since they have been found to confer antiarrhythmic activity and inhibition of free fatty acid mobilization. 4) a-Hydroxy derivatives with two-carbon side chains (e.g., isoproterenol) have usually been associated with sympathomimetic properties.
The first compound in the series of halogen substituted N-tert-butyl-2-phenylpropanolamines to show the CNS activity, using the potentiation of amphetamine as a possible screen for antidepressant activity, was 3,4-dichlorophenyl-N-tert-butylaminopropanol (Figure 2.14) [44]. Mehta continues to observe [44], since, a priori, it was conceivable that the chemically stable aminoketones and aminoalcohols could be interconvertible in vivo, there was uncertainty as to which form was responsible for the observed activity. Thus a series of aminoketones was made and tested; bupropion was the fourth compound in this series to be designed and screened as a potential antidepressant using the modified antitetrabenazine screen developed by Sulser and Soroko [45]. Mehta observes [44] that it was quite apparent that the aminoketones rather than the aminoalcohols were of primary interest and, as the amine moiety was tert-alkyl, bupropion was rather stable. Bupropion possessed the optimal variations in its chemical structure necessary to achieve maximum activity and therapeutic index. The drug was expected to result in vivo in relatively innocuous metabolites and to have a high degree of both water and lipid solubility, resulting in good systemic absorption after oral administration [44]. US patents protecting the compound were published in 1974 and 1975 [47], and there is an earlier German patent (1971) describing its synthesis [48]. Bupropion, like amitriptyline, produced a dose-dependent prevention of tetrabenazine-induced sedation in mice [43]. It also prevented tetrabenazine-induced
OH Cl
H N
Cl
H3C
CH3 H3C CH3
Figure 2.14 3,4-Dichlorophenyl-N-tert-butylaminopropanol.
2.4 Bupropion
blepharospasm and fall in rectal temperature, and it corrected the hunched posture characteristic of tetrabenazine action [43]. In addition, like amitriptyline, it markedly antagonized the 6 C drop in rectal temperature seen after reserpine, and was not a locomotor stimulant in mice [43]. Unlike amitriptyline, bupropion antagonized the intense motor activity produced by dextroamphetamine in mice [43]. Bupropion did not inhibit monoamine oxidase; it was approximately 60-fold less potent than amitriptyline as an inhibitor of norepinephrine uptake in rat hypothalamus synaptosomes (IC50 ¼ 6.5 mM) whereas it was 20-fold more potent than amitriptyline as an inhibitor of dopamine uptake in striatal synaptosomes (IC50 ¼ 3.4 mM) [43]. It had little effect on 5-HT uptake in concentrations as high as 10 mM [43]. Bupropion is chiral and it has been separated into its two enantiomers [49]. No significant differences were found [49] in the activities in the tetrabenazine-induced sedation model in mice or in the uptake of norepinephrine and dopamine into synaptosomes. However, the enantiomers are not very stable and the racemization half-life for the ()enantiomer, under physiological conditions (pH 7.6), was suggested to be approximately 44 min [49]. A phase I clinical study in 12 healthy subjects revealed no differences from lactose and it was concluded [50] that bupropion, at the doses studied (of 50 and 100 mg), was devoid of stimulant or sedative properties, or cardiovascular effects. Bupropion was approved by the US Food and Drug Administration (FDA) as an antidepressant on December 30, 1985 and marketed under the name of WellbutrinÔ. However, a significant incidence of seizures at the originally recommended dosage (400–600 mg) caused the drug to be withdrawn in 1986. Subsequently, the risk of seizures was found to be highly dose dependent, and bupropion was reintroduced to the market in 1989 with a maximum recommended dose of 450 mg/day. A sustained release formulation was approved by the FDA in 1996 and has been used clinically to treat depression. Placebo-controlled double-blind studies have confirmed the efficacy of bupropion for clinical depression [51]. Furthermore, available clinical data suggest that bupropion is an effective and generally welltolerated option in the treatment of major depressive disorder [52]. Perhaps then, bupropion should not be regarded as a standalone drug, although its mechanism of action appears to be different from other antidepressant drugs; like other antidepressants, its actions involve biogenic amine transmission, but it exerts a different combination of effects on biogenic amines. Bupropion is, however, the first non-nicotine medication to gain approval as an aid to smoking cessation and it was placed on the market for this purpose in 1997 under the name ZybanÔ. This use arose from finding that smokers who were taking bupropion (as Wellbutrin) as antidepressant medication found that they had a reduced desire or craving to smoke cigarettes [53]. It is administered in 150 mg doses in a sustained release formulation twice daily and reduces the severity of nicotine cravings and withdrawal symptoms. The treatment course lasts for 7 to 12 weeks with the patient halting the use of tobacco about 10 days into the course. The efficacy of bupropion is reported to be similar to that of nicotine replacement therapy [54].
j41
j 2 Standalone Drugs
42
N HN N Figure 2.15 Varenicline.
Bupropion has, however, been joined by another product on the market since 2006, when Pfizer launched varenicline (Figure 2.15) as ChantixÔ in the United States and ChampixÔ in Europe. Varenicline acts by a different mechanism since it is an a4b2 nicotinic acetylcholine receptor partial agonist [55]. Both drugs, bupropion and varenicline, now have black box warnings from the US FDA (July 2009) [56] to highlight the risk of serious mental health side effects including depression, hostility, and suicidal thoughts. The suicide aspect seems to be much worse for varenicline that, since its approval in 2006, is reported to have been associated with 98 suicides and 188 attempts. Bupropion, since 1997, has been associated with 14 suicides and 17 attempts.
2.5 Ezetimibe
High plasma concentrations of low-density lipoprotein-cholesterol (LDL-C) are known to play an active role in the development of atherosclerotic coronary heart disease. The latter being a major cause of death and cardiovascular morbidity in the Western world. For this reason, much effort has been expended in seeking to reduce the serum cholesterol levels by drug treatment. The two significant sources for cholesterol are endogenously synthesized cholesterol and dietary cholesterol. Early discoveries found ways to reduce the equilibrium level of cholesterol. Cholestyramine and colestipol, for example, are basic anion exchange resins that sequester bile acids in the gastrointestinal tract to prevent reabsorption. The sequestered bile acids are then excreted, which results in plasma cholesterol being converted into bile acids to normalize the bile acid levels. This conversion of cholesterol lowers the plasma concentration of LDL-C. Clofibrate, and the various other fibrates that followed, reduces the plasma triglyceride concentrations. In most patients, plasma cholesterol and LDL-C concentrations also fall. The fibrates were subsequently shown to be agonists of the PPAR-a receptor (peroxisome proliferator-activated receptors that modulate carbohydrate and fat metabolism). The statins are specific inhibitors of hydroxymethylglutaryl coenzyme A (HMGCoA) reductase that were introduced into clinical practice in the 1980s. In low doses, the statins exerted a relatively selective effect on hepatic cholesterol synthesis. As the statins became established, their potencies, or dose levels, were increased in order to have a more profound effect on lowering of the LDL-C levels seen in the blood [57]. However, this gave rise to an increased incidence of such an unwelcome side effect as rhabdomyolysis especially when used in combination with fibrates.
2.5 Ezetimibe
Cholesterol absorption inhibitors have been described [58a] by scientists at Pfizer. These are synthetic saponins, tigogenin cellobiosides, tiqueside, and pharmaqueside. The latter was stated in 2002 to be in phase III clinical trials for the treatment of hypercholesterolemia, but further results do not appear to have been reported. Other efforts to inhibit the absorption of dietary cholesterol focused on the inhibition of Acyl-CoA:cholesterol acyltransferase (ACAT), the major enzyme associated with cholesterol esterification. Inhibition of this enzyme blocks absorption of intestinal cholesterol. As part of a broad chemical program to discover novel ACAT inhibitors [58b], scientists at Schering-Plough Research Institute (in Kenilworth, NJ, USA) investigated the synthesis and in vivo testing of conformationally restricted compounds related to two known chemical classes of ACAT inhibitors, namely, SA 58035 and CI 976 (Figure 2.16). Burnett et al. describe [58b] bridging of the two carbon atoms of the ethyl linkage and the nitrogen atom in SA 58035 by using 2-azetidinone containing two phenyl groups. The desired compound A was not active, but a secondary compound B, arising from acylation, did show some activity, pariculary in vivo. The latter provided an initial lead that was followed up and, by analogy with their previous work in ACAT, methoxy groups were introduced. This work eventually led to the first drug candidate, the chiral trans-azetidinone SCH 48461, for development (Figure 2.17). Surprisingly there was a strong divergence between the in vitro ACAT assay (measuring inhibition of the esterification of cholesterol with oleic acid) and the in vivo test that measured the inhibition of the rise in plasma cholesterol levels in cholesterol-fed hamsters. These results suggested the existence of another mechanism of action and further work suggested that it was novel and upstream from ACAT. Furthermore, SCH 48461 was shown to reduce serum cholesterol in human clinical trials [59]. The above findings led to abandonment of the in vitro assay. Having to rely only on an in vivo assay made it difficult to separate potential effects on intrinsic potency from effects on pharmacokinetics. This was especially difficult since SCH 48461 was extensively metabolized in vivo, making it unclear as to exactly what was the active species. Van Heeck et al. [60a] describe that an experimental protocol was devised to determine whether there were active metabolites and how they might contribute to the in vivo profile of SCH 48461. The studies revealed the rapid appearance of a complex metabolic mixture in the bile, which was more potent as an inhibitor of
O
CH3(CH2)9 Me
SiMe2(C10H21)
HN O
OMe
HN MeO
SA 58035 Figure 2.16 ACAT inhibitors.
CI 976
OMe
j43
j 2 Standalone Drugs
44
PhCH2 CO
N
N
O
O
OMe
OMe
compound B
compound A
OMe
OH OH
F N
N
O
O
OMe
F
SCH 48461
SCH 58235 (ezetimibe)
Figure 2.17 Compounds leading to ezetimibe.
cholesterol absorption. Rosenblum et al. listed [60b] the putative sites of metabolism of SCH 48461, as shown in Figure 2.18, and directed their synthesis effort to making the most probable metabolites for testing. Their results led them inter alia to introduce two hydroxyl groups as metabolic products and two fluorine atoms to block metabolism sites (Figure 2.19). The result was the compound SCH 58235, ezetimibe [61], which was reported to be 50 times more potent than SCH 48461 in the
demethylation benzylic oxidation
OMe
N
demethylation
O pendant phenyl oxidation
OMe ring opening
Figure 2.18 Putative sites of metabolism of SCH 48461.
2.5 Ezetimibe
dealkylated stereoselectively oxidized
OH OH F N O F oxidation blocked
oxidation blocked Figure 2.19 Design of (SCH 58235) ezetimibe.
cholesterol-fed hamster assay. This result provides an impressive story of serendipitous discovery of a drug working by a novel mechanism, together with outstanding integration of synthetic and medicinal chemistry with metabolic and pharmacological studies, to make a potent therapeutic product. The discovery of ezetimibe led to a 10-year search for its mechanism of action. The researchers at Schering-Plough showed [62] that Niemann-Pick C1-Like 1 (NPC1L1) protein plays a critical role in the absorption of intestinal cholesterol across the plasma membrane of the intestinal enterocyte. This protein is believed to be a molecular target [63] of ezetimibe. By inhibiting cholesterol absorption at the level of the brush border of the intestine, ezetimibe reduces the amount of lipoprotein cholesterol circulated to the liver. In response to reduced cholesterol delivery, the liver reacts by upregulating LDL-C receptor that, in turn, leads to increased clearance of cholesterol from the blood [64]. Ezetimibe is marketed as a 10 mg tablet under the name ZetiaÔ and is also available in combination with simvastatin; it has also been approved for a combination with fenofibrate. Ezetimibe is a standalone product as, so far, there are no analogues yet available, probably because the mechanism of action was published only in 2005. Thus, this remarkable example of drug discovery started out as an attempt to make an analogue of leads that, though characterized pharmacologically, had not yet yielded a clinically useful product. A serendipitous discovery of a different mechanism of action led to the characterization of a previously unknown mechanism of cholesterol uptake and the clever design of a very potent candidate drug. This work represents a true breakthrough in the search for drugs that reduce the intake of dietary cholesterol and provides an outstanding example of analogue-based drug research leading to the discovery of a pioneer drug.
j45
j 2 Standalone Drugs
46
2.6 Lamotrigine
Lamotrigine (Figure 2.20) is a widely used anticonvulsive agent. Its predominant indication is in the treatment of epilepsy and bipolar disorder [65, 66]. The discovery process was partly serendipitious, based on the observation that folic acid produces epileptogenic foci and that antiepileptic drugs such as phenytoin, phenobarbital, and carbamazepine have antifolate properties [67, 68]. Thus, a correlation between antiepileptic and antifolate properties was assumed. A series of aminotriazine compounds was prepared by chemists at Wellcome in the United Kingdom as potential antifolate agents. Lamotrigine was the lead from this series and was first disclosed in a 1981 patent. The patent reports significant anticonvulsant activity with an ED50 of 2.4 mg/kg in mice by oral administration [69]. Nevertheless, the compound had little effect on folate levels, and subsequent work confirmed that the original hypothesis linking folates and antiepileptics was misguided. In vitro studies demonstrated that lamotrigine primarily acts as a blocker of voltage-sensitive sodium ion channels [70]. The promising activity and tolerability of lamotrigine led to its progression to clinical studies, with phase I studies confirming its safety and potential superiority to established drugs such as phenytoin and diazepam [71]. Lamotrigine was first approved in 1994 as an antiepileptic drug for the treatment of partial seizures. Lamotrigine is the only medication besides topiramate used in the treatment of seizures associated with Lennox–Gastaut syndrome, a severe form of epilepsy. Following its widespread use as an antiepileptic, it was noticed that patients reported higher levels of happiness and mastery, or perceived internal locus of control, independent of seizure control [72]. This led to investigation of lamotrigine as an antipsychotic and it received approval in 2003 for the treatment of bipolar I disorder, the first drug to do so since lithium. In addition, off-label uses of lamotrigine include the treatment of peripheral neuropathy, migraines, borderline personality disorder, and refractory unipolar depression. Lamotrigine has virtually complete bioavailability with no first-pass effect. It is 55% bound to plasma proteins and reaches a peak plasma concentration in 2.5 h. The halflife in healthy adults is 24–35 h, with clearance primarily as the glucuronide conjugate in urine. Metabolism by uridine diphosphate glucuronyl transferases is competitive and susceptible to drug–drug interactions. However, lamotrigine does not induce cytochrome P-450 isozymes and thus does not affect plasma levels of other Cl Cl N H2N
NH2 N N
Figure 2.20 Lamotrigine.
2.7 Metformin
Cl Cl
Cl
N H2N
NH2 N
Figure 2.21 JZP-4.
medications. It is a well-tolerated drug, with skin rash being the most common side effect with an incidence of 5–10%. Other side effects include headaches, dizziness, and insomnia. The pharmacodynamics of lamotrigine may be more complex than its action on sodium channels, as its side-effect profile is different from other drugs such as oxcarbazepine that act on sodium channels [73]. Overall, lamotrigine acts as a mood stabilizer and inhibits the release of excitatory amino acid neurotransmitters such as aspartate and glutamate. The standalone status of lamotrigine has recently been challenged by a compound, elpetrigine, from GlaxoSmithKline (Figure 2.21). The switch from triazine to pyrazine and from dichloro- to trichlorophenyl results in increased potency for sodium and calcium channels, and potential reduction of the dermatological side effects [74, 75]. Elpetrigine is currently in clinical development, with phase I trials completed.
2.7 Metformin
Metformin is the most widely used oral hypoglycemic agent. It is the first-line drug for the treatment of type 2 diabetes and the only oral antidiabetic besides glibenclamide in the World Health Organization Model List of Essential Medicines [76]. Unusually for a drug molecule, it is a simple biguanide in structure and has more nitrogen than carbon atoms. The discovery can be traced back to medieval times, when extracts of the French lilac Galega officinalis were used to treat the frequent and painful urination accompanying diabetes mellitus [77]. The active constituent was later identified as galegine or isoprenylguanidine (Figure 2.22). Guanidine itself was shown by Watanabe to be elevated in the blood following removal of the parathyroid gland and suggested as the reason for decreased blood sugar levels following
HN
H N NH2 galegine
HN
NH2 NH2
guanidine
Figure 2.22 First antidiabetic guanidines.
j47
j 2 Standalone Drugs
48
NH2
H N
HN
N H
NH2
Synthalin NH2
H N
HN
NH
N H
NH2
NH
Synthalin B
Figure 2.23 First marketed antidiabetic guanidine derivatives.
parathyroidectomy [78]. In supporting animal studies, rabbits injected with guanidine show a fall in blood sugar levels. Guanidine was too toxic for therapeutic use, while galegine was less so, and extracts of G. officinalis were briefly used as an antidiabetic in the early 1920s. These observations stimulated interest in the evaluation of guanidine derivatives, particularly diguanidines and biguanides. Frank at the University of Breslau prepared a series of diguanidines separated by a methylene chain. These compounds were more potent and less toxic than the monoguanidines [79]. From this series, Synthalin (Figure 2.23) progressed to clinical trials in 1926 and was marketed by Schering AG for the treatment of mild diabetes. Reports of adverse effects led to the introduction of Synthalin B with a longer methylene chain as a safer alternative. Nevertheless, both compounds were withdrawn in the 1940s due to potential liver and kidney toxicity. Meanwhile, depression of blood sugar levels was inhibitory to the reproduction of trypanosomes and Synthalin was found to have trypanocidal activity. This eventually led to the discovery of the amidine drugs stilbamidine and pentamidine, still in use for the treatment of trypanosomiasis and other protozoal infections. At the University of Vienna, Slotta and Tschesche reported a series of biguanides, including metformin, with hypoglycemic activity [80]. The compounds were nontoxic in animals, but these studies were not extended to humans and essentially forgotten for decades with the introduction of insulin. In the 1950s, Jean Sterne a physician at the Hospital Laennec and Aron Laboratories in Paris independently investigated biguanides as antidiabetic agents and selected metformin (Figure 2.24) for clinical development, naming it Glucophage (glucose eater) [81]. Simultaneously, the US Vitamin Corporation had examined a series of biguanides, from which phenformin emerged as the clinical candidate [82]. A year later, Mehnert in Germany reported studies with buformin [83].
NH Me
N Me
NH
N H
metformin
NH 2
NH N H
N H
NH NH 2
phenformin
Figure 2.24 Metformin and its withdrawn derivatives.
NH N H
NH
N H
buformin
NH 2
2.8 Topiramate
SAR studies with biguanides indicate that hypoglycemic activity is lost if more than one nitrogen is substituted. Among mono- and disubstituted biguanides, chains longer than five atoms were not tolerated. Despite extensive investigation, the precise mechanism of action of biguanides remains unknown. They do not increase insulin production in either the fasting or postprandial state. The primary effect of metformin is inhibition of gluconeogenesis in the liver, and increased glucose uptake across the cell membrane in peripheral tissues. A number of molecular targets have been proposed, although separating the primary effector from downstream consequences of glucose regulation is complicated. Phenformin and buformin were the first biguanides to receive clinical approval due to their greater potency than metformin [84]. Lactic acidosis is the most serious side effect of biguanides. It is more pronounced with phenformin and buformin than metformin, probably due to decreased metabolism of the alkyl chain in some patients leading to prolonged drug exposure. Both phenformin and buformin were withdrawn from the market in most countries in the 1970s, leading to renewed interest in metformin. Clinical studies demonstrated that metformin is unique in having antihyperglycemic activity without causing overt hypoglycemia or weight gain unlike sulfonylureas or insulin. Furthermore, the drug is still efficacious in cases of insulin resistance. Metformin was first marketed in France in 1979 by Lipha, now Merck, that had acquired Aron Laboratories and later received FDA approval in 1994. Metformin has 50–60% oral bioavailability with negligible binding to plasma proteins. Its plasma half-life is estimated at 1.5–4.9 h, reaching a peak concentration 1–2 h after oral dosing. Metformin does not undergo significant metabolism, and is excreted intact in urine. The most serious potential side effect is lactic acidosis, and for this reason it is contraindicated in patients with impaired liver or kidney function. Lactic acidosis is believed to be an on-target effect as metformin inhibits gluconeogenesis, the pathway by which lactate buildup is normally prevented by conversion to glucose. The most common adverse effect is gastrointestinal upset, which is rare upon prolonged steady use of the drug. In addition to antidiabetic therapy, metformin is under investigation for other diseases that feature insulin resistance such as polycystic ovary syndrome, nonalcoholic fatty liver disease, and premature puberty. The favorable effects of metformin in lowering blood pressure, serum triglycerides, total cholesterol, and low-density lipoprotein-cholesterol suggest that it is beneficial for the treatment of cardiovascular disease. Metformin has a remarkable history in terms of its discovery. The compound was first prepared in 1922 but did not receive approval for more than 50 years. Since then, it has become established as the first-line drug for the treatment of type 2 diabetes and is likely to be useful for additional therapeutic indications.
2.8 Topiramate
Topiramate (Figure 2.25) was identified in the early 1980s as an anticonvulsant agent in a pharmacological model that measures the ability of compounds to prevent
j49
j 2 Standalone Drugs
50
O O S O NH2
O O
O O
O
topiramate
O O S O NH2
O O O S O O
H N
NH2 S O O
O O
RWJ 37947
H N
NH2 S O O
S JNJ-26990990
benzylsulfamide
Figure 2.25 Topiramate and related compounds.
maximal electroshock seizures in mouse [85, 86]. Structurally, it bears no resemblance to previously used anticonvulsant agents and was originally synthesized as a chemical intermediate during a program to identify inhibitors of fructose-1,6bisphosphatase as potential antidiabetic agents [87, 88]. In combination with the sulfamate functionality, which appears to be essential for activity, many variations on the scaffold are tolerated. These range from relatively simple phenylethyl groups to the rather sophisticated sugar-derived core of topiramate itself. The key publication on the discovery process emphasizes the importance of oral bioavailability, duration of action, and minimal neurotoxicity as important features in the selection of the drug for clinical development [85]. Topiramate is generally used in patients who are unresponsive to other anticonvulsant medications or is used in combination with other anticonvulsants to treat intractable seizures. Topiramate has also been approved for the prophylactic treatment of migraine headaches in some countries and this is now the most common use. Topiramate is a structurally unique anticonvulsant agent. There are no former abandoned analogues. Topiramate displays the following actions related to seizure reduction: (a) antagonism of the AMPA/kainate subtype of the glutamate receptor, (b) blockage of voltage-dependent sodium channels in nerve cells, decreasing excessive nerve-cell firing, (c) increase in the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor [89]. Topiramate also inhibits carbonic anhydrase, particularly isozymes II and IV. The relation of this activity to seizure reduction is unclear although recent patent applications covering topiramate analogues indicate that reduction of carbonic anhydrase activity could be beneficial in decreasing side effects seen with topiramate, such as paresthesia. Because there is so far no single clear mechanism of action that links to the pharmacological effects, a target-based screening approach to the identification of new pharmacological analogues is not applicable. A number of publications and patents from the original discovery group have appeared and some more potent analogues of topiramate have been disclosed [90, 91]. These efforts employed the same pharmacological models as in the original discovery. One analogue from these efforts, RWJ 37947, a cyclic sulfate analogue of topiramate, reportedly entered development, but no new information on this compound has appeared since 2002. A recent report on the design of additional topiramate analogues [92] indicates that the high potency of this compound against
2.9 Valproate
j51
carbonic anhydrase enzymes was thought likely to lead to undesirable side effects in certain patients and prevented its further development. Two recent patents and one publication disclose analogues, such as JNJ-26990990 (Figure 2.25), which bear some resemblance to the structural motifs in the original manuscript on topiramate [92–94]. A full report that details the optimization process leading to this clinical candidate has appeared. The switch to a sulfamide series was motivated by a desire to generate topiramate analogues with andiabetic and antiobesity effects but devoid of anticonvulsant activity. However, subsequent screening of these sulfamides with simplified structures revealed promising anticonvulsant activity. JNJ-26990990 in particular shows broad-spectrum activity in a number of seizure models and is only a very weak inhibitor of carbonic anhydrase enzymes. JNJ26990990 entered phase II clinical trials in October 2007. Somewhat analogous anticonvulsants, such as benzylsulfamide (Figure 2.25), have also been discovered from a pharmacophore-based design approach, but they appear not to have progressed to clinical development [95] (Figure 2.25).
2.9 Valproate
The usefulness of valproic acid (Figure 2.26) as an anticonvulsant was made as a serendipitous discovery [96, 97] during the investigation of khelline derivatives as potential anticonvulsants. After finding it difficult to dissolve some derivatives in common organic solvents, a suggestion led to the use of valproic acid as a solubilizer. Anticonvulsant activity was observed in all the samples and valproic acid itself was found to be the anticonvulsant agent. The initial human epilepsy trials were reported in 1964 followed by first approval in France in 1967. Valproate is a widely used anticonvulsant agent because of its activity against different types of seizures. It is also approved for the treatment of acute and chronic migraine and for mania. Valproic acid is a pioneer drug, that is, the first of its class to reach the market. There are no former or previously used analogues. Valproic acid is associated with significant side effects such as reproductive dysfunction and teratogenicity, and there is interest in developing improved analogues [98]. A number of structurally similar compounds have a valproate-like profile in animal seizure models. Valpromide, the amide derivative of valproic acid, is slightly more potent in animal models and is rapidly transformed to valproate in man,
O
O
O OH
NH2
O NH2
NH2 F
valproic acid
valpromide
Figure 2.26 Valproic acid and related compounds.
valnoctamide
j 2 Standalone Drugs
52
essentially acting as a prodrug. It is marketed as an antiepileptic drug and antipsychotic agent in Europe. Valnoctamide, a metabolically stable analogue of valpromide, has been marketed as an anxiolytic and sedative since the mid-1960s. It also exhibits greater anticonvulsant potency than valproate in animal models and is significantly less embryotoxic than valproic acid; however, its usefulness as an antiepileptic in man remains to be determined. Recently, a constrained cyclopropane analogue of valpromide (Figure 2.26) was reported to have superior activity in the MES models used in the discovery of vaproate and topiramate [99]. Since the broad spectrum of utility of valproic acid probably arises from its diverse actions at the molecular level, a target-based screening approach to the identification of pharmacological analogues remains problematic.
2.10 Summary
Nearly every drug has one or more analogues, which are similar to the original drug both in their structures and in their pharmacological mechanism of action (full analogues) or their similarity is restricted to the pharmacological mechanism of action (pharmacological analogues). We analyzed the Top 100 most frequently used drugs based on their sales data in 2006 and, interestingly, their value amounted to 51% of the global sales of all drugs, which indicates their importance. Among these 100 drugs, 9 standalone drugs were identified, that is, compounds that are pioneer drugs for which there are no effective analogues. In this chapter, we have described the serendipitous discovery of these standalone drugs and the past and present efforts to design analogues that would improve upon their properties. Six standalone drugs, namely, acetaminophen, bupropion, lamotrigine, metformin, topiramate, and valproate, have no clear mechanism of action. They display some weak in vitro activities; however, there is no proven correlation between these in vitro activities and their pharmacological properties in animals. Acetylsalicylic acid is a selective irreversible COX-1 inhibitor, but in a higher dosage it loses its selectivity. Aripiprazole is a partial agonist of the D2/3 receptors, but other targets (5-HT2A, 5-HT2B) may also play a role in its in vivo activity. The mechanism of action of ezetimibe was discovered only recently (2005). Elucidation of the mechanism of action and serendipitous observations may lead to new useful analogues of these standalone drugs.
Acknowledgment
We thank Duane Burnett, William Greenlee, and Bruce E. Maryanoff for carefully reading and reviewing the manuscript.
References
References 1 Cahn, A. and Hepp, P. (1886) Das
2
3
4 5
6
7
8
9
10
11
12
13
antifebrin, ein neues fiebermittel. Centralbl. Klin. Med., 7, 561. US Food and Drug Administration ordered the withdrawal of drugs containing phenacetin in 1983. von Mering, J. (1893) Beitr€age zur kenntnis der antipyretica. Ther. Monatsch., 7, 577–587. Lester, D. and Greenberg, L.A. (1947) J. Pharm. Exp. Ther., 90, 68. Flinn, F.B. and Brodie, B.B. (1948) The effect on the pain threshold of N-acetyl p-aminophenol. A product derived in the body from acetanilide. J. Pharm. Exp. Ther., 94, 76. Brodie, B.B. and Axelrod, J. (1948) The fate of acetanilide in man. J. Pharm. Exp. Ther., 94, 29–38. H€ ogest€att, E.D., Jonsson, B.A., Ermund, A., Andersson, D.A., Bjork, H., Alexander, J.P., Cravatt, B.F., Basbaum, A.I., and Zygmunt, P.M. (2005) Conversion of acetaminophen to the bioactive Nacylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic conjugation in the nervous system. J. Biol. Chem., 280, 31405–31412. Ottani, A., Leone, S., Sandrini, M., Ferrari, A., and Bertolini, A. (2006) The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur. J. Pharmacol., 531 (1–3), 280–281. Hinz, B., Cheremina, O., and Brune, K. (2008) Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J., 22, 383–390. Thomas, S.H. (1993) Paracetamol (acetaminophen) poisoning. Pharmacol. Ther., 60, 91–120. Wallace, J.L. (2004) Acetaminophen hepatotoxicity: NO to the rescue. Br. J. Pharmacol., 143, 1–2. Bessems, J.G.M. and Vermeulen, N.P.E. (2001) Paracetamol(acetaminophen)induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit. Rev. Toxicol., 31, 55–138. Nelson, S.D., Forte, A.J., and McMurtry, R.J. (1978) Decreased toxicity of the
14
15
16
17
18
19
20
21
22
23
24
N-methyl analogues of acetaminophen and phenacetin. Res. Commun. Chem. Pathol. Pharmacol., 22 (1), 61–71. Vaccarino, A.L., Paul, D., Mukherjee, P.K., Rodrigez de Turco, E., Marcheselli, V.L., Xu, L., Trudell, M.L., Minguez, J.M., Matia, M.P., Sunkel, C., Alvarez-Builla, J., and Bazan, N.G. (2007) Bioorg. Med. Chem., 15, 2206–2215. Sinning, C., Watzer, B., Coste, O., N€ using, R.M., Ott, I., Ligresti, A., Di Marzo, V., and Imming, P. (2008) New analgesics synthetically derived from paracetamol metabolite N-(4-hydroxyphenyl)(5Z,8Z,11Z,14Z)-icosatetra5,8,11,14-enamide. J. Med. Chem., 51 (24), 7800–7805. Schmid, B., K€otter, I., and Heide, L. (2001) Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. Eur. J. Clin. Pharmacol., 57, 387–391. Piria, R. (1839) Recherches sur la salicine et les produits qui en derivent. C.R. Acad. Sci. (Paris), 8, 479–485. Maclagan, T. (1876) The treatment of rheumatism by salicin and salicylic acid. Br. Med. J., 1, 627. Kolbe, H. (1860) Über die synthese der salicyls€aure. Ann. Chem. Pharm., 113, 125–127. Stricker, S. (1876) Über die resultate der bahandlung der polyathritis rheumatica mit salicyls€aure. Berl. Klin. Wochenschr., 13, 1–2, 15–16, 99–103. Vane, J.R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 231, 232–235. Milton, A.S. and Wendlandt, S. (1970) A possible role for prostaglandin E1 as a modulator of temperature regulator in the central nervous system of the cat. J. Physiol., 207, 76–77. Di Rosa, M., Giroud, J.P., and Willoughby, D.A. (1971) Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenin and turpentine. J. Physiol., 104, 15–29. Hemler, M. and Lands, W.E.M. (1976) Purification of the cyclooxygenase that
j53
j 2 Standalone Drugs
54
25
26
27 28
29
30
31
32
33
34
forms prostaglandins. J. Biol. Chem., 251, 5575–5579. Roth, G.J. and Majerus, P.W. (1975) The mechanism of the effect of aspirin on human platelets: 1. Acetylation of a particulate fraction protein. J. Clin. Invest., 56, 624–632. Xie, W., Chipman, J.G., Robertson, D.L., Erikson, R.L., and Simmons, D.L. (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Sci. USA, 88, 2692–2696. Schr€or, K. (2009) Acetylsalicylic Acid, Wiley-Blackwell, p. 35. Smith, J.B. and Willis, A.L. (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature, 231, 235–237. Moriarty, L.M., Lally, M.N., Carolan, C.G., Jones, M., Clancy, J.M., and Gilmer, J.F. (2008) Discovery of a True aspirin prodrug. J. Med. Chem., 51, 7991–7999. Lewis, D.A. and Lieberman, J.A. (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron, 28, 325–334. Charpentier, P., Gaillot, P., Jacob, R., Gaudechon, J., and Buisson, P. (1952) Recherches sur les dimethylaminopropylN-phenothiazines substituees. Comptes Rendus de lAcademie des Sciences, 235, 59–60. Courvoisier, S., Fournel, J., Ducrot, R. et al. (1953) Proprietes pharmacodynamiques du chlorhydrate de chloro-(3dimethylamino-30 -propyl)-10phenothiazine (4560 R.P.). Arch. Int. Pharmacodyn., 92, 305. Janssen, P.A.J., Van deWesteringh, C., Jagneau, A.W.M., Demoen, P.J.A., Hermans, B.K.F., Van Daele, G.H.P., Schelleck, K.H.L., Van der Eycken, C.A.M., and Niemegerm, C.J.E. (1959) Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-4phenylpiperidino)butyrophenone. Part I. Synthesis and screening data in mice. J. Med. Pharm. Chem., 1, 281–287. Schmutz, J. and Eichenberger, E. (1982) Chronicles of Drug Discoveries, vol. 1 (eds J.S. Bindra and D. Lednicer), John Wiley & Sons, Inc., New York, pp. 39–60.
35 Wooley, D.W. and Shaw, E. (1954) A
36
37
38
39
40
41
42
biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. USA, 40, 228. Carlsson, A. and Lindquist, M. (1963) Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol., 20, 140–144. Kebabian, J.W. and Calne, D.B. (1979) Multiple receptors for dopamine. Nature, 277, 93. Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., and Carlsson, M.L. (2001) Interaction between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol., 41, 237–260. Banno, K., Fujioka, T., Kikuchi, T., Oshiro, Y., Hiyama, T., and Nakagawa, K. (1988) Studies on 2(1H)-quinolone derivatives as neuroleptic agents. I. Synthesis and biological activities of (4-phenyl-1piperazinyl)-propoxy-2(1H)-quinolone derivatives. Chem. Pharm. Bull., 36 (11), 4377–4388. Oshiro, Y., Sato, S. Kurahashi, N., Tanaka, T., Kikuchi, T., Tottori, K., Uwahodo, Y., and Nishi, T. (1198) Novel antipsychotic agents with dopamine autoreceptor agonist properties; synthesis and pharmacology of 7-[4-(4-phenyl-1piperazinyl)butoxy]-3,4-dihydro-2(1H)quinolone derivatives. J. Med. Chem., 41, 658–667. Williams, M.A. (2004) A return to the fundamentals of drug discovery. Curr. Opin. Invest. Drugs, 5, 29–33. Butini, S., Gemma, S., Campiani, G., Franceschini, S., Trotta, F., Borriello, M., Ceres, N., Ros, S., Coccone, S.S., Bernetti, M., De Angelis, M., Brindisi, M., Nacci, V., Fiorini, I., Novellino, E., Cagnotto, A., Mennini, T., Sandager-Nielsen, K., Andreasen, J.T., Scheel-Kruger, J., Mikkelsen, J.K., and Fattorusso, C. (2009) Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J. Med. Chem., 52, 151–169.
References 43 Soroko, F.E., Mehta, N.B., Maxwell, R.A.,
44
45
46
47
48
49
50
51
52
53
Ferris, R.M., and Schroeder, D.H. (1977) Bupropion hydrochloride (() a-tbutylamino-3-chloropropiophenone HCl): a novel antidepressant agent. J. Pharm. Pharmacol., 29, 767–770. Mehta, N.B. (1983) The chemistry of bupropion. J. Clin. Psychiatry, 44 (Sec 2), 56–59. Sulser, F. and Soroko, F.E. (1965) On the role of brain norepinephrine release in the antibenzoquinolizine actions of desipramine. Psychopharmacolgy, 8, 191–200. Baltzly, R. and Mehta, N.B. (1968) N-sec and N-t-alkyl derivatives of methoxamine and related compounds. J. Med. Chem., 11, 833–844. Mehta, N.B. (1974) Meta-chloro substituted a-butylaminopropiophenones. US Patent 3,819,706 to Burroughs Wellcome Co.; US Patent 3,885,046 (1975). Mehta, N.B. and Yeowell, D.A. (1971) German Patent 2,059,618 to Wellcome Foundation. Musso, D.L., Mehta, N.B., Soroko, F.E., Ferris, R.M., Hollingsworth, E.B., and Kenney, B.T. (1993) Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion. Chirality, 5, 495–500. Peck, A.W., Bye, C.E., Clubley, M., Henson, T., and Riddington, C. (1979) A comparison of bupropion hydrochloride with desamphetamine and amitriptyline in healthy subjects. Br. J. Clin. Pharmacol., 7, 469–478. Fava, M., Rush, A.J., Thase, M.E., Clayton, A., Stahl, S.M., Pradko, J.F., and Johnston, J.A. (2005) 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim. Care Companion J. Clin. Psychiatry, 7, 106–113. Dhillon, S., Yang, L.P., and Curran, M.P. (2008) Bupropion: a review of its use in the management of major depressive disorder. Drugs, 68, 653–689. Tonneson, P., Tonstad, S., Hjalmarson, A., Lebargy, F., Van Spiegel, P.I., Hider, A., Sweet, R., and Townsend, J. (2003) A multicentre randomized double-blind, placebo-controlled 1 year study of
54
55
56
57
58
59
bupropion SR for smoking cessation. J. Intern. Med., 254, 184–192. Wu, P., Wilson, K., Dimoulas, P., and Mills, E.J. (2006) Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health, 6, 300–315. Jorenby, D.E., Hays, J.T., Rigotti, N.A., Azoulay, S., Watsky, E.J., Williams, K.E., Billing, C.B., Gong, J., and Reeves, K.R. (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA, 296, 56–63. Osterwell, N. (2009) Chantix and Zyban to receive boxed warnings for serious neuropsychiatric symptoms. Medscape Med. News, http://www.medscape.com/ viewarticle/705163. Kerpel-Fronius, S. and Fischer, J. (2006) Optimizing the clinical pharmacologic properties of the HMG-CoA reductase inhibitors, Chapter 4, in Analogue-Based Drug Discovery (eds J. Fischer and C.R. Ganellin), IUPAC, Wiley-VCH Verlag GmbH, Weinheim, pp. 137–156. (a) McCarthy, P.A., DeNinno, M.P., Morehouse, L.A., Chandler, C.E., Bangerter, F.W., Wilson, T.C., Urban, F.J., Walinsky, S.W., Cosgrove, P.G., Duplantier, L., Etienne, J.B., Fowler, M.A., Lambert, J.F., ODonnell, J.P., Pezzullo, S.L., Watson, H.A., Wilkins, R.W., Jr., Zaccaro, L.M., and Zawistoski, M.P. (1996) 11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster. J. Med. Chem., 39, 1935–1937; (b) Burnett, D.A., Caplen, M.A., Davis, H.R., Jr., Burrier, R.E., and Clader, J.W. (1994) 2-Azetidinones as inhibitors of cholesterol absorption. J. Med. Chem., 37, 1733–1736. Bergman, M., Morales, H., Mellars, L., Kosoglou, T., Burrier, R., Davis, H.R., Sybertz, E.J., and Pollare, T. (1995) The clinical development of a novel cholesterol absorption inhibitor. Proceedings of the XII International Symposium on Drugs Affecting Lipid Metabolism, Houston, TX, November 7–10, 1995.
j55
j 2 Standalone Drugs
56
60 (a) Van Heeck, M., France, C.F., Compton,
66 Bhagwagar, Z. and Goodwin, G.M. (2005)
D.S., Mcleod, R.L., Yumibe, N.P., Alton, K.B., Sybertz, E.J., and Davis, H.R., Jr. (1997) In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharmacol. Exp. Ther., 283, 157–163; (b) Rosenblum, S.B., Huynh, T., Afonso, A., Davis, H.R., Jr., Yumibe, N., Clader, J.W., and Burnett, D.A. (1998) Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4fluorophenyl)-(3S)-hydroxypropyl]-(4S)(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem., 41, 973–980. Clader, J.W. (2004) The discovery of ezetemibe: a view from outside the receptor. J. Med. Chem., 47, 1–9. Altmann, S.W., Davis, H.R., Jr., Zhu, L.J., Yao, X., Hoos, L.M., Tetzloff, G., Iyer, S.P., Maguire, M., Golovko, A., Zeng, M., Wang, L., Murgolo, N., and Graziano, M.P. (2004) Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 303, 1201–1204. Garcia-Calvoa, M., Lisnock, J.M., Bull, H.G., Hawes, B.E., Burnett, D.A., Braun, M.P., Crona, J.H., Davis, H.R., Jr., Dean, D.C., Detmers, P.A., Graziano, M.P., Hughes, M., MacIntyre, D.E., Ogawa, A., ONeill, K.A., Iyer, S.A.N., Shevell, D.E., Smith, M.M., Tang, Y.S., Makarewicz, A.M., Ujjainwalla, F., Altmann, S.W., Chapman, K.T., and Thornberry, N.A. (2005) The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA, 102, 8132–8137. Lammert, F. and Wang, D.Q.H. (2005) New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology, 129, 718–734. Choi, H. and Morrell, M.J. (2003) Review of lamotrigine and its applications in epilepsy. Ex. Opin. Pharmacother., 4, 243–251.
Lamotrigine in the treatment of bipolar disorder. Exp. Opin. Pharmacother., 6, 1401–1408. Reynolds, E.H., Chanarin, I., Milner, G., and Matthews, D.M. (1966) Anticonvulsant therapy, folic acid and vitamin B12 metabolism and mental symptoms. Epilepsia, 7, 261–270. Leach, M.J., Marden, C.M., and Miller, A.A. (1966) Anticonvulsant therapy, megaloblastic hematopoeisis and folic acid metabolism. Q. J. Med., 35, 521–537. Baxter, M.G., Elphick, A.R., Miller, A.A., and Sawyer, D.A. (1981) 1,2,4-Triazine derivatives, pharmaceutical compositions and intermediates utilized for their preparation. European Patent 21121. Leach, M.J., Marden, C.M., and Miller, A.A. (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia, 27, 490–497. Cohen, A.F., Ashby, L., Crowley, D., Land, G., Peck, A.W., and Miller, A.A. (1985) Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br. J. Clin. Pharmacol., 20, 619–629. Smith, D., Baker, G., Davies, G., Dewey, M., and Chadwick, D.W. (1993) Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia, 34, 312–322. Leach, M.J., Randall, A.D., Stefani, A., and Hainsworth, A.H. (2002) Lamotrigine: mechanisms of action, in Antiepleptic Drugs, 5th edn (eds R.H. Levy, R.H. Mattson, B.S. Meldrum, and E. Perucca), Lippincott Williams & Wilkins, Philadelphia, pp. 363–369. Foreman, M.M., Hanania, T., Stratton, S.C., Wilcox, K.S., White, S., Stable, J.P., and Eller, M. (2008) In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Pharmacol. Biochem. Behav., 89, 523–534. Foreman, M.M., Hanania, T., and Eller, M. (2009) Anxiolytic effects of lamotrigine and JZP-4 in the elevated plus maze and in
61
62
63
64
65
67
68
69
70
71
72
73
74
75
References
76
77
78
79
80
81
82
83
84
85
86
87
the four plate conflict test. Eur. J. Pharmacol., 602, 316–320. Goodarzi, M.O. and Bryer-Ash, M. (2005) Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obesity Metab., 7, 654–665. Bailey, C.J. and Day, C. (2004) Metformin: its botanical background. Pract. Diabetes Int., 21, 115–117. Watanabe, C.K. (1918) Studies in the metabolism changes induced by administration of guanidine bases. I. Influence of injected guanidine hydrochloride upon blood sugar content. J. Biol. Chem., 33, 253–265. Frank, E., Nothmann, M., and Wagner, A. (1926) Über synthetisch dargestellte K€ orper mit insulinartiger Wirkung auf den normalen und den diabetischen organismus. Klin. Woch., 5, 2100–2107. Slotta, K.H. and Tschesche, R. (1929) Die blutzuckersenkende Wirkung der biguanide. Chem. Ber., 62, 1398–1405. Sterne, J. (1957) Du nouveau dans les antidiabetiques. La N,Ndimethylamineguanyl guanide (N.N.D.G.). Maroc Med., 36, 1295–1296. Ungar, G., Freedman, L., and Shapiro, S.L. (1957) Pharmacological studies of a new oral hypoglycaemic drug. Proc. Soc. Exp. Biol. Med., 100, 190–192. Mehnert, H. and Seitz, W. (1958) Weitere ergebnisse der diabetesbehandlung mit blutzuckersenkenden biguaniden. Munch. Med. Woch., 100, 1849–1851. Schafer, G. (1983) Biguanides: a review of history, pharmacodynamics and therapy. Diabetes Metab. Rev., 9, 148–163. Maryanoff, B.E., Nortey, S.O., Gardocki, J.F., Shank, R.P., and Dodgson, S.P. (1987) Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-betaD-fructopyranose sulfamate and related compounds. J. Med. Chem., 30, 880–887. Maryanoff, B.E. and Gardocki, J.F. (1985) Anticonvulsant sulfamate derivatives, US Patent 4,513,006. Van Passel, L., Arif, H., and Hirsch, L.J. (2006) Topiramate for the treatment of epilepsy and other nervous system disorders. Exp. Rev. Neurother., 6, 19–31.
88 http://www.orangebookblog.com/
Ortho_20motion_20PI.pdf(2006). 89 Rogawski, M.A. (2006) Molecular targets
90
91
92
93
94
95
96
versus models for new antiepileptic drug discovery. Epilepsy Res., 68, 22–28. Maryanoff, B.E., Costanzo, M.J., Shank, R.P., Schupsky, J.J., Ortegon, M.E., and Vaught, J.L. (1993) Anticonvulsant sugar sulfamates. Potent cyclic sulfate and cyclic sulfite analogues of topiramate. Bioorg. Med. Chem. Lett., 3, 2653–2656. Maryanoff, B.E., Costanzo, M.J., Nortey, S.O., Greco, M.N., Shank, R.P., Schupsky, J.J., Ortegon, M.E., and Vaught, J.L. (1998) Structure–activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J. Med. Chem., 41, 1315–1343. Parker, M.H., Smith-Swintosky, V.L., McComsey, D.F., Huang, Y., Brenneman, D., Klein, B., Malatynska, E., White, H.S., Milewski, M.E., Herb, M., Finley, M.F.A., Liu, Y., Lubin, M.L., Qin, N., Iannucci, R., Leclercq, L., Cuyckens, F., Reitz, A.B., and Maryanoff, B.E. (2009) Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies. J. Med. Chem., 52 (23), 7528–7536. Parker, M.H., Reitz, A.B., and Maryanoff, B.E., Preparation of benzo-fused heteroaryl sulfamide derivatives for the treatment of epilepsy and related disorders, WO2006023861(2006). McComsey, D.F., Parker, M.N., Reitz, A.B., and Maryanoff, B.E.,Preparation of sulfamates and sulfamides with oxygen containing ring systems useful for the treatment of epilepsy and related disorders, WO2006007435(2006). Gavernet, L., Barrios, I.A., Sella Cravero, M., and Bruno-Blanchl, L.E. (2007) Design, synthesis, and anticonvulsant activity of some sulfamides. Bioorg. Med. Chem., 15, 5604–5614. Sneader, W. (1995) Drug Prototypes and their Exploitation, John Wiley & Sons, Ltd., Chichester, p. 752.
j57
j 2 Standalone Drugs
58
97 Henry, T.R. (2003) The history of valproate
in clinical neuroscience. Psychopharmacol. Bull., 37 (Suppl. 2), 5–16. 98 Rogawski, M.A. (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res., 69, 273–294.
99 Pessah, N., Bialer, M., Wlodarczyk, B.,
Finnell, R.H., and Yagen, B. (2009) 1Fluoro-2,2,3,3-tetramethylcyclopropane carboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. J. Med. Chem., 52, 2233–2242.
Janos Fischer
Professor, Richter Plc., Gyömro˝i út 19/21, 1103 Budapest, Hungary Janos Fischer is a Senior Research Scientist at Richter Plc., Budapest, Hungary. He received his MSc and PhD degrees in organic chemistry from the Eotvos University of Budapest under Professor A. Kucsman. Between 1976 and 1978, he was a Humboldt Fellow at the University of Bonn under Professor W. Steglich. He has worked at Richter Plc. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest is analoguebased drug discovery. He is the author of some 100 patents and scientific publications. In 2004, he was elected as a Titular member of the Chemistry and Human Health Division of IUPAC. He received an honorary professorship at the Technical University of Budapest.
C. Robin Ganellin
Professor, University College London, Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK C. Robin Ganellin studied chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the coinventors of the revolutionary drug, cimetidine (also known as Tagamet). In 1986, he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Professor Emeritus of Medicinal Chemistry. Professor Ganellin is coinventor of over 160 patents and has authored over 260 scientific publications. He was President of the Medicinal Chemistry Section of the IUPAC and is Chairman of the IUPAC Subcommittee on Medicinal Chemistry and Drug Development.
References
Arun Ganesan
Professor, University of Southampton, School of Chemistry, Southampton S017 1BJ, UK A. Ganesan was born in Malaysia and graduated from the National University of Singapore, with a degree in chemistry and microbiology (1985) and an Honours degree in chemistry (1986). He obtained his PhD in 1992 from the University of California-Berkeley, working under the supervision of Professor Clayton H. Heathcock in the area of synthetic methodology and natural product total synthesis. Following a postdoctoral position with Professor Gregory L. Verdine at Harvard University in 1992–1993 working on DNA binding proteins, he began his independent career in 1993 as a Senior Research Chemist at the Center for Natural Product Research in Singapore. In 1996, he was promoted to Principal Investigator at the Institute, where he headed the Medicinal and Combinatorial Chemistry Group. He moved to Southampton in 1999 as a Reader to join National Combinatorial Center of Excellence. Ganesan is a Treasurer of the Royal Society of Chemistrys High Throughput Chemistry and New Technologies subject group and a member of the Organic Division Executive. He serves on the IUPAC Subcommitee for Medicinal Chemistry and Drug Development. He is a past Chair of the Gordon Research Conference and was awarded a JSPS fellowship as visiting professor at the Tokyo Institute of Technology, Japan. He is on the advisory board of QSAR and Combinatorial Science and Current Chemical Biology. He is a cofounder and Director of Karus Therapeutics (http://www.karustherapeutics.com), a spin-off of the University of the Southampton, and a Business Fellow of the London Technology Network. John Proudfoot
Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877-0368, USA John Proudfoot is a Medicinal Chemist with over 20 years of experience in drug design, ranging from fragment-based lead identification to late-stage lead optimization. He received his doctorate from the University College Dublin in Ireland, working with Professor Dervilla Donnelly. After postdoctoral studies under Professor Carl Djerassi at Stanford University and under Professor John Cashman at the University of California, San Francisco, he joined Boehringer Ingelheim Pharma in 1987. He is a coinventor of 28 issued US patents, including the one for the marketed drug, nevirapine, the first nonnucleoside HIV-1 reverse transcriptase inhibitor to receive regulatory approval.
j59
j61
3 Application of Molecular Modeling in Analogue-Based Drug Discovery Gy€orgy G. Ferenczy
3.1 Introduction
Analogue-based drug discovery benefits from molecular modeling and computational chemistry in various ways. The search for new medicaments that are similar to existing ones is an approach where the knowledge accumulated for the parent molecule drives drug discovery efforts. This requires a thorough understanding of all aspects of the effect of the parent molecule and this is supported by computational studies ranging from bioinformatics to pharmacokinetics. When research is not restricted to close structural analogues, the role of molecular modeling includes the extension of the notion of analogy; important features related to, but not apparent from the structural formula, can be identified and exploited in the design of analogues. One can mention, as examples, the better appreciation of three-dimensional structures by conformational analysis, the derivation of certain properties from the electronic structure of molecules and pharmacophore models that help to distinguish between properties that are important and those that are unimportant for binding to the target. The identification of features or structural motifs that are not relevant for interaction with the target is usually also fundamental, as it helps to design molecules that are outside competitor patent space that is a critical point in analogue-based research. Moreover, the unimportant parts of a molecule are suitable points for modifications in order to improve selectivity profile and pharmacokinetic properties that may be crucial aspects in developing an analogue with properties superior to the original molecule. The availability of information for the original molecule is highly advantageous for modeling approaches. In fact, a critical aspect of molecular modeling is to apply it at the appropriate time when, on the one hand, enough information is available to develop predictive models and, on the other hand, the model is able to provide nonobvious information that represents a useful contribution to the research. Analogue-based discovery, by definition, is based on information gathered for the original drug molecule that can be used as input for modeling work. Structure-based approaches that exploit the atomic resolution structure of the target are efficient and increasingly applied in molecular modeling and they may also
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
62
be applied in analogue-based research. Experimental or homology-based enzyme/ receptor structures may make it possible to design structurally loosely related functional analogues. The above discussion already indicates that, although analogue-based drug research has some particular features, the molecular modeling approaches applied are not specific. This is all the more so since molecular modeling – and we can state that to a large extent drug discovery in general – is largely based on the concept of analogy even if research is directed to the discovery of a novel molecule rather than an analogue of an existing drug. One can mention here that lead optimization is basically the search of an improved analogue of the lead molecule, and even lead identification by virtual screening often exploits the information available for known ligands of a target protein to optimize the virtual screening protocol. In this chapter, the discussion is restricted to examples where the lead is a drug, drug candidate, or an endogenous ligand of the target. Perhaps, it is not fair to term some of these drugs as analogues for two reasons. One is that they deviate considerably from their parent structure and this is partly due to the involvement of molecular modeling in the research process. The other reason is that when the parent molecule is not a marketed drug that already passed all stages of the development, then the research directed toward a structural analogue has an increased risk. In the past, molecular modeling was considered to be most useful in optimizing binding to the target. However, with increasing importance of ADMET properties in the early phases of drug research, molecular modeling plays an increasingly important role in optimizing properties such as metabolism, CYP inhibition and induction, and hERG channel activity. Nevertheless, these aspects of molecular modeling are less pronounced in the following discussions mainly because these drug discovery programs started several years ago. The examples presented are based on scientific publications that describe, quote, or at leastindicatetheuseofmodelingtechniquesinthediscoveryofanalogues.Incertaincases, the discovery process has been published in detail, while in some other cases it can only be approximately recovered. Thus, the examples presented may not reflect the complete contribution of modeling techniques in the course of a particular analogue research project. Nevertheless, they illustrate the contribution of molecular modeling in this field. No attempt has been made to describe all aspects of the discovery processes; rather the focus is on molecular modeling contributions. The research that led to the drugs or drug candidates described below began several years ago and since then, structural information on some of the targets has become available. This makes it possible to reevaluate certain hypotheses and observations made in the course of the discovery and it is particularly instructive for future applications.
3.2 Cilazapril: An ACE Inhibitor
Angiotensin-converting enzyme (ACE), part of the renin–angiotensin system, is an appropriate target for antihypertensive drugs [1]. Captopril (1) of Bristol-Meyers
3.2 Cilazapril: An ACE Inhibitor
Squibb was the first marketed nonpeptidic ACE inhibitor to be launched in the early 1980s. N SH
O O
OH
1, captopril
The development of captopril was preceded by the identification of a polypeptide that was first isolated and then synthesized and was shown to inhibit ACE [2]. A schematic model of the ACE active site (vide infra) was built after the recognition of its similarity to pancreatic carboxypeptidase A [3]. The model guided structure–activity studies that led to the discovery of SQ20881, a nonapeptide, and later to captopril. The clinical investigations of these compounds proved that they are effective antihypertensives. Side effects of captopril were attributed to the mercapto function and its replacement by weaker chelating functions led to the discovery of enalapril (2, Merck) [4].
O
O N H
N O O
OH
2, enalapril
The design of another ACE inhibitor by researchers at Roche is a well-documented example where computational methods made a significant contribution. The research used as starting points the two-dimensional model of the active site [3] (Figure 3.1) and the earlier structure–activity studies of captopril and related compounds [3–6]. An analysis of the available conformations of captopril generated limits for the relative positions of the three interaction points defined by the carboxy, amide, and thiol functions [7]. Three related bicyclic systems (3, 4, 5) were chosen so that they were able to hold these functions and their functionalization was expected to predictably influence their conformations. O HS N n
N N
O O 3
OH
j63
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
64
O R1
N
R2
N O O
OH
4 O
R1 R2 O
COOH 5
A series of compounds was prepared, conformations were investigated by NMR, and X-ray crystallography and biological activities were measured. The collected data revealed relationships between the relative positions of the functional groups and the ACE inhibition demonstrated by the molecules. Even the best molecules were, however, less active than captopril and enalapril. This was attributed to the finding that, according to NMR and X-ray experiments, the ring systems hold the functional groups in a relative position that corresponds to a high-energy conformation of alanylproline as it was calculated by molecular mechanics [8]. Therefore, new 7,6 and 8,6-bicyclic systems (6, 7) were synthesized in accordance with molecular graphic studies that suggested conformations with appropriate orientation of the carboxyl, carbonyl, and zinc-coordinating groups.
“CARBOXYPEPTIDASE A”
Zn++
NH
R
O
CH
C
“ANGIOTENSIN–CONVERTING ENZYME”
Zn++
+
CH2 O– NH
CH
C O
NH
R2
O
CH
C –O
–O
O C
C O
NH
R1
O
CH
C
R3
O
O C
CH2 CH
C
–S
CH2 CH
CH2 O– CH2 CH
H
+
R NH CH
C O O–
N
CH
N
CH
C O O–
CH3 O C
O–
C O
Figure 3.1 Schematic representation of the binding of substrates and inhibitors at the active site of pancreatic carboxypeptidase A, and the hypothetical active site of angiotensin-converting enzyme. Reprinted with permission from Ondetti et al. [3]. Copyright (1977) AAAS.
3.2 Cilazapril: An ACE Inhibitor
Y N N R2
O
CO2 R1
6
Y N N R2
O
CO2R1
7
Among the synthesized compounds, a dicarboxylic acid derivative of 7 was found to be the most active ACE inhibitor. Its monoethylester, cilazapril (8), is a prodrug with superior biological characteristics [8] and was launched in 1990.
N O
N
O
N H
O
CO2H
8, cilazapril
Cilazapril thus contains interacting functions similar to capropril, but the chemical nature of these functions and the skeleton that holds them are significantly different. The replacement of the thiol group with homophenylalanine and the introduction of the ester group are equivalent to the modifications appearing in enalapril with respect to captopril. On the other hand, a completely new feature of cilazapril is the bicyclic skeleton that is able to present the functional groups in a favorable orientation, and owing to its rigidity offers free energy gain by decreasing the entropy penalty upon binding. The crystal structures of several ACE–ligand complexes were published later. They include the complexes of captopril and enalapril [9]. The experimental structures confirm the presence of the presumed principal interactions, and the conformations of the ligands in the complex are consistent with the results of modeling studies (Figure 3.2).
j65
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
66
Figure 3.2 Important interactions in the Captopril–ACE complex (PDB ID: 1UZF [9]). Captopril carbons are shown in green and carbons of interacting residues are white. N-atoms are blue, O-atoms are red, and the
S-atom is yellow. Only polar H-atoms are shown and they are colored blue green. H-bonds are indicated by dashed yellow lines and other interactions are indicated by magenta lines.
3.3 Atorvastatin: A HMG-CoA Reductase Inhibitor
The biosynthesis of cholesterol involves a key step in which 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) is transformed to mevalonate by HMG-CoA reductase (HMGR). The inhibition of this process is an effective way to decrease serum cholesterol levels, and hypocholesterolemic agents decrease the risk of coronary artery disease [10]. The first HMGR inhibitors discovered were either fungal metabolites or synthetic derivatives thereof, such as compactin (9, Sankyo), lovastatin (10, Merck & Co), simvastatin (11, Merck & Co), and pravastatin (12, Sankyo). O
HO O
O O H
9, compactin
3.3 Atorvastatin: A HMG-CoA Reductase Inhibitor
O
HO O
O O
H
10, lovastatin
O
HO O
O O
H
11, simvastatin
O
OH
HO HO
O O
H
HO
12, pravastatin
Another series of HMGR inhibitors (13) with a different lipophilic group was disclosed by Merck Sharpe and Dohme [11–13].
j67
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
68
O
HO O
A
B Y X
13
This initiated at Parke-Davis a search for inhibitors containing a lactone and a hydrophobic moiety together with the optimal spacer in between. A series of molecules with the general formula 14 was synthesized and their cholesterol synthesis inhibition was measured [14]. O
HO O X R1
N
R2
14
First, X ¼ ethyl was identified as the optimal spacer. Then, structure–activity studies and the comparative conformational analysis of this series, compactin (9), and a molecule in the Merck series (13) led to the proposal that the X ¼ ethyl bridge in 14 (ethylene 13) adopts a nearly perpendicular position with respect to the pyrrole ring. For certain molecules, for example, Merck (13), this is the only allowed conformation, while in some other cases, the observed lower potency is attributed to the fact that this conformation is energetically disfavored. The authors of Ref. [14] also note that the calculated minimum energy conformation does not agree with the one found experimentally in the crystal of compactin [15]. The latter X-ray conformation corresponds to a secondary minimum with slightly higher energy. On the basis of the observed SAR of the series 14, it was postulated that for an optimal potency the extension of the R1 and R2 substituents cannot exceed 5.9 and 3.3 A, respectively. Further studies aimed at finding correlation between the potency and the charge distribution of the R1 group. This was prompted by the polar nature of the isobutyric ester containing fungal metabolite inhibitors (cf. molecules 9 and 10). However, it was concluded that potency is insensitive to the polarity of the R1 group. The relatively low potency of compounds of type 14 with respect to certain members of series 13 prompted the structural comparison of these molecules. The superposition of the structures revealed that a methyl group (in para position with
3.3 Atorvastatin: A HMG-CoA Reductase Inhibitor
O
HO O F F H3C
N
CH3
CH3 Figure 3.3 Overlay of HMGR inhibitor templates. Drawing from Roth [16], with permission from Elsevier. Copyright (2002).
respect to the ethylene) in 13 occupies a position that is vacant in series 14 [16] (Figure 3.3). Indeed, the 3,4-dichloro- and 3,4-dibromo-pyrrole derivatives of 14 exhibited a significant potency increase. As the dihalogen-substituted compounds were found to be toxic, additional substituents were investigated [16, 17]. Among them, the Ph and CONHPh substitutions were found to be highly potent and appear in atorvastatin calcium (15, Parke-Davis) that has been marketed since 1997. 2+
Ca
O
O HO HO F N O HN
2 15, atorvastatin calcium
The X-ray structure of HMGR-atorvastatin [18] complex makes it now possible to interpret former findings and to assess the predictions made by modeling (Figure 3.4). The binding pocket and its interactions with the ligand are in line with former observations concerning the size restriction of the R1 and R2 substituents of molecule 14, the insensitivity of the affinity to the polarity of R1 and the availability
j69
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
70
Figure 3.4 Atorvastatin in the binding pocket of HMGR (PDB ID: 1HWK [18]). The pocket is colored according to the electrostatic potential: blue – negative; red – positive. Annotations highlight features discussed in the text.
of space for substituents at the 3 and 4 positions of pyrrole. Moreover, the predicted nearly perpendicular orientation of the ethyl spacer with respect to the pyrrole ring was indeed observed in the experimental complex structure.
3.4 PDE4 Inhibitors
Phosphodiesterases (PDEs) are involved in the transformation of cyclic nucleotides into their corresponding 50 -monophosphates. Several subtypes of PDEs have been described. PDE4 is a cyclic 30 ,50 -adenosine monophosphate (cAMP) specific isozyme that is dominant in immune and inflammatory cells and also in airway smooth muscle. The inhibition of PDE4 is proposed for the treatment of asthma and chronic obstructive pulmonary disease (COPD) [19]. A pioneering compound in PDE4-specific inhibition is rolipram (16) developed at Schering AG. O NH
O
O 16, rolipram
This compound did not reach the market due to its undesirable side effects, but it served as a prototype of selective PDE4 inhibitors. A large number of rolipram
3.4 PDE4 Inhibitors
congeners have been synthesized and tested for PDE4 inhibition. These studies led to the identification of the features essential for PDE4 binding. This pharmacophore model helped to find inhibitors with an improved side-effect profile compared to rolipram. The structure–activity studies identified a dialkoxyphenyl group and a hydrogen bond acceptor (carbonyl of pyrrolidone in rolipram) as a minimum requirement for efficient PDE4 binding [20, 21]. It was also found that steric hindrance limits the size of the para-alkoxy substituent. The relative orientation of the alkoxy groups and the hydrogen acceptor moiety was investigated by conformational analysis of rolipram analogues and by superposition of some rigid molecules. No unambiguous assignment of a bioactive conformation was possible, but investigations suggested a basically extended conformation in which the carbonyl group points away from the para-alkoxy substituent [20, 21]. The typical distance between the dialkoxy phenyl group and the carbonyl dipole was proposed to have a value of 8–9 A [20]. The replacement of the pyrrolidone in rolipram by a 1,4-substituted cyclohexane ring fulfilled the criteria set by the above-described pharmacophore model and allowed extension of the structure–activity studies [21]. The introduction of the cyclohexane ring offered the advantage of a more rigid structure without a chiral center. The optimization of this series led to the discovery of cilomilast (17, GlaxoSmithKline) that was subject of an approval letter by FDA. Later, however, cilomilast development was discontinued. O
N O
O
OH 17, cilomilast
In other rolipram-based series, the pyrrolidone ring was replaced by benzamide derivatives and analogues. Among them, roflumilast (18, Nycomed) is under registration [22].
O O Cl O
F
N
N H
F
Cl 18, roflumilast
The crystal structures of several PDE4 complexes have been published since 2000 [23] and it is instructive to compare these experimental complex structures with the pharmacophore model that was derived with no atomic resolution structural knowledge of the target protein. The complexes of rolipram [24–27], cilomilast [27],
j71
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
72
and some more molecules confirm the crucial role of the dialkoxyphenyl moiety. The two ether oxygen atoms are hydrogen bonded to the side-chain amide N-atom of a glutamine residue, and the phenyl ring is surrounded by hydrophobic residues. This part of the molecule essentially replaces the adenine part of cAMP, the natural ligand of PDE4 [28]. The role of the pyrrolidone ring is not straightforward to interpret. In all except one X-ray structure [25], it apparently does not make any direct interaction with either the metals or the enzyme residues. The pyrrolidone carbonyl group is hydrogen bonded to a water molecule that, in turn, is hydrogen bonded to other water molecules having hydrogen bonds with the enzyme. The lack of more direct interactions is somewhat unexpected as the sensitivity of the binding affinity to this structural motif of the ligand was clearly observed. On the other hand, the comparison of the structures of rolipram and cilomilast (Figure 3.5) reveals that the relative position of the hydrogen bond acceptor with respect to the dialkoxy groups is not unequivocally defined, even though the presence of both seems to be important for binding. A possible explanation is that the ligand protrudes into an ordered set of water molecules contributing to the coordination of the metal ions and residues in the pocket and then for an efficient binding, the ligand has to provide appropriately positioned functions whose interactions are able to compensate for the disturbed hydrogen bonding network. An additional difficulty in interpreting rolipram binding has also to be noted. Rolipram binds to the full-length PDE4 with two different affinities [29], but the high-affinity binding is not observed in the truncated protein containing the catalytic domain appearing in the X-ray structures. As the large PDE4 binding pocket is not fully occupied by either rolipram or cilomilast, larger molecules may also be well accommodated. However, they can bind at the expense of expelling ordered water molecules. The free energy balance of such a binding is difficult to predict, although results in Ref. [30] indicate that it may be advantageous in the case of large-enough enthalpy gain. This would open the possibility to design inhibitors that create more direct interactions with the enzyme.
Figure 3.5 Superposition of rolipram (blue; PDB ID: 1OYN [24]) and cilomilast (brown; PDB ID: 1XOM [27]) in the PDE4 binding pocket. The water molecules are removed.
3.5 GPIIb/IIIa Antagonists
3.5 GPIIb/IIIa Antagonists
GPIIb/IIIa is a membrane-associated glycoprotein belonging to the integrin family of receptors. It plays a critical role in platelet aggregation. Antagonists prevent aggregation and thus thrombosis and are potentially suitable for the treatment of cardiovascular, cerebrovascular, and peripheral vascular diseases [31]. The peptide sequence Arg-Gly-Asp (RGD) has been recognized as the adhesive motif present in macromolecules, such as fibrinogen, that mediate platelet aggregation. Fibrinogen is a covalent dimer, the two halves of which have identical sequences, and it binds to GPIIb/IIIa on adjacent platelets and cross-links them. Small RGD containing peptides inhibit fibrinogen binding to platelets and inhibit platelet aggregation [32]. Thus, small peptides, peptidomimetics, or other molecules capable of binding to the RGD recognizing motif of GPIIb/IIIa may find therapeutic applications [33], and research was focused on developing RGD analogues. SK&F-107260 (19, developed by SmithKline Beecham) is a cyclic RGD analogue that owing to its more rigid structure exhibits higher affinity for GPIIb/IIIa than for RGD itself.
S O H2N
N
H N
S HN O
H N
O OH
N H
O
NH
O
19, SK&F-107260
The synthetic peptide eptifibatide (20, jointly developed by COR Therapeutics and Schering-Plough and launched in 1998) is also an RGD analogue whose improved profile is probably also due to its relative rigidity. NH NH2 O
N H H N
HN O
OH
O
O
N H
O
HN O
S
S H2N
N H O
20, eptifibatide
O N
NH
j73
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
74
Structure–activity studies with peptides identified the critical structural characteristics for RGD analogues. They include a basic group (guanidino of arginine) and an acidic group (carboxylate of aspartic acid) with a distance of 12–15 A between them. The spacer exerts an effect on the affinity by its length, rigidity, influence on the acidity and basicity of the end groups, and potentially also through direct interactions with the receptor. A large number of structural studies on the conformation of RGD containing peptides and mimics have been performed to clarify the relative orientation of the basic and acidic groups. The information accumulated suggests that the end groups are optimally linked by a linear spacer whose rigidity is a significant factor for affinity (see, e.g., Ref. [34]). Indeed, it was found that affinity is a linear function of the number of rotatable bonds with a slope of 0.7 kcal/mol (G.G. Ferenczy, unpublished), the value associated with the free energy cost of freezing a rotatable bond upon binding. Several small molecules that bind to the GPIIb/IIIa receptor and inhibit platelet aggregation in the nanomolar range have been described. An early representative, tirofiban hydrochloride [35] (21, Merck & Co), has been marketed since 1998. O S O OH
HN
O O H Cl
21, tirofiban hydrochloride
3.6 HIV Protease Inhibitors
Human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). HIV protease is responsible for the cleavage of precursor polyproteins to structural and functional proteins. This aspartic protease is one of the targets of anti-HIV therapy. First-generation protease inhibitors (PIs), such as saquinavir (22), indinavir (23), ritonavir (24), nelfinavir (25), and amprenavir (26), are all transition-state analogues with a hydroxyethylene core.
O H N
N
O N H
O 22, saquinavir
NH2 O
N OH H
H N
H
3.6 HIV Protease Inhibitors
N
OH
H N
N
N O
NH
N
H N
OH
O
23, indinavir S N
OH
O N H
O
S
H N
O
N
O
24, ritonavir
HO
H N
O
S
O
N
N H
H
OH H
25, nelfinavir
H N
O O
O
OH N O
S
NH2 O
26, amprenavir
The rapid discovery and development of these peptidomimetic agents were supported by atomic resolution X-ray crystallographic structures of the HIV protease and its complexes. These first-generation PIs have several shortcomings. Most important is drug resistance that comes from mutations as the response of the virus to drug treatments. In addition, inadequate pharmacokinetics manifests itself in one or several ways such as short plasma half-life, poor aqueous solubility, high protein binding, and modest oral bioavailability.
j75
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
76
The development of second-generation PIs was focused on addressing the abovementioned issues. First-generation PIs were used as starting points to develop improved agents. In order to reduce the effect of mutations on the activity of inhibitors, some interactions with the side chains of HIV protease were replaced by interactions with the protein backbone. The search for improved PIs and the interpretation of their activity were supported by structural biology and molecular modeling. The analysis of the X-ray structure of HIV protease with ritonavir (24) revealed that the isopropyl group on the thiazolyl ring interacts with the isopropyl group of the Val82 side chain of the S3 pocket [36]. This is in line with the reduced Ki value of ritonavir toward proteases mutated at this position. The omission of the P3 group reduced the activity but with the advantage of low serum binding. The activity was partially regained with the introduction of conformational constraint by cyclic urea (27) [36].
OH
O N
HN
N H
O
S
H N
N
O O
27, A-1555564
Twoalternativemodelsforthepositionandinteractionsofthecyclicureamoietywereset up. One of them is hydrogen-bonded with Asp29 and the other is hydrogen-bonded with Asp30 of the HIV protease. The degree of the intramolecular van der Waals interaction between the urea and the P1 benzyl group is also different in the two models [36]. Finally, the P20 (thiazolyl)methoxycarbonyl group was replaced by the dimethylphenoxyacetyl group leading to lopinavir (28).
OH
O N
HN O
N H
H N
O O
28, lopinavir
HIV protease inhibitors with a dimethylphenoxyacetyl group were first described in Refs [37, 38]. The X-ray structures of complexes with this group showed a shift of main-chain and side-chain atoms of residues 29 and 30 revealing a new region of conformational flexibility in the HIV protease [37]. The advantage of the dimethyl with respect to the monomethyl substitution was attributed, in part, to more favorable binding entropy of the former, as it always puts one of the methyl groups in a position with a beneficial interaction. The X-ray structure also showed that the methyl group
3.6 HIV Protease Inhibitors
j77
Table 3.1 Similarity coefficients between parent compounds and optimized drugs.
Parent compound
Optimized compound
Similarity coefficient [41]
N O
N
O
N SH
N H
O O
O
O
0.34
O
OH cilazapril
captopril
O
HO O
O O
H
O
O
0.14
HO compactin
HO O
HO
F O
0.29
N
F
O HN Cl atorvastatin
Ref. [13] compound 100
O O Cl
O NH
O
O
F F
O
rolipram
N
N H
0.27
Cl roflumilast (Continued)
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
78
Table 3.1 (Continued)
Parent compound
Optimized compound
Similarity coefficient [41]
NH H2N
H N
O
N H
NH2
O
O
N H
S
HO
HN
O
HO
0.43
O OH O
O
O tirofiban hydrochloride
RGD S N HN N O O
N
NH
O
O HN HN
NH
NH O
0.39
OH
OH
O
O
O
S N ritonavir
lopinavir
has an optimal size and that larger substituents on the phenyl ring probably result in clashes with protein residues [38]. The X-ray crystal structure of lopinavir in complex with the HIV protease was published in 2002 [39]. It confirmed that in line with the design strategy the interaction of lopinavir with Val82 is significantly reduced. The dimethylphenoxyacetyl group occupies a position that was anticipated. The cyclic urea binds both to the backbone and to the side chain of Asp29 and it is accompanied with a slight movement of the protein backbone near Gly48. Lopinavir is an improved analogue of ritonavir with an increased HIV protease inhibitory activity that is moderately affected by mutations of Val82. Its bioavailability is highly enhanced when coadministered with ritonavir, a potent CYP3A4 inhibitor [40]. Lopinavir, coformulated with ritonavir, was launched by Abbott first in the United States in 2000.
References
3.7 Epilogue
Five examples of analogue-based drug discovery were presented. In all these cases, molecular modeling made a substantial contribution to the introduction of significant structural modifications. An indication of the important differences between the parent compounds and the optimized drugs is their low similarity coefficients presented in Table 3.1 [41]. In all these examples, the focus was on the interaction with the target and how the information and models available for the ligand–target interaction could be used to keep or improve affinity while other, typically pharmacokinetic, characteristics were optimized. On the other hand, modeling and computational methods are more and more able to predict properties relevant to pharmacokinetics, thus providing additional support to the optimization in analogue-based drug discovery projects.
References 1 Wong, J., Patel, R.A.,and Kowey, P.R.
2
3
4
5
(2004) The clinical use of angiotensinconverting enzyme inhibitors. Prog. Cardiovasc. Dis., 47, 116–130. Ondetti, M.A., Williams, N., Sabo, E.F., Pluscec, J., Weaver, E.R.,and Kocy, O. (1971) Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry, 10, 4033–4039. Ondetti, M.A., Rubin, B.,and Cushman, D.W. (1977) Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science, 196, 441–444. Patchett, A.A., Harris, E., Tristram, E.W., Wyvratt, M.J., Wu, M.T., Taub, D., Peterson, E.R., Ikeler, T.J., Ten Broeke, J., Payne, L.G., Ondeyka, D.L., Thorsett, E.D., Greenlee, W.J., Lohr, N.S., Hoffsommer, R.D., Joshua, H., Ruyle, W.V., Rothrock, J.W., Aster, S.D., Maycock, A.L., Robinson, F.M., Hirschmann, R., Sweet, C.S., Ulm, E.H., Gross, D.M., Vassil, T.C.,and Stone, C.A. (1980) A new class of angiotensinconverting enzyme inhibitors. Nature, 288, 280–283. McEvoy, F.J., Lai, F.M.,and Albright, J.D. (1983) Antihypertensive agents:
6
7
8
9
angiotensin converting enzyme inhibitors. 1-[3-(Acylthio)-3aroylpropionyl]-L-prolines. J. Med. Chem., 26, 381–393. Kim, D.H., Guinosso, C.J., Buzby, G.C., Herbst, D.R., McCaully, R.J., Wicks, T.C., and Wendt, R.L. (1983) (Mercaptopropanoyl)indoline-2carboxylic acids and related compounds as potent angiotensin converting enzyme inhibitors and antihypertensive agents. J. Med. Chem., 26, 394–403. Hassall, C.H., Kr€ohn, A., Moody, C.J.,and Thomas, W.A. (1984) The design and synthesis of new triazolo, pyrazolo-, and pyridazo-pyridazine derivatives as inhibitors of angiotensin converting enzyme. J. Chem. Soc. Perkin. Trans. I, 155–164. Attwood, M.R., Hassal, C.H., Kr€ohn, A., Lawton, G.,and Redshaw, S. (1986) The design and synthesis of the angiotensin converting enzyme inhibitor cilazapril and related bicyclic compounds. J. Chem. Soc. Perkin. Trans. I, 1011–1019. Natesh, R., Schwager, S.L.U., Evans, H.R., Sturrock, E.D.,and Acharya, K.R. (2004) Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular
j79
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
80
10
11
12
13
14
15
16
angiotensin I-converting enzyme. Biochemistry, 43, 8718–8724. Eisenberg, D.A. (1998) Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am. J. Med., 104 (Suppl. 1), 2S–5S. Williard, A.K., Novello, F.C., Hoffman, W.F.,and Cragoe, E.J., Jr., Substituted pyranone inhibitors of cholesterol synthesis. US Patent 4,459,422 (1984). Stokker, G., Hoffman, W., Alberts, A., Cragoe, E., Deana, A., Gilfillan, J., Huff, J., Novello, F., Prugh, J., Smith, R.,and Willard, A. (1985) 3-Hydroxy-3methylglutaryl-coenzyme A reductase inhibitors. I. Structural modification of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives. J. Med. Chem., 28, 347–358. Stokker, G.E., Alberts, A.W., Anderson, P.S., Cragoe, E.J., Gilfillan, A.A., Hirshfield, J., Holtz, W.J., Hoffman, W.F., Huff, J.W., Lee, T.J., Novello, F.C., Prugh, J.D., Rooney, C.S., Smith, R.L.,and Willard, A.K. (1986) 3-Hydroxy-3methylglutaryl-coenzyme A reductase inhibitors. 3. 7-(3,5-Disubstituted-[1,10 biphenyl]-2-yl)-3,5-dihydroxy-6-heptenoic acids and their lactone derivatives. J. Med. Chem., 29, 170–181. Roth, B.D., Ortwine, D.F., Hefle, M.L., Stratton, C.D., Sliskovic, D.R., Wilson, M.W.,and Newton, R.S. (1990) Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-Pyrrol-1-ylethyl)-4hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus. J. Med. Chem., 33, 21–31. Endo, A., Kuroda, M.,and Tanzawa, K. (1976) Competitive inhibition of 3hydroxy-3-methylglutaryl coenzyme a reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett., 72, 323–326. Roth, B.D. (2002) The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Progr. Med. Chem., 40, 1–22.
17 Roth, B.D., Blankley, C.J., Chucholowski,
18
19
20
21
22 23
24
A.W., Ferguson, E., Hoefle, M.L., Ortwine, D.F., Newton, R.S., Sekerke, C.S., Sliskovic, D.R., Stratton, C.D.,and Wilson, M.W. (1991) Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J. Med. Chem., 34, 357–366. Istvan, E.S.and Deisenhofer, J. (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 292, 1160–1164. Burnouf, C.and Pruniaux, M.P. (2002) Recent advances in PDE4 inhibitors as immunoregulators and antiinflammatory drugs. Curr. Pharm. Des., 8, 1255–1296. Marivet, M.C., Bourguignon, J.-J., Lugnier, C., Mann, A., Stoclet, J.-C.,and Wermuth, C.-G. (1989) Inhibition of cyclic adenosine-30 ,50 -monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogs. J. Med. Chem., 32, 1450–1457. Christensen, S.B., Guider, A., Forster, C.J., Gleason, J.G., Bender, P.E., Karpinski, J.M., DeWolf, W.E., Jr., Barnette, M.S., Underwood, D.C., Griswold, D.E., Cieslinski, L.B., Burman, M., Bochnowicz, S., Osborn, R.R., Manning, C.D., Grous, M., Hillegas, L.M., Bartus, J.O., Ryan, M.D., Eggleston, D.S., Haltiwanger, R.C.,and Trophy, T.J. (1998) 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J. Med. Chem., 41, 821–835. http://www.nycomed.com/en/Menu/ RD/Pipeline/ accessed March 2009. Xu, R.X., Hassell, A.M., Vanderwall, D., Lambert, M.H., Holmes, W.D., Luther, M.A., Rocque, W.J., Milburn, M.V., Zhao, Y., Ke, H.,and Nolte, R.T. (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science, 288, 1822–1825. Huai, Q., Wang, H., Sun, Y., Kim, H.Y., Liu, Y.,and Ke, H. (2003) Threedimensional structures of PDE4D in
References
25
26
27
28
29
30
31
32
complex with roliprams and implication on inhibitor selectivity. Structure, 11, 865–873. Xu, R.X., Rocque, W.J., Lambert, M.H., Vanderwall, D.E., Luther, M.A.,and Nolte, R.T. (2004) Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J. Mol. Biol., 337, 355–365. Zhang, K.Y.J., Card, G.L., Suzuki, Y., Artis, D.R., Fong, D., Gillette, S., Hsieh, D., Neiman, J., West, B.L., Zhang, C., Milburn, M.V., Kim, S.-H., Schlessinger, J.,and Bollag, G. (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell, 15, 279–286. Card, G.L., England, B.P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C., Tabrizizad, M., Gillette, S., Ibrahim, P.N., Artis, D.R., Bollag, G., Milburn, M.V., Kim, S.-H., Schlessinger, J.,and Zhang, K.Y.J. (2004) Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure, 12, 2233–2247. Ke, H., Colicelli, J.,and Huai, Q. (2003) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry, 42, 13220–13226. Rocque, W.J., Tian, G., Wiseman, J.S., Holmes, W.D., Zajac-Thompson, I., Willard, D.H., Patel, I.R., Wisely, G.B., Clay, W.C., Kadwell, S.H., Hoffman, C.R., and Luther, M.A. (1997) Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry, 36, 14250–14261. Hamelberg, D.,and McCammon, J.A. (2004) Standard free energy of releasing a localized water molecule from the binding pockets of proteins: doubledecoupling method. J. Am. Chem. Soc., 126, 7683–7689. Huang, F.and Hong, E. (2004) Platelet glycoprotein IIb/IIIa inhibition and its clinical use. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 2, 187–196. Plow, E.F., Pierschbacher, M.D., Ruoslahti, E., Marguerie, G.,and
33
34
35
36
37
38
Ginsburg, M.H. (1985) The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc. Natl. Acad. Sci. USA, 82, 8057–8061. Shebuski, R.J., Berry, D.E., Bennett, D.B., Romoff, T., Storer, B.L., Ali, F.,and Samanen, J. (1989) Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration. Thromb. Haemost., 61, 183–188. Fischer, M.J., Bruce, G., Harms, C.S., Kline, A.D., Mullaney, J.T., Nunes, A., Scarborough, R.M., Arfsten, A.E., Skelton, M.A., Um, S.L., Utterback, B.G.,and Jakubowski, J.A. (1997) Non-peptide RGD surrogates which mimic a Gly-Asp b-turn: potent antagonists of platelet glycoprotein IIbIIIa. J. Med. Chem., 40, 2085–2101. Egbertson, M.S., Chang, C.T.-C., Duggan, M.E., Gould, R.J., Halczenko, W., Hartman, G.D., Laswell, W.L., Lynch, J.J., Jr., Lynch, R.J., Manno, P.D., Naylor, A.M., Prugh, J.D., Ramjit, D.R., Sitko, G.R., Smith, R.J., Turchi, L.M.,and Zhang, G. (1994) Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J. Med. Chem., 37, 2537–2551. Sham, H.L., Kempf, D.J., Molla, A., Marsh, K.C., Kumar, G.N., Chen, C.-M., Kati, W., Stewart, K., Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Vasavanoda, S., McDonald, E., Saldivar, A., Wideburg, N., Chen, X., Niu, P., Park, C., Jayanti, V., Grabowski, B., Granneman, G.R., Sun, E., Japour, A.J., Leonard, J.M., Plattner, J.J.,and Norbecki, D.W. (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother., 32, 3218–3224. Tong, L., Pav, S., Mui, S., Lamarre, D., Yoakim, C., Beaulieu, P.,and Anderson, P.C. (1995) Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere. Structure, 3, 33–40. Beaulieu, P.L., Anderson, P.C., Cameron, D.R., Croteau, G., Gorys, V., Grand-Matre,
j81
j 3 Application of Molecular Modeling in Analogue-Based Drug Discovery
82
C., Lamarre, D., Liard, F., Paris, W., Plamondon, L., Soucy, F., Thibeault, D., Wernic, D., Yoakim, C., Pav, S.,and Tong, L. (2000) 20 ,60 -Dimethylphenoxyacetyl: a new achiral high affinity P3-P2 ligand for peptidomimetic-based HIV protease inhibitors. J. Med. Chem., 43, 1094–1108. 39 Stoll, V., Qin, W., Stewart, K.D., Jakob, C., Park, C., Walter, K., Simmer, R.L., Helfrich, R., Bussiere, D., Kao, J., Kempf, D., Sham, H.L.,and Norbeck, D.W. (2002) X-ray crystallographic structure of
ABT-378 (lopinavir) bound to HIV-1 protease. Bioorg. Med. Chem., 10, 2803–2806. 40 Chrusciel, R.A., Thalsrivongs, S.,and Nicholas, J.A. (2001) HIV protease inhibitors in early development, in Protease Inhibitors in AIDS Therapy (eds R.C. Ogdenand C.W. Flexner), Marcel Dekker, New York, pp. 119–137. 41 Tanimoto similarity coefficients calculated with FCFP_4 fingerprints by SciTegic Pipeline Pilot 7.0.1.100 from Accelrys Software Inc.
Gy€ orgy G. Ferenczy
Chinoin Zrt., Sanofi-aventis, Tó u. 1-5, 1045 Budapest, Hungary Gy€orgy G. Ferenczy received his PhD from the E€ otv€ os University in Budapest in 1988. His early career involved quantum chemical method development and applications to extended systems. He was a postdoctoral fellow at the University of Oxford, UK, and at the University of Nancy, France. He was in the Drug Design Group of Gedeon Richter Plc., Budapest, as a Research Scientist and Group Leader. In 1999, he joined Chinoin Ltd., a member of the Sanofi-Aventis group. He has authored and coauthored 50 scientific papers and patents.
j83
4 Issues for the Patenting of Analogues Stephen C. Smith
4.1 Introduction
The statement in the first edition of this book that The most fruitful basis to discover a new drug is to start with an old drug, and this has been the most common and reliable route to new products [1] encapsulates the main issue in patenting new drug analogues, that is, they are in fact related to existing drugs and so may attract the charge of being obvious over them. For any invention to be patentable, it has to be new in a strict formal sense over what is already known, inventive, which is not obvious over what is already known, and be useful in a broadly industrial context. Drug products are no different, but because most are in some sense analogues of a known drug, it is the requirement to be inventive over what is known that generally provides the biggest hurdle to patenting new analogues. Given the enormous expense of bringing a new drug to sale, ensuring that patent protection is obtained in most major markets and maintained for a reasonable period to recover the investment and generate profit for shareholders is critical. No company can afford to find that, shortly after launching a new product, a competitor is able to introduce the same product without their permission. Although patent attorneys and other legal professionals will do their best to provide adequate protection and ameliorate any problems that may arise, the role of the inventor and associated research staff is critical to ensuring that drug patents have the best possible foundation. Getting a patent granted by satisfying the requirements of patent offices is of course the initial objective, but having its validity survive prolonged attack from determined competitors is the ultimate aim. Any product with annual US sales of the order of US$ 80 million plus is almost certain to find the validity of its US patent challenged as part of an Abbreviated New Drug Application (ANDA) related challenge to introduce a generic version. Consequently, it is necessary to try to challenge proof the validity of any patent protecting a new chemical entity (NCE) by taking extra care during the application stage. Here, the inventors – who usually include one or more medicinal chemists – have a critical role to play.
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 4 Issues for the Patenting of Analogues
84
This chapter aims to give medicinal chemists and others involved in new drug research a basic survival guide to the patent system and how it is applied, in particular to patenting drug analogues. What follows can necessarily be only a broad overview of the situation for drug analogues, but it is hoped it will give medicinal chemists and others involved in new drug research enough understanding and practical information to avoid some of the pitfalls in the patenting process and allow them to have an informed dialogue with their legal advisers.
4.2 Patents: Some Fundamentals
Patents are exclusive rights granted for inventions in all fields of technology that meet the basic criteria for patentability. They are not available for designs, artistic works, or intellectual activities for which other intellectual property (IP) rights may be available such as registered designs and copyright. Like other property rights, patents may be sold, licensed, mortgaged, or otherwise commercialized. Patents are national rights that allow the owner to stop other people from doing what is claimed in the patent without the owners permission during a set time within the state concerned and while renewal fees are being paid. They do not give any positive right to commercialize an invention since specific permission may be required from other rights holders or the state (e.g., marketing authorization for a drug product). A patent is a special legal instrument first developed in Europe1) in the fifteenth century to promote technological development by providing timelimited protection from competition (monopoly) in exchange for public disclosure of how to make and use the technology concerned. They require a formal application accompanied by a patent specification that sets out in detail what is protected by legal claims (typically found at the end of the patent specification) and the nature of the invention and how it can be made and used, including in the case of chemical inventions detailed examples of making and often testing of compounds falling within the legal claims. In all major countries, the specifications of unexamined patent applications are now published or made available on-line 18 months after the earliest of their filing and priority dates.2) The process of obtaining a granted patent varies (typically from 2 to 10 years) from the filing of the application during which time the patentability is examined and argued with the applicant against set criteria. Until relatively recently, many states restricted the availability of patent protection for pharmaceutical inventions, permitting only claims to processes for manufacturing an active ingredient. But now all major countries grant patents for pharmaceutical 1) The earliest known English patent for invention was granted by Henry VI to Flemish-born John of Utynam in 1449 giving him a 20-year monopoly for a method previously unknown in England for making stained glass that was needed for the windows of Eton College. 2) In the United States of America, it is still possible to prevent publication of a patent
application after 18 months by, at the time of filing, so requesting on the basis that the application will not be filed in a foreign country that itself provides for publication after 18 months. However, securing patents in at least the EU and Japan as well as the USA is the norm for analogue patenting and so this possibility is of little practical value.
4.3 Patentability
inventions with claims to chemical products, formulations, and processes for manufacture. These patents are granted for a period of at least 20 years, starting from the date when the application was filed.3) The advantage of patents that claim the chemical products themselves (product patents) is that they have the effect of preventing unauthorized commercial use of a claimed compound for any use (not just that found by the patentee) irrespective of how it has been made. A claim to a process for manufacturing a product by contrast only restricts the use of the process itself. This may be difficult for the patent owner to prove in practice without access to the manufacturing plant and so many patent systems particularly in Europe reverse the normal evidence requirements (the burden of proof) where infringement of a patented process is suspected. The alleged infringer then has to prove that the claimed process is not being used. Both granted patents and patent applications give rise to publications destroying the novelty of any of the subject matter disclosed in the specification should this be claimed in patent applications filed later. Granted patents in addition may restrict the freedom of competitors to commercialize anything within the patent claims without a license from the patent owner (patentee).
4.3 Patentability
The criteria that must be satisfied in deciding the patentability of an invention, that is, whether a patent may be granted or whether it should remain in force, are essentially the same in all major countries. In summary, the subject matter must be suitable material for a patent – it must not be specifically excluded by national law: thus, a method of treatment or diagnosis practiced on the human or animal body is excluded in most countries other than the United States of America; (2) novel in comparison with what is in the prior art – this includes publications of any sort (including abstracts of conference proceedings) and documented uses of the invention anywhere in the world in any language before the priority date of the application; (3) inventive over the relevant closest prior art – this includes publications and uses as in No. 2 above, but they must be relevant to the technical area and normally in relation to a single document rather than a combination of documents unless they are directly related to each other or else establish the level of general knowledge in the technical area, such as textbooks, manuals, and so on; (4) useful or capable of use primarily in an industrial context – in the United States of America useful has been very broadly interpreted to include methods of doing business or carrying out research, but in most other countries some technical character is needed; and (1)
3) In the United States of America, the term of drug analogue patents may be extended by up to 5 years for delays in the regulatory approval process and in Europe similar extended protection in the form of patent-like supplementary protection certificates is also available for up to 5 years.
j85
j 4 Issues for the Patenting of Analogues
86
(5)
adequately described – there must be sufficient information in the patent specification for someone of reasonable skill in the relevant art to make and use the invention; for example, in the pharmaceutical context, the information must be sufficient for a medicinal chemist to make a compound and understand how it would be used in a drug.
For drug analogue patenting, the first criterion does not normally give problems, but satisfying the requirements of the remaining criteria, and especially that of being inventive, presents the most challenges both when patents are being written (drafted) and when they are being defended in litigation.
4.4 Important Elements of the International Patent System
It is important to stress at the outset that there is no such thing as a world patent giving rights everywhere. However, there are a number of unified patent examination and processing systems such as that provided by the European Patent Office (EPO) securing protection in up to 36 European states as designated by the applicant.4) Such systems allow a single patent application to be filed and examined in an official language (English, French, or German in the case of the EPO) leading eventually to a group of separate patents applicable in the individual nation states required. The international patent system is underpinned by three key major treaties: Paris Convention: 5) This allows a person to file a patent application in his own country, establishing a priority date for the invention, and then wait up to a year before deciding to file in other countries and still rely on the priority date of the first patent application, thus allowing opportunity to further evaluate the invention before incurring the substantial cost of foreign patent applications. Patent Cooperation Treaty (PCT): 6) This enables a person to obtain patent protection eventually in a large number of states that are signatories of the treaty 4) See EPO web site for more information: http://www.epo.org. 5) The Paris Convention for the Protection of Industrial Property, governing patents, trade marks, industrial designs, and so on, was originally signed in Paris in 1883; it has been amended several times, most recently in Stockholm in 1967 and is now acceded to by 173 states (May 2009); it requires signatories to grant reciprocal protection to a national of another signatory state and sets out basic rules that all contracting states must follow in relation to patent and other IP rights; see also World IP Organisation web site at http://www.wipo.int/treaties/en/ip/paris/. 6) The Patent Cooperation Treaty is administered by the World Intellectual Property
Organisation (WIPO) based in Geneva, Switzerland, and is open to any state that is a member of the Paris Convention; under the treaty, anyone who is a national or resident of a PCT contracting State may file an International Application either with the national patent office of the contracting State of which the applicant is a national or resident or, at the applicants option, with the International Bureau of WIPO in Geneva; filing a single PCT application allows protection to be obtained in all signatory states (141 with the accession of Peru and Chile in March 2009) on completion in due course of the relevant national patent requirements; see also the PCT web site at http://www.wipo.int/pct/en/.
4.5 Priority
by filing a single International Patent Application (often referred to as a PCT application). Besides reducing overall costs, the use of the PCT has the advantage of increasing by up to 18 months the time before a decision has to be made on foreign filing. This is useful where there is a continuing research activity such as on particular drug analogues where initially promising leads may disappear and the direction of research change, requiring a change in the patenting strategy. As a result, most organizations seeking patent protection internationally for pharmaceutical inventions now use the PCT as their preferred route. Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPs): This was established in 1995 as part of a global open trade deal and sets out the minimum levels of protection that each government has to give to the patents and other intellectual property rights of fellow members of the World Trade Organization. This was particularly important in establishing that it was improper to discriminate against particular technologies such as pharmaceuticals or whether they were imported or locally produced. Adoption of TRIPs led to changes in the patent law of both developed and developing countries including the United States of America and India and established a minimum patent term of 20 years from the date of filing the applications.
4.5 Priority
In competitive and rapidly evolving technology areas such as drug research, it is important to secure early patent protection for inventions as soon as possible after they are made so that priority is established for the invention. This is because in all countries except the United States the patent is accorded to the first person to file a patent application. In the United States, the patent is granted to the first inventor rather than the first person to apply for a patent and an elaborate practice of patent interferences has been developed to determine the true first inventor. The Paris Convention (see above) was developed to allow a single early-filed patent application in one country to be used for up to 1 year as the basis for any number of corresponding foreign applications claiming the priority of the original national application (Figure 4.1). Everything in the second application that is literally within (or properly based on) the first application is regarded as having the same filing date as the first application – the
1st (priority) application filed
0 months
2nd updated application filed – claiming priority for subject matter also in 1st application
12 months
Figure 4.1 Priority under the Paris convention.
j87
j 4 Issues for the Patenting of Analogues
88
priority date – when considering patentability over the prior art. To retain priority, the subject matter in the later application must be directly and unambiguously derivable from that in the first, the so-called priority application. In principle, there is no limit to the number of priority establishing applications that may be filed within the year from the first application and from which the later foreign applications may claim priority. However, they will ultimately need to be translated into the language of the state in which the priority is being asserted and so in practice for drug analogue inventions it is rare for there to be more than three priority applications. The advantage of this arrangement for analogue research is that it allows the first application to include claims amounting to a years research plan based on initial activity in a few lead compounds that have so far been prepared and tested. Then, as the research plan is explored and additional interesting compounds are discovered these can be either added to a new priority establishing application or else included in the foreign patent applications. For example, suppose a first application was filed claiming naphthalene derivatives having a halogen substituent based on the activity of a chloronaphthalene included in the patent specification, then a claim to halogenonaphthalenes in a second application filed up to a year later would be entitled to the priority date of the first application. This would be important if a competitor filed an application also claiming halogenonaphthalenes or if there were to be a publication of the chloronaphthalene itself some time between the first and the second patent applications since, if the priority was not maintained, then a valid patent could not be obtained by the originator.
4.6 Novelty
Deciding whether claimed subject matter is novel in relation to the prior art is critical in any assessment of validity of a patent; if novelty is not present there, then consideration of inventive step (which itself can always be argued or refuted with evidence of unexpected effects) simply is not possible. In the case of chemical inventions, it does not matter at all for what purpose, if any, the compound was used and so disclosure or use in any technical art may be considered. It is enough that the compound was made somewhere else to destroy the novelty of a later patent claim to the compound. However, it may well be that other aspects related to the known compound are still novel and inventive, such as pharmaceutical formulations or new medical uses. Thus, for example, 2,6-diisopropylphenol (Figure 4.2), the active entity of the intravenous anesthetic propofol, was first described as a stabilizer for rubber and so could not at the time when its anesthetic properties were discovered in 1977 be claimed as a compound itself but only as a special injectable formulation.7) 7) The first medical use for a known compound can now be protected under European law, that is, a product claim in the form of known substance X for use as a medicine is now permissible in Europe. Methods of medical treatment involving administration of a known substance have always been patentable in the United States.
4.6 Novelty
OH
Figure 4.2 Propofol (DiprivanÒ ).
O
O S
O H
NH2 X
O O
O O H H O (a)
CH2OSO2NHR1
R5
R2 R4
R3 (b)
Figure 4.3 (a) Topiramate (TopamaxÒ ) and (b) generic structure including topiramate.
The objective of all patent claims is to define the limits of the invention in such a way that all essential features are included and defined as generally as possible without covering embodiments (examples) that are already known or which are obvious from what is known or those that cannot be made or which simply do not work. This may be relatively straightforward for mechanical inventions but can be difficult for chemical inventions such as new drug analogues where the draftsman wants to include in the claims all of those analogues that could readily be conceived by a competitor based on the compounds actually exemplified in the patent specification. This frequently leads to the use of complex definitions in patent claims involving a generalized structural formula with individual substituents defined in lists of alternatives such as that shown above for the McNeil anticonvulsant, topiramate (Figure 4.3). Such claims8) typically include thousands or even millions of alternative compounds. Fortunately, no patent office takes the view that all possible compounds that can theoretically be listed within a general formula are implicitly described once the structure is published. What then is the effect of such a published patent? The novelty is certainly destroyed for all compounds that are specifically mentioned or listed in worked examples and the rest of a patent specification once it is published. Sometimes, subtle linguistic devices are employed by patent draftsman to indicate which compounds have actually been prepared and evaluated in bioassays and which are mere possibilities. For example, the following compounds were obtained implies that actual synthesis has occurred whereas the compounds in the table may be obtained implies that it is simply possible to make the listed compounds. In the latter case, such disclosures will still be novelty destroying unless it can be shown that such compounds cannot be made by any of the processes
8) See Appendix 4.B.
j89
j 4 Issues for the Patenting of Analogues
90
described in the specification or other well-known means – if they can be so made the disclosure is often referred to as enabling, that is, there is sufficient description for a chemist with reasonable basic skills to make the compound(s) concerned.
4.7 Inventive Step: Nonobviousness
The problem with most inventions is that with hindsight they may appear to be obvious or to lack the necessary inventive step over what is already known. Consequently, showing inventive step is almost always the biggest hurdle that drug analogue patents must clear since, by definition, they start from an existing molecule already known to have useful pharmacological properties. The fact that increasing logic and theory has been applied in recent years to research processes to increase the likelihood of candidate drugs emerging quickly from drug discovery programs can make it more difficult to show that arriving at a useful analogue of an existing drug is other than predictable. From the patent perspective, so far at least the discovery process and subsequent development of clinically useful analogues of existing drugs continue to remain uncertain and regularly give rise to unexpected results. Lack of predictability and/or unexpected results in comparison with the relevant close prior art are required if inventive step is to be shown. The US Supreme Court set down in a decision in 1966 [2] (which is still followed today) the key components of obviousness determinations: the determination of nonobviousness is made after establishing the scope and content of prior art, the differences between the prior art and the claims at issue, and the level of ordinary skill in the pertinent art. The Court also considered possible secondary considerations that might be taken into account as evidence of nonobviousness, such as commercial success, long-felt but unmet needs, and the lack of success of others to solve the underlying problem. So, it is necessary to decide what is the claimed invention and consider both chemical structural differences and the underlying properties of the closest compounds in the art in deciding whether an inventive step exists. The size of the inventive step is of no concern – there simply has to be one, the so-called scintilla of invention. For pharmacological analogues, where the new drug molecule has similar pharmacological activities but there are no real chemical or structural similarities with the prior art drug, then an inventive step is clearly present. However, for most drug analogues some sort of structural similarity can be discerned between the new molecule and the starting drug. This means that in virtually all applications for drug analogues patents, examiners will allege that the invention lacks an inventive step simply because of perceived structural similarity with the closest compound in the prior art (the so-called a priori or prima facie obviousness). Analogues of a natural product whose structure has not previously been published are of course a clear exception. The degree of structural or chemical closeness that makes one compound obvious from another is of course subjective and therefore arguable. The person required to
4.7 Inventive Step: Nonobviousness
judge this is the notional person of ordinary skill in the art, that is, for drug analogues, usually a skilled medicinal chemist. This hypothetical person is considered to be aware of all the background literature, have all the skills of a synthetic chemist at the time the application was filed, and have a general understanding of how molecules may be evaluated for potential drug use, but this person may not be in any way inventive. In complex cases, the notional person may be considered as a team, spanning a number of specialist skill sets such as pharmacology and formulation science. It is possible to give some rough guidance on what is likely to attract an obviousness allegation. Thus, if the relationship with the prior art is one of isomerism (positional or spatial), homology (such as propyl or ethyl for methyl), or involves replacing groups within a series (such as bromo for chloro) or generally recognized to be similar in properties (such as cyano or nitro for halogeno), then an a priori obviousness objection is likely to be made. Successfully countering (rebutting) such an objection by argument alone may be difficult and instead it may be necessary to use evidence of unexpected properties or difficulties in moving from the prior art to the claimed molecules. What then is the closest relevant prior art for assessing inventive step? First, this may not necessarily be the same as the known drug that was the starting point for the research. Thus, the structurally closest compounds to the claimed analogues may have a totally unrelated set of industrially useful properties (e.g., as dyestuffs) or they may have been simply published without any apparent utility in an academic paper. In both of these cases, it should be possible to counter an obviousness argument by saying that the useful pharmacological properties of the new analogues were unexpected and could not have been predicted from what was known in the prior art. In general, patent specifications only need to contain an indication of the relevant prior art without disclosing the closest piece of prior art, although applicants will usually have to get close to specifying it in order to properly set out the advantages of the invention. If it is clear from the outset that the new analogues have a very close relationship with a known drug, then the nature of the unexpected properties (such as unexpectedly superior activity, bioavailability, stability, lack of side effects or toxicity, etc.) and details of how they can be demonstrated (e.g., any special testing systems) should be set out in general terms in the patent specification. However, it is generally better to await the nature of any obviousness challenge before presenting actual evidence of the unexpected properties since these are likely to be required in comparison with what is cited as the closest prior art by the relevant patent examiner. While overcoming objections of obviousness by providing suitable evidence of unexpected effects is attractive, it may give rise to problems when a patent is the subject of litigation, especially in the United States of America. The evidence and those who produced it are then subjected to close scrutiny by the parties to the litigation examining the nature and extent of the comparisons made and the conduct of the testing. Consequently, evidence should only be offered to dispose of an obviousness objection after counterarguments have failed. Such counterarguments
j91
j 4 Issues for the Patenting of Analogues
92
might be based on structural dissimilarities with the prior art compounds, contrary teaching in the literature such as structure–activity relationships leading away from the new analogues, a long-felt want for the invention indicated by false starts or failures, or difficulties in synthesizing the new analogues. However, mere evidence of the commercial success of the patented drug may not be sufficient since there may be other reasons for this such as substantial expenditure on marketing. The finding that the new analogues possess additional useful properties, even if unexpected, may not always be sufficient if the analogues exhibit similar underlying properties to those of the original drug. Thus, such properties might be seen as a bonus rather than as demonstrating an inventive step if a series of novel betareceptor antagonists structurally very similar to the known drug propranolol were found to have similar levels of antagonist properties but had greater stability. However, if the extra property was perhaps to be cardioselectivity and it was to be shown that this had previously been difficult to achieve, then this would probably have supported the presence of an inventive step. Although all the major developing countries employ similar principles when approaching assessment of inventive step to those set out by the US Supreme Court above, in practice the approaches may differ. Thus, the European Patent Office in examining an inventive step adopts the so-called problem–solution approach that, after determining the closest relevant prior art, establishes what it considers to be the objective technical problem to be solved by inspecting the patent specification and looking for the features that distinguish the invention over the prior art and then decides whether the solution – the claimed invention – would have been obvious to the notional skilled person starting from the closest prior art. In this context, when setting up the notional technical problem to be solved, it is not appropriate to use compounds from the prior art that although structurally closest to the claimed compounds would have been disregarded as irrelevant by the person skilled in the art.9) US courts have taken a similar view and held that it is not reasonable to expect that a skilled medicinal chemist would remove a structural feature known to convey superior properties to a known drug when starting to search for new improved analogues [3]. They have also rejected an attempt to suggest that one structurally analogous compound would be necessarily chosen from among the 54 in total described in an earlier patent as the starting point for improved analogues without clear teaching that it was preferred [4]. Finally, it must be mentioned that it is not usually acceptable to construct an obviousness argument based on a mosaic of parts from many different unrelated prior art documents. If several documents are used, they must be clearly linked and it must be possible to show how the skilled man would inevitably be led to combine them to reach the claimed invention.
9) European Technical Board of Appeal, decision T334/92, Eisai Benzodiazines: here the EPO was held to have improperly based the notional problem on a 20-year old reference that, although including structurally very similar compounds to the antiangina agents claimed, had been disregarded by other groups working in the area as a starting point for new antiangina drugs; see http://legal.europeanpatent-office.org/dg3/biblio/t920334eu1.htm.
4.9 Selection Inventions
4.8 Utility: Industrial Application
Unless compounds have some useful property that can be used in some industrial context, they cannot be validly patented. Consequently, it is important to ensure that all the molecules included in a drug analogue patent specification possess the underlying biological activity at a level that is useful. It is frequently tempting, during a large synthetic program to produce drug analogues, to include every compound made irrespective of the extent of biological activity shown in the assay systems. Yet including any significant number of such inactive compounds introduces a fatal weakness into any eventual patent since a determined competitor may well be able to discover such an area of inactivity and thus challenge the patent for lack of utility. Showing useful pharmacological properties in the target disease situation in humans or animals is normally not possible since most patents on drug analogues are applied for well before any clinical evaluation has been possible. However, data from in vitro assays or testing in an animal surrogate and which is reasonably correlated with the end disease can be used to satisfy the therapeutic utility requirement for patentability. This information correlating any assay or animal testing with the disease should be provided in the specification together with test data at least in general terms for the analogues described in the examples. Before the 1980s, in the United States of America patent applications asserting use in treating cancer in humans were regularly rejected as lacking utility because such use was considered incredible. However, this is fortunately no longer the case and [Patent] Office personnel must determine if the asserted utility for the invention is credible based on the information disclosed in the application [5].
4.9 Selection Inventions
Selection inventions, as the name implies, involve the selection of a small number of compounds previously included within a known broadly defined group of compounds (usually within the scope of the claims of an earlier patent) and finding that the selected compounds possess some unexpected useful properties such as surprisingly higher activity. However, selection inventions still have to satisfy the novelty and inventive step criteria for patentability but the resultant patents are self-standing and have an independent 20-year term. Consequently, they can be particularly useful where there is a new drug analogue research program continuing over several years and the initial patents may not contain the eventual drug development candidate. Of course, if the selection has been made from within the broad groups of compounds claimed in a patent that is still in force and that has been granted to a competitor, then commercializing one of the selected compounds will require a license under the competitors patent. Equally, the competitor could not commercialize a compound claimed in the selection patent without a license. Normally, such a situation would be dealt with by cross-licensing of both patents.
j93
j 4 Issues for the Patenting of Analogues
94
Establishing novelty for a selection invention can be very difficult. None of the compounds in the selection must have been described before or suggested as possibly obtainable anywhere in the prior art and for any purpose. This includes not being mentioned in patent claims. As mentioned before, a typical main claim to drug analogues may nominally include hundreds of thousands of possibilities, the majority of which have not been made. Making a small selection of compounds from such a large number of possibilities is not usually a problem in terms of novelty, unless the earlier patent specification suggests that certain optional groups of compounds are preferred alternatives. However, the subsidiary claims in the patent will likely contain a general formula with short lists of alternative substituents including perhaps only a few tens or hundreds of compounds. The novelty of compounds selected from such narrow claims may thus be in doubt. It is not possible to give hard and fast rules about what size of group will be considered as novel over the prior disclosed broad group since such assessments are highly fact specific and there is considerable variation among the United States of America, Europe, and Japan. Suffice it to say that selection patents must necessarily have narrowly defined claims in terms of the number of molecules included and ideally contain only a handful. In addition to novelty, an inventive step must be shown over the prior art, that is, the known compounds from which the selection is made. This can either be based on a new and valuable property, such as the one making the compounds useful in a new disease situation, a substantial reduction in adverse properties such as toxicity or side effects, or else a substantial increase in the underlying activity of the prior art compounds, but in all cases where the new property or size of the change in properties could not have been predicted from the prior art. The nature and extent of the properties providing the inventive step and how they can be demonstrated must be properly set out in the patent specification. Also, it is even more important than in ordinary patents on drug analogues to ensure that all claimed compounds within the selection possess the unexpected and useful properties.
4.10 Enantiomers
Enantiomers of racemic drugs are probably the closest structural analogues and a patent protecting an enantiomeric form, the ultimate selection invention of one from two molecules. The first hurdle to patentability is to demonstrate novelty over the known racemic form. Fortunately, most countries take the view that an enantiomer of a known racemic form that has never been known or existed except in the presence of the other enantiomer is formally novel and move the inquiry to inventive step. At one time, it was unusual to consider separating individual enantiomers of clinically useful drugs partly because of the additional cost of manufacture, but today it is the norm and many drugs are now used as single enantiomers. It has also become easier with modern technology to produce such enantiomers on a large-scale commercial basis either by stereoselective synthesis or by physical separation
4.11 Prodrugs and Active Metabolites
F
N
O N Figure 4.4 Escitalopram (LexaproÒ ).
techniques such as chiral HPLC. Consequently, it is difficult now to argue that the skilled person would not routinely attempt to separate a racemic candidate drug molecule to establish how the useful biological property, side effects, and toxicity were distributed between the individual enantiomers. However, things that are obvious to try are not necessarily obvious in fact because there may be all sorts of reasons why success cannot be achieved [6]. As a result, patents claiming a single enantiomer often start with a presumption that they lack an inventive step over the known racemic form of the drug. Such a presumption can be disposed of only by concrete evidence of unexpected properties in the enantiomers. In addition, there can be difficulties arising from whether the information in the patent specification is sufficient to support a product claim to the enantiomer however prepared and without any use limitation. An interesting set of legal judgments in the English courts [7] illustrate many of the issues of patentability referred to in this chapter and involve the enantiomeric antidepressant drug escitalopram (Figure 4.4). These decisions are self-contained and present the various issues in clear terms.
4.11 Prodrugs and Active Metabolites
Both of these may be regarded as analogues of known drugs and may even be interrelated. Prodrugs are normally chemically simple derivatives or precursors of the parent drug that are not active until the drug moiety is presented in vivo and they are usually designed to overcome some deficiency in the original drug, for example, esters, ethers, oxidizable precursors, and so on of the drug molecule. Prodrugs may be difficult to patent and the issued patents susceptible to challenge when the drug itself is already known. They first need to pass the novelty hurdle that may be difficult since many simple derivatives such as alkyl esters will probably have appeared routinely together with phrases such as or a prodrug thereof in drug patent specifications. The prodrug concept is well known and so prodrugs of existing drugs are at face value obvious unless the added element forming the prodrug itself contains some special or unusual structural component or it can be shown that the prodrug possesses surprising or unexpected benefits, such as dramatically improved bioavailability, duration of effect, and so on.
j95
j 4 Issues for the Patenting of Analogues
96
O
S OH N
N N
O
H
O
Figure 4.5 Hetacillin.
NH2 NH
H S N
O O
OH O Figure 4.6 Ampicillin.
One prodrug that was the subject of extensive patent litigation was hetacillin, the acetone condensate of the antibiotic ampicillin (Figures 4.5 and 4.6). This prodrug is inactive as an antibiotic until administered to humans when ampicillin is rapidly regenerated in the blood stream. As a result, its sale was eventually held in the United Kingdom to be an infringement of the existing patent on ampicillin [8]. Active metabolites may be patented insofar as their existence has not been published and it is not obvious that they will be produced from the drug itself. Since such metabolites are generally found only when the drug is administered to humans, any patent application is likely to be filed several years after the application protecting the drug itself and so will lead to later expiring patents. Consequently, there is the opportunity to maintain effective patent protection for a product even after the patent protecting the active ingredient has expired by alleging infringement of the active metabolite patent when the drug is administered to patients. Examples of patented active metabolites that resulted in litigation include the antihistamines fexofenadine, which is a carboxylic acid formed rapidly in vivo following administration of terfenadine (Figures 4.7 and 4.8) and desloratidine, which is the major metabolite of loratidine (Figures 4.9 and 4.10).
OH O
N OH OH Figure 4.7 Fexofenadine (AllegraÒ ).
4.12 The Patenting Process from the Inventors Standpoint
N OH OH
Figure 4.8 Terfenadine (SeldaneÒ ).
H N
N Cl Figure 4.9 Desloratidine (ClarinexÒ ).
O
O
CH3
N
N Cl Figure 4.10 Loratadine (ClaritinÒ ).
Attempts to enforce the relevant patents on these active metabolites against companies commercializing the parent drug have met with varying results [9] in different countries, demonstrating the problems particularly of novelty in patenting this type of drug analogue.
4.12 The Patenting Process from the Inventors Standpoint
Having a patent application filed for a drug invention is a major achievement for most medicinal chemists especially if they are one of the named inventors. However, it sets in train a series of events that can involve the inventor with the patent system for many years especially where a successful drug product results. The whole patenting process to obtain patents in the United States of America, Europe, Japan, and other commercially important countries can easily take up to 10–12 years by which time most medicinal chemists will have moved onto new projects if not new job roles.
j97
j 4 Issues for the Patenting of Analogues
98
However, their involvement with the patents on which they are inventors may nonetheless continue, often in the following respects. 4.12.1 Inventorship
Deciding who are to be the inventors for a patent application – the inventorship – is an important legal matter affecting the ultimate validity of any patent and is resolved by the patent attorney handling the application. Inventorship is not decided like authorship of scientific papers but in the light of all the facts surrounding the invention, how it was arrived at, and who was associated with the critical steps involved. However, in the case of a new set of analogues based on an existing drug, it is probable that there will be at least one medicinal chemist inventor. 4.12.2 The Priority Patent Application
The medicinal chemist inventor is first likely to be involved when filing a priority establishing patent application – the priority application – is being considered. At this stage, a decision must be made on the extent of the compounds to be included in the claims and which synthetic methods are to be included. Then, there will be a request to supply written examples of compounds that have been made and tested. It is important at this stage to inform the patent draftsman of any compounds that are inactive so that they can be excluded from the claims either by careful construction of the substituent definitions in the general formula or by specific disclaimer.10) 4.12.3 Prior Art Disclosure
The patent draftsman must also be told about any relevant publications, seminars, or the like – prior art – that seem at all relevant to the compounds being patented. It is probable that a formal search for relevant prior art will be carried out that will pick up patent specifications and scientific journal articles, but the research team working on the invention is best placed to identify less well-documented prior art such as conference abstracts. Under the requirements of US law, the inventors and others in the research team associated with the patented invention must provide the patent attorney handling any corresponding US patent application with publications and other pertinent information so that this can be submitted to the US patent examiner who is assigned to process the application. This is a continuing obligation under US law until a US 10) Disclaimers are found at the end of the claim and are typically in the form: what we claim is a compound of the formula A wherein the substituents R1, R2 and R3 have any of the following meanings. . .; but excluding the compounds of the formula A wherein R1 is methyl or ethyl, R2 is hydrogen and R3 is fluoro. . . .
4.12 The Patenting Process from the Inventors Standpoint
patent is granted – failure to comply may lead to a charge of fraud on the patent office and result in the patent being unenforceable, should the patent be litigated. 4.12.4 Patent Specification Review
It is tempting for inventors to read only the examples and technical description of patent specifications, particularly because the documents tend to be repetitive and legalistic and contain seemingly standard wording about dosages, formulations, and the like – the so-called boiler-plate text. However, especially at the drafting stage, inventors should make sure they read all of the patent specification carefully. It is easy for cut and paste word-processing errors to creep in and it is very likely that the inventor will be the person on the witness stand asked to explain what he or she meant by the text! Also, it is not possible to correct errors other than those for which a correction is obvious by reading the text once patent applications have been filed. That said, it is still important to complete reviewing the draft quickly so that the application can be filed with the earliest possible date – the inventors are on the critical path to doing this and may sometimes be the rate-limiting step in the patent application process. 4.12.5 Best Mode of Carrying Out the Invention
A US patent application must comply with another special requirement and the specification must set forth the best mode contemplated by the inventor of carrying out his invention. In the case of analogue patents, this means that the best analogue known to the inventor at the time the application is filed must be included somewhere in the specification. It simply has to appear somewhere but does not have to be flagged up as the best mode. The penalty for not disclosing it is invalidity of the eventual US patent. It must also be present in a foreign-filed priority application if priority is to be maintained in the United States of America. 4.12.6 Foreign Patent Applications
Some nine months after the priority application has been filed, a decision has to be made whether to continue with the patenting process by filing further patent applications in foreign countries, updating the material in, and claiming priority from, the earlier application. These new filings may be made via a single PCT application and/or individual national applications. If a PCTapplication is filed, then after some degree of centralized examination of formal matters as well as a search for prior art affecting novelty and inventive step, it will lead to a series of national applications or regional applications (such as through the European Patent Office) that will then be further examined before any patents are granted. Under the Paris Convention, these applications must be filed within 12 months of the earliest priority application which is an inextensible deadline. However, since translations are often
j99
j 4 Issues for the Patenting of Analogues
100
required, the process to prepare the updated specification for the new applications is usually started several months before the deadline. At this stage, the inventor again needs to supply further examples of analogues based on the original invention and confirm their useful biological properties and mention any inactivity of the analogues. The best mode requirement must also be updated by including the latest preferred analogues. The updated specification will also need to be carefully checked since this may be the final point at which it is possible to easily correct errors and omissions – new matter cannot generally be added after filing which is one reason why patent specifications tend to be so verbose–everything needs to be present that may be needed during the lifetime of the patent, which can be up to 25 years for a drug analogue patent. 4.12.7 Patent Application Publication
Assuming the priority application is maintained by filing one or more corresponding applications, the patent specification will be published more or less as originally filed 18 months after the earliest priority application, or shortly afterwards. This date is important for inventors since patent applications from competitors published after this date, apart from in the United States of America,11) must necessarily be based on later-filed priority applications and cannot then validly claim the same invention. Usually, the application is published together with an official search report of the prior art although this may be published separately. This report indicates which prior published material is considered most relevant to the novelty and inventive step of the invention and gives an early indication of how difficult it may be to obtain a granted patent. 4.12.8 Patent Examination
All patent offices have some backlog of applications and so it may be some time (perhaps as long as 2–3 years) after a patent application has been filed and examination requested before the relevant patent office will issue an official letter – sometimes referred to as an office action – with a fixed date for reply. The letter12) will be 11) As mentioned earlier, in the United States of America it is the person who is first to make the invention and not the first patent applicant who is awarded an eventual patent following a complex and lengthy patent interference procedure. For drug analogue patents, this procedure critically depends on being able to establish dates on which an example from the patent was first conceived and made and tested in the laboratory for its therapeutic purpose. It is most important therefore to keep proper dated laboratory documentation of the preparation and test-
ing of compounds with the pages signed and dated by the person who carried out the work and the signature corroborated by someone independent of the research work. 12) The official letters issued to patent applicants may contain some off-putting language like all claims rejected, final rejection, and the like. However, these are formal official positions that can be argued against and usually overcome by the patent attorney with technical assistance from the inventor.
4.12 The Patenting Process from the Inventors Standpoint
received first by the patent attorney handling the application who will usually ask for technical input from the inventors about replying to any objections about patentability over cited references. This input has to be given high priority over other work since, although extensions may be obtainable (often with payment of a fine), failure to reply on time to the patent office may lead to the patent application being considered abandoned and all rights lost. In some patent offices (such as in the United States), it is possible to meet with the examiner in person, in an attempt to resolve difficulties and the inventor may usefully also attend, as may the patent attorney. Several official letters and replies may be required before either a notice of the intention to grant a patent or confirmation of its rejection is received. In the latter situation, it is usual to appeal the rejection to the appropriate Appeal Board within the patent office or to the relevant court. In both cases, the inventor will be required to provide technical inputs to help the legal professionals argue the appeal that is likely to be critical to its eventual success. Considerable care should be exercised before any additional experimental data is generated for the purpose of overcoming objections in official letters, especially comparative test data with prior art molecules. Negative data from such testing cannot be ignored and must also be communicated to the examiner considering a US patent application, even if the testing was carried out in connection with a non-US application. 4.12.9 Opposition to Grant
In Europe, before a European patent becomes effective in the national states designated when the application was filed, it is possible for an interested party to oppose the patent grant. This must be done within 9 months of the publication date of the patent specification in the form in which it is to be granted. Thus, the end of the European opposition period is another important milestone in the patenting process. If an opposition is filed, then the inventors input is central to its legal defense and further time commitment can be expected for several years.13) If no opposition is filed, then the application immediately becomes a bundle of national patents that can then be enforced, albeit separately, in the countries concerned. Afterward, these patents may only be challenged before the individual national courts and so successfully opposing patent grant can be a cost-effective way of disposing of a European patent.
13) Decisions of the Opposition Division of the EPO can be appealed adding still further time until the matter is finally resolved – as an extreme example, European Patent 58481 protecting continuous release depot formulations for polypeptide drug moieties such as the anticancer agent goserelin (ZoladexÒ )
was originally opposed by 12 companies and the final appeal upholding the patent in amended form was only given on February 28, 2001 just 11 months before the patent expired at the end of its 20-year patent term on February 28, 2002!
j101
j 4 Issues for the Patenting of Analogues
102
4.12.10 Patent Litigation
Most patent systems that used to provide opposition before patent grant (such as those in the United Kingdom, Japan, and the Republic of Korea) have now replaced this with the ability to apply to revoke the patent challenging its validity at any time during its lifetime. One important exception is India, which allows for oppositions before and after a patent is granted. In addition, in most infringement proceedings, the alleged infringer will challenge patent validity in a counterclaim for revocation or invalidation of the patent. Again, the inventor will be needed to provide important technical support to the legal action. As already mentioned, the validity of any US patent protecting a drug with significant US sales is likely to be challenged in a US Federal Court since an applicant to register a generic version for sale with the US Food and Drug Administration (FDA) must certify that the patent is invalid or else not infringed if the generic is to be sold before the patent expires.14) This may then trigger infringement proceedings against the applicant for the generic product and involvement of the inventor as a key witness over a period of several years until the litigation is resolved and any appeal concluded. Such litigation involves extensive discovery of background documents and technical papers including those held by the inventors anywhere in the world. It is most important therefore to adopt good document retention practices, discarding informal notes and draft documents, and so on (including electronic copies and e-mails) when they are superseded by final versions.
4.13 Pitfalls for the Unwary: Granted Versus Published Patents, Scientific Publications
It is important to recognize the difference between published patent applications and granted patents. Applications are published essentially as the applicant submitted them and having had only very limited formal examination, for example, to amend the title or abstract. Consequently, the claims may appear unreasonably broad. Published granted patents have been subject to full examination for patentability and the extent of the claims may well have been considerably restricted. It is these claims that need to be assessed when considering potential infringement situations. However, just because a granted patent has been published does not mean that it is necessarily still in force since it may have lapsed through failure to pay the renewal fees. 14) In the United States of America, on filing an ANDA for a generic version of a registered NCE drug, one of the following four certifications must be made: para (i) no patent is listed in the FDAs Orange Book of patent exclusivities for the registered NCE product; para (ii) the listed patent has expired; para (iii) the listed patent will have expired before the
requested approval takes effect; and para (iv) the listed patent is invalid or will not be infringed by the generic version. The filing of a para (iv) certification is a statutory act of infringement and must be copied to the relevant patentee who then has up to 45 days to start infringement proceedings against the applicant for the generic registration.
4.13 Pitfalls for the Unwary: Granted Versus Published Patents, Scientific Publications
Most patent owners regularly review their portfolio of patents and relinquish some, so it must never be assumed that an important patent is still in force – the relevant official patent registers must be checked first.15) At the end of a drug analogue research program, the research team frequently wishes to publish its scientific findings in a major, peer-reviewed journal. However, it is important to check the proposed publication with the attorney handling the relevant patent applications before submitting the text to a journal – its publication may influence the timing of further new patent applications, especially if it includes the rationale or theory for making new analogues or their pharmacological properties.
Appendix 4.A Some Patent Jargon Terms16)
One of the problems for researchers when first venturing into the arena of patents is the specialist language and jargon used. Like all jargon, some of it may be specific to particular countries or even companies, but explanations are offered below for some of the more commonly used terms. Priority Date: The earliest date to which subject matter or claims is entitled when considering the impact of prior art: it is usually the filing date of an earlier application – the priority application – that was the first filed by the applicant for the invention anywhere in the world. Prior Art: Everything known, used, or described publicly anywhere in the world usually in documented form and pertinent to the technical area(s) with which the invention is concerned before the filing date of the patent application or the earliest priority date from which it is entitled to claim priority; it includes the general knowledge of practitioners in the art at the relevant date as documented in standard reference works. Patent: This term is used loosely with a variety of meanings depending on the context. Strictly, it refers to the legal document including a detailed final specification and claims issued (granted) by the country concerned after examination of an application. However, it is frequently used as shorthand for a patent specification alone whether in examined, final form, or in unexamined, early published form. It is also used as a verb meaning to protect an invention by filing and prosecuting a patent application to obtain a granted patent.
15) Checking the global patent status for a particular product is a specialized task best dealt with by patent attorneys, but several registers are available on-line and can be easily checked by inventors, for example, the European patent register can be searched free of charge at http://www.epoline.org/portal/ public/registerplus. 16) Much of the jargon is peculiar to the national patent system in use and so many different
glossaries of patent-related terms are available on the Internet; examples include that provided by Delphion: http://www.delphion. com/help/glossary; the European Patent Office: http://www.epo.org/help/glossary. html; the US Patent & Trademark Office: www.uspto.gov/main/glossary/index.html; and P.W. Grubb, in Patents for Chemicals, Pharmaceuticals, and Biotechnology, 4th edn, OUP 2004, ISBN: 0-19-927378-2.
j103
j 4 Issues for the Patenting of Analogues
104
Patent Family: A group of essentially similar patents (or applications) for the same invention filed in different countries based on the same priority applications. Prosecution: Progressing a patent application from first filing to grant or rejection and involving responding to questions and objections raised by patent offices during examination. Markush Claim: A claim including a list of alternative compounds of a generally similar nature either in relation to their properties or biological activity or else having a common structural element – named after a US inventor, Eugene A. Markush, who in 1924 succeeded in getting a US patent with this type of claim.
Appendix 4.B A Typical Broad Chemical Claim: US Patent Ser. No. 4,513,006 (Topiramate)
A sulfamate of the following formula (I): X
CH2OSO2NHR1
R5
R2 R4
R3
wherein X is oxygen; R1 is hydrogen or alkyl; and R2, R3, R4, and R5 are independently hydrogen or lower alkyl, and R2 and R3 and/or R4 and R5 together may be a group of the following formula (II): R6
O C
R7
O
wherein R6 and R7 are the same or different and are hydrogen, are lower alkyl, or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
Appendix 4.C Further Reading
P.W. Grubb, Patents for Chemicals, Pharmaceuticals and Biotechnology, 4th edn, OUP 2004, ISBN 0-19-927378-2; this book provides comprehensive background to international patenting for chemists and other scientists. The web sites of the US [http://www.uspto.gov/], European [http://www.epo.org/], and Japanese patent offices [http://www.jpo.go.jp/] are useful sources of general information about patents, trade marks, and other intellectual property rights.
References
References 1 Fischer, J. and Ganelllin, C.R. (2006)
2
3
4
5
6
Introduction to Analogue-Based Drug Discovery, IUPAC, 1st edn, Wiley-VCH Verlag GmbH, Weinheim, p. xix. Graham vs. John Deere Co., 383 U.S. 1, (1966) (US Supreme Court). This case involving agricultural plough improvements set important precedents still followed today for consideration of non-obviousness: http://supreme.justia. com/us/383/1/case.html. Eisai vs. Dr Reddys Labs and others, US Court of Appeals for the Federal Circuit (CAFC) (2008). In this case involving a challenge to the US Patent 5,045,552 for the antiulcer agent rabeprazole, it was alleged that the closest prior art was the drug lansoprazole that contained a 2,2,2trifluoroethoxy group known to confer excellent lipophilicity. The court held that the record contains no reasons a skilled artisan would have considered modification of lansoprazole by removing the lipophilicity-conferring fluorinated substituent as an identifiable, predictable solution. So, the issue of the comparability of the trifluorethoxy group of lansoprazole with the structurally similar 3methoxypropoxy group of the new antiulcer analogue rabeprazole could not arise for considering it an inventive step. Instead, the structurally more distant drug omeprazole that contains a methoxy substituent was the proper comparison drug; see www.cafc. uscourts.gov/opinions/07-1397.pdf. Takeda vs. Alphapharm, US CAFC (2007). This case concerns the antidiabetic agent pioglitazone and provides a clear summary of the US position on inventive step in relation to structural analogues and the proper choice of the prior art compound for consideration of obviousness; see http:// www.cafc.uscourts.gov/opinions/06-1329. pdf. US Manual of Patent Examining Practice (2008): http://www.uspto.gov/web/offices/ pac/mpep/documents/2100_2107_03.htm. Apotex vs. Sanofi-Sythelabo Canada (Canadian Supreme Court, 2008). The Court rejected an allegation that the enantiomeric antiplatelet agent clopidrogel
(PlavixÒ ) was anticipated by (lacked novelty over) or was obvious from the corresponding racemate that was described amongst 21 specific analogues out of more than 250 000 possible molecules within the claims of an earlier patent. In the words of the Court, For a finding that an invention was obvious to try, there must be evidence to convince a judge on a balance of probabilities that it was more or less selfevident to try to obtain the invention. Mere possibility that something might turn up is not enough. Here, when the relevant factors are considered, the invention was not self-evident from the prior art and common general knowledge in order to satisfy the test. While there were five wellknown methods to separate this racemate into its isomers, there was no evidence that a person skilled in the art would have known which of the five known separation techniques would work with this racemate. See http://scc.lexum. umontreal.ca/en/2008/2008scc61/ 2008scc61.html. 7 Lundbeck vs. Generics (UK) et al. EWCA Civ 311 (UK Court of Appeal) (2008); see http:// www.bailii.org/ew/cases/EWCA/Civ/ 2008/311.html. Generics (UK) et al. vs. Lundbeck UKHL 12 (House of Lords) (2009); see http://www.bailii.org/uk/cases/ UKHL/2009/12.html. 8 Beecham Group vs. Bristol Labs (UK House of Lords), see (1978). Reports of Patent Cases, 153. 9 see, for example, Merrell Dow Pharmaceuticals (now Sanofi-Aventis) vs. Norton (UK House of Lords) (1995). Here the Court held that the fenofoxadine patent was invalid over the earlier terfenadine patent since It enabled the public to work the invention by making the acid metabolite in their livers. The fact that they would not have been able to describe the chemical reaction in these terms does mean that they were not working the invention. Whether or not a person is working a product invention is an objective fact independent of what he knows or thinks about what he is doing; see http://www.bailii.org/uk/cases/
j105
j 4 Issues for the Patenting of Analogues
106
UKHL/1995/14.html; see also Schering Corporation vs. Geneva Pharmaceuticals (USA: CAFC). Here the Court reaffirmed the principle that something which would be an infringement after a patent was granted would be a novelty destroying anticipation if it occurred before grant; it then held that the claims to the metabolite desloratidine [DCL] were invalid since the earlier patent for loratidine effectively disclosed the metabolite by describing the administration of the parent drug to patients; in particular the Court stated that this Court has recognized that a person may infringe a claim to a metabolite if the person ingests a compound that
metabolizes to form the metabolite. . . . The [loratidine] patent discloses administering loratadine to a patient. . . . The inherent result of administering loratadine to a patient is the formation of DCL. The patent thus provides an enabling disclosure for making DCL. However, the Court observed that there was no objection to the validity of the claims to formulations containing DCL and that similarly claims directed to a pure or isolated form of the metabolite would also have been valid; see http://www.ll.georgetown.edu/FEDERAL/ judicial/fed/opinions/02opinions/021540.html.
Stephen C. Smith
UK and European Patent Attorney NuPharm Intellectual Property, New Farm, Twemlow Green, Holmes Chapel, Cheshire CW4 8BS, UK Stephen C. Smith is Managing Director of NuPharm Intellectual Property, a company he set up in 2001 to provide IP consultancy services after he retired from AstraZeneca Plc., where he was Global Head of patents, beginning his career as a medicinal chemist. He is a member of the Board of the Intellectual Property Institute and of the newly established UK Patent Regulation and IP Regulation Boards. Steve is a UK and European Patent Attorney and a Chartered Chemist. He has a BSc (Hons) degree from the University of Nottingham and a DPhil in organic chemistry from the University of Sussex.
Part II Analogue Classes
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j109
5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes Jens-Uwe Peters and Patrizio Mattei 5.1 Introduction
The symptoms of diabetes mellitus, a metabolic disorder characterized by hyperglycemia (abnormally high blood glucose) due to inadequate insulin levels, have been described since antiquity. The introduction of insulin replacement therapy for diabetes in 1922 was a major feat in the history of medicine and was awarded with the Nobel Prize in medicine in the following year. Later in the 1920s, the first oral antidiabetic drugs (OADs) were introduced. Although they were imperfect and later withdrawn, they led to the recognition that two types of diabetics exist – the juvenile type, requiring insulin therapy, and the late-onset type, which also benefits from OAD treatment [1, 2]. The late-onset form, today known as type 2 diabetes, accounts for more than 90% of all diabetic patients and affects about 4% of the world population [3]. The treatment of type 2 diabetes aims to normalize blood glucose levels by diet, exercise, and medication, and is monitored by measuring glycosylated hemoglobin (HbA1c) as a long-term marker of elevated blood glucose. The amount of HbA1c reflects the average glucose level over the last 120 days (the life span of red blood cells) and should be maintained below 7% [4]. Each percentage reduction in HbA1c leads to a 21% reduction of the risk for any diabetes-related end point [5]. Poorly controlled, chronic hyperglycemia causes microvascular damage, which affects organs with delicate capillary systems such as the eyes and kidneys, and can lead to blindness and renal failure. In addition, hyperglycemia leads to atherosclerosis of larger vessels, which increases the risk of myocardial infarction and stroke. An important complication resulting from micro- and macroangiopathy are lesions of the lower limbs (diabetic foot) that may ultimately require amputation. Unfortunately, the majority of diabetic patients do not reach recommended HbA1c levels and are therefore at risk of developing these disabling comorbidities. Furthermore, the prevalence of type 2 diabetes has increased over recent years, mainly due to higher life expectancies and an increasing prevalence of obesity [3]. Several classes of OADs have been introduced into clinical practice since the 1950s and are widely prescribed. However, they all come along with side effects such as hypoglycemia, weight gain, or gastrointestinal Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
110
problems. Moreover, they often fail to achieve sustained glycemic control. Thus, there is a critical unmet need for OADs with novel modes of action. In the late 1980s, several research groups could show that the peptidic hormone GLP-1 (glucagon-like peptide 1), which is secreted by the L-cells of the intestinal epithelium in response to food ingestion, is a potent stimulator of glucose-dependent insulin release. This finding raised hopes that exogenous GLP-1 might be used to stimulate the impaired insulin secretion in type 2 diabetic patients. Disappointingly, single subcutaneous injections of GLP-1 were ineffective in normalizing blood glucose [6]. A few years later, it was discovered that DPP-IV (dipeptidyl peptidase IV), a serine protease first isolated in 1966, rapidly cleaves and inactivates GLP-1 [7]. Several research groups recognized the implications of this finding: . . .
Inhibition of DPP-IV should prevent the rapid degradation of GLP-1 and should thus increase circulating GLP-1 levels. Increased GLP-1 levels should enhance glucose-dependent insulin secretion, leading to lower blood glucose levels. Consequently, DPP-IV inhibitors should have an antidiabetic effect.
The glucose-lowering/antidiabetic effect of DPP-IV inhibitors was soon demonstrated in animals and humans and triggered enormous research activities throughout the pharmaceutical industry in the first decade of the new millennium [8].
5.2 In Vitro Assays and Animal Models for the Assessment of DPP-IV Inhibitors
The discovery of DPP-IV inhibitors was facilitated by the availability of robust and high-throughput in vitro assays, which often rely on a simple chromogenic or fluorogenic readout. For instance, DPP-IV cleaves Ala-Pro-AFC, a peptidyl derivative of 7-amino-4-trifluoromethylcoumarin (AFC), and the green fluorescence of the cleavage product, AFC, can be distinguished from the violet-blue fluorescence of the substrate (Figure 5.1). The cleavage of Ala-Pro-AFC serves as a measure of DPP-IV activity in an in vitro assay, in which the candidate inhibitor is evaluated by its ability to suppress the formation of fluorescent AFC. Furthermore, animal models with high relevance to the human disease state were available. For instance, the oral glucose tolerance test (OGTT) in diabetic rats measures the glucose excursion, or the insulin response, after an oral ingestion of a standardized amount of glucose, and is equivalent to the OGTTused in the diagnosis of diabetes in humans. The efficaciousness of DPPIV inhibitors can be evaluated in such an animal model by their ability to reduce the glucose excursion after their administration prior to the glucose challenge.
5.3 Substrate-Based DPP-IV Inhibitors
Speculations about the relevance of DPP-IV in the processing of bioactive peptides, and its potential role in diseases such as cancer and AIDS, might have provided much
5.3 Substrate-Based DPP-IV Inhibitors
CF3 N
H2N O
O
DPP-IV O
N H
O
Ala-Pro-AFC CF3 N
H2N O
O
+ OH
Ala-Pro-OH
H2N
O
O
AFC green fluorescent
Figure 5.1 DPP-IV liberates AFC from its dipeptidyl derivative, Ala-Pro-AFC. The green fluorescence of the product is used as a readout in a DPP-IV inhibition assay.
of the impetus for DPP-IV inhibitor research in the 1980s [9]. At this time, the ACE inhibitor success story had just proven that substrate-based design is a viable approach to drug discovery, and it seems natural that this concept was also pursued in DPP-IV research. DPP-IV is an endopeptidase that releases dipeptides from the Nterminus of a wide variety of peptidic hormones, with a preference for proline at the penultimate position. This proline preference is pronounced in small substrates (such as Ala-Pro-AFC, Figure 5.1), even if the larger peptide GLP-1 (30 amino acids) is cleaved after an alanine (Figure 5.2). In the early 1990s, several academic research groups disclosed dipeptide-like DPP-IV inhibitors, in which a pyrrolidine or a thiazolidine replaces the proline, and an attached amino acid with a free amino group mimics the N-terminus of a substrate peptide (Figure 5.3). The scissile peptide bond was either omitted, as in the prototypical DPP-IV inhibitor P32/98 [10], or replaced by a functional group designed to mimic the proteolytic transition state or to covalently bind to the enzymes active site serine. For instance, prolineboronic acids such as 1 have been designed as transition-state analogues and are reversible, slow-binding inhibitors with activities in the low nanomolar range [11]. Phosphonates such as 2 are irreversible inhibitors, which form stable esters with DPP-IVs catalytically active serine. However, these early types of serine-interacting inhibitors did initially not provide clear advantages over the noncovalent inhibitors, as they were too unstable, too unselective, or did not show a substantially improved activity. Nevertheless, the boronic acid dutogliptin, a DPP-IV inhibitor discovered by Phenomix, has
+
H3 N
His - Ala - Glu - Gly - Thr - Phe - ...
cleavage by DPP-IV Figure 5.2 DPP-IV cleaves GLP-1 at the penultimate position from the N-terminus.
j111
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
112
N
H2N
N
N H
S
O
O P32/98
N H
B(OH)2
1 IC50 = 20 nM
K i = 123 nM Demuth et al., 1991
N PO(OPh)2
O
2
Flentke et al., 1991
irreversible Powers et al., 1995
N
N
H N N H
O
H2N B(OH)2
O N
Dutogliptin
3
IC50 = 25 nM Phenomix, 2005
Ki = 2.2 nM Ferring, 1996
Figure 5.3 Early substrate-based DPP-IV inhibitors and dutogliptin.
apparently overcome these limitations and entered phase 3 clinical development in 2008 [12, 13]. In 1994, a publication demonstrated that nitriles could be used as serine-interacting motifs in inhibitors of prolyl endopeptidase (PEP), a serine protease related to DPP-IV [14]. So far, nitriles had only been known to be cysteine protease inhibitors, but were regarded unreactive to typical serine proteases. This surprising finding prompted Sherwin Wilks research group at the City University of New York, and researchers working with Paul D. Jenkins at Ferring Pharmaceuticals, to introduce nitriles into their substrate-based DPP-IV inhibitors [15–17]. These new cyanopyrrolidine-type DPP-IV inhibitors, for example, 3 (Figure 5.3), turned out to have an approximately 100-fold improved inhibitory potency, and additionally both a good selectivity profile and an acceptable chemical stability. Up to this point, the role of DPP-IV in glucose homeostasis was not fully recognized. Rolf Mentlein et al. from the University of Kiel had already demonstrated in 1993 that GLP-1 is a substrate of DPP-IV in vitro [7], but this did not necessarily mean that DPP-IV would be the main metabolic enzyme of GLP-1 in vivo. Actually, 3 was proposed as a potential immunomodulator, as DPP-IV is identical to CD26, a component of the T-cell receptor complex. In 1995, Jens Holst and coworkers from the University of Copenhagen concluded from their studies that DPP-IV is responsible, at least in part, for the observed rapid degradation of GLP-1 in humans and proposed that inhibition of DPP-IV could be a useful adjunct in the management of type 2 diabetes [19]. Shortly thereafter, a collaborating team of scientists working with Hans-Ulrich Demuth from the University of Halle and Christopher H.S. McIntosh and Ray A. Pederson from the University of British Columbia patented DPP-IV
5.3 Substrate-Based DPP-IV Inhibitors
inhibition as a method to lower blood glucose [20]. The patent application was disclosed in 1997 and demonstrated that DPP-IV inhibition with P32/98 did indeed improve glucose tolerance in rats. Demuth, who had spent most of his academic career working on DPP-IV, would later start the biotech company, Probiodrug, to exploit this invention and to bring P32/98 into the clinic. The improvement in glucose tolerance by P32/98 was then reproduced in human healthy volunteers and diabetic patients. P32/98 and the epimeric allo-isoleucyl-thiazolidide were licensed to Merck in late 2000. However, development of both compounds was discontinued in February 2001, after Merck had identified unacceptable toxicity profiles for both compounds. Later, insufficient selectivity over the related dipeptidases DPP-8 and/or DPP-9 was postulated to be the reason for the observed toxicities [21]. At that time, Merck had already identified fluoropyrrolidine 4 (Figure 5.4) as a potential development compound. Because the rationale for subtype selectivity was compelling, 4 was rejected on the basis of a selectivity of only 50-fold over DPP-8 and DPP-9, and medicinal chemistry focused on HTS-based DPP-IV inhibitors, which culminated in the discovery of sitagliptin (see Section 5.4). Further exploration of the substrate analogue series provided 5, with a selectivity of >10 000-fold over DPP-8/9 [22]. This compound was brought forward as a backup for sitagliptin [23]. Another potent and selective difluoropyrrolidine derivative, PF-00734200, has been discovered by Pfizer. This compound was reported to be in phase 2 clinical studies in September 2008 [24, 25]. During this time, the cyanopyrrolidines originally discovered by Sherwin Wilk and the group at Ferring had become the most popular class of DPP-IV inhibitors, as judged by the number of patent applications [18]. While the SAR around the cyanopyrrolidine ring was rather limited, a wide variety of attached amino acids with lipophilic or polar, negatively or positively charged, side chains were tolerated, which provided ample room for proprietary structures.
OCF3
N N
N
O S O NH
N
N N
N
F
O
F
H N
H2N O
4 IC50 = 35 nM Merck, 2004
N
H2N O 5 Ki = 8.8 nM Merck, 2004
Figure 5.4 Pyrrolidides without a serine-interacting motif.
F
N
F
F N H
N O
PF-00734200 IC50 = 13 nM Pfizer, 2005
j113
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
114
N
N H
N
H2N
O
O
N N
6 IC50 = 2 nM
7 IC50 = 64 nM
H N NC
N
N H
N O N
NVP-DPP728 IC50 = 22 nM Novartis, 1998 Figure 5.5 Scaffold change leading to N-alkylglycine DPP-IV inhibitors; NVP-DPP728 was efficacious in a proof-of-concept trial.
An important extension of this SAR was made already in 1996 by scientists at Novartis. Edwin B. Villhauer, a chemist with a long-standing interest in diabetes, was looking for a new project when Jens Holsts paper was published in 1995. Within a few days, he and his colleagues had a DPP-IV project running. Cells that happened to express DPP-IV were just available and provided an in vitro assay. A paper from 1988, describing a DPP-IV substrate with sarcosine (N-methylglycine) as an N-terminal amino acid [26], caught Villhauers attention and led him to explore N-alkylglycine cyanopyrrolidines, in which the side chain of the pyrrolidine-attached amino acid is, formally, shifted to the nitrogen atom (e.g., 6 ! 7, Figure 5.5) [27]. The novel Nalkylglycine cyanopyrrolidines were amenable to resin-based chemistry, which was a very popular technology in those years, enabling the preparation of 1300 diverse compounds within 7 months. Only a few inhibitors with low nanomolar activities were identified in this campaign, one of them carrying a (5-nitro-pyridin-2-yl)aminoethyl substituent. Replacement of the nitro functionality by a nitrile then led to NVP-DPP728 (Figure 5.5) with an improved selectivity over DPP-II and PPCE (postproline cleaving enzyme), which were then standard enzymes in DPP-IV selectivity studies. Within only 9 months, the Novartis project team had identified a development compound. Clinical trials with NVP-DPP728 began in 1998. A first phase 2 trial based on the then widely held paradigm that any type 2 diabetes patient treated with a DPP-IV inhibitor should experience an immediate benefit, gave disappointing results and almost stopped the project. A detailed data analysis suggested that patients with a certain level of pancreatic beta cell activity might benefit over a longer time frame. A second trial designed with the hindsight from this analysis was a huge success: after 4 weeks of treatment, NVP-DPP728 reduced
5.3 Substrate-Based DPP-IV Inhibitors
postmeal glucose excursion, fasting glucose, and 24 h mean glucose. For the first time, it was shown that chronic DPP-IV inhibition in diabetic patients was safe and also led to a reduction in HbA1c levels [28]. NVP-DPP728s relatively short half-life of 0.85 h was initially not seen as a disadvantage. On the contrary, the many possible physiological roles of DPP-IV made it desirable for a proof-of-concept compound that any potential adverse effects would abate quickly after a discontinuation of administration. DPP-IV cleaves, at least in vitro, not only GLP-1 but also several peptidic hormones, neurotransmitters, and chemokines. Of particular concern was initially the fact that DPP-IV is identical to CD26, a surface protein on activated T-cells, which mediates stimulatory signals; fortunately, it was found that NVP-DPP728 had no immunosuppressant effect. (Later on it was shown that the enzymatic activity of DPP-IV is not required for T-cell function.) It might have been envisioned that NVP-DPP728 could be a short-acting, meal-dependently administered drug to reduce postprandial glucose excursion. Such a treatment would allow an intermittent recovery of DPP-IV activity, and the normal regulation of other potential DPP-IV substrates, thus minimizing side effects. However, a team of Novo Nordisk researchers, collaborating with the Miami School of Medicine, demonstrated in 2001 that a 24 h infusion of GLP-1 over 7 days gave a much better outcome for diabetic patients than a 16 h infusion, indicating that a 24-h blockade of DPP-IV was needed to maximize the therapeutic effect [29]. In 2002, Ferring researchers published their results with the long-acting DPP-IV inhibitor FE 999011 (Figure 5.6), which clearly showed that full inhibition of DPP-IV over 24 h gave the best results in animal models of diabetes [30]. In the following years, most companies therefore focused on inhibitors with high metabolic stability, and today all clinically proven inhibitors show >50% plasma DPP-IV inhibition over 24 h. Apart from the demonstrated clinical efficacy and the facile synthetic access, there might be yet another reason why the N-alkylglycine inhibitors became very popular throughout the industry in the following years: it was generally perceived that they had a superior chemical stability. As already mentioned, cyanopyrrolidine DPP-IV inhibitors, and other substrate-based inhibitors with an electrophilic serine-interacting motif, are chemically unstable in solution. This solution instability is due to an intramolecular reaction between the amino function and the electrophilic motif, as depicted in Scheme 5.1. The short solution half-life typically of a few hours was
N
H2 N O
N FE 999011 Ki = 3.8 nM Ferring, 1996 Figure 5.6 Studies with FE 999011 showed that sustained inhibition of DPP-IV leads to best results in animal models of diabetes.
j115
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
116
R cyclization
N
H2N O
N
O
N
R
N H
NH
Scheme 5.1 The limited solution stability of cyanopyrrolidine DPP-IV inhibitors is due to an intramolecular reaction between the mandatory amino and cyano functionalities.
causing problems for formulation and was made responsible for the short in vivo halflife of some compounds. To overcome this limitation, many research groups explored N-alkylglycines with sterically hindered amines, which would undergo cyclization less readily. Early on, Novartis scientists had identified an adamantyl derivative 8 (Figure 5.7), which was one of the most potent inhibitors discovered in their program. Also, the primary metabolites of this compound were found to be highly active. Already in 1998, Villhauer synthesized one of the putative metabolites, LAF-237, which turned out to have an excellent solution stability, potent inhibitory activity, and good selectivity over related enzymes [31]. The improved pharmacokinetic profile and longer lasting pharmacodynamic effect of LAF-237 led to a replacement of Novartis front-runner NVP-DPP728. LAF-237 was later named vildagliptin, in reference to Villhauer, its inventor [32]. Vildagliptin has been, after sitagliptin, the second compound to obtain market approval in the European Union and other countries. In the United States, Novartis has paused its efforts to seek regulatory approval after the FDA had requested additional data to address concerns about the tolerability in patients with renal impairment and skin lesions in nonhuman primates [33] (although no skin OH N H
N O
N H
CN
8 IC50 = 3 nM
N O
CN
LAF-237, vildagliptin IC50 = 3.5 nM Novartis, 2000
HO N
H2N O
9 Ki = 7 nM
N
H2N CN
O
N
H2N CN
10 Ki = 0.9 nM
Figure 5.7 Discovery of vildagliptin and saxagliptin.
O
CN
saxagliptin Ki = 0.6 nM BMS, 2001
5.3 Substrate-Based DPP-IV Inhibitors Table 5.1 Chemical stabilities of primary amine inhibitors.
Compound
Half-lifea)
3 (Figure 5.3) FE 999011 (Figure 5.6) 9 (Figure 5.7)
5h 27 h 42 h
a)
In aqueous buffer at pH 7.2; 39.5 C.
lesions have been observed in humans during clinical trials [67]). Vildagliptin is only moderately selective over DPP-8 and DPP-9. Following the highly publicized Merck study on the potential toxicities associated with DPP-8/9 inhibition [21], Novartis undertook long-term rodent toxicity studies with vildagliptin at exposures that are high enough for complete inhibition of DPP-IV, DPP-8, and DPP-9. As vildagliptin did not display any of the toxicities observed with P32/98 and structurally related molecules, the toxicity of the compounds studied by Merck is more likely the result of unidentified off-target effects that are independent of DPP-8/9, and the relevance of isoform selectivity remains unclear [34]. Researchers at Bristol-Myers Squibb found that converting a tertiary (3, Figure 5.3) to a quaternary alpha-carbon (FE 999011, Figure 5.6) improves the solution half-life by fivefold (Table 5.1). The long-lasting pharmacodynamic effect of FE 999011 might, at least in part, be attributed to this improved solution stability. Also, the introduction of a methylene bridge into the cyanopyrrolidine ring leads to steric bulk that similarly improves the chemical stability (compare FE 999011 and 9, Table 5.1). Molecular modeling demonstrated that these effects are, in both cases, due to intramolecular van der Waals interactions. These interactions disfavor a cis conformation of the amide, which is a prerequisite for cyclization, and thereby increase stability [35]. These findings led the Bristol-Myers Squibb scientists, in striking analogy to the efforts at Novartis, to 10 with an adamantyl substituent. This compound showed an excellent plasma-DPP-IV inhibition after oral dosing in rats, despite a low bioavailability (2%). This seemed to indicate that 10 is converted into an active metabolite in vivo, which prompted the synthesis of a hydroxy analogue as a putative metabolite. Quite similar to the vildagliptin story, it was found that this metabolite, later named saxagliptin (Figure 5.7), was highly potent and had an excellent solution stability [36]. This high solution stability, together with a relatively high distribution volume, makes saxagliptin a long-acting DPP-IV inhibitor. Bristol-Myers Squibb and AstraZeneca have shared the clinical development and filed a New Drug Application in 2008 [37]. Other companies also came up quickly with N-alkylglycines with a wide variety of quaternary N-substituents. TS-021, 11, and ABT-279 (Figure 5.8) are examples of Nalkylglycines that were evaluated in clinical trials. Taisho scientists identified TS-021, which had a much higher solution stability than a previously explored primary amine and an alkylglycine analogue without a quaternary N-substituent [38]. This improved stability translated into markedly higher plasma concentrations in rats, as measured 6 h after oral administration. An oral dose of TS-021 of 0.3 mg/kg in rats almost completely inhibited plasma DPP-IV activity for 120 min and exhibited a significant
j117
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
118
F HO
N
N
N H
N
N
O
N H
N O N
N TS-021 IC50 = 4.6 nM Taisho, 2002
11 IC50 = 20 nM Roche, 2003
N N
N
N H
HOOC
O N
ABT-279 Ki = 1.0 nM Abbott, 2004 Figure 5.8 Various N-alkylglycine compounds in clinical development.
antihyperglycemic effect. The compound underwent phase I clinical studies in 2004, and was licensed to Eli Lilly in 2005; however, no further development was reported. Roches clinical compound, 11, was well tolerated in healthy volunteers up to doses of 2 g. In a multiple-dose study, the oral administration of 400 mg of 11 twice daily achieved >50% inhibition of plasma DPP-IV activity over the 12 h dose interval [39]. ABT-279 features a 5-ethynyl substituent on the cyanopyrrolidine ring, which had been demonstrated to improve selectivity over DPP-8/9 [40]. Indeed, the compound has an excellent selectivity over these enzymes as well as related peptidases and other safety-relevant targets. In healthy volunteers, ABT-279 was well tolerated up to doses of 1 g. A primary amine inhibitor with a bulky side-chain, GSK-23A (Figure 5.9), was discovered at GlaxoSmithKline [41]. A combination of steric and electronic effects
OMe
F F F
F
O S O H2N
N
N
H2N O
O
N
N GSK-23A Ki = 53 nM GSK, 2003 Figure 5.9 GSK-23A and denagliptin.
denagliptin Ki = 22 nM GSK, 2003
5.4 Sitagliptin and Analogues
might be responsible for a reduced nucleophilicity of the free amine function, which leads to an extraordinarily long half-life of 1733 h in aqueous buffer at pH 7.2 and 37 C. Denagliptin, another compound from the same company, was developed up to phase 3, but was finally put on hold in 2006 due to unfavorable data from preclinical long-term toxicology experiments [42, 43]. Today, we can look back on more than two decades of research on substrate-based DPP-IV inhibitors. These dipeptide-like compounds provided the first tools to elucidate the function of DPP-IV in vivo. Especially, P32/98 and NVP-DPP728 have played a pivotal role in establishing DPP-IVs role in glucose homeostasis and in establishing DPP-IV as a therapeutic target for type 2 diabetes. The exciting results obtained with these and other compounds triggered a race in the pharmaceutical industry toward DPP-IV inhibitors as a novel class of antidiabetic medicines, and many companies embarked on fast-follower projects with similar substrate-based compounds. This research culminated in the discovery of vildagliptin, which has obtained market approval in several countries, and other advanced compounds undergoing clinical development. However, other important classes of DPP-IV inhibitors have also emerged more recently, as will be shown in the next sections.
5.4 Sitagliptin and Analogues
Sitagliptin has been the first DPP-IV inhibitor to be approved as a treatment for type 2 diabetes. Launched by Merck in 2006, the annual sales for 2008 have already exceeded US$ 1000 million. The medicinal chemistry team led by Ann E. Weber started in 1999 and initially focused on substrate analogue inhibitors (see Section 5.3). After the identification of unwanted off-target activity as possible reason for multiorgan toxicity, the objective became to achieve a high (>1000-fold) selectivity over related proline peptidases, especially DPP-8 and DPP-9 [23, 44, 45]. The link between activity at DPP-8/9 and toxicity remains a matter of debate, but the goal per se has successfully guided the team toward the discovery of sitagliptin. A high-throughput screening of the Merck sample library was performed in parallel with the medicinal chemistry work on substrate analogues. The screening produced only very few hits, among which the legacy compounds 12 and 13 (Figure 5.10) were followed up. At that time, no structural information of DPP-IV was available, and it was (wrongly) assumed that the pyrrolidine subunit of 13 might reside in the S1 substrate specificity pocket. As a consequence, the pyrrolidine was replaced with a thiazolidine, in analogy with substrate analogues such as P32/98. The truncated molecule 14, with a much reduced molecular weight, was roughly equipotent to 13 but left little room for structural variations. The trifluorophenyl derivative, 15, had a respectable potency but poor pharmacokinetic properties and an insufficient selectivity over DPP-8 [46]. In the meantime, the weakly active HTS hit 12 was combined with the 3-amino-4phenylbutyryl side chain of 13. The resulting hybrid molecule 16 was more than 100fold more potent. A fluorine substituent at C(2) (17) led to an additional fourfold
j119
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
120
Ph
Ph O
N
N
O O O S N H
O
H2N
NH
NH2
N
N
12 IC50 = 11000 nM
O O S N H
NH R
16 (R = H) IC50 = 134 nM 17 (R = F) IC50 = 34 nM
NH2 N O
O
N H
O
HN
NH2
R
O HN
N O F
Cl
18 (R = CH2Ph) IC50 = 139 nM 19 (R = H) IC50 = 3700 nM
13 IC50 = 1900 nM NH2
R N
S
R
N
R
O
NH2
N N
N
R 14 (R = H) IC50 = 3000 nM 15 (R = F) IC50 = 120 nM
F F
O F
20 (R = H) IC50 = 68 nM Sitagliptin (R = CF3 ) IC50 = 18 nM Merck, 2003
Figure 5.10 Evolution of sitagliptin from screening hits 12 and 13.
potency improvement. By removing the decoration of the piperazine, 18 and 19 were obtained. Molecule 18 was reasonably potent and selective but displayed a poor pharmacokinetic profile, which was attributed to the metabolic instability of the piperazine ring [47]. Unsubstituted piperazine 19 was only marginally active but had a low molecular weight and set the stage for further refinement. Incorporation of the 2,4,5-trifluoro substitution pattern on the phenethylamine and replacement of the piperazine by a triazolopiperazine led to a significant improvement in potency. The poor bioavailability of 20 was improved to excellent values by installation of a trifluoromethyl group in the triazole ring, resulting in sitagliptin [48]. Interestingly, triazolopiperazines (systematic name: 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine) have only recently found widespread use. The parent compound was first disclosed by Merck, as late as 2001, as an intermediate for GABAA ligands as cognition enhancers [49] and soon became a fashionable building block in various Merck projects [50, 51]. Since the public disclosure of sitagliptin as development
5.4 Sitagliptin and Analogues
compound in 2004, the trifluoromethyl-substituted triazolopiperazine has become a frequently used amine subunit across the medicinal chemistry community. Sitagliptin was discovered in the absence of biostructural information. However, as soon as Merck had determined the cocrystal structure of sitagliptin within DPP-IV, the rational design of sitagliptin analogues became feasible. The cocrystal structure shows that the trifluorophenyl group occupies the S1 pocket of the enzyme; this pocket is a central recognition motif and normally accommodates the penultimate amino acid of the substrate (Figure 5.11). The fluorine atoms at C(4) and C(5) optimally fit the hydrophobic niche in the back of the S1 pocket, whereas the fluorine at the ortho position makes a favorable electrostatic interaction with the side chains of Asn710 and Arg125 [52]. Like the class of substrate-based inhibitors, which use a pyrrolidine or thiazolidine derivative to fill the S1 pocket, this class has a rather limited SAR around the trifluorophenyl group. Accordingly, a number of sitagliptin analogues have been made, which use the 2,4,5-trifluorophenethylamine subunit for selective recognition of DPP-IV but differ in the remaining part of the molecule for additional interactions with the target and refinement of the pharmacokinetic properties. For instance, Merck has designed the cyclic analogue 21 (Figure 5.12), in which the butyryl moiety of sitagliptin is replaced by a cyclohexane. Like sitagliptin, 21 is potent and selective over DPP-8/9 but has improved pharmacokinetic properties, with lower clearance and longer half-lives across species [53]. Researchers at Abbott have adapted the major fragments of the Merck inhibitors sitagliptin and 21 to create their own DPP-IV inhibitor, ABT-341. This compound is a potent DPP-IV inhibitor, is selective over DPP-8/9, and has excellent pharmacokinetic properties, comparable to 21 [54]. Despite the similarity to sitagliptin, the binding mode of ABT-341 is different from that of sitagliptin, in that the triazolopyrazinecarbonyl subunit occupies a different part of the binding pocket and induces some conformational change at the target [55]. The compound was selected as
N N F3C
N
S1 pocket
O
F
N
-
F +
H3N
H F
HN Arg125
N H
NH2
H2N
O
Asn710 Figure 5.11 Schematic illustration of key interactions of sitagliptin with DPP-IV: the trifluorophenyl substituent resides in the lipophilic S1 pocket. The ortho-F makes favorable electrostatic interactions with Arg125
and Asn710. The protonated amine binds to a negatively charged surface of the protein (comprised of Glu205, Glu206, and Tyr662, not shown for clarity).
j121
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
122
N
F 3C N F 3C
N N
NH2
F
N
N
N F
NH2
N
F F
F
O F
21 IC50 = 21 nM Merck, 2006
ABT-341 K i = 1.3 nM Abbott, 2006 O O S N
N
O
H
H
NH2
F F
H O F 22 Novartis, 2007
Figure 5.12 Sitagliptin analogues with a 2,4,5-trifluorophenethylamine motif.
development candidate, but no clinical development has been reported as of December 2008. Several years after the discovery of vildagliptin, Novartis has also embarked on a DPP-IV follow-on project, using sitagliptin as seed structure. As a late entrant to the phenethylamine class, compound 22, with a bicyclic subunit, has been identified as a potent DPP-IV inhibitor [56].
5.5 Xanthines and Analogues
The natural products theophylline, theobromine, and caffeine are known as xanthine alkaloids. They are among the oldest drugs, mainly exhibiting vasodilatory and stimulating effects, which can be rationalized through their actions as (nonselective) phosphodiesterase inhibitors and adenosine receptor antagonists [57]. Owing to their rich pharmacology and chemical tractability, xanthine derivatives are well represented in corporate screening libraries. After DPP-IV had emerged as an attractive target for type 2 diabetes, several companies performed a high-throughput screening to identify novel classes DPP-IV inhibitors. Compound 23 (Figure 5.13) is a commercially available lead-like xanthine derivative that inhibits DPP-IV in the low micromolar range. As a consequence, 23 has been discovered as a screening hit by a number of research teams. For instance, Merck invested some limited resources on substituent alterations of 23 with little success but then focused on more promising activities (see preceding sections) [44]. On the other hand, Novo Nordisk and Boehringer Ingelheim have identified
5.5 Xanthines and Analogues
R
O
R N
N 3 R
N
1
N
O
j123
7
O
O N
HN O
N N
N
N
NH
N
N
O
N
N
NH2
Xanthine R1 = R3 = R7 = H Theophylline R1 = R3 = Me, R7 = H Theobromine R1 = H, R3 = R7 = Me Caffeine R1 = R3 = R7 = Me
23 IC50 = 3900 nM
24 IC50 = 82 nM Boehringer Ingelheim, 2002
NC O
O N
N O
O
N
N
N
N
N
O
N N
N
NH2
NH2 26 IC50 = 6 nM
25 Novo Nordisk, 2003
O N
N N
O
O N
N N N
N
N
N N
N N N
NH2 Linagliptin IC50 = 1 nM Boehringer Ingelheim, 2004
NH2 27 IC50 = 1 nM Boehringer Ingelheim, 2004
Figure 5.13 Linagliptin and other DPP-IV inhibitors originating from a commercially available screening compound, 23.
a 3-aminopiperidine subunit to be a superior replacement for the piperazine moiety (compounds 24 and 25) and filed patent applications, which overlap to a significant degree [58]. Boehringer Ingelheim has best succeeded in elaborating the xanthine series: modification of the substituents at N(1) and N(7) led to 26, which was very potent on DPP-IV but had unacceptable off-target activities at the hERG channel and the muscarinic receptor M1. Replacement of the substituent at N(7) by a 2-butynyl group and installation of a quinazolylmethyl substituent in lieu of the phenacyl group gave linagliptin, in which the hERG interaction was greatly reduced and the selectivity over the M1 receptor was increased to 300-fold [59]. Comparative preclinical in vivo characterization with vildagliptin, saxagliptin, sitagliptin, and alogliptin shows that linagliptin has a superior potency and longer duration of action [60]. Linagliptin has entered phase 3 clinical trials in 2008. The X-ray crystal structure of linagliptin within DPP-IV reveals that the 2-butynyl group resides in
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
124
CN
CN
O
O N
O N
Br
N R
CN
N
N N
N
N
N NH2
28 R = H IC50 = 13 nM 29 R = F IC50 = 4 nM
NH2 30 IC50 = 5 nM
O
NH2
Alogliptin IC50 = 7 nM Syrrx/Takeda, 2005
Figure 5.14 Structural insight led to a successful core replacement of xanthine 25, and finally to alogliptin.
the S1 pocket. The 4-methylquinazolinone group stacks on top of a tryptophan residue of the protein (Trp629); this p–p interaction [61] is not exploited by other classes of DPP-IV inhibitors and contributes to the very high affinity of linagliptin. The main binding contribution of the xanthine moiety comes from another p–p interaction, a stacking of the central uracil ring with a tyrosine side chain (Tyr547). Comparable aromatic–aromatic interactions can also be affected by a wide variety of other heterocycles [58]. For instance, Boehringer Ingelheim has reported analogue 27, in which the xanthine core has been replaced by an imidazopyridazinone. This compound is equipotent to linagliptin but has a superior selectivity over M1 (>1000-fold) and a different pharmacokinetic profile [62]. Researchers at Syrrx (now Takeda San Diego) have performed a remarkable scaffold hopping exercise, which provided interesting new classes of patentable DPP-IV inhibitors. Supported by high-throughput structural biology and molecular modeling as the companys core expertise, they started from seed structures such as Novo Nordisks xanthine derivative 25 (Figure 5.14). In 25, the cyanobenzyl substituent fills the cavity of the S1 pocket. The cyano group does not engage in a covalent interaction with the enzyme (in contrast to the cyano group in the cyanopyrrolidine series) but makes a favorable electrostatic interaction with the side chains of Asn710 and Arg125, similar to that of the ortho-fluorine of sitagliptin [52]. In search for central scaffolds that could take advantage of the p–p interaction with Tyr547 like the xanthine core of 25, they identified 4-quinazolinone as a suitable heterocyclic replacement. Indeed, compound 28 was very potent. Pharmacokinetic shortcomings were amended by introducing a fluorine at the metabolically vulnerable position of the quinazolinone. Compound 29 had attractive pharmacological and pharmacokinetic properties but showed unacceptable levels of CYP3A4 and hERG inhibition. To minimize the interaction at these off-targets, more polar heterocycles were explored as quinazolinone replacements. Pyrimidinone 30 and the analogous uracil compound, later named alogliptin, retained the potency, and greatly improved the selectivity over the off-targets. Alogliptin, which is the least lipophilic in this series, showed the most favorable pharmacological profile and no evident safety issues [63, 64]. Alogliptin has progressed through clinical development very rapidly, and a New Drug Application has been filed in December 2007.
5.6 Pharmacological Comparison of DPP-IV Inhibitors
5.6 Pharmacological Comparison of DPP-IV Inhibitors
DPP-IV is a chemically very tractable target, and several DPP-IV inhibitors have progressed into clinical trials as medicines to treat type 2 diabetes. In this highly competitive field, the structural diversity is remarkable, with a primary or secondary amino group as the sole recurring motif. Nevertheless, a comparison of phase 3 clinical data at therapeutic doses shows that vildagliptin, sitagliptin, and alogliptin (as representative compounds from each structural class) have similar clinical efficacies. Thus, the average reduction of glycosylated hemoglobin (HbA1c) is 0.5–0.8% after 24 or 26 weeks of treatment at therapeutic doses (Table 5.2). It should be noted that the magnitude of the HbA1c reduction depends on the severity of the disease. For instance, vildagliptin (50 mg twice a day) achieves an HbA1c reduction of 0.6% from a baseline-HbA1c of 8% but a reduction of 1.6% from a baseline of 10% (similar patterns for HbA1c changes are reported for other classes of OADs). While the determination of meaningful changes in HbA1c requires long-term treatment of diabetic patients and a correct estimation of the therapeutic dose, DPPIV inhibition has the benefit of offering an instant-readout biomarker that can forecast the efficacy of the drug in an exploratory setting: DPP-IV activity can be easily determined in blood plasma by measuring the turnover rate of a peptidic substrate using UV spectroscopy. Thus, the notion that sustained inhibition of DPP-IV activity leads to a maximal therapeutic effect [29, 30] has been exploited by Merck in designing phase 1 clinical studies. In healthy volunteers, near-maximal (80%) DPP-IV inhibition was achieved at daily doses of 100 mg (Figure 5.15). The dose of 100 mg/day was confirmed in phase 2 studies to be therapeutically adequate in type 2 diabetic patients and later taken on to phase 3. The successful implementation of a simple pharmacodynamic readout as biomarker enabled Merck to progress sitagliptin from entry into human to phase 3 in only 2.1 years [65]. For vildagliptin, the DPP-IV inhibition after administration of 50 mg is greater than 80% over 12 h but reduced to about 20% after 24 h [66]. Accordingly, the recommended dosing regimen for vildagliptin in the majority of settings is 50 mg
Table 5.2 HbA1c changes after chronic administration of DPP-IV inhibitors (phase 3 data).
Number of subjects Duration of treatment Dose Dosing regimen HbA1c baseline Mean change from baseline HbA1c HbA1c change from placebo
Vildagliptin [67]
Sitagliptin [68]
Alogliptin [74]
90 24 weeks 50 mg Twice daily 8.6% 0.8% 0.5%a)
229 24 weeks 100 mg Once daily 8.0% 0.6% 0.8%b)
131 26 weeks 25 mg Once daily 7.90% 0.59% 0.57%c)
a) 95% confidence interval: (0.8; 0.1); p < 0.05 compared to placebo. b) 95% confidence interval: (1.0; 0.6); p < 0.001 compared to placebo. c) p < 0.001 compared to placebo.
j125
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
126
Placebo
Plasma DPP-IV activity [%]
100 80 60
Sitagliptin (25 mg)
40
Alogliptin (25 mg)
20
Sitagliptin (100 mg)
0 0
6
12 Time after dosing [h]
Figure 5.15 Time course of inhibition of plasma DPP-IV activity after administration of placebo [75], and multiple daily oral doses of sitagliptin (after 10 days, healthy
18
24
volunteers) [75], and alogliptin (after 14 days, type 2 diabetic patients) [69]. Adapted with permission from Excerpta Medica, Inc.: Clinical Therapeutics, copyright 2006, 2008.
twice a day [67]. Alogliptin achieves near-maximal DPP-IV inhibition over 24 h already at much lower doses – a 25 mg dose has approximately the same effect as a 100 mg dose of sitagliptin (Figure 5.15). DPP-IV inhibitors are typically hydrophilic compounds that are rapidly absorbed. Otherwise, the pharmacokinetic properties of the individual DPP-IV inhibitors are quite distinct (Table 5.3): sitagliptin has a relatively low clearance and a large volume of distribution. This translates into a long terminal half-life. Protein binding is low. Sitagliptin is predominantly excreted unchanged through the kidneys, with limited metabolic contribution through CYP3A4 and CYP2C8. Accordingly, patients with renal impairment should use lower doses [68]. In comparison, vildagliptin has a higher clearance and lower volume of distribution, which is reflected in a relatively short half-life. Protein binding is very low. CYPdependent metabolism does not occur. The major elimination pathway is hydrolytic Table 5.3 Pharmacokinetic data of DPP-IV inhibitors.
Sitagliptin [68] Dose tmax Clearance Volume of distribution Half-life Bioavailability Protein binding Renal excretion of parent
100 mg 1–4 h 350 ml/min 198 l 12.4 h 87% 38% 79%
Vildagliptin [67] 50 mg 1.7–2.5 h 680 ml/min 71 l 2 h (intravenous), 3 h (oral) 85% 9.3% 23%
5.7 Concluding Remarks
metabolism at the cyano group, followed by renal excretion of the inactive metabolite; renal excretion of parent drug accounts only for a minor fraction. Vildagliptin is not recommended for renally impaired patients due to insufficient data. Additional safety concerns are related to elevated levels of liver aminotransferases and skin lesions; therefore, monitoring for liver function and skin disorders is recommended [67]. For the less advanced DPP-IV inhibitors, only limited pharmacokinetic information is available. Alogliptin has pharmacokinetic properties similar to sitagliptin, with an apparent half-life of about 20 h and mainly renal excretion of unmetabolized drug [69]. Saxagliptin is also renally excreted, as parent and active metabolite, both of which have apparent half-lives of about 3 and 5 h, respectively [70]. The conversion of saxagliptin to its active metabolite is mediated by CYP3A4/5, a clear difference from its close structural analogue, vildagliptin [71]. Finally, linagliptin has a completely different pharmacokinetic profile in that renal excretion is only a minor elimination route. The compound is largely bound to plasma proteins, has a very long apparent terminal half-life of about 3 days, and has a bioavailability of 30% [72]. Taken together, DPP-IV inhibitors achieve an average HbA1c reduction of 0.5–0.8% after 6 months, independent of the structural class. Inhibition of DPPIV activity is a relevant biomarker for antihyperglycemic efficacy, and near-maximal inhibition over 24 h is required for an optimal effect. Besides, the individual compounds differ significantly in their mode of metabolism and excretion, which may be an important consideration for the individual patient.
5.7 Concluding Remarks
DPP-IV inhibitors represent only one of the many classes of drugs to treat patients with type 2 diabetes. The main goal of management of type 2 diabetes is to achieve glycemic levels as close to the nondiabetic range (HbA1c at 4–6%) as practicable, in order to reduce the risk of late-stage complications. A consensus algorithm of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) released in 2008 calls for a therapeutic intervention in cases where HbA1c exceeds 7%. In principle, most patients diagnosed with type 2 diabetes would massively benefit from weight loss and increased physical activity, but only a minority is willing and able to adhere to lifestyle changes in the long term. Therefore, medical management is the common practice, with metformin as first-line treatment. In cases where the HbA1c goal of 7% is not met with metformin alone, either insulin or a sulfonylurea should be added. Alternatively, when hypoglycemia (as frequent side effect of insulin and sulfonylureas) is particularly undesirable, pioglitazone or a GLP1 agonist can be used as an add-on to metformin. Other approved classes of drugs including DPP-IV inhibitors are not within the list of preferred agents, in part due to their limited clinical data [73].
j127
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
128
Sitagliptin, launched in 2006, is often used in combination with metformin. Its rapid rise in popularity is due to the favorable safety profile (no hypoglycemia, no weight gain, and no gastrointestinal side effects). The absence of competition from other DPP-IV inhibitors has also contributed to a highly successful start for this drug. Vildagliptin has been approved in several countries, and other DPP-IV inhibitors are expected to be introduced in the near future. They all lower HbA1c to a similar extent but have quite diverse pharmacokinetic properties. The result of ongoing studies, with focus on long-term benefits and safety, will determine the future role of DPP-IV inhibitors among the options to treat type 2 diabetes.
References 1 Priesel, R. and Wagner, R. (1927) Das
2
3
4
5
6
7
Synthalin in der Behandlung der kindlichen Zuckerkrankheit. Klin. Wochenschr., 6, 884–889. Meyer, U., Schuhmann, A., and Friedrich, C. (2002) Zufall und gezielte Entwicklung! Geschichte der oralen Antidiabetika. Pharmazie in unserer Zeit, 31, 242–250. Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047–1053. American Diabetes Association (2009) Standards of medical care in diabetes: 2009. Diabetes Care, 30, S13–S61. Stratton, I.M., Adler, A.I., Neil, A.W., Matthews, D.R., Manley, S.E., Cull, C.A., Hadden, D., Turner, R.C., and Holman, R.R. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 321, 405–412. Nauck, M.A., Wollschl€ager, D., Werner, J., Holst, J.J., Ørskov, C., Creutzfeldt, W., and Willms, B. (1996) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia, 39, 1546–1553. Mentlein, R., Gallwitz, B., and Schmidt, W.E. (1993) Dipeptidyl-peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem., 214, 829–835.
8 Drucker, D.J.and Nauck, M.A. (2006) The
9
10
11
12
13
incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368, 1696–1705. Demuth, H.U., Neumann, U., and Barth, A. (1989) Reactions between dipeptidyl peptidase IV and diacyl hydroxylamines: mechanistic investigations. J. Enzyme Inhib., 2, 239–248. Schoen, E., Born, I., Demuth, H.U., Faust, J., Neubert, K., Steinmetzer, T., Barth, A., and Ansorge, S. (1991) Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol. Chem. Hoppe-Seyler, 372, 305–311. Gutheil, W.G.and Bachovchin, W.W. (1993) Separation of L-proline-DLboronylproline into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight binding inhibition. Biochemistry, 32, 8723–8731. OFarrell, A.M., van Vliet, A., Farha, K.A., Cherrington, J.M., Campbell, D.A., Li, X., Hanway, D., Li, J., and Guler, H.P. (2007) Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multipledose studies in healthy subjects. Clin. Ther., 29, 1692–1705. Garcia-Soria, G., Gonzalez-Galvez, G., Argoud, G.M., Gerstman, M., Littlejohn, T.W., Schwartz, S.L., OFarrell, A.M.,
References
14
15
16
17
18
19
20
21
Li, X., Cherrington, J.M., Bennett, C., and Guler, H.P. (2008) The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus. Diabetes Obes. Metab., 10, 293–300. Tanaka, Y., Niwa, S., Nishioka, H., Yamanaka, T., Torizuka, M., Yoshinaga, K., Kobayashi, N., Ikeda, Y., and Arai, H. (1994) New potent prolyl endopeptidase inhibitors: synthesis and structure–activity relationships of indan and tetralin derivatives and their analogs. J. Med. Chem., 37, 2071–2078. Li, J., Wilk, E., and Wilk, S. (1995) Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidylpeptidase IV (CD 26). Arch. Biochem. Biophys., 323, 148–154. Ashworth, D.M., Atrash, B., Baker, G.R., Baxter, A.J., Jenkins, P.D., Jones, D.M., and Szelke, M. (1996) 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett., 6, 2745–2748. Ashworth, D.M., Atrash, B., Baker, G.R., Baxter, A.J., Jenkins, P.D., Jones, D.M., and Szelke, M. (1996) 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett., 6, 1163–1166. Peters, J.U. (2007) 11 years of cyanopyrrolidines as DPP-IV inhibitors. Curr. Top. Med. Chem., 7, 579–595. Deacon, C.F., Nauck, M.A., Toft-Nielsen, M., Pridal, L., Willms, B., and Holst, J.J. (1995) Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 44, 1126–1131. Demuth, H.U., Rosche, F., Schmidt, J., Pauly, R.P., McIntosh, C.H.S., and Pederson, R.A. (1997). Verfahren zur Senkung des Blutglukosespiegels in S€augern. Ger. Offen. DE19616486, Probiodrug Gesellschaft f€ ur Arzneimittelforschung mbH. Lankas, G.R., Leiting, B., Roy, R.S., Eiermann, G.J., Beconi, M.G., Biftu, T., Chan, C., Edmondson, S., Feeney, W.P., He, H., Ippolito, D.E., Kim, D., Lyons,
22
23
24
25
26
K.A., Ok, H.O., Patel, R.A., Petrov, A.N., Pryor, K.A., Qian, X., Reigle, L, Woods, A., Wu, J.K., Zaller, D., Zhang, X., Zhu, L., Weber, A.E., and Thornberry, N.A. (2005) Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes, 54, 2988–2994. Edmondson, S.D., Mastracchio, A., Mathvink, R.J., He, J., Harper, B., Park, Y.J., Beconi, M., Di Salvo, J., Eiermann, G.J., He, H., Leiting, B., Leone, J.F., Levorse, D.A., Lyons, K., Patel, R.A., Patel, S.B., Petrov, A., Scapin, G., Shang, J., Roy, R.S., Smith, A., Wu, J.K., Xu, S., Zhu, B., Thornberry, N.A., and Weber, A.E. (2006) (2S,3S)-3-Amino-4-(3,3difluoropyrrolidin-1-yl)-N,N-dimethyl-4oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6ylphenyl)butanamide: a selective a-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 49, 3614–3627. Weber, A.E. and Thornberry, N. (2007) Case history: Januvia (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann. Rep. Med. Chem., 42, 95–109. Ammirati, M.J., Andrews, K.M., Boyer, D.A., Brodeur, A.M., Danley, D.E., Doran, S.D., Hulin, B., Liu, S., McPherson, R.K., Orena, S.J., Parker, J.C., Polivkova, J., Qiu, X., Soglia, C.B., Treadway, J.L., Van Volkenburg, M.A., Wilder, D.C., and Piotrowski, D.W. (2009) (3,3-Difluoropyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin2-yl-piperazin-1-yl)-pyrrolidin-2-yl]methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor. Bioorg. Med. Chem. Lett., 19, 1991–1995. Pfizer website, http://media.pfizer.com/ files/research/pipeline/2008_0930/ pipeline_2008_0930.pdf, accessed 16 December 2008. Heins, J., Welker, P., Schoenlein, C., Born, I., Hartrodt, B., Neubert, K., Tsuru, D., and Barth, A. (1988) Mechanism of prolinespecific proteinases: (I) substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium
j129
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
130
27
28
29
30
31
32
meningosepticum. Biochim. Biophys. Acta, 954, 161–169. Villhauer, E.B., Brinkman, J.A., Naderi, G.B., Dunning, B.E., Mangold, B.L., Mone, M.D., Manisha Russell, M.E., Weldon, S.C., and Hughes, T.E. (2002) 1[2-[(5-Cyanopyridin-2-yl)amino] ethylamino]acetyl-2-(S)pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem., 45, 2362–2365. Ahren, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.A., Sandqvist, M., Bavenholm, P., Efendic, S., Eriksson, J.W., Dickinson, S., and Holmes, D. (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care, 25, 869–875. Larsen, J., Hylleberg, B., Ng, K., and Damsbo, P. (2001) Glucagon-like peptide1 infusion must be maintained for 24 h/ day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care, 24, 1416–1421. Sudre, B., Broqua, P., White, R.B., Ashworth, D., Evans, D.M., Haigh, R., Junien, J.-L., and Aubert, M.L. (2002) Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes, 51, 1461–1469. Villhauer, E.B., Brinkman, J.A., Naderi, G.B., Burkey, B.F., Dunning, B.E., Prasad, K., Mangold, B.L., Russell, M.E., and Hughes, T.E. (2003) 1-[[(3-Hydroxy-1adamantyl)amino]acetyl]-2-cyano-(S)pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem., 46, 2774–2789. Ahren, B., Gomis, R., Standl, E., Mills, D., and Schweizer, A. (2004) Twelve- and 52week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care, 27, 2874–2880.
33 Novartis media release (2008) http://
34
35
36
37
38
hugin.info/134323/R/1236488/263845. pdf, accessed 16 December 2008. Burkey, B.F., Hoffmann, P.K., Hassiepen, U., Trappe, J., Juedes, M., and Foley, J.E. (2008) Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes. Metab., 10, 1057–1061. Magnin, D.R., Robl, J.A., Sulsky, R.B., Augeri, D.J., Huang, Y., Simpkins, L.M., Taunk, P.C., Betebenner, D.A., Robertson, J.G., Abboa-Offei, B.E., Wang, A., Cap, M., Xin, L., Tao, L., Sitkoff, D.F., Malley, M.F., Gougoutas, J.Z., Khanna, A., Huang, Q., Han, S.-P., Parker, R.A., and Hamann, L.G. (2004) Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of a-aminoacyl-L-cis-4,5-methanoprolinenitrile-based inhibitors. J. Med. Chem., 47, 2587–2598. Augeri, D.J., Robl, J.A., Betebenner, D.A., Magnin, D.R., Khanna, A., Robertson, J.G., Wang, A., Simpkins, L.M., Taunk, P., Huang, Q., Han, S.-P., Abboa-Offei, B., Cap, M., Xin, L., Tao, L., Tozzo, E., Welzel, G.E., Egan, D.M., Marcinkeviciene, J., Chang, S.Y., Biller, S.A., Kirby, M.S., Parker, R.A., and Hamann, L.G. (2005) Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 48, 5025–5037. Bristol-Myers Squibb/AstraZeneca news release (2008) http://investor.bms.com/ phoenix.zhtml?c¼106664&p¼irol-news Article_Print&ID¼1178078&highlight¼, accessed 16 December 2008. Fukushima, H., Hiratate, A., Takahashi, M., Mikami, A., Saito-Hori, M., Munetomo, E., Kitano, K., Chonan, S., Saito, H., Suzuki, A., Takaoka, Y., and Yamamoto, K. (2008) Synthesis and structure–activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem., 16, 4093–4106.
References 39 Hunziker, D. (2007) Chemistry, Biology
40
41
42
43
44
45
and development of a cyanopyrrolidine type DPP-IV inhibitor. 3rd Anglo-Swedish Medicinal Chemistry Meeting, Are (Sweden), March 11–14, 2007. Madar, D.J., Kopecka, H., Pireh, D., Yong, H., Pei, Z., Li, X., Wiedeman, P.E., Djuric, S.W., Von Geldern, T.W., Fickes, M.G., Bhagavatula, L., McDermott, T., Wittenberger, S., Richards, S.J., Longenecker, K.L., Stewart, K.D., Lubben, T.H., Ballaron, S.J., Stashko, M.A., Long, M.A., Wells, H., Zinker, B., Mika, A.K., Beno, D.W.A., Kempf-Grote, A.J., Polakowski, J., Segreti, J., Reinhart, G.A., Fryer, R.M., Sham, H.L., and Trevillyan, J.M. (2006) Discovery of 2-[4-{{2-(2S,5R)2-cyano-5-ethynyl-1-pyrrolidinyl]-2oxoethyl]amino]-4-methyl-1-piperidinyl]4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and welltolerated inhibitor of dipeptidyl peptidaseIV, useful for the treatment of diabetes. J. Med. Chem., 49, 6416–6420. Haffner, C.D., McDougald, D.L., Reister, S.M., Thompson, B.D., Conlee, C., Fang, J., Bass, J., Lenhard, J.M., Croom, D., Secosky-Chang, M.B., Tomaszek, T., McConn, D., Wells-Knecht, K., and Johnson, P.R. (2005) 2-Cyano-4-fluoro-1thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV. Bioorg. Med. Chem. Lett., 15, 5257–5261. Haffner, C.D., McDougald, D.L., Randhawa, A.S., Reister, S.M., and Lenhard, J.M. (2003) Preparation of fluoropyrrolidinecarbonitrile derivatives as dipeptidyl peptidase inhibitors. PCT Int. Appl. WO2003002531, SmithKline Beecham Corporation. GlaxoSmithKline press release (2006) http://www.gsk.com/investors/reports/ gsk_q32006/q32006.pdf, accessed 16 December 2008. Thornberry, N.A.and Weber, A.E. (2007) Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem., 7, 557–568. Edmondson, S.D., and Kim, D. (2008) Methods and principles in medicinal chemistry, in Antitargets: Prediction of Drug Side Effects, vol. 38 (eds R.J. Vazand
46
47
48
49
50
51
T. Klabunde), Wiley-VCH Verlag GmbH, Weinheim, pp. 401–422. Xu, J., Ok, H.O., Gonzalez, E.J., Colwell, L.F., Habulihaz, B., He, H., Leiting, B., Lyons, K.A., Marsilio, F., Patel, R.A., Wu, J.K., Thornberry, N.A., Weber, A.E., and Parmee, E.R. (2004) Discovery of potent and selective b-homophenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 14, 4759–4762. Brockunier, L.L., He, J., Colwell, L.F., Habulihaz, B., He, H., Leiting, B., Lyons, K.A., Marsilio, F., Patel, R.A., Teffera, Y., Wu, J.K., Thornberry, N.A., Weber, A.E., and Parmee, E.R. (2004) Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 14, 4763–4766. Kim, D., Wang, L., Beconi, M., Eiermann, G.J., Fisher, M.H., He, H., Hickey, G.J., Kowalchick, J.E., Leiting, B., Lyons, K., Marsilio, F., McCann, M.E., Patel, R.A., Petrov, A., Scapin, G., Patel, S.B., Roy, R.S., Wu, J.K., Wyvratt, M.J., Zhang, B.B., Zhu, L., Thornberry, N.A., and Weber, A.E. (2005) (2R)-4-Oxo-4-[3-(trifluoromethyl)5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 48, 141–151. Bryant, H., Chambers, M.S., Jones, P., Macleod, A.M., and Maxey, R.J. (2001) Substituted 1,2,3-triazolo[1,5-a] quinazolines for enhancing cognition. PCT Int. Appl. WO01/44250, Merck Sharp & Dohme Limited Collins, I.J., Hannam, J.C., Harrison, T., Lewis, S.J., Madin, A., Sparey, T.J., and Williams, B.J. (2002) Synthesis of sulfonamido-substituted bridged bicycloalkyl derivatives as c-secretase inhibitors. PCT Int. Appl. WO02/36555, Merck Sharp & Dohme Limited Bilodeau, M., Hartman, G.D., Hoffman, J.M., Luma, W.C., Manley, P.J., Rodman, L., Sisko, J.T., Smith, A.M., and Tucker, T.J. (2002) Preparation of pyrimidinylaminothiazoles as tyrosine kinase inhibitors. PCT Int. Appl. WO02/ 45652, Merck & Co., Inc.
j131
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
132
52 Kuhn, B., Hennig, M., and Mattei, P.
53
54
55
56
57
58
(2007) Molecular recognition of ligands in dipeptidyl peptidase IV. Curr. Top. Med. Chem., 7, 609–619. Biftu, T., Scapin, G., Singh, S., Feng, D., Becker, J.W., Eiermann, G., He, H., Lyons, K., Patel, S., Petrov, A., Sinha-Roy, R., Zhang, B., Wu, J., Zhang, X., Doss, G.A., Thornberry, N.A., and Weber, A.E. (2007) Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. Bioorg. Med. Chem. Lett., 17, 3384–3387. Pei, Z., Li, X., von Geldern, T.W., Madar, D.J., Longenecker, K., Yong, H., Lubben, T.H., Stewart, K.D., Zinker, B.A., Backes, B.J., Judd, A.S., Mulhern, M., Ballaron, S.J., Stashko, M.A., Mika, A.K., Beno, D.W.A., Teinhart, G.A., Fryer, R.M., Preusser, L.C., Kempf-Grote, A.J., Sham, H.L., and Trevillyan, J.M. (2006) Discovery of ((4R,5S)-5-amino-4-(2,4,5trifluorophenyl)cyclohex-1-enyl)-(3(trifluoromethyl)-5,6-dihydro-[1,2,4] triazolo[4,3-a]pyrazin-7(8H)-yl) methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 49, 6439–6442. Pei, Z. (2008) From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr. Opin. Drug Discov. Dev., 11, 512–532. Fei, Z., Wu, Q., Zhang, F., Cao, Y., Liu, C., Shieh, W.-C., Xue, S., McKenna, J., Prasad, K., Prashad, M., Baeschlin, D., and Namoto, K. (2008) A scalable synthesis of an azabicyclooctanyl derivative, a novel DPP-4 inhibitor. J. Org. Chem., 73, 9016–9021. Hardman, J.G., Linbird, L.L. (eds.), (2001) Goodman & Gilmans The Pharmacological Basis of Therapeutics, 10th edn, McGraw-Hill. Szczepankiewicz, B.G., and Kurukulasuriya, R. (2007) Aromatic heterocycle-based DPP-IV inhibitors: xanthines and related structural types. Curr. Top. Med. Chem., 569–578.
59 Eckhardt, M., Langkopf, E., Mark, M.,
60
61
62
63
64
65
Tadayyon, M., Thomas, L., Nar, H., Pfrengle, W., Guth, B., Lotz, R., Sieger, P., Fuchs, H., and Himmelsbach, F. (2007) 8(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl3-methyl-1-(4-methyl-quinazolin-2ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, longacting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 50, 6450–6453. Thomas, L., Eckhardt, M., Langkopf, E., Tadayyon, M., Himmelsbach, F., and Mark, M. (2008) (R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4methyl-quinazolin-2-ylmethyl)-3,7dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther., 325, 175–182. Meyer, E.A., Castellano, R.K., and Diederich, F. (2003) Interactions with aromatic rings in chemical and biological recognition. Angew. Chem. Int. Ed., 42, 1210–1250. Eckhardt, M., Hauel, N., Himmelsbach, F., Langkopf, E., Nar, H., Mark, M., Tadayyon, M., Thomas, L., Guth, B., and Lotz, R. (2008) 3,5-Dihydro-imidazo[4,5-d] pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorg. Med. Chem. Lett., 18, 3158–3162. Feng, J., Zhang, Z., Wallace, M.B., Stafford, J.A., Kaldor, S.W., Kassel, D.B., Navre, M., Shi, L., Skene, R.J., Asakawa, T., Takeuchi, K., Xu, R., Webb, D.R., and Gwaltney, S.L. (2007) Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem., 50, 2297–2300. Gwaltney, S.L. (2008) Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV. Curr. Top. Med. Chem., 8, 1545–1552. Krishna, R., Herman, G., and Wagner, J.A. (2008) Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J., 10, 401–409.
References 66 He, Y.-L., Wang, Y., Bullock, J.M., Deacon,
67
68 69
70
71
72
C.F., Holst, J.J., Dunning, B.E., LigherosSaylan, M., and Foley, J.E. (2007) Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J. Clin. Pharmacol., 47, 633–641. European Medicines Agency, Galvus product information (2008) http://www. emea.europa.eu/humandocs/PDFs/ EPAR/galvus/H-771-PI-en.pdf, accessed 16 December 2008. US Food and Drug Administration (2008) Januvia prescribing information, July 23. Covington, P., Christopher, R., Davenport, M., Fleck, P., Mekki, Q.A., Wann, E.R., and Karim, A. (2008) Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther., 30, 499–512. Boulton, D.W.and Geraldes, M. (2007) American Diabetes Association, 67th Scientific Sessions, Poster 606-P. Cole, P., Serradell, N., Bolós, J., and Castañer, R. (2008) Saxagliptin: dipeptidyl peptidase IV inhibitor antidiabetic agent. Drugs Future, 33, 577–586. H€ uttner, S., Graefe-Mody, E.U., Withopf, B., Ring, A., and Dugi, K.A. (2008) Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of
BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J. Clin. Pharmacol., 48, 1171–1178. 73 Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., and Zinman, B. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32, 193–203. 74 DeFronzo, R.A., Fleck, P.R., Wilson, C.A., and Mekki, Q. (2008) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebocontrolled study. Diabetes Care, 31, 2315–2317. 75 Bergman, A.J., Stevens, C., Zhou, Y., Yi, B., Laethem, M., De Smet, M., Snyder, K., Hilliard, D., Tanaka, W., Zeng, W., Tanen, M., Wang, A.Q., Chen, L., Winchell, G., Davies, M.J., Ramael, S., Wagner, J.A., and Herman, G.A. (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebocontrolled study in healthy male volunteers. Clin. Ther., 28, 55–72.
Patrizio Mattei
F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland Patrizio Mattei was born in Thalwil, Switzerland, in 1968. He studied chemistry at the Eidgen€ ossische Technische Hochschule in Z€ urich, where he also carried out his doctoral work under the supervision of Professor Fran¸cois Diederich. After a postdoctoral fellowship in Professor Donald Hilverts group at the Scripps Research Institute in La Jolla, California, he joined F. Hoffmann-La Roche Ltd. as a medicinal chemist in 1999. He is coinventor of more than 40 patents and patent applications, 5 of which are related to DPP-IV inhibitors.
j133
j 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes
134
Jens-Uwe Peters
F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland Jens-Uwe Peters studied chemistry at the University of G€ottingen, where he worked with Professor A. de Meijere, and conducted his doctoral research at the Technical University of Berlin under the guidance of Professor S. Blechert. After 1 year of postdoctoral studies in the group of Professor J. Rebek at the Scripps Research Institute, La Jolla, he joined the Medicinal Chemistry group at F. Hoffmann-La Roche, Ltd. in 1999. Since then, he has been contributing to Roches DPPIV project and to numerous other drug discovery projects.
j135
6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction Nils Griebenow, Helmut Haning, and Erwin Bischoff
6.1 Introduction
The second messengers, cyclic 30 ,50 -adenosine monophosphate (cAMP) and cyclic 30 ,50 -guanosine monophosphate (cGMP), play a pivotal role in mediating a plethora of functional responses to hormones and other cellular transmitters. Their intracellular concentrations are adjusted by their synthesis through adenylyl cyclase and guanylyl cyclase, and by their degradation through cyclic nucleotide phosphodiesterases to the physiologically inactive 50 -nucleoside monophosphates. Cyclic nucleotides and phosphodiesterases (PDEs) were discovered almost simultaneously in the late 1950s by Sutherland and coworkers [1–3]. Eleven members of the superfamily of phosphodiesterases are known today. They substantially differ in their tissue distribution, physicochemical properties, substrate and inhibitor specificities, and regulatory mechanisms. The sensitivity of the physiological processes regulated by cyclic nucleotides requires precise and rapid regulation of the level of these second messengers according to the requirements of the physiological status of the cell. A precise modulation of PDE function is crucial for maintaining cyclic nucleotide levels within a narrow concentration range. This is consistent with, for example, the changed phenotype of mice deficient in distinct PDEs, demonstrating the importance of finely balanced cyclic nucleotide levels [4–6]. Due to their key role in the regulation of physiological processes, inhibitors of PDEs can be used as therapeutic tools for various diseases. PDE5 is one member of the super family that specifically hydrolyzes cGMP, and a number of new PDE5 inhibitors have recently been introduced. Increasing knowledge of the molecular structure of the enzyme and the catalytic center may help gain a better understanding of the structure–activity relationship (SAR) of new inhibitors. Furthermore, potent and selective inhibitors provide pharmacological tools to investigate the physiological functions of PDE5, which may provide novel therapeutic opportunities for this class of inhibitors beyond the well-established treatment of erectile dysfunction (ED).
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
136
This chapter summarizes the molecular biology, regulation, biochemistry, and functions of the PDE5 isozyme. The structure–activity relationships of the known PDE5 inhibitors from distinct structural classes are discussed from the standpoint of structural diversity rather than from a pharmacological point of view. In addition, the pharmacological effects, the clinical applications, and emerging applications for PDE5 inhibitors are presented. IC50 values are quoted as reported in the original source, and no discrimination is made between IC50 values derived from PDEs of different origin.
6.2 Pharmacology of Phosphodiesterases 6.2.1 The Phosphodiesterase Family
The mammalian phosphodiesterase superfamily (type 1 PDEs) of isoenzymes today consists of 11 different subfamilies of gene products that have been characterized on the basis of their amino acid sequences, substrate specificities, intracellular and extracellular regulators, and pharmacological properties. Numerous reviews demonstrate the enormous increase in knowledge of the structural features, catalytic mechanisms, regulation, physiology, and inhibitors of this intriguing class of enzymes, although many details of their function remain unclear [7–16, 23]. Several of the isoenzymes are encoded by different genes that in addition to the presence of different splice variants brings the number of different PDE proteins up to approximately 50 in mammalian cells. The increasing knowledge of the genomic relationships, and a better understanding of the regulation and the functional characteristics of the different family members, has generated a new systematic nomenclature [17]. Under this nomenclature, a PDE family is designated by an Arabic numeral followed by a capital letter designating the gene within the respective family and the second Arabic numeral indicates the variant product derived from a single gene (e.g., PDE4A2 denominates PDE family 4, gene A, splice variant 2). The mammalian PDEs share a common structural organization, with a conserved catalytic domain located close to the C-terminus and a regulatory domain mostly close to the N-terminus of the protein. The catalytic domain contains a signature motif HD (X2)H(X4)N common to all mammalian PDEs that have consensus metal binding domains (Zn2 þ , Mg2 þ , Mn2 þ ) related to those of metal-ion phosphohydrolases [18]. Someof these PDEs(PDE2, PDE5, PDE6,and PDE10)bind cGMP with highspecificity at homologous allosteric sites that are arranged in tandem in their amino terminal domains [19]. In addition to their regulatory function of hydrolyzing cAMP and cGMP, they may also have a function as intracellular receptors or as a sink for cGMP [10, 19]. However, the physiological meaning of this latter property is not yet fully understood. Some of these PDEs are targets for many drugs that are used to treat cardiovascular diseases, asthma, erectile dysfunction, and other diseases. Different isoenzymes are characterized according to their substrate specificity, sequence homology, kinetic
6.2 Pharmacology of Phosphodiesterases Table 6.1 The superfamily of phosphodiesterases.
Name
Km (mm)
Characteristics
Number of genes
cAMP
cGMP
Ca2 þ -CaMstimulated cGMPstimulated
1–30
3
3
30–100
10–30
1
PDE3
cGMP-inhibited
0.1–0.5
0.1–0.5
2
PDE4
cAMP-specific
0.5–4
>50
4
PDE5
cGMP-specific
>40
1.5
1
PDE6 PDE7
Photoreceptor cAMP high affinity cAMP high affinity
2000 0.2
60 >1000
4 2
0.7
>100
2
>100
0.07
1
PDE10
cGMP high affinity Dual substrate
0.5
3
1
PDE11
Dual substrate
1
0.5
1
PDE1 PDE2
PDE8
PDE9
Primary tissue distribution
IBMX sensitivity
VSMC, brain, lung, heart Adrenal cortex, brain, heart, liver, corp. cav., olfact, bulbous Heart, lung, liver, immunocytes, pancreas Immunocytes, lung, brain VSMC, SMC, lung, corp. cav., platelets Retina Skeletal muscle, T-cells Widely expressed, most abundant in testis, ovary, intestine, colon Broadly expressed, liver, kidney Broadly expressed, in mice most abundant in brain, testes Testes, brain, corp. cav., skeletal muscle, prostate
þ þ
þ
þ þ
þ þ
þ
þ
VSMC: vascular smooth muscle cells; SMC: smooth muscle cells; CaM: calmodulin; corp. cav.: corpus cavernosum.
properties, and sensitivity to certain known PDE inhibitors. Table 6.1 shows these properties together with the predominant tissue expression of various PDEs. 6.2.2 Pharmacological Effects of cGMP
Nitric oxide, nitrovasodilators, and natriuretic peptides act as relaxants, regulating smooth muscle tone by direct activation of guanylyl cyclase, which leads to the
j137
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
138
elevation of cGMP. Thus, influencing cGMP levels by modulating PDE or guanylate cyclase activity remains an interesting pharmacological approach to regulate smooth muscle tone. Activation of cGMP-dependent protein kinase G (PKG) appears to mediate all cGMP-induced relaxant effects [20]. Disruption of the PKG I gene totally abolishes nitric oxide (NO)/cGMP-dependent relaxation of smooth muscle in mouse aorta and also causes erectile dysfunction in mice [21]. However, PKGs physiological function in the phosphorylation and activation of PDE5 has not yet been established. It is suggested that only minimal PDE5 activity is required to control the intracellular cGMP levels in close proximity to proteins involved in cGMP-induced relaxation of smooth muscle. These include myosin light-chain phosphatase and proteins associated with the regulation of intracellular Ca2 þ concentration, for example, Ca2 þ -activated K þ channel and IP3 receptor-associated cGMP kinase substrate (IRAG). In each of these cases, activation of PDE5 may provide a negative feedback regulation of cGMP and PKG when the intracellular concentration of cGMP reaches a high level. Regulation of PDE5 via dephosphorylation by myosin phosphatase might be physiologically as important as regulation of PDE5 phosphorylation by PKG in providing a relaxation contraction cycle [22]. Increased cGMP levels have also been shown to inhibit smooth muscle cell (SMC) proliferation that is a key event in the development of arteriosclerotic lesions [24, 25]. 6.2.3 PDE5: Regulation, Activation, and Structure
PDE5 catalytic activity is regulated by a plethora of mechanisms that significantly contribute to negative feedback regulation of cGMP signaling and are quite complex [26–29]. Until recently, PDE5 was known as the cGMP-binding cGMP-specific PDE because it contains allosteric sites and a catalytic site that are both highly specific for cGMP (Figure 6.1). PDE5 is a modular protein with a N-terminal R domain and a C-terminal C domain (Figure 6.1) [30]. There is significant communication between the PDE5 R domain and the C domain, and this property fashions a complex and well-integrated modulation of enzyme activity. The cGMP binding sites in the R domain and the catalytic site are not evolutionarily related, but both exhibit approximately 100-fold specificity to cGMP versus cAMP. When the C domain alone is generated as a recombinant protein, it is a monomer that retains the salient features of catalysis exhibited by PDE5 holoenzyme [31, 32]. PDE5 exhibits a Km value for cGMP of approximately 2–3 mM, a concentration that is generally considered to be well above normal physiological concentration range for cGMP. Comprehensive studies using site-directed mutagenesis of conserved amino acids in the C domain of PDE5 first identified residues that are important for contact with the critical divalent cations, those that contribute to binding of the substrate, and many of those that are key to potent interaction of inhibitors such as sildenafil, vardenafil, and tadalafil [33–35]. The N-terminal R domain of PDE5 contains a number of functional subdomains that impact PDE5 catalytic function and its interaction with inhibitors. The
6.2 Pharmacology of Phosphodiesterases
Figure 6.1 Working model of PDE5. PDE5 is a dimer of two identical approximately 100 kDa subunits. It has a C-domain located in the more carboxyl-terminal portion of the protein and an R-domain located in the more amino-terminal portion. Dimerization occurs through interactions at multiple points in the regulatory domain indicated by the black bars. The catalytic machinery is depicted as two ovals that reflect the two divalent cations that provide for catalytic hydrolysis of cGMP. Cyclic GMP is also bound to
allosteric sites in the R-domain including a highaffinity site in GAF A (indicated by the deep oval binding pocket) and perhaps in GAF B; GAF B has been shown to have numerous regulatory functions in PDE5 and may have weak cGMP binding activity as indicated by the shallow oval pocket. PDE5 can be specifically phosphorylated by PKG at a single site, Ser-102, in the R-domain, and exposure of this serine is regulated by binding of cGMP and other ligands to protein.
subdomains include two GAFs (GAF A and GAF B; GAF: cGMP-specific cGMPstimulated PDE, Adenylate cyclase, and FhlA), a single phosphorylation site (Ser-102) that is preferentially phosphorylated by PKG, and dimerization contacts [30]. Highaffinity allosteric cGMP binding is provided by the GAF cyclic GMP-hydrolyzing phosphodiesterases. High-affinity allosteric cGMP binding is provided by GAF A subdomain [36, 37], but whether GAF B can also bind cGMP is not known. In the holoenzyme, binding of cGMP to the allosteric cGMP binding sites is low, but occupation of the catalytic site by either cGMP or PDE5 inhibitors stimulates cGMP binding to the allosteric sites [38, 39]. Cyclic GMP occupation of the allosteric sites increases affinity of the catalytic site for cGMP and inhibitors. Furthermore, when the allosteric sites are occupied by cGMP, PDE5 undergoes a conformational change that exposes Ser-102 for rapid phosphorylation by PKG [39]. Phosphorylation of Ser-102 in turn increases both the affinity of the allosteric cGMP-binding sites for cGMP and the affinity of the catalytic site for substrate or inhibitors [27, 40]).
j139
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
140
O O N N
N
N
N
N
N
O Vardenafil (2)
O Sildenafil (1)
O O N
N
O
N
HN
O O S N H
N
N H
HN
O O S N
N
HN
O O S N
N
O
N
HN
N N O
O
Udenafil (4) N
O
N
N
O HN
O
OH N
O N H O
N
N N
Avanafil (6)
Mirodenafil (5)
N
HO
Tadalafil (3)
S O O
O O O S N
N O
HN N
N
N
O
SLX-2101 (7)
Cl
Figure 6.2 Drugs on the market and under clinical trials.
Multiple lines of evidence suggest that PDE5 exists in at least two conformations and that the distribution of the PDE5 population between these conformers can be regulated by phosphorylation/dephosphorylation, oxidation/reduction, and binding of cGMP or inhibitors. These stepwise modulations of structure and function in PDE5 are tightly controlled and regimented and bear significant consequences for feedback regulation of cGMP levels and inhibitor potency. First of all, cGMP occupation of the allosteric cGMP binding site increases the affinity of the catalytic site for cGMP, the substrate, or inhibitors such as sildenafil, vardenafil, or tadalafil. In the absence of PDE5 inhibitors, the rate of hydrolysis of cGMP is increased since the PDE5 catalytic site is usually not saturated with cGMP; with higher affinity of the catalytic site for cGMP, more will be bound to the site and hydrolyzed. As a substrate mimic, a similar event occurs for PDE5 inhibitors, that is, cGMP binding to the allosteric sites increases the affinity for the inhibitor [41]. However, the inhibitor is not degraded by PDE5 and will remain bound to the catalytic site for a longer period of time, thus representing a feed-forward process that enhances inhibitor potency. Phosphorylation of Ser-102 increases both allosteric cGMP binding and affinity of the catalytic site for cGMP or inhibitors, thereby fostering improved function of the catalytic site. The physiological and pharmacological impacts of the regulatory processes described above are clear and are likely to occur in many tissues. For example, when cGMP is elevated in vascular smooth muscle, as occurs in the penile corpus cavernosum during sexual arousal, these regulatory factors, including increased
6.2 Pharmacology of Phosphodiesterases
allosteric cGMP binding and phosphorylation of Ser-102, impact PDE5 function and the physiological process associated with the vasodilation that leads to penile erection. Activation of guanylyl cyclases to produce more cGMP will increase the activity of the catalytic site in at least three ways to degrade cGMP (Figure 6.1). First, elevation of cGMP will cause more degradation of cGMP, simply due to a greater supply of cGMP to the PDE5 catalytic site. Secondly increased cytosolic cGMP will foster cGMP binding to the allosteric cGMP-binding sites of PDE5, and this will further increase hydrolysis of cGMP at the catalytic site. Third, phosphorylation of Ser-102 on PDE5 will further increase the affinity of allosteric cGMP binding and foster greater catalytic activity. All these effects act to dampen or terminate the cGMP signaling initiated by sexual arousal and act in concert as a negative feedback regulatory process. The increased affinity of the enzyme for the substrate would also provide improved competition with inhibitors that act at the catalytic site as well, thereby blunting the potency of inhibitors to some extent. However, in a physiological setting, effects of potent PDE5 inhibitors prevail since cGMP accumulates, thereby providing vasodilation sufficient for improved penile tumescence. Negative feedback control of the cGMP pathway through sequestration by PDE5 could occur in some cells. In the corpus cavernosum, the concentration of PDE5 allosteric cGMP binding GAF A is more than 100 nM [42], higher than the concentration of cGMP (basal 20 nM). Most of this cGMP would be tightly bound to GAF A and unavailable for its target receptors such as PKG. Increased sequestration by this process would be expected to occur after cGMP elevation and stimulation of the other negative feedback systems described above. Whether or not PDE2 concentration is high enough in most cells to mediate significant sequestration of cGMP, or cAMP, has not been demonstrated. PDE6 concentration in retinal photoreceptor cells is clearly high enough to impart sequestration [43]. Some of the same sequence of events described as providing negative feedback regulation of cGMP level can also enhance the potency and efficacy of PDE inhibitors. PDE5 inhibitors occupy the catalytic site of PDE5 to block cGMP access and thereby inhibit cGMP degradation. As a result, cGMP is readily available to bind to PDE5 allosteric cGMP-binding sites, bind to and activate PKG, and foster phosphorylation of Ser-102 on PDE5 by PKG, which enhances inhibitor binding at the catalytic site and increases the cGMP level further (Figure 6.1). Increased cGMP binding to the allosteric sites in turn promotes tighter binding of inhibitors at the catalytic site that elevates cGMP even more. In the presence of the inhibitor, this regulatory process becomes a feed-forward process to promote potency and efficacy of the pharmacological action of competitive inhibitors. Furthermore, prolonged exposure of PDE5 to inhibitors causes the enzyme to undergo a conformational change that increases the affinity of the enzyme for the inhibitor. Altogether, these effects that in nature provide a powerful counter to cGMP elevation in tissues containing PDE5 also provide a powerful feed-forward process to improve potency and action of PDE5 inhibitors. Recently, the crystal structure of the catalytic domain (residues 537–860) of human PDE5 in complex with three PDE5 inhibitors, sildenafil [44], tadalafil [45], and vardenafil [46] has been published [32] (Fig. 6.2). Herein, the catalytic domain consists of three helical subdomains, an N-terminal cyclin-fold region, a linker
j141
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
142
region, and a C-terminal helical bundle, whereas the active site of PDE5 is located at the center of the C-terminal helical bundle domain. The substrate pocket has a total volume of about 330 A3 and is approximately 10 A deep, with a narrow opening and a wider inner space. In detail, it is composed of four subsites, a metal binding site (M site) [29], core pocket (Q pocket), hydrophobic pocket (H pocket), and lid region (L region). The binding mode of sildenafil [47] differs from that of tadalafil (Figure 6.3). Sildenafil occupies the lid region with the N-methyl-piperazin moiety, whereas tadalafil makes no interaction with the L region of the protein. The core of sildenafil forms a bidentate hydrogen bond to the O-atom of Gln817, while the NH of tadalafil
Figure 6.3 Schematic representation of interactions made by sildenafil (a) and tadalafil (b) in complex with PDE5.
6.2 Pharmacology of Phosphodiesterases
makes a single hydrogen bond to the Gln817. The more extensive interactions with the H pocket may be one of the reasons why tadalafil maintains high affinity without binding to the L region as well as the M site. However, there is a conflicting evidence for a different binding mode of vardenafil compared to that of sildenafil [48]. 6.2.4 PDE5 Inhibitors and Erectile Dysfunction
Based on the vasorelaxing effects of cGMP, PDE5 was originally targeted for the treatment of hypertension, including pulmonary hypertension, coronary heart disease, and angina. Later on, erectile dysfunction emerged as an interesting indication for PDE5 inhibitors. Male erectile dysfunction is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance (NIH Consensus Conference 1993 [49]). ED can have a profound effect on the quality of life. Subjects frequently report anxiety, loss of self-esteem, lack of self-confidence, and difficulties in relationships with their partners. The prevalence of ED is age-related. Severe or complete ED has a prevalence of about 5% in men aged 40 and 15% in men aged 70, but less severe forms of ED are more prevalent [50]. It can also occur as a result of some defect in neurotransmission of nonadrenergic, noncholinergic (NANC) neurons in the penis associated with a variety of pre-existing factors such as hypertension, and/or coronary heart disease, diabetes, hormone levels, age, spinal cord injury, and psychological influences. Prostatectomy as a consequence of surgical treatment of prostate cancer is a further major risk factor. ED is multifactorial in etiology and frequently involves an interplay of both psychological and organic factors. Prior to the advent of sildenafil, the treatment of ED involved the use of vacuum constriction devices, penile prosthesis implantation, or intracavernosal injections with vasodilating agents. Sildenafil was the first orally active drug used for the treatment of ED that had a noteworthy commercial success. Reviews on the prevalence, pathophysiology, and risk factors associated with ED are numerous [51–54], so are summaries on its pharmacology and efficacy of treatment [55, 56]. An excellent overview of ED treatment options and compounds in development was recently published [57]. Penile erection is a hemodynamic process involving relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. This relaxation results in increased blood flow into the trabecular spaces of the corpora cavernosa [53, 58]. Smooth muscle relaxation is mediated by nitric oxide that, during sexual stimulation, either directly or psychosomatically, is synthesized in the nerve terminals of parasympathetic, nonadrenergic, noncholinergic (NANC) neurons in the penis and also by the endothelial cells of the blood vessels and the lacunar spaces of the corpora cavernosa. NO activates smooth muscle cell soluble guanylate cyclase, resulting in an increased intracellular cGMP level that leads to relaxation of smooth muscle of the corpus cavernosum and of the penile arterioles [59–62]. The level of cGMP is regulated by a balance between its rate of synthesis via guanylate cyclase and its
j143
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
144
hydrolysis to the physiologically inactive GMP by the cGMP hydrolyzing phosphodiesterases. These are the calmodulin-stimulated PDE type 1 (PDE1), the cGMP activated PDE type 2 (PDE2), and the cGMP specific PDE type 5 (PDE5). Recently, a new cGMP specific PDE type 9 (PDE9) was described; however, its tissue distribution and physiological role are not yet known [63]. The most plentiful cGMP-PDEs in the human corpus cavernosum are PDE5 [64] (about 70%) and PDE2 (30%) [36]. Other reports describe significant amounts of PDE3, PDE4, and PDE5 [65]. Inhibition of PDE5 increases the level of cGMP after release of NO at parasympathetic nerve terminals during sexual stimulation, thus enhancing relaxation of smooth muscle. As a result, vascular tone in the arteries leading to the penis decreases. This causes increased blood flow and an enlargement of the cavernosal tissue that induce penile erection [53, 66, 67]. A prerequisite to PDE5 inhibition as a therapeutic principle is sexual stimulation. The selectivity of vasorelaxation of penile tissue is mainly based on the increased synthesis of cGMP in the cavernosal tissue during sexual stimulation. Although PDE5 is the main cGMP-metabolizing enzyme in cavernosal tissue, this unique situation of increased cGMP concentrations after nerval stimulation contributes more strongly to the selective vasodilation in cavernosal tissue than the localization of PDE5 in this tissue [68]. This is also the reason for the fact that only minor effects on systemic blood pressure have been observed in clinical studies with PDE5 inhibitors. Most of the reversible mild to moderate side effects reported for PDE5 inhibitors are mechanism related and a consequence of the abundant distribution of the enzyme in almost all smooth muscle cells. Although varying from compound to compound, the most frequent and dose-dependent side effects are headache and, to a minor extent, nasal congestion. All these effects can be interpreted as a result of the general dilation of small arterial vessels. Nonselective inhibition of PDE1 that is also a cGMP metabolizing PDE and predominantly localized in vascular smooth muscle cells (VSMCs) can also contribute to this effect. Greater selectivity could improve this profile. Dyspepsia is also often reported as a side effect, which can be explained by the high expression of PDE5 in the lower esophagus [69]. Another reported side effect is visual disturbances. These ophthalmologic effects are probably related to the inhibition of PDE6 activity present in the retina that is responsible for signal transduction in the eye [70]. Table 6.2 summarizes the existing PDE5 inhibitors on the ED market, along with compounds in clinical development for ED. Below, we would like to give a short update on the current status. First approved in 1998, sildenafil has been found to be effective in improving erections in a large numbers of men with ED resulting from a variety of causes [71–73]. Sildenafil is rapidly absorbed, with a tmax of approximately 1 h and a half-life of approximately 4 h. A number of placebo-controlled clinical trials have found sildenafil effective in treating ED resulting from both psychogenic and organic causes, such as spinal cord injury, and in other special populations such as diabetics. Several studies have shown sildenafil to improve erections in over 80% of men in the broad ED population and slightly less in the more challenging-to-treat diabetic population (between 56% [74] and 64% [75], compared to much lower placebo rates).
6.2 Pharmacology of Phosphodiesterases Table 6.2
PDE5 inhibitors on the market and under clinical development for erectile dysfunction.
Compound name
Company
Development status
Sildenafil Vardenafil Tadalafil Udenafil Mirodenafil Avanafil SLX-2101
Pfizer Bayer Schering Pharma Lilly Dong-A Pharmaceutical SK Chemicals VIVUS Surface Logix
Launched 1998 (Viagra) Launched 2003 (LevitraÒ ) Launched 2003 (CialisÒ ) Launched 2005 (ZydenaÒ ) Launched 2007 (M-vixÒ ) Phase II Phase II
Sildenafil has been generally well tolerated, with adverse events primarily associated with PDE5 inhibition in other locations resulting in flushing, headache, dyspepsia, and rhinitis. However, there have been a small percentage of men who have reported blue color vision changes, which can be linked to the inhibition of PDE6. Vardenafil was first approved by US regulators in 2003 [76]. The drug was demonstrated to have a selectivity 257-fold higher for PDE5 than PDE1, and 16fold higher for PDE5 compared to PDE6. In contrast, sildenafil was only 60-fold more selective in its blocking effect of PDE5 compared to the blockade of PDE1, and 7-fold more selective in terms of PDE6. Maximum plasma concentrations after oral administration have been reported as early as 0.7 h with a half-life of 4–5 h. In two RigiScan studies, vardenafil increased rigidity and prolonged the duration of erections compared to placebo-treated men with ED. A large phase II study of men with mild to severe ED indicated that vardenafil significantly improved erectile function (EF) in them. Efficacy was noted irrespective of etiology and age, as well as baseline severity. Phase III programs have confirmed these early results in a broader population with common comorbidities such as diabetes and hypertension, where up to 85% of men reported improved erection at 26 weeks [77]. In a specific study in men with diabetes mellitus, up to 72% of men at the highest 20 mg dose responded, compared to 13% on placebo. Physicians interviewed by Decision Resources, for example, cite vardenafil as their preferred first-line therapy for diabetics with ED [76]. An especially challenging-to-treat condition is ED following prostatectomy, and a significant increase in response with vardenafil was seen, with 65% responding compared to 13% on placebo, in men with nerve-sparing surgery [78]. Adverse effects have been generally mild to moderate and tend to decrease with time [79–81]. The most common adverse events could again be linked to generalized PDE5 inhibition and the incidence of vision disturbances has been rare. Tadalafil was launched in Europe and the United States in the first half of 2003 [82]. While high concentrations of tadalafil are seen in plasma, the tmax of the most recent formulation has been reported to be about 2 h. In contrast to sildenafil and vardenafil, tadalafil shows a prolonged half-life of 17.5 h [2, 83, 84]. Physicians have already dubbed tadalafil the weekend pill because its effects can last up to 36 h, whereas the other PDE inhibitors duration of action is generally 4–8 h. In a series of small phase
j145
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
146
II studies with an early formulation, clear efficacy was seen over placebo. In a phase III study with diabetic patients, improved erection in up to 64% of men was reported compared to 25% on placebo [85]. Adverse events again were PDE5-related although a consistent finding seems to be a higher incidence of back pain and myalgia than for vardenafil and sildenafil [84]. No color vision disturbances were reported, consistent with the high selectivity for PDE5 over PDE6. Udenafil, a pyrazolopyrimidinone, was developed by Dong-A Pharmaceutical Co., Ltd. and has been available in Korea in the form of 100 and 200 mg tablets since December 2005. Phase III clinical data showed that in men with mild to severe ED, the drug produced a significant improvement in erectile function score after 12 and 24 weeks of treatment. The drug was well tolerated and the adverse events were in general the same as with other PDE5 inhibitors. Biochemical potency and selectivity are similar to sildenafil. The pharmacokinetic profile (tmax of 1–1.5 h and T1/2 of 11–13 h) suggests that the drug will have a fast onset of action and a duration of possibly 24 h [86]. Mirodenafil, a pyrrolopyrimidinone structurally related to the pyrazolopyrimidinones and imidazotriazinones, entered the Korean market in 2007 [87]. In vitro potency against PDE5 (0.33 nM) is about 10 times higher compared to sildenafil. Selectivity compared to the other PDEs is similar to the marketed PDE5 inhibitors. Data from an 8-week multicenter, randomized double-blind, placebo-controlled phase II clinical study with 116 patients were presented at the International Society of Sexual Medicine 2006 conference in Cairo [88]. With dosages of 50, 100, and 150 mg, the erectile function domain score on the International Index of Erectile Function (IIEF) increased from a main baseline of approximately 13–15 to 21, 24.6, and 23, respectively. More than 50% of the patients returned to normal erectile function after 8 weeks (IIEF-EF 26) with the 100 mg dose. The recommended starting dose is 50 mg. The drug should be taken 1 h before sexual activity. A phase III study was performed with the 50 and the 100 mg dose with 516 patients in Korea. No clinical studies in other countries have been reported so far. Avanafil originated first at Tanabe Seiyaku as TA-1790 and is being developed by Vivus, Inc. Biochemically, the compound has a higher selectivity compared to sildenafil with respect to PDE1, PDE6, and PDE11, and the IC50 for PDE very close to sildenafil [89]. The half-life is rather short (T1/2 ¼ 60–90 min). A multicenter, randomized double-blind, placebo-controlled phase II clinical study included 284 with mild to moderate ED. Doses from 50 to 300 mg were taken 30 min before initiation of sexual activity. At the highest dose up to 64% were able to complete the intercourse compared to 28% in the placebo group. After treatment for a period of 12 weeks when the drug was taken 30 min before starting sexual activity, the EF of the IIEF score increased from 10.0 to 22.7. The most common adverse events were headache and flushing [90]. SLX-2101, an imidazotriazinone, is a long-acting PDE5 inhibitor. The biochemical potency IC50 (0.04 nM) is much higher than that of sildenafil. Selectivity with respect to PDE1, PDE3, and PDE6 is comparable to that of sildenafil [91], which seems to support the observation that the imidazotriazinone scaffold is especially suited for PDE5 inhibition. Phase I data were presented before the European Society of Sexual
6.3 Pyrimidinone PDE5 Inhibitors
Medicine in December 2005 [92]. RigiScan data from healthy volunteers were obtained in a dose range from 10 to 80 mg and showed erectile effects 6 h postapplication without visual sexual stimulation and up to 24–24.5 h with visual sexual stimulation. The pharmacokinetic profile showed a tmax at 1 h and a T1/2 from 9 to 14 h. The compound produces an active metabolite that has nearly the same potency and selectivity like the original drug [93]. Apart from ED, additional phase II studies on Raynauds disease and hypertension were also announced for 2006 and 2007, respectively.
6.3 Pyrimidinone PDE5 Inhibitors
Inhibitors incorporating the pyrimidinone heterocycle, likewise cGMP (8), the natural substrate of PDE5, constitute the largest class of PDE5 inhibitors. O N
HN H2N
N
N OH O O
cGMP (8)
O P OH O
Various natural products carrying this structural element are weak and generally nonselective PDE inhibitors, for example, caffeine (9), theophylline (10), and theobromine (11). The PDE inhibitory activity of theophylline that is used for the treatment of asthma is in the double-digit micromolar range [94]. These natural products together with the structure of cGMP itself provided a basis for the further development of more potent and/or more selective synthetic PDE5 inhibitors. O Me O
N N
O
Me N
Me
N
O
Me Caffeine (9)
O H N
N N
N
Me Theophylline (10)
HN O
Me N
N
N
Me Theobromine (11)
6.3.1 Xanthines and cGMP Analogues
IBMX (isobutylmethylxanthine (12)) is the prototypical synthetic xanthine PDE inhibitor. It shows a PDE5 inhibitory activity of 10 mM with little or no apparent
j147
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
148
selectivity for a panel of other PDEs (IC50 ¼ 7 mM for PDE1, 10 mM for PDE4, and >10 mM for PDE2) [95].
Me
N
O
O
O
O
N
H N
Me
N
O
N N
H N
n-Pr
N
O
N
N n-Pr
i-Bu
i-Bu
H N
N
Cl IBMX (12)
1,3-Dipropyl-8-(4-chlorbenzyl) xanthine (14)
8-(Norbornylmethyl)-IBMX (13)
A literature survey revealed a number of modified IBMX congeners [96–98]. Introduction of lipophilic groups at C8 of the IBMX framework leads to significantly improved PDE5 inhibition. 8-(Norbornylmethyl)-IBMX (13) has a nanomolar IC50 (1.5 nM) with considerably improved selectivity (IC50 PDE1 ¼ 30 nM, IC50 PDE4 > 10 mM). Overall, these compounds are characterized by a dual PDE1/PDE5 inhibition profile and a weaker inhibition of PDE2, 3, or 4. Interestingly, the introduction of a slightly larger alkyl substituent at N-2, as in 1,3-dipropyl-8-(4chlorobenzyl)xanthine (14), completely suppressed the PDE1 activity (>10 mM), an effect similar to tetracyclic guanidines. However, PDE5 activity is also reduced to 600 nM. Recently, researchers at Novartis have published novel 8-quinoline or 8-isoquinoline xanthine derivatives [99] with nanomolar PDE5 inhibitory activity as exemplified by (15) (IC50 ¼ 2 nM). However, no selectivity data are reported for these compounds. Researchers at Schering recently published xanthine PDE5 inhibitors with amino substituents in the imidazole 2-position, such as dasantafil (16) [100]. Br O N
O
O Me O
H N
N N i-Bu
N
N
N (15)
OMe
O
N
H N
OH
N
HO Dasantafil (16)
By combining structural motifs from xanthines and pyrimidinone PDE5 inhibitors (i.e., alkoxy-sulfonamidophenyl substituents) representatives of the 6-phenylpyrrolopyrimidinone series, such as (17), were synthesized [101, 102].
6.3 Pyrimidinone PDE5 Inhibitors
O Me
H N
N
On-Pr
N
O
SO2 N
R
n-Pr
N Me
(17) R = H, Cl or Br
PDE5 inhibition is in the low nanomolar range, but no selectivity data, and little SAR information, are provided. However, potency was raised by increasing the size of the pyrrolo substituent R from H to Cl or Br (14, 4.2, and 4.5 nM, respectively), but a further increase in steric bulk does not improve potency. It could be speculated that a hydrogen bond between the pyrrole NH and the alkoxy substituent on the phenyl ring serves to keep the two halves of the molecule in an almost planar arrangement. In an extension of this work, the same group from Almirall Prodesfarma reported on heterocyclic fused congeners of the above-mentioned compounds [103, 104]. Subnanomolar PDE5 inhibitors were obtained in this dihydrotriazolopurinone series and one such compound, (18), shows an IC50 of 0.34 nM.
N N H N
N O
N n-Pr
N
SO2 N
OH
N n-PrO (18)
Modified cGMP analogues have also been reported as PDE5 inhibitors [105]. Among these, the heterofused derivative (19) showed the most potent PDE5 inhibition with an IC50 of 12 nM. The analogous cGMP congener (20) was only weakly active (15 mM). OH
OH O
O N
N N H
N
HN
S
S N
N OH
H2N
N
OH O
O (19)
N
O O P OH O
(20)
O O P OH O
j149
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
150
6.3.2 PDE5 Inhibitors Incorporating the Purinone Nucleus 6.3.2.1 Zaprinast Although by definition not a purinone, Zaprinast (21) is mentioned here because it constitutes an intriguing starting point for the development of potent PDE5 inhibitors. Zaprinast (M&B 22948, 2-propoxyphenyl-8-azapurin-6-one) was synthesized in an approach to prepare xanthine derivatives as antiallergic compounds and was proposed as a clinical candidate for use in allergic asthma [106]. Detailed studies demonstrated the ability of Zaprinast, like other xanthines, to inhibit PDEs, especially PDE5 (Ki ¼ 130 nM) [192]. Zaprinast has been widely used to investigate the important role of cGMP as a second messenger in smooth muscle cells generated by nitric oxide and as a pharmacological tool for the evaluation of PDE5 inhibition in various conditions. O n-PrO
N
HN
X N
N 1
R 2
R
X
R1
R2
(21) Zaprinast (22) SKF 96231 (23)
N CH CH
H H n-Pr
H H
(24)
CH
NH2
-SO 2 N
N Me
-SO2 N
N Et
Zaprinast set a milestone in the further evolution of more potent PDE5 inhibitors with the introduction of the orthoalkoxyphenyl moiety at the 2-position of the pyrimidinone nucleus. It is assumed that this serves to keep the alkoxyphenyl substituent in an almost planar arrangement with respect to the rest of the molecule [107]. 6.3.2.2 Purinones Using the heterocyclic core of cGMP as a scaffold, potent and selective cGMPcompetitive PDE5 inhibitors were discovered. Incorporation of the 2-alkoxyphenyl motif from Zaprinast into purinones [108], as in SKF 96231 (22), and later by varying the substituents on the aryl ring, led to potent and selective PDE5 inhibitors, exemplified by (23) that has an IC50 of 6.4 nM and a selectivity of more than 10 000 versus PDE4 [109].
6.3 Pyrimidinone PDE5 Inhibitors
Extending the scope of this class of PDE5 inhibitors, Pfizer claimed heterocyclesubstituted purinones with essentially the same range of potency [110]. Interestingly, not only alkyl but also aryl substituents are tolerated on the imidazole ring as exemplified by (24) (IC50 < 10 nM). 6.3.3 Pyrazolopyrimidinone PDE5 Inhibitors 6.3.3.1 Pyrazolo[3,4-d]Pyrimidin-4-One PDE5 Inhibitors A large number of patents and publications appeared describing PDE5 inhibitors of this class, most of which are low nanomolar inhibitors [111–118]. Compounds that have attracted special attention are DMPPO (25), which was described as a potent and selective PDE5 inhibitor (IC50 ¼ 3 nM) with good selectivity versus PDE1, PDE2, PDE3, and PDE4 (IC50 ¼ 1000, 3000, 10 000, and 22 000 nM, respectively), and WIN 58237 (26), which was described as inhibiting PDE5 with an IC50 of 170 nM. The latter compound does not inhibit either PDE1 or PDE3 but has little selectivity for PDE4 (IC50 ¼ 300 nM) [119]. O
R
HN R
1
3
N N
N R
2
R1 (25) DMPPO MeSO2NH
(26) WIN 58237
4-Pyridyl
(27) SR265579 (28)
2-ethoxy-4-pyridyl
R2
R3
Me
Me
c-Pentyl
Me
c-Pentyl Me
Et Me
On-Pr
O N
N H
OnPr
Researchers at Sterling Winthrop investigated an analogue of WIN 58237, SR265579 (WIN 65579) (27), for the potential treatment of asthma. Introduction of the 2-alkoxy substituent in the pyridyl moiety of WIN 58237 improved PDE5 inhibitory activity to 6.4 nM (Ki) with a 14-fold selectivity for PDE4 and a 33-fold selectivity for PDE3. PDE1 and PDE2 are inhibited only at considerably higher concentrations [120]. SR265579 lowers arterial blood pressure in conscious spontaneously hypertensive rats following both intravenous and oral dosing. SR265579 also increases plasma cGMP levels and reinstates vascular responsiveness to
j151
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
152
nitroglycerin in conscious rats that are nitroglycerin-tolerant. No further development is reported [121]. Inhibitory activity was retained by a variety of substituents on the aromatic ring. Apart from sulfonamides, ureas are also tolerated and lead to potent inhibitors, for example, (28), IC50 ¼ 1.5 nM. In a similar way to other pyrimidinone PDE5 inhibitors, researchers at Pfizer extended the existing SAR by claiming pyrazolopyrimidines including 6-heteroaryl substitution [122]. 6.3.3.2 1,6-Dihydro-7H-Pyrazolo[4,3-d]Pyrimidin-4-One PDE5 Inhibitors As early as 1985, this heterocyclic scaffold was used for the synthesis of PDE inhibitors (e.g., by researchers at Warner-Lambert) [123]. Compound (29) showed the highest PDE1 activity (80% inhibition of PDE1 at 10 mM). Compound (30) was described as inhibiting locomotor activity in a mouse model [124]. O
1
2
N
HN R
R
N N R
3
R1
R2
R3
(29) (30)
Bn c-Pentyl
Me Et
Me Me
(31)
MeO
Et
c-Pentyl
Et
c-Pentyl
Me
c-Pentyl
On-Pr
(32)
(33) N
This structural motif was elaborated further with compounds of the type exemplified by (31), which had an IC50 of 23 nM. By incorporating the now well-established alpha alkoxy aryl moiety, single-digit nanomolar PDE5 inhibitors were obtained (IC50 ¼ 1.6 nM for (32)) [125]. Interestingly, changing the alkoxyphenyl to a quinoline moiety results in potent PDE1 inhibitors (e.g., (33) IC50 PDE1 ¼ 97 nM) [126]. Due to its clinical significance and its commercial success, sildenafil (1) is the most studied pyrazolo[4,3-d]pyrimidinone PDE5 inhibitor and has become one of the most widely recognized molecular structures within the medicinal chemistry community in much the same way as ViagraÒ is recognized globally as a brand name. Its structure was originally contained in a patent application published in 1992 [127].
6.3 Pyrimidinone PDE5 Inhibitors
The in vitro and clinical profiles of sildenafil have been extensively reviewed [128, 129, 193]. Sildenafil is a potent PDE5 inhibitor (IC50 originally reported as 3.6 nM) with good selectivity for PDE1, 2, 3, and 4 [130]. Initially, it was developed for cardiovascular indications and later found to be active in the indication of male erectile dysfunction. O R R
3
R N
HN
N
2
N R R
4
5
1
R1 (1) Sildenafil Me N (34)
HO(CH2)2 N
n-Pr
Et N
R3
R4
R5
H
OEt
Me
n-Pr
N SO2- -O(CH2)2O- Me
O
(35) (36)
N SO2-
R2
n-Pr
H
On-Pr Me
H
On-Pr O
n-Pr
NH-
N SO2-
N
n-Pr
In an approach to increase the selectivity of sildenafil against PDE6, Kim et al. reported the synthesis of modified sildenafil analogues [131]. In comparison to sildenafil (in this study, IC50 for PDE5 ¼ 1.76 nM, IC50 for PDE6 ¼ 24.6 nM), incorporating the 2-alkoxy substituent into a ring (34), IC50 for PDE5 ¼ 6.25 nM, IC50 for PDE6 ¼ 7.34 nM) or changing the sulfonamide to an amide (35), IC50 for PDE5 ¼ 0.27 nM, IC50 for PDE6 ¼ 0.43 nM) failed to increase the selectivity of the molecules, although in the case of the amide substituents the potency was markedly increased [132, 133]. Larger substituents on N-1 of the pyrazole ring are also tolerated, exemplified by the morpholino compound (36), which has an IC50 of 1.9 nM [134]. As for the purinone system, the Pfizer group also claimed heterocyclic substituted pyrazolopyrimidinones in a series of patent applications, for example, (37) IC50 for PDE5 ¼ 8.5 nM [135]. Compound (37) resembles Novartis xanthine series and earlier benzylated IBMX derivatives (e.g., 15). Contrary to first reports, larger substituents such as 2-pyridylmethoxy (38, IC50 for PDE5 ¼ 5.7 nM) are allowed on the 6-pyridyl substituent [136]. The 2-alkoxy substituent has also been cyclized onto the ring, but no biological data have been reported [137].
j153
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
154
O R
1
O
N
HN
N R N
X
R
R
2
3
4
SO2
X
R1
R2
R3
R4
(37)
N
n-Pr
Me2N(CH2)2NH-
2-Pyridyl-CH2-
n-Pr
(38)
N
2-Pyridyl-CH2-
Et N
N
Me
Et
(39)
N
n-Bu
Et N
N
Me2NCOCH2-
Et
(40)
N
MeO(CH2)2-
Et N
N
2-Pyridyl-CH2-
Et
(41)
CH
Et
Et N
N
MeO(CH2)2-
Et
In later applications, the Pfizer group claimed pyridyl pyrazolo-pyrimidinones that exhibit a high selectivity for PDE5 over PDE6, thereby overcoming one of the shortcomings of sildenafil [137–141]. Compound (39) shows potent PDE5 inhibitory activity (IC50 ¼ 0.45 nM) and an increased selectivity for PDE6 (344-fold). Inhibition of PDE6 has putatively been linked to the ophthalmic effects of sildenafil (blue vision). Compound (40) was a preferred compound in a patent application, indicating a high interest in the molecule. Recently, a patent application covering PDE5 inhibitors of this type for use in the treatment of diabetic ulcers has appeared, including sildenafil and compound (41), but no activity has been reported [142]. In addition to sildenafil, several other pyrazolo[4,3-d]pyrimidin-4-ones (UK 114542, UK 357903, UK 390957, UK 369003, DA-8159) have been reported to be in clinical development for the indication of erectile dysfunction [143]. 6.3.4 Imidazotriazinone PDE5 Inhibitors
Imidazo[5,1-f ][1,2,4]triazin-4(3H)-ones are purine isosteres that were first described in the patent literature as bronchodilators. Furthermore, products of their synthesis have been described as C-nucleoside isosteres and purine analogues [144–152]. Imidazotriazinones were described by the group at Bayer [153, 154] as potent and selective PDE5 inhibitors and as dual PDE1/5 inhibitors [155].
6.3 Pyrimidinone PDE5 Inhibitors
In comparison to other pyrimidinone PDE5 inhibitors, it was demonstrated that this heterocyclic class consistently yields PDE5 inhibitors with higher potency and selectivity [156]. Vardenafil (2), the N-ethyl piperazine analogue, is an especially potent PDE5 inhibitor (IC50 ¼ 0.7 nM) and is selective for PDE1 (250-fold) and PDE6 (16-fold). Vardenafil also shows potent activity in a rabbit model of erectile dysfunction [157, 158]. O EtO
Me
HN N
N
N 2
R 1
R
SO2
R1
R2
(2) Vardenafil
Et N
N
n-Pr
(42)
HO
N
n-Pr
(43) (44)
Et2NHO(CH2)2(Et)N-
n-Pr c-Pentyl
In this series, there is broad tolerance of the sulfonamide N-substituent including cyclic and noncyclic, basic and neutral moieties (compound (42) PDE5 IC50 1 ¼ nM, PDE1 IC50 ¼ 100 nM; (43) PDE5 IC50 ¼ 4 nM, PDE1 IC50 ¼ 100 nM). Branched substituents on the imidazo ring (e.g., 44) resulted in extremely potent dual inhibitors of PDE1 and PDE5 with single-digit nanomolar IC50 values for both enzymes. The group at Pfizer has filed a patent application for 2-pyrido imidazotriazinones, but no activity data have been given for these types of compounds [159]. 6.3.5 Imidazoquinazolinones
Researchers from Bristol-Myers Squibb have recently published the structure of a new series of potent PDE5 inhibitors incorporating the N-3-benzylimidazoquinazolinone skeleton. Comparing their activity and selectivity with that of sildenafil, the authors describe the new compounds as having comparable potency and improved selectivity for PDE6. Practically, all compounds of this series show a more than 1000-fold selectivity for PDE1, 2, 3, and 4 and a more than 20-fold selectivity for PDE6, compared to a reported 8-fold selectivity in case of sildenafil [160–162].
j155
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
156
O n-PrO
2
R N
HN N
N
1
R
R1
R2
(45)
H2NCO-
F
(46)
Et N
OMe N SO2-
Both the amide (45) and the sulfonamide analogues (46) are subnanomolar PDE5 inhibitors. Compound (45) (IC50 PDE5 ¼ 0.48 nM) shows a more than 10 000-fold selectivity for PDE1, 2, 3, and 4 and a 60-fold selectivity for PDE6. Compound (46) (IC50 PDE5 ¼ 0.62 nM) also has a comparable selectivity profile with an improved selectivity for PDE6 (90-fold). 6.3.6 Pyrazolopyridopyrimidines
In an extension of the work on imidazoquinazolinones, another BMS group reported on pyrazolopyridopyrimidinones (47), which incorporate an ortho-alkoxyphenyl substituent and show low nanomolar PDE5 inhibition (48) [163]. As shown in Table 6.3, attaching a large benzylamine substituent (49) leads to a considerable increase in potency and selectivity. This result resembles the effects of adding larger substituents to the N-2 of pyrazolopyrimidinones that also led to increased selectivity for PDE6 (cf. compound (39)). 6.3.7 Miscellaneous Heterocylic-Fused Pyrimidinone PDE5 Inhibitors
Pyrimidinones fused to six-membered heterocycles such as pyridines, pyrimidines, and triazines were originally reported by the group at Smith Kline & French, with the most potent compound showing a PDE5 inhibition of 550 nM [164]. Dumaitre et al. gave an overview of several heterocycle variations in the pyrimidinone PDE5 inhibitor series [89]. By introducing the 2-propoxyphenyl substitution pattern, they were able to show considerable differences in PDE5 inhibitory potency between the
6.3 Pyrimidinone PDE5 Inhibitors Table 6.3 PDE selectivity profile of pyrazolopyridopyrimidinone PDE5 inhibitors.
O n-PrO
R N
HN N
N
N N H
SO2 (47)
NMe2 R
(48)
PDE5 (nM)
H
Selectivity PDE1/5
PDE2/5
PDE3/5
PDE4/5
PDE6/5
2.1
400
2000
>104
3200
22
0.3
>105
>105
>105
>104
160
NH
(49)
F
different heterocycles tested. In their study, the known pyrazolopyrimidinones showed the most potent PDE5 inhibition (Table 6.4). Continuing this series of heterocycle-fused pyrimidinones, workers at SK Chemicals claimed pyrrolopyrimidinone derivatives to be PDE5 inhibitors [165]. PDE5 inhibition for the best compounds was in the subnanomolar range, the most potent compound being (64) (IC50 ¼ 0.27 nM). The methyl and n-propyl substituents on the pyrrole seemed to be optimal for this heterocyclic class, and substitution of the phenyl ring para to the alkoxy group resulted in potent PDE5 inhibition. No information was provided on the selectivity profile of this class of PDE5 inhibitors. O EtO
Me N
HN N
n-Pr
N HOOC
SO2 (64)
j157
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
158
Table 6.4 Miscellaneous heterocycle fused pyrimidinone PDE5 inhibitors.
O n-PrO
HN
HET N
(50) Structure (HET) (51)
PDE5 IC50 (nM) 200
N N N H
N (52)
80
N H N (53)
300
N (54)
70
N N
(55)
(56)
50
100
S
CH3 60
(57)
S
S (58)
50
S (59)
80
CH3 (60)
N N H
150
6.3 Pyrimidinone PDE5 Inhibitors Table 6.4 (Continued)
PDE5 IC50 (nM)
Structure (HET)
CH3 N
(61)
8
N CH3
CH3 (62)
100
N O CH3
(63)
30
S N
The Pfizer group also claimed quinazolinones (65) (IC50 ¼ 6.5 nM) [166] and pyridopyrimidinones (66) (IC50 ¼ 1.2 nM, IC50 PDE3 ¼ 220 nM) as PDE5 inhibitors [167]. Similarly, the group at Taisho Seiyaku demonstrated that alkoxy substituents are tolerated on the pyridopyrimidinone as exemplified by (67), which has a reported IC50 of 2.9 nM [168]. O 2
R
X
HN
O
N 3
R 1
R
X
R1
(65)
C-Me
(66)
N
HOOC
(67)
N
O
HO(CH2)2 N
N SO 2-
N SO2-
R2
R3
n-Pr
H
Et
n-Pr
n-Pr
OMe
O N N H
Further exploring the types of heterocycles fused to the pyrimidinone, researchers at Taisho Pharma claimed benzofuryls (e.g., (68), IC50 ¼ 18 nM) and both thienyl
j159
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
160
isomers (69) (IC50 ¼ 1.7 nM) and (70) (IC50 ¼ 3.5 nM) [169, 170]. O
O n-PrO
O
HN N
n-PrO
O n-PrO
N
HN N
S NH
O
NH
O N
N
NH2
(70)
(69)
(68)
S
HN
O
Overall, the variation in the right-hand side heterocycle fused to the pyrimidinone nucleus has resulted in the discovery of a variety of potent and selective PDE5 inhibitors, leaving this class of enzyme inhibitors in a very mature state.
6.4 Nonpyrimidone PDE5 Inhibitors 6.4.1 Hexahydropyrazino-Pyrido-Indole-1,4-Diones
This class of PDE5 inhibitors was elaborated from ethyl b-carboline-3-carboxylate (b-CCE (71)), which has a modest inhibitory activity toward PDE5 (IC50 ¼ 0.8 mM) [171, 172]. The most prominent member of this class, IC 351 (tadalafil, CialisÔ (3)), was originally discovered by Glaxo and Icos in a collaboration that was terminated in 1997 [173, 174]. In 1998, Eli Lilly partnered with Icos to develop tadalafil for the treatment of ED [175, 176]. O O
N O
N
N H
N
O
N H
O O
β-CCE (71)
Tadalafil (IC 351) (3)
IC 351 inhibits human recombinant PDE5 with an IC50 of 2 nM [177] and is selective against a panel of phosphodiesterases (selectivity for PDE1–PDE4 and PDE7–PDE10 >10 000; and 780 for PDE6), with the remarkable exception of PDE11 (IC50 ¼ 37 nM) [178]. In the latter study, an IC50 of 6.7 nM was reported for PDE5,
6.4 Nonpyrimidone PDE5 Inhibitors
thus indicating a selectivity ratio of about 5 for PDE11 over PDE5. Intracellular cGMP increase in rat aortic smooth muscle cells has been reported with an EC50 of 200 nM [179]. A whole series of patents covering the underlying tetrahydro-b-carboline framework have appeared [180–187]. Not only diketopiperazines such as tadalafil gave potent PDE5 inhibitors but also incorporation of five-membered hydantoins resulted in high potency (IC50 for (72) <10 nM, IC50 for ((73) ¼ 7 nM). Alkoxy substitution in the para position of the phenyl ring in the lower part of the molecule is a consistent feature of the most potent inhibitors. The last example (74) demonstrates that acyl derivatives of the tetrahydro-b-carboline skeleton can also provide potent PDE5 inhibitors [188]. Icos appears to have concentrated on tricyclic compounds of this class [189, 190]. O
O N
N
N H
O
N
N
N H
O
O O
MeO (72)
(73) O
NMe2
N
N H
O O O
(74)
The group at Ortho McNeil has disclosed related b-carboline PDE5 inhibitors in which the acyl group has been replaced by the electron-deficient heterocycles pyridine (75) (Ki ¼ 4 nM) and pyrimidine (76) (Ki ¼ 24 nM) [191].
N
N H
N
N H N
N N N N
N Me O (75) Ki=4 nM
O (76)
Ki=24 nM
Me
j161
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
162
6.5 Conclusions
The field of PDE5 inhibitors has reached a high degree of maturity. Common problems of medicinal chemistry such as potency, selectivity, physicochemical properties, and oral bioavailability have been successfully addressed with the known PDE5 inhibitors. The discovery of further PDE subtypes and/or the need for specific drug tissue distribution patterns may further increase the knowledge of this PDE inhibitor class. In addition, knowledge gained on different kinase inhibitor classes might be fruitful for the development of PDE inhibitors and vice versa. Since a plethora of PDEs are already known and new subtypes are still being discovered (although all family members have been discovered in the course of the human genome project), scientists in the PDE5 inhibitor field are constantly challenged to continue the search for either more selective inhibitors, compounds with a specifically desirable combination of different PDE inhibitory properties, or compounds demonstrating a very specific tissue distribution. In addition, the utility of PDE5 inhibitors beyond erectile dysfunction promises to be a fascinating area of future research.
References 1 Rall, T.W. and Sutherland, E.W. (1958)
2
3
4
5
6
Formation of a cyclic adenenine ribonucleotide by tissue particles. J. Biol. Chem., 232, 1065–1076. Butcher, R.W. and Sutherland, E.W. (1962) Adenosine 30 ,50 -phosphate in biological materials: I. Purification and properties of cyclic 30 ,50 -nucleotide phosphordiesterase and use of this enzyme to characterize adenosine 30 ,50 phosphate in human urine. J. Biol. Chem., 237, 1244–1259. Sutherland, E.W. (1972) Studies on the mechanism of hormone action. Science, 177, 401–408. Petersen-Jones, S.M. (1998) Animal models of human retinal dystrophies. Eye, 12, 566–570. Jin, S.L., Richard, F.J., Kuo, W.P., DErcole, A.J., and Konti, M. (1999) Impaired growth and fertility of cAMPspecific phosphodiesterase PDE4D deficient mice. Proc. Natl. Acad. Sci. USA, 96 (21), 11998–12003. Hansen, G., Jin, S., Umetsu, D.T., and Konti, M. (2000) Absence of muscarinic cholinergic airway responses in mice
7
8
9
10
11
deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc. Natl. Acad. Sci. USA, 97 (12), 6751–6756. Mehats, C., Andersen, C.B., Filopanti, M., Jin, S.-L.C., and Conti, M. (2002) Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocr. Metab., 13, 29–35. Essayan, D.M. (2001) Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol., 108, 671–680. Soderling, S.H. and Beavo, J.A. (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol., 12, 174–179. Francis, S.H., Turko, I.V., and Corbin, J.D. (2000) Cyclic nucleotide phosphordiesterases: relating structure and function. Prog. Nucleic. Acid. Res. Mol. Biol., 65, 1–52. ODonnell, J.M. (2000) William Harvey research conference on PDE inhibitors: drugs with an expanding range of therapeutic uses. Exp. Opin. Invest. Drugs, 9, 621–625.
References 12 Houslay, M.D., Sullivan, M., and Bolger,
13
14
15
16
17
18
19
20
21
G.B. (1998) The multienzyme PDE4 cyclic adenosine monophosphatespecific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. (S.D.), 44, 225–342. Houslay, M.D. and Milligan, G. (1997) Tailoring cAMP-signaling responses through isoform multiplicity. Trends Biochem. Sci., 22, 217–224. Manganiello, V.C., Taira, M., Degerman, E., and Belfrage, P. (1995) Type III cGMPinhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Cell. Signal, 7, 445–455. Thompson, W.J. (1991) Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol. Ther., 51, 13–33. Hurley, J.B. (1987) Molecular properties of the cGMP cascade of vertebrate photoreceptors. Annu. Rev. Physiol., 49, 793–812. Beavo, J.A., Konti, M., and Heaslip, R.J. (1994) Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol., 45, 399–405. Francis, S.H., Colbran, J.L., McAllisterLucas, L.M., and Corbin, J.D. (1994) Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J. Biol. Chem., 269, 22477–22480. Gopal, V.K., Francis, S.H., and Corbin, J.D. (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur. J. Biochem., 268, 3304–3312. Pfeifer, A., Klatt, P., Massberg, S., Ny, L., Sausbier, M., Hirneiss, C., Wang, G.X., Korth, M., Aszodi, A., Andersson, K.E., Krombach, F., Mayerhofer, A., Ruth, P., Fassler, R., and Hofmann, F. (1998) Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J., 17, 3045–3051. Hedlund, P., Aszodi, A., Pfeifer, A., Alm, P., Hofmann, F., Ahmad, M., Fassler, R.,
22
23
24
25
26
27
28
29
30
and Andersson, K.-E. (2000) Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc. Natl. Acad. Sci. USA, 97, 2349–2354. Rybalkin, S.D., Rybalkina, I., Feil, R., Hofman, F., and Beavo, J.A. (2002) Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J. Biol. Chem., 277, 3310–3317. Bender, A.T. and Beavo, J.A. (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev., 58, 488–520. Rybalkin, S.D., Rybalkina, I., Beavo, J.A., and Bornfeldt, K.E. (2002) Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ. Res., 90, 151–157. Osinski, M.T., Rauch, B.H., and Schror, K. (2001) Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol. Pharmacol., 59, 1044–1050. Corbin, J.D. and Francis, S.H. (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem., 274 (20), 13729–13732. Corbin, J.D., Turko, I.V., Beasley, A., and Francis, S.H. (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotidedependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur. J. Biochem./FEBS, 267 (9), 2760–2767. Mullershausen, F., Friebe, A., Feil, R., Thompson, W.J., Hofmann, F., and Koesling, D. (2003) Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J. Cell. Biol., 160 (5), 719–727. Rybalkin, S.D., Rybalkina, I.G., ShimizuAlbergine, M., Tang, X.-B., and Beavo, J.A. (2003) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J., 22 (3), 469–478. McAllister-Lucas, L.M., Sonnenburg, W.K., Kadlecek, A., Seger, D., Hai, L.T., Colbran, J.L., Thomas, M.K., Walsh, K.A., Francis, S.H., Corbin, J.D., and Beavo,
j163
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
164
31
32
33
34
35
36
37
38
J.A. (1993) The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J. Biol. Chem., 268, 22863–22873. Fink, T.L., Francis, S.H., Beasley, A., Grimes, K.A., and Corbin, J.D. (1999) Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J. Biol. Chem., 274 (49), 34613–34620. Sung, B.J., Hwang, K.Y., Jeon, Y.H., Lee, J.I., Heo, Y.-S., Kim, J.H., Moon, J., Yoon, J.M., Hyun, Y.-L., Kim, E., Eum, S.J., Park, S.-Y., Lee, J.-O., Lee, T.G., Ro, S., and Cho, J.M. (2003) Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature, 425 (6953), 98–102. Corbin, J., Francis, S., and Zoraghi, R. (2006) Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil. Int. J. Impot. Res., 18 (3), 251–257. Turko, I.V., Francis, S.H., and Corbin, J.D. (1998) Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase. J. Biol. Chem., 273 (11), 6460–6466. Zoraghi, R., Francis, S.H., and Corbin, J.D. (2007) Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry, 46, 13554–13563. Rybalkin, S.D., Rybalkina, I.G., Feil, R., Hofmann, F., and Beavo, J.A. (2002) Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J. Biol. Chem., 277 (5), 3310–3317. Zoraghi, R., Bessay, E.P., Corbin, J.D., and Francis, S.H. (2005) Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J. Biol. Chem., 280 (12), 12051–12063. Bessay, E.P., Zoraghi, R., Blount, M.A., Grimes, K.A., Beasley, A., Francis, S.H., and Corbin, J.D. (2007) Phosphorylation
39
40
41
42
43
44 45 46 47
48
of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Front. Biosci., 12, 1899–1910. Thomas, M.K., Francis, S.H., and Corbin, J.D. (1990) J. Biol. Chem., 265 (25), 14971–14978. Bessay, E.P., Blount, M.A., Zoraghi, R., Beasley, A., Grimes, K.A., Francis, S.H., and Corbin, J.D. (2008) Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. J. Pharmacol. Exp. Ther., 325, 62–68. Blount, M.A., Zoraghi, R., Ke, H., Bessay, E.P., Corbin, J.D., and Francis, S.H. (2006) A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Mol. Pharmacol., 70 (5), 1822–1831. Gopal, V.K., Francis, S.H., and Corbin, J.D. (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur. J. Biochem./FEBS, 268 (11), 3304–3312. Cote, R.H. (2006) Photoreceptor phosphodiesterase (PDE6): A G-proteinactivated PDE regulating visual excitation in rod and cone photoreceptor cells, in Cyclic Nucleotide Phosphodiesterases in Health and Disease (eds J. Beavo, S.H. Francis, and M.D. Houslay), CRC Press, Boca Raton, pp. 165–193. PDB reference: 1udt. PDB reference: 1udu. PDB reference: 1uho. Wang, H., Liu, Y., Huai, Q., Cai, J., Zoraghi, R., Francis, S.H., Jackie, D., Corbin, J.D., Robinson, H., Xin, Z., Lin, G., and Ke, H. (2006) Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J. Biol. Chem., 281, 21469–21479. Wang, H., Ye, M., Robinson, H., Francis, S.H., and Ke, H. (2008) Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of
References
49 50
51
52
53
54
55 56
57
58
59
60
vardenafil and sildenafil. Mol. Pharmacol., 73, 104–110. NIH Consensus Conference (1993) Impotence. JAMA, 270, 83. Feldman, H.A., Goldstein, I., Hatzichristou, D.G., Krane, R.J., and McKinlay, J.B. (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol., 151, 54–61. Anderson, K.-E. and Wagner, G. (1995) Physiology of penile erection. Physiol. Rev., 75, 191–236. Giuliano,F.andRampin,O.(2000)Central neural regulation of penile erection. Neurosci. Biobehav. Rev., 24, 517–533. Schultheiss, D. and Stief, C.G. (1999) Physiology and pathophysiology of erection: consequences for present medical therapy of erectile dysfunction. Andrologica, 31 (Suppl. 1), 59–64. Melman, A. and Gingell, C.J. (1999) The epidemiology and pathophysiology of erectile dysfunction. J. Urol., 161, 5–11. Lue, T. (2000) Erectile dysfunction. N. Engl. J. Med., 342, 1802–1813. Gingell, J.C. and Lockyer, R. (1999) Emerging pharmacological therapies for erectile dysfunction. Exp. Ther. Patents, 9, 1689–1696. Richer, S.C. (2009) www.scripnews.com, http://www.scripnews.com/home/ news/PUBLICATIONS—New-fromScrip-Reports—The-TherapeuticMarket-for-Male-and-Female-SexualDysfunction-24924?autnID¼/ contentstore/scripnews/ newsletterarchive/S00750470.xml. Meinhardt, W., Kropmann, R.F., Vermeij, P., Nigelholt, A.A., and Zwartendijk, J. (1997) The influence of medication on erectile function. Int. J. Impot. Res., 9, 17–26. Ignarro, L.J., Bush, P.A., Buga, G.M., Wood, K.S., Fukuto, J.M., and Rajfer, J. (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun., 170, 843–850. Lugg, J.A., Gonzales-Cadaved, N.F., and Rajfer, J. (1995) The role of nitric oxide in erectile function. J. Androl., 16, 2–4.
61 Holmquist, F., Stief, C.G., Jonas, U., and
62
63
64
65
66
67
68
69
70 71
Anderson, K.-E. (1991) Effects of the nitric oxide synthase inhibitor NG-nitroL-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol. Scand., 143, 299–304. Burnett, A.L. (1997) Nitric oxide in the penis: physiology and pathology. J. Urol., 157, 320–324. Soderling, S.H., Bayuga, S.J., and Beavo, J.A. (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem., 273, 15553–15558. Rajfer, J., Aronson, W.J., Bush, P.A.,Dorey, F.J., and Ignarro, L.J. (1992) Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med., 326, 2, 90–94. Taher, A., Meyer, M., Stief, C.G., Jonas, U., and Forsman, W.G. (1997) Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J. Urol., 15, 32–35. Saenz de Tejada, I., Blanco, R., Goldstein, I., Azadzoi, K., De las Morenas, A., Krane, R.J., and Cohen, R.A. (1988) Cholinergic neurotransmission in human corpus cavernosum. I. Responses of isolated tissue. Am. J. Physiol., 254 (3Pp2:H459467). Lue, T.S., Takamura, T., Umraiya, M., Schmidt, R.A., and Tanagho, E.A. (1984) Hemodynamics of canine corpora cavernosa during erection. Urology, 24 (4), 347–352. Murray, K.J. (1993) Phosphodiesterase VA inhibitors. Drug News Perspect., 6, 150–156. Bortolotti, M., Mari, C., Giovannini, M., Pinna, S., and Migioli, M. (2001) Effects of sildenafil on esophageal motility of normal subjects. Dig. Dis. Sci., 46, 2301–2306. Stryer, L. (1986) Cyclic GMP cascade of vision. Ann. Rev. Neurosci., 9, 87–119. Xia, Y., Chackalamannil, S., Czarniecki, M., Tsai, H., Vaccaro, H., Cleven, R., Cook, J., Fawzi, A., Watkins, R., and Zhang, H. (1997) Synthesis and evaluation of polycyclic pyrazolo[3,4-d]
j165
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
166
72
73
74
75
76
77
78
79
80
81
pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors. J. Med. Chem., 40, 4372–4377. Ballard, S.A., Gingell, C.J., Tang, K., Turner, L.A., Price, M.E., and Naylor, A.M. (1998) J. Urol., 159, 2164–2171. Cartledge, J. and Eardley, I. (1999) Sildenafil. Exp. Opin. Pharmacother., 1 (1), 137–147. Langtry, H.D. and Markham, A. (1999) Sildenafil: a review of its use in erectile dysfunction. Drugs, 57, 967–989. Rendell, M.S., Rajfer, J., Wicker, P.A., and Smith, M.D. (1999) Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA, 281, 421–426. Neumeyer, K. and Kirkpatrick, P. (2004) Fresh from the pipeline: tadalafil and vardenafil. Nat. Rev. Drug Discov., 3, 295–296. Sorbera, L.A., Martin, L., Rabasseda, X., and Castaner, J. (2001) Vardenafil. Drugs Fut., 26, 141–144. Hellstrom, W.J.G., Gittelman, M.C., Shapiro, J., Thibonnier, M., and Segerson, T. (2001) Vardenafil improved erectile function in men with a broad range of erectile dysfunction etiologies and severities: a phase III trial. Int. J. Impot. Res., 13 (Suppl. 5; abstract 25), S65. Brock, G., Taylor, T., Seger, T.M.,and Vardenafil PROSPECT Group Canada (2002) Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy. Eur. Urol., 1 (Suppl. 1; abstract 598), 152. Porst, H., Rosen, R., Padma-Nathan, H., Goldstein, I., Giuliano, F., Ulbrich, E., Bandel, T.,and Vardenafil Study Group (2001) The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int. J. Impot. Res., 13, 192–199. Goldstein, I., Young, J.M., Fischer, J., Mollen, M., Chu, F., Shapiro, J., Segerson, T., and Taylor, T. (2001) Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function in
82
83
84
85
86
87
88
89
90
91
patients with diabetes mellitus. Diabetes, 50 (Suppl. 2; abstract 456), A114. Meuleman, E.J.H. (2003) Review of tadalafil in the treatment of erectile dysfunction. Exp. Opin. Pharmacother., 4, 2049–2056. Pryor, J. (2002) Vardenafil: update on clinical experience. Int. J. Impot. Res., 14 (Suppl. 1), 65–69. Padma-Nathan, H., McMurray, J.G., Pullman, W.E., Whitaker, J.S., Saoud, J.B., Ferguson, K.M., and Rosen, R.C. (2001) The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int. J. Impot. Res., 13, 2–9. Porst, H. (2002) IC351 (tadalafil, Cialis): update on clinical experience. Int. J. Impot. Res., 14 (Suppl. 1), 57–64. Salem, E.A., Kendirci, M., and Hellstrom, W.J.G. (2006) Drug evaluation: udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr. Opin. Invest. Drugs, 7, 661–669. Hatzimouratidis, K. and Hatzichristou, D.G. (2008) Looking to the future for erectile dysfunction therapies. Drugs, 68, 231–250. Paick, J.S., Choi, H.K., Kim, S.C., Ahn, T.Y., Kim, J.J., Park, N.C., Park, J.K., Park, K.S., and Lee, S.W. (2006) J. Sex. Med., 3 (Suppl. 5), 393. Kotera, J., Fujishige, K., Michibata, H., Yuasa, K., Kubo, A., Nakamura, Y., and Omori, K. (2000) Characterization and effects of methyl-2-(4-aminophenyl)-1,2dihydro-1-oxo-7-(2-pyridinylmethoxy)-4(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem. Pharmacol., 60, 1333–1341. Kaufmann, J.M., Aurora, C.O., and Dietrich, J.W. (2006) Safety and efficacy of avanafil, a new phosphodiesterase type5 (PDE5) inhibitor for treating erectile dysfunction. J. Urol., 175 (Suppl. 4), 299. Sweetnam, P., Campbell, S., Grogan, M., Kirk, B., McGonigle, S., Paradise, E., and
References
92
93
94
95
96
97
98 99
100
Goldstein, I. (2006) SLx-2101, a novel long-acting phosphodiesterase-5 (PDE5) inhibitor for erectile dysfunction: in vivo and in vitro studies. J. Sex. Med., 3, 14–69. Prince, W., Campbell, A.S., Tong, W. et al. (2006) SLx-2102, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J. Urol., 175 (S4), 924. Gur, S., Sikka, S.C., and Hellstrom, W.J.G. (2008) Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Exp. Opin. Invest. Drugs, 17, 855–864. Schmidt, D.T., Watson, N., Dent, G., Ruhlmann, E., Branscheid, D., Magnussen, H., and Rabe, K.F. (2000) The effect of selective and non-selective phosphodiesterase inhibitors on allergenand leukotriene C(4)-induced contractions in passively sensitized human airways. Br. J. Pharmacol., 131, 1607–1618. Sekhar, K.R., Grondin, P., Francis, S.H., and Corbin, J.D. (1996) Design and synthesis of xanthines and cyclic GMP analogs as potent inhibitors of PDE5, in The Handbook of Immunopharmacology, Phosphodiesterase Inhibitors, Academic Press, New York, pp. 135–146. Garst, J.E., Kramer, G.L., Wu, Y.J., and Wells, J.N. (1976) Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7substituted derivatives of 1-methyl-3isobutylxanthine. J. Med. Chem., 19, 499–503. Kramer, G.L. and Wells, J.N. (1979) Effects of phosphodiesterase inhibitors on cyclic nucleotide levels and relaxation of pig coronary arteries. Mol. Pharmacol., 16, 813–822. Chen, I.-J. (2002) British Patent Appl. GB2367819. Bhalay, G., Collingwood, S.P., Fairhurst, R.A., Gomez, S.F., Naef, R., and Sandham, D.A. (2001) PCT Int. Appl. WO0177110;(2001) Chem. Abstr., 135, 303908. Chackalamannil, S., Wang, Y., Boyle, C., and Stamford, A. (2002) PCT Int. Appl. WO0224698;(2002) Chem. Abstr., 13, 240775.
101 Vega Noverola, A., Gracia Ferrer, J., Feixas
102
103
104
105
106
107
108
109
110
111
112
Gras, J., and Prieto Soto, J.M. (1999) PCT Int. Appl. WO9962905;(1999) Chem. Abstr., 132, 12326. Vidal Juan, B., Gracia Ferrer, J., Prieto Soto, J.M., and Vega Noverola, A. (2001) PCT Int. Appl. WO0194350;(2001) Chem. Abstr., 136, 37621. Gracia Ferrer, J., Feixas Gras, J., Prieto Soto, J.M., Vega Noverola, A., and Vidal Juan, B. (2001) PCT Int. Appl. WO0107441;(2001) Chem. Abstr., 134, 131550. Vidal Juan, B., Esteve Trias, C., Gracia Ferrer, J., and Prieto Soto, J.M. (2002) PCT Int. Appl. WO0212246;(2002) Chem. Abstr., 136, 183827. Connolly, B.J., Willits, P.B., Warrington, B.H., and Murray, K.J. (1992) 8-(4Chlorophenyl)thio-cyclic AMP is a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA). Biochem. Pharmacol., 44, 2303–2306. Broughton, B.J., Chaplen, P., Knowles, P., Lunt, E., Pain, D.L., Woolridge, K.R.H., Ford, R., Mashall, S., Walker, J.L., and Maxwell, D.R. (1974) New inhibitor of reagin-mediated anaphylaxis. Nature, 251, 650–652. Wilson, S.R., Wilson, R.B., Shoemaker, A.L., Woolridge, K.R.H., and Hodgson, D.J. (1982) Antiallergenic 8-azapurines. 3. Structural characterization of 2-(2propoxyphenyl)-8-azahypoxanthine, 2-[2propoxy-5-(propylsulfonyl)phenyl]-8azahypoxanthine, and 2-[2-propoxy-5-(Nmethyl-N-isopropylsulfamoyl)phenyl]-8azahypoxanthine. J. Am. Chem. Soc., 104, 259–264. Coates, W.J. (1990) European Patent Appl. EP352960;(1990) Chem. Abstr., 113, 40713. Terrett, N.K. (1994) PCT Int. Appl. WO9400453;(1990) Chem. Abstr., 121, 35196. Maw, G.N. and Rawson, D.J. (2001) European Patent Appl. EP1092718;(1990) Chem. Abstr., 134, 295831. Dumaitre, B.A. and Dodic, N. (1995) European Patent Appl. EP0636626;(1995) Chem. Abstr., 123, 228202. Dumaitre, B. and Dodic, N. (1996) Synthesis and cyclic GMP
j167
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
168
113
114
115
116
117
118
119
120
121
122
123
phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d] pyrimidones. J. Med. Chem., 39, 1635–1644. Coste, H. and Grondin, P. (1995) Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem. Pharmacol., 50, 1577–1585. Bacon, E.R., Daum, S.J., and Singh, B. (1996) PCT Int. Appl. WO9628429;(1996) Chem. Abstr., 125, 301016. Bacon, E.R. and Singh, B. (1996) PCT Int. Appl. WO9628448;(1996) Chem. Abstr., 126, 117991. Dumaitre, B.A. and Dodic, N. (1995) European Patent Appl. EP636626;(1995) Chem. Abstr., 123, 228202. Ellis, P. and Terrett, N.K. (1994) PCT Int. Appl. WO9428902;(1994) Chem. Abstr., 122, 187627. Campbell, S.F. (1996) PCT Int. Appl. WO9616657;(1996) Chem. Abstr., 125, 105133. Silver, P.J., Dundore, R.L., Bode, D.C., de Garavilla, L., Buchholz, R.A., van Aller, G., Hamel, L.T., Bacon, E., Singh, B., Lesher, G.Y., Hlasta, D., and Pagani, E.D. (1994) Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther., 271, 1143–1149. K€ ogel, B., Schneider, J., Gleitz, J., Wilffert, B., and Peters, T. (1999) Effects of AL 107, a novel semisynthetic cardiac glycoside, on the cardiovascular system in anaesthetized Beagle dogs with pentobarbital-induced cardiac insufficiency. Arzneimittelforschung, 49, 679–684. Silver, P.J., Pagani, E.D., Dundore, R.L., de Garavilla, L., Bode, D.C., and Bacon, E.R. (1998) Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5. Eur. J. Pharmacol., 349, 263–268. Bunnage, M.E., Street, S.D.A., Mathias, J.P., and Wood, A. (2000) European Patent Appl. EP0995751;(2000) Chem. Abstr., 132, 293775. Hamilton, H.W. (1985) European Patent Appl. EP0201188
124 Hamilton, H.W. (1988) PCT Int. Appl.
125
126
127
128
129
130
131
132
133
WO8800192;(1988) Chem. Abstr., 109, 6544. Bacon, E.R. and Singh, B. (1996) PCT Int. Appl. WO9628448;(1996) Chem. Abstr., 126, 117991. Bacon, E.R., Singh, B., and Lesher, G.Y. (1994) US Patent Appl. US5294612; (1994) Chem. Abstr., 121, 205376. Bell, A.S., Brown, D., and Terrett, N.K. (1992) European Patent Appl. EP0463756;(1992) Chem. Abstr., 116, 255626. Gibson, A. (2001) Phosphodiesterase-5 inhibitors and nitrergic transmission – from zaprimast to sildenafil. Eur. J. Pharm., 411, 1–10. Hatzichristou, D.G. (2002) Sildenafil citrate: lessons learned from 3 years of clinical experience. Int. J. Impot. Res., 14 (Suppl. 1), 43–52. Terrett, N.K., Bell, A.S., Brown, D., and Ellis, P. (1996) Sildenafil (VIAGRAÔ), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett., 6, 1819–1824. Kim, D.-K., Lee, N., Lee, J.Y., Ryu, D.H., Kim, J.-S., Lee, S.-H., Choi, J.-Y., Chang, K., Kim, Y.-W., Im, G.-J., Kim, N.-H., and Ryu, J.-H. (2001) Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogues. Bioorg. Med. Chem., 9, 1609–1616. Kim, D.-K., Lee, N., Lee, J.Y., Ryu, D.H., Kim, J.-S., Lee, S.-H., Choi, J.-Y., Chang, K., Kim, Y.-W., and Im, G.-J. (2001) Synthesis and phosphodiesterase 5 inhibitory activity of new 5-phenyl-1,6dihydro-7H-pyrazolo[4,3-d]pyrimidin-7one derivatives containing an Nacylamido group on a phenyl ring. Bioorg. Med. Chem., 9, 1895–1899. Kim, D.-K., Lee, J.Y., Lee, N., Ryu, D.H., Kim, J.-S., Lee, S., Choi, J.-Y., Ryu, J.-H., Kim, N.-H., and Im, G.-J. (2001) Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5-sulfonamide moiety of a phenyl ring. Bioorg. Med. Chem., 9, 3013–3021.
References 134 Bunnage, M.E., Mathias, J.P., Street,
135
136
137
138
139
140
141
142
143
144
145
146
147
S.D.A., and Wood, A. (1998) PCT Int. Appl. WO9849166;(1998) Chem. Abstr., 129, 330741. Wood, A. (2000) European Patent Appl. EP0995750;(2000) Chem. Abstr., 132, 293774. Bunnage, M.E., Mathias, J.P., Street, S.D.A., and Wood, A. (1999) PCT Int. Appl. WO9954333;(1999) Chem. Abstr., 131, 310644. Badwan, A.A.H. and El-Abadelah, M.M.M. (2000) European Patent Appl. EP1057829;(2000) Chem. Abstr., 134, 17499. Devries, K.M., Levett, P.C., Negri, J.T., and Wood, A.S. (2001) European Patent Appl. EP1092720;(2001) Chem. Abstr., 134, 295832. Hughes, M.L. and Storey, R.A. (2001) PCT Int. Appl. WO0127101;(2001) Chem. Abstr., 134, 295824. Allerton, C.M.N., Barber, C.G., Maw, G.N., and Rawson, D.J. (2001) PCT Int. Appl. WO0127112;(2001) Chem. Abstr., 134, 311220. Bunnage, M.E., Devries, K.M., Harris, L.J., Levett, P.C., Mathias, J.P., Negri, J.T., Street, S.D.A., and Wood, A.S. (2001) PCT Int. Appl. WO0127113;(2001) Chem. Abstr., 134, 295836. Wood, R.E., Davies, M.J., and Siegel, R.L. (2001) PCT Int. Appl. WO0151042;(2001) Chem. Abstr., 135, 107336. Yoo, M., Kim, W., Chang, M.S., Lim, J.I., Kim, D.S., Kim, I.Y., Lim, T.K., Ahn, B.O., Kang, K.K., Son, M., Doh, H., Kim, S., Shim, H., Oh, T., Kim, H., and Kim, D.G. (2000) PCT Int. Appl. WO0027848;(2000) Chem. Abstr., 132, 334469. Garside, S.C., Hartley, D., Lunts, L.H.C., and Oxford, A.W. (1973) Ger. Offen. 2255172;(1973) Chem. Abstr., 79, 53376. Oxford, A.W. and Hartley, D. (1978) Ger. Offen. 2811780;(1978) Chem. Abstr., 89, 215442. Garside, S.C., Hartley, D., Lunts, L.H.C., and Oxford, A.W. (1978) Swiss Patent CH594671;(1973) Chem. Abstr., 79, 53376. Marshall, D.R. (1983) Process investigation into the devlopment of
148
149
150
151
152
153
154
155
imidazotriazinones. Chem. Ind. (London), 9, 331–335. Mitchell, W.L., Hill, M.L., Newton, R.F., Ravenscroft, P., and Scopes, D.I.C. (1984) Synthesis of C-nucleoside isosteres of 9-(2-hydroxyethoxymethyl)guanine (acyclovir). J. Heterocycl. Chem., 21, 697–699. Knutsen, L.J.S., Judkins, B.D., Newton, R.F., Scopes, D.I.C., and Klinkert, G. (1985) Synthesis of imidazo-fused bridgehead-nitrogen 2-deoxyribo-Cnucleosides: coupling-elimination reactions of 2,5-anhydro-3,4,6-tri-Obenzoyl-D-allonic acid. J. Chem. Soc. Perkin Trans. I., 621–630. Knutsen, L.J.S., Judkins, B.D., Mitchell, W.L., Newton, R.F., and Scopes, D.I.C. (1984) Synthesis of imidazo-fused bridgehead-nitrogen C-nucleosides via dehydrative coupling reactions of 2,5anhydro-3,4,6-tri-O-benzoyl-D-allonic acid. J. Chem. Soc. Perkin Trans. I., 229–238. Bhattacharya, B., Rao, T.S., Lewis, A.F., and Revankar, G.R. (1993) Synthesis of certain N- and C-alkyl purine analogs. J. Heterocycl. Chem., 30, 1341–1349. Clarke, R., Garside, S.C., Lunts, L.H.C., Hartley, D., Hornby, R., and Oxford, A.W. (1979) Bicyclic heterocycles with nitrogen at the ring junction 1. Synthesis and chemistry of imidazo[5,1-f ]-1,2,4triazines. J. Chem. Soc. Perkin Trans. I., 1120–1124. Niewohner, U., Es-Sayed, M., Haning, H., Schenke, T., Schlemmer, K.-H., Keldenich, J., Bischoff, E., Perzborn, E., Dembowsky, K., Serno, P., and Nowakowski, M. (1999) PCT Int. Appl. WO9924433;(1999) Chem. Abstr., 130, 352283. Saenz de Tejada, I., Angulo, J., Cuevas, P., Fernandez, A., Moncada, I., Allona, A., Lledó, E., K€orschen, H.G., Niew€ohner, U., Haning, H., Pages, E., and Bischoff, E. (2001) The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res., 13, 282–290. Niewoehner, U., Es-Sayed, M., Haning, H., Schenke, T., Schmidt, G., Schlemmer,
j169
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
170
156
157
158
159
160
161
162
163
164
K.-H., Bischoff, E., Dembowsky, K., and Perzborn, E. (1999) PCT Int. Appl. WO9967244;(1999) Chem. Abstr., 132, 49985. Haning, H., Niewohner, U., Schenke, T., Es-Sayed, M., Schmidt, G., Lampe, T., and Bischoff, E. (2002) Bioorg. Med. Chem. Lett., 12 (6), 865–868. Bischoff, E., Niewoehner, U., Haning, H., EsSayed, M., Schenke, T., and Schlemmer, K.-H. (2001) The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model. J. Urol., 165, 1316–1318. Bischoff, E. and Schneider, K. (2001) A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Int. J. Impot. Res., 13, 230–235. Maw, G.N. (2001) European Patent Appl. EP1092719;(2001) Chem. Abstr., 134, 295843. David, P., Rotella, D.P., Sun, Z., Zhu, Y., Krupinski, J., Pongrac, R., Seliger, L., Normandin, D., and Macor, J.E. (2000) Optimization of substituted N-3benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors. J. Med. Chem., 43, 5037–5043. Rotella, D.P., Sun, Z., Zhu, Y., Krupinski, J., Pongrac, R., Seliger, L., Normandin, D., and Macor, J.E. (2000) N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. J. Med. Chem., 43, 1257–1263. Macor, J.E., Rotella, D.P., Weller, H.N., Cushman, D.W., III, and Yevich, J.P. (1999) PCT Int. Appl. WO9964004;(1999) Chem. Abstr., 132, 35712. Bi, Y., Stoy, P., Adam, L., He, B., Krupinski, J., Normandin, D., Pongrac, R., Seliger, L., Macor, J.E., Watson, A., and Macor, J.E. (2001) The discovery of novel, potent and selective PDE5 inhibitors. Bioorg. Med. Chem. Lett., 11, 2461–2464. Coates, W.J., Flynn, S.T., and Rawlings, D.A. (1989) European Patent Appl. EP347146;(1989) Chem. Abstr., 113, 6363
165 Kim, D.-K., Lee, J.Y., Ryu, D.H., Lee, N.K.,
166
167
168
169
170
171
172
173
174
175
176
Lee, S.H., Kim, N.-H., Kim, J.-S., Ryu, J.H., Choi, J.-Y., Im, G.-J., Choi, W.-S., Kim, T.K., and Cha, H. (2001) PCT Int. Appl. WO0160825;(2001) Chem. Abstr., 135, 195571. Terrett, N.K. (1993) PCT Int. Appl. WO9312095;(1993) Chem. Abstr., 119, 225972. Bell, A.S. and Terrett, N.K. (1994) PCT Int. Appl. WO9405661;(1994) Chem. Abstr., 121, 57528. Oota, T., Taguchi, M., Kawashima, Y., and Hatayama, K. (1996) Jpn. Kokai Tokkyo Koho JP8104679;(1996) Chem. Abstr., 125, 114672a. Oota, T., Kawashima, Y., and Hatayama, K. (1995) Jpn. Kokai Tokkyo Koho JP07330777;(1995) Chem. Abstr., 124, 289561. Oota, T., Kawashima, Y., and Hatayama, K. (1995) Jpn. Kokai Tokkyo Koho JP07267961;(1995) Chem. Abstr., 124, 146193. Daugan, A., Grondin, P., Ruault, C., Le Monnier de Gouville, A.-C., Coste, H., Kirilovsky, J., Hyafil, F., and Labaudiniere, R. (2003) The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11atetrahydro-1H-imidazo[10 ,50 :1,6]pyrido [3,4-b]indole-1,3(2H)-dione analogues. J. Med. Chem., 46, 4525–4532. Daugan, A., Grondin, P., Ruault, C., Le Monnier de Gouville, A.-C., Coste, H., Lingert, J.M., Kirilovsky, J., Hyafil, F., and Labaudiniere, R. (2003) The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino [10 ,20 :1,6]pyrido[3,4-b]indole-1,4-dione analogues. J. Med. Chem., 46, 4533–4542. Daugan, A. (1995) PCT Int. Appl. WO9519978;(1995) Chem. Abstr., 124, 55977. Daugan, A. (1997) PCT Int. Appl. WO9703675;(1997) Chem. Abstr., 126, 203727. Norman, P. (1999) IC-351 ICOS Corp. Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs, 1, 268–271. Sorbera, L.A., Martin, L., Leeson, P.A., and Castaner, J. (2001) IC-351: treatment of
References
177
178
179
180
181
182
183
184
185
erectile dysfunction, treatment of female sexual dysfunction, phosphodiesterase 5 inhibitor. Drugs Fut., 26, 15–19. Daugan, A. and Gellibert, F. (2000) US Patent Appl. US6143746;(2000) Chem. Abstr., 133, 329627. Gbekor, E., Betheil, S., Fawcett, L., Mount, M., and Phillips, S. (2002) Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur. Urol. Suppl., 1 (Suppl. 1), 63. Daugan, A. and Labaudiniere, R.F. (1996) PCT Int. Appl. WO9632003;(1996) Chem. Abstr., 126, 18895. Pomerol, J.M. and Rabasseda, X. (2003) Tadalafil, a further innovation in the treatment of sexual dysfunction. Drugs Today, 39, 103–113. Daugan, A. (1995) PCT Int. Appl. WO9519978;(1995) Chem. Abstr., 124, 55977. Daugan, A. and Gellibert, F. (1997) PCT Int. Appl. WO9703985;(1997) Chem. Abstr., 126, 199582. Whitaker, J.S., Saenz de Tejada, I., and Ferguson, K.M. (2001) PCT Int. Appl. WO0180860;(2001) Chem. Abstr., 135, 339295. Oren, P.L., Anderson, N.R., and Kral, M.A. (2001) PCT Int. Appl. WO0108686; (2001) Chem. Abstr., 134, 152653. Allemeier, L.L., Brashear, D.L., Ferguson, K.M., and Pullman, W.E. (2000) PCT Int.
186
187
188
189
190
191
192
193
Appl. WO0066114;(2000) Chem. Abstr., 133, 329631. Orme, M.W., Sawyer, J.S., and Schultze, L.M. (2002) PCT Int. Appl. WO0210166; (2002) Chem. Abstr., 136, 107344. Orme, M.W., Sawyer, J.S., Daugan, A.C.M., Brown, R.F., and Schultze, L.M. (2002) PCT Int. Appl. WO0228858;(2002) Chem. Abstr., 136, 294852. Bombrun, A. (1997) PCT Int. Appl. WO9743287;(1997) Chem. Abstr., 128, 34753. Bombrun, A. (2001) US Patent Appl. US6306870;(2001) Chem. Abstr., 135, 303782. Bombrun, A. (2000) US Patent Appl. US6043252;(2000) Chem. Abstr., 132, 236994. Sui, Z., Guan, J., Macielag, M.J., Jiang, W., Qiu, Y., Kraft, P., Bhattacharjee, S., John, T.M., Craig, E., Haynes-Johnson, D., and Clancy, J. (2003) Synthesis and biological activities of novel b-carbolines as PDE5 inhibitors. Bioorg. Med. Chem. Lett., 13 (4), 761–765. Turko, I.V., Ballard, S.A., Francis, S.H., and Corbin, J.D. (1999) Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol. Pharmacol., 56, 124–130. Corbin, J.D. and Francis, S.H. (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil.J.Biol.Chem.,274,13729–13732.
Erwin Bischoff
Bayer Schering Pharma AG, Cardiovascular Research, 42096 Wuppertal, Germany Erwin Bischoff studied biochemistry at the universities of T€ ubingen and Freiburg, Germany, and has been at Bayer AG since 1975. Since 1990, his research has focused on the metabolism of cyclic nucleotides, in particular the cGMPmetabolizing phosphodiesterases. Since 1995, he has investigated projects related to the treatment of erectile dysfunction. He was directly involved in the discovery of the PDE5 inhibitor vardenafil. From screening of potential drug candidates, he has guided and directed all preclinical trials on vardenafil.
j171
j 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction
172
Nils Griebenow
Bayer Schering Pharma AG, Medicinal Chemistry, 42096 Wuppertal, Germany Nils Griebenow was born in Jever, Friesland, Germany, in 1964. He received his diploma and PhD degree in chemistry from the Phillips University of Marburg, working under the supervision of Professor Manfred T. Reetz at the Max Planck Institute for Coal Research, M€ ulheim. In 1995, he joined the Bayer Healthcare AG setting up combinatorial chemistry at its central research facility. In 2002, he moved to the pharmaceutical division of Bayer Healthcare AG, working in various therapeutic areas. He is coinventor of 15 patents and patent applications, and has coauthored 21 peer-reviewed papers and book chapters.
Helmut Haning
Bayer Schering Pharma AG, Medicinal Chemistry, 42096 Wuppertal, Germany Helmut Haning was born in Trier, Germany, in 1965. He studied chemistry at the Johannes Gutenberg University in Mainz and at the Max Planck Institute for Coal Research in M€ ulheim, Ruhr, where he carried out his doctoral work under Professor M.T. Reetz. After a postdoctoral assignment with Professor W. Oppolzer at the University of Geneva in the field of alkaloid synthesis, he joined Bayer in 1995. He is the coinventor of the PDE5 inhibitor, Vardenafil. At present, he is Head of the Medicinal Chemistry Department in Wuppertal, Germany.
j173
7 Rifamycins, Antibacterial Antibiotics and Their New Applications Enrico Selva and Giancarlo Lancini
7.1 Discovery of the Pioneer Drug
At the end of 1957, an actinomycete strain was isolated in the Lepetit Laboratories in Milan, Italy, from a soil sample collected from the Mediterranean coast near St. Rafael. This microorganism, originally classified as Streptomyces mediterranei, and finally as Amycolatopsis mediterranei, produced a complex of related antibiotics called the rifamycins. The four main components of the novel complex, called rifamycins A, C, D, and E, showed potent antimicrobial activity but poor tolerability at the site of parenteral administration [1]. A fifth acidic substance, rifamycin B, was coproduced in minor quantities by the strain. It was poorly active but became easily available when it was fortuitously observed that rifamycin B was produced preferentially when the strain culture was buffered with 2 g/l of diethyl barbituric acid (barbital). A subsequent critical observation was that the antibacterial activity of solutions of rifamycin B increased on standing, indicating its transformation into a more potent derivative(s). This spontaneous process [2] consisted of oxidation of rifamycin B to generate rifamycin O followed by mild hydrolysis yielding rifamycin S (Figure 7.1). The structures of these molecules were later elucidated by Prelog and coworkers [3]. The quinone rifamycin S showed potent antibacterial activity but suboptimal profile in vivo, with toxicity and poor tolerability. These issues were resolved by reducing rifamycin S to the corresponding hydroquinone, rifamycin SV. This antibiotic was developed and became the first marketed rifamycin, with the trade name Rifocine.
7.2 Clinically Used Rifamycins
Rifamycin SV was the archetype of a group of congeners subsequently developed for clinical use (Figure 7.2). The main therapeutic interest has been centered on their potent activity against mycobacteria, pathogenic Gram-positive cocci, and Neisseriae. Rifampicin is by far the most widely used drug, mainly for treatment of tuberculosis
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 7 Rifamycins, Antibacterial Antibiotics and Their New Applications
174
CH3
CH3 H3C
CH3
O OH
O H3C
CH3 O
OH
OH OH
OH
H N
H3C
O
O
O
O
Rifamycin B
H N
CH3 O
O
O
H3C
O
O
O
O
O Rifamycin O
CH3
OH
O
CH3
OH OH
OH
H N
H3C
H N
H3C
O
O O
O
O Rifamycin SV
O
O
OH
CH3
O
Rifamycin S
CH3
Figure 7.1 Transformation of rifamycin B into rifamycin S.
and leprosy. Rifapentine has been successively approved for the treatment of tuberculosis in the United States of America and Italy, and rifabutin has been approved in the United States for limited clinical use only. Other specific infections are treated with rifamycin SV, rifamide, and rifaximin. The process that led to their design, investigation, and development is typical of other antibiotics of microbial origin. It was driven by advancements in comprehension of mechanism of action, structure–activity relationships, and pharmacokinetic behavior (examined in the two subsequent sections), and was oriented both by the medical needs of the time and by the evolving strategies of the pharmaceutical industry.
7.3 Mode of Action of Rifamycins and Structural Requirements for Activity
Rifamycins are characterized by an aromatic ring spanned by an aliphatic bridge, and antibiotics with this structural feature are referred to as ansamycins (ansa in Latin means the handle of an amphora). Other known ansamycins are the streptovaricins and the tolypomycins (biologically similar to rifamycins), and also geldanamycin and maytansines (biologically quite distinct having antiblastic activity). The spatial model of rifamycin SV, shown in Figure 7.3, is derived from X-ray [4] and NMR studies [5]. Extensive investigations of the structure–activity relationships of rifamycins [6, 7] have demonstrated that the following features are essential for activity: (i) the presence of free hydroxyl groups at positions C-21 and C-23; (ii) the presence of
7.3 Mode of Action of Rifamycins and Structural Requirements for Activity
CH3
CH3 H3C
j175
CH3
O OH
O H3C
CH3 O
OH OH
OH
H N
H3C
CH3 O
O O
O
O CH3
Y=H
Y
Rifamycin SV CH3
Y = CH2CO N
OH
OH
H3C
H N
O OH
N
O
H3C
H N
O
N
O
O
Rifamide
CH3
N
N
X = CH3
Rifampicin
X=
Rifapentine
X
CH3
OH
OH
O
O
N O CH3
CH3 N Rifabutin
H N
N
O
N
O
OH
H3C
CH3
Rifaximin
CH3
CH3 Figure 7.2 Rifamycins developed to market.
a keto or hydroxyl group at position C-1 and of a free hydroxyl at position C-8; (iii) preservation of the relative spatial position of (i) and (ii) that is determined by the conformation of the ansa chain. The model in Figure 7.3 indeed shows that the critical groups at positions C-1, C-8, C-21, and C-23 are exposed on the same side of the macrocycle and are precisely positioned in space by the ansa conformation. The antibiotic inhibits at low concentrations the bacterial DNA-dependent RNA polymerase (RNApol) [8]. The inhibition is mediated by the formation of a noncovalent complex between one molecule of rifamycin and the b-subunit of a molecule of RNA polymerase. The rifamycin:enzyme complex maintains the capacity to bind the DNA template and allows the formation of the first phosphodiester bond. The subsequent
j 7 Rifamycins, Antibacterial Antibiotics and Their New Applications
176
Figure 7.3 Spatial model of rifamycin SV.
steps leading to the synthesis of long-chain RNA are, however, impaired [9]. The crystal structure of the rifampicin:RNApol complex of Thermus aquaticus [10] confirms the role critical for binding played by the groups at position C-1, C-8, C-21, and C-23. It shows also that the antibiotic binds within the DNA/RNA channel corresponding to the b-subunit region in which mutations lead to resistance. Interestingly, the antibiotic binds in a site positioned more than 12 A apart from the catalytic center of the enzyme. Thus, it does not interfere, for instance, by mimicking the substrate or the transition states of the polymerization reaction but by inhibiting steps subsequent to the formation of the first phosphodiester bond. The active site is highly conserved between prokaryotes and eukaryotes and remains unaffected, thus explaining the selective activity against bacterial enzymes. In fact, the mammalian RNApol is not inhibited by the antibiotic [8]. Accordingly, rifamycins show low intrinsic toxicity to mammalian cells and are inactive against fungi and protozoa. They show high potency against Gram-positive pathogens (minimal inhibitory concentrations (MIC) from 0.005 to 0.1 mg/ml) and Mycobacterium tuberculosis (MICs < 0.01 mg/ml). Enteric Gram-negative pathogens are moderately sensitive. The effects of the antibiotic on bacteria depend typically on the sensitivity of their RNApols and on cell permeability. Except for specific mutations to resistance, the RNApols of Gram-positive and Gram-negative bacteria show comparable sensitivity to the antibiotic. However, permeability into cells is mediated by passive diffusion and is lower in Gram-negative than in Gram-positive cells [11]. As a result, enteric bacteria are less sensitive. Investigations of a large variety of chemical derivatives showed that modifications of the aromatic nucleus on positions 3 and/or 4 typically maintain potent activity against the enzyme, provided that the key positions and the ansa remain unaltered. The modifications at positions 3 and 4 alter, however, the physicochemical properties of the molecule and consequently their capacity to diffuse into the bacterial cell. For instance, the fermentation product rifamycin B is active against the enzyme but is
7.5 Profiles of Rifamycins Targeted at Tuberculosis Treatment
inactive against whole cells, including Gram-positives, because of permeability barriers caused by the presence of an ionized carboxylic group in its structure; the low activity mentioned earlier was due to a spontaneous degradation to the active rifamycin S. The corresponding amides (rifamide, for instance) are weakly ionized at physiological pH and show high activity [6]. Several classes of rifamycins with substitutions either at the 3 or at the 4 positions showed high antimicrobial potency [6]. In some cases, their antibacterial activity has been correlated with their lipophilicity [12]. It was observed, however, that derivatives with high lipophilic characteristics can acquire an additional mode of action, losing specificity for bacterial RNApol.
7.4 Modulation of Chemotherapeutic Properties
Rifamycins SV and rifamide were the first rifamycins to be developed. Their clinical use has been limited because of their suboptimal pharmacokinetic profiles resulting in insufficient antibiotic levels in serum and tissues. When administered orally, rifamycin SV is partially absorbed from the gastrointestinal tract. Moreover, the absorbed drug is concentrated in the liver and rapidly eliminated in the bile, failing to provide detectable blood levels [13]. Parenteral administration is also poorly effective due to quick excretion through the bile. Aiming at improving oral efficacy, and particularly for tuberculosis, the research at the Lepetit Laboratories was thus focused on synthesizing derivatives showing greater absorption from the gastrointestinal tract and slower rate of biliary excretion. It was found that modifications at position 4 yielded products with improved bacteriological activity but no better absorption and distribution, whereas derivatives substituted at position 3 were generally improved in both their in vitro activity and their pharmacokinetic characteristics [14]. The main goal was achieved by the synthesis of 3-[[(4-methyl-1-piperazinyl)imino]methyl] rifamycin SV, denoted rifampicin, obtained by condensation of 3-formyl rifamycin S with N-amino-N0 -methylpiperazine [14] (Figure 7.4).
7.5 Profiles of Rifamycins Targeted at Tuberculosis Treatment
Rifampicin resulted in one of the more effective therapeutic agents for combination therapy of tuberculosis. Subsequently, analogues were searched with longer lasting serum and tissue levels, and rifapentine was synthesized in the Lepetit Laboratories in 1975. The antibiotic was then developed to clinical use by Hoechst Marion Roussel for intermittent administration regimens in tuberculosis therapy. An additional rifamycin targeted at tuberculosis treatment, namely, rifabutin, was synthesized in 1975 in the Archifar Laboratories. Although similar to rifampicin in its antibacterial activity, it was found more active against Mycobacteria of the M. avium complex and was therefore clinically developed by Farmitalia Carlo Erba.
j177
j 7 Rifamycins, Antibacterial Antibiotics and Their New Applications
178
CH3
CH3 H3C
OH
O H3C
CH3
O CH3 O
OH O
OH
H3C
O
OH H N
H N
H3C CH3 O
HCHO, HNEt 2 CH2
O
O O
O
O
O
O
O CH3
CH3
N CH3
CH3
MnO2
OH
OH
H2N
H N
H3C
N
O
O
OH
N
OH H N
H3C
O
CH
O
OH
N CH3
O N
CH3
N CH3
O
OH
C H
O
CH3
Figure 7.4 Synthesis of rifampicin.
7.6 Rifampicin (INN), Rifampin (USAN)
Proprietary names: Rifadin, Rimactane. In combination with Isoniazid: Rifinah, Rimactazid. In combination with Isoniazid and Pyrazinamide: Rifater. Rifampicin shows good in vitro potency [15–17] against Gram-positive cocci (Table 7.1), including methicillin-resistant Staphylococci and penicillin-resistant Streptococcus pneumoniae. Enterococci are less sensitive. Clostridium difficile, Corynebacterium spp., and Leisteria monocytogenes are highly susceptible (MIC 0.025–0.5 mg/ml). Among Gram-negatives, pathogenic Neisseria and Moraxella spp. are highly susceptible. Bacteroides fragilis is also susceptible whereas enteric Gramnegative bacteria are generally less sensitive (MIC 1–32 mg/ml). Chlamydia trachomatis and C. psittaci are inhibited at low concentrations (0.025–0.5 mg/ml). M. tuberculosis, M. kansasi, M. marinum, and M. leprae are all susceptible, with the majority of these strains inhibited by <0.01 mg/ml. M. fortuitum and members of the M. avium complex are, on the contrary, rather insensitive [18, 19]. Resistant mutants emerge with relative ease during treatment [18]. This is typical of rifamycins. It is caused by point mutations occurring in several amino acids of the RNApol that lead to various levels of resistance. The mutation rate to resistance is about 107 in Gram-positive cocci and in Escherichia coli and around 109 to 1010 in M. tuberculosis. Typically, there is no cross-resistance with any other class of antibiotics in clinical use and resistance is not transferable. During rifampicin treatment, the gastrointestinal flora rapidly mutates to resistance but reverts to susceptibility within a few weeks upon cessation of treatment.
7.6 Rifampicin (INN), Rifampin (USAN) Table 7.1 Activity of rifampicin against common pathogenic bacteria.
Strain
MIC (mg/ml)
S. aureus S. pyogenes S. pneumoniae E. faecalis M. tuberculosis N. gonorrheae N. meningitidis H. influenzae E. coli K. pneumoniae P. aeruginosa
0.008–0.06 0.03–0.1 0.06–4 1–4 0.1–1 0.06–0.5 0.01–0.5 0.25–1 8–32 16–32 32–64
From Kucers et al. [16], Parenti and Lancini [17].
Because emergence of resistant mutants is likely to occur in the course of prolonged therapies, rifampicin is used in combination with one or more unrelated drugs. Many synergistic interactions with other agents have been reported, but the principal value of combined therapy is attributed to the suppression of emergence of resistant mutants. As mentioned before, rifampicin was promoted to clinical use because of its pharmacokinetic properties [20]. When orally administered, rifampicin is well absorbed, but a high variability has been found in preparations from different manufacturers. Peak plasma levels noticeably differ between individuals and are delayed by food, which affects absorption and decreases peak levels in plasma. Food, however, does not substantially reduce the time in which effective antibacterial levels are maintained. Elimination is mainly through the bile. The process is dose dependent and the proportion passing the liver to be excreted in the urine increases with dosage. Rifampicin is principally metabolized in the liver to its desacetyl derivative, which is also excreted in the bile and urine. Intravenous and oral administration shows similar areas under the curve (AUC) and elimination half-lives. Binding to plasma protein is about 80%, but, due to its lipid solubility, rifampicin is widely distributed in the internal organs, bones, and fluids, including tears, saliva, ascitic fluid, and abscesses. The antibiotic penetrates into cells, and is active against intracellular bacteria. Low concentrations are found in the cerebrospinal fluid, but these are substantially higher when the meninges are inflamed. The most important clinical use of rifampicin is in the treatment of tuberculosis and leprosy. The drug is also recommended for the prevention of meningitis in persons who have been in contact with patients suffering from this disease [21]. Because of its importance for the treatment of tuberculosis and concerns about emergence of resistant organisms, it was recommended that the drug be reserved solely for this purpose. However, in view of evolving medical needs, the drugs use has been proposed for the treatment of severe infections such as pneumococcal or
j179
j 7 Rifamycins, Antibacterial Antibiotics and Their New Applications
180
staphylococcal meningitis, Staphylococcus aureus endocarditis, severe staphylococcal sepsis, and osteomyelitis [21, 22]. Rifampicin appears relatively nontoxic, even when administered for a long period.
7.7 Rifapentine
(Proprietary name: Priftin) Available in the United States of America and in some South American and Asian countries Rifapentine is structurally related to rifampicin, differing in the presence of cyclopentyl instead of methyl group on the piperazine moiety (Figure 7.2). Rifapentine shows antibacterial activity similar to rifampicin. It is, however, more active against atypical mycobacteria, especially M. avium complex (MIC < 0.06–0.5 mg/ml) [23]. The principal advantage of rifapentine in respect to rifampicin is the persistence of blood levels, which provides therapeutic levels for at least 72 h after a single administration [24] (Table 7.2), thus allowing less frequent dosing. In combination with other drugs, it is indicated for short-course therapy of tuberculosis both in the intensive phase (twice-weekly regimen) and in the continuation phase, in which once-a-week dosage is sufficient. This improves patient compliance, a critical factor in the therapy of tuberculosis [25]. Oral absorption of rifapentine is substantially increased by food. The antibiotic is well distributed in the body with concentrations in most organs exceeding plasma levels. The drug accumulates in cells providing a therapeutic advantage for inhibition of intracellular mycobacteria. In macrophages, a 24 : 1 ratio of intracellular versus extracellular concentrations was estimated [26]. In an analogy to rifampicin, rifapentine is metabolized mainly to its 25-desacetyl derivative, which is cleared more rapidly than the parent antibiotic. The main route of elimination is through the bile in the feces, with a minor fraction (17%) recovered in the urine. Rifapentine is an inducer of liver cytochromes. Other drugs concurrently administered may require adjustments in dosage because rifapentine accelerates liver metabolism. For instance, treatment with rifapentine of patients with AIDS resulted in a 70% reduction of AUC of the antiviral drug indinavir. Table 7.2
Pharmacokinetic parameters of rifampicin and rifapentine.
Dose (oral) Cmax Tmax T1/2 Distribution volume Plasma protein binding
Rifampicin
Rifapentine
300 mg 4 mg/ml 2h 2.5 h 1.5 l/kg 80%
600 mg 12 mg/ml 5h 13 h 1.5 l/kg 97%
From Parenti and Lancini [17]. Cmax: maximum plasma concentration.T1/2: half-life. Tmax: time to maximum plasma concentration
7.9 Rifamycins Beyond Tuberculosis
7.8 Rifabutin
Rifabutine; ansamycin; LM-427; ansatipine. Proprietary name: Mycobutin. Available in several countries including the United States of America and United Kingdom. Rifabutin is a semisynthetic spiropiperidyl derivative of rifamycin S approved for prevention of mycobacterial infections (Figure 7.2). In general, the antibiotic is as potent in vitro as rifampicin, but to some extent it is more active on the M. avium/intracellular complex (MIC 0.01–2 mg/ml) [27, 28]. In one study, it was found that the majority of M. avium complex strains are not inhibited by 1.0 mg/ ml of rifampicin, but approximately 87% of them are sensitive to 1.0 mg/ml of rifabutin [28]. It should be noted that M. avium complex comprises several bacterial species (29). In M. tuberculosis, M. leprae, S. aureus, and C. trachomatis, the frequency of spontaneous resistant strains is somewhat lower with rifabutin than with rifampicin, although the mechanism of resistance is the same. Oral administration of 300 mg of rifabutin achieves 0.38 mg/ml Cmax levels with 3.3 h Tmax, 16 h T1/2, and 9.3 l/kg volume of distribution [17, 30]. Organ concentrations are high, and in lungs the average concentration is 6.5 times that in plasma. Plasma protein binding is 85%. Oral absorption is rapid but incomplete, oral bioavailability being only 12–20% with considerable interpatient variation [31]. Clinical value has been demonstrated in preventing or delaying mycobacterial infections in immunocompromised patients. The drug has been approved in the United States and Italy for the prevention of M. avium/intracellular infections in AIDS patients [32]. Although some efficacy was observed in the treatment of tuberculosis, its use for this condition is not recommended. Interaction with other drugs used in AIDS treatment has been reported due to the induction of liver enzymes by the antibiotic [33].
7.9 Rifamycins Beyond Tuberculosis
When the unique potential of rifampicin in the treatment of tuberculosis was demonstrated, its use for the treatment of other infectious diseases was strongly limited by regulatory agencies on the ground that resistant Mycobecteria would emerge if patients unaware of harboring tuberculosis are treated with this antibiotic for common infections. To partially overcome these limitations, chemists at the Alfa Farmaceutici S.p.A. synthesized in 1983 a derivative of rifamycin SV, namely, rifaximin, that was not absorbed when administered orally. The antibiotic, while useful for the treatment of gastrointestinal infections, does not reach a concentration in the lung so as to select resistant Mycobacteria. Rifamycin SV and rifamide have been the rifamycins first developed and remain in use for limited and specific indications in some countries.
j181
j 7 Rifamycins, Antibacterial Antibiotics and Their New Applications
182
7.10 Rifamycin SV and Rifamide
Proprietary names: Chibro-Rifamycin, Otofa, Rifocine Rifamycin SV is obtained by elimination of a glycolic moiety from rifamycin B and was the first rifamycin put to clinical use. Rifamide is the diethyl amide of rifamycin B (Figure 7.2). These two products share very similar biological properties and have been marketed as alternatives to one another in several countries [6, 13, 34]. Their good antimicrobial activity against Gram-positive organisms and M. tuberculosis is typical of the family. The efficacy is, however, poor in tuberculosis because of insufficient drug blood levels. As mentioned before, both drugs are absorbed orally but are rapidly eliminated through the bile. Their high concentrations in the bile is, however, effective in treating infections of the biliary tract, even when due to the generally less sensitive Gram-negative bacilli [35]. The water solubility of these molecules quickly made available formulations suitable for intramuscular injection and these preparations have had some clinical utility. However, the introduction in the United Kingdom of an injectable form of rifampicin superseded the use of rifamide, which was withdrawn from the UK market.
7.11 Rifaximin
Proprietary names: Normix, Rifacol, Fatroximin, Rifaxidin, Rifaximina (Spanish); Rifaximine (French), Ritacol, Xifaxan. Available in several European countries, the United States, and Mexico. Rifaximin is a semisynthetic derivative of rifamycin S (Figure 7.2) with a spectrum of activity similar to that of the other rifamycins. It is poorly absorbed from the gastrointestinal tract [36]. Up to 90% of the administered rifamixin is concentrated in the gut with less than 0.2% in the liver and kidney and less than 0.01% in other tissues. The antibiotic is effective against a variety of gastrointestinal complications and is extensively used in the treatment of irritable bowel disease [37], travel diarrhea [38], and diverticulitis [39]. Rifaximin has also been proposed for the treatment of chronic hepatic encephalopathy [40] and for topical treatment of bacterial vaginitis [41]. A novel interest is related to emerging gastrointestinal infections caused by C. difficile strains that are high producers of toxins. These severe infections have been reported initially in North America and recently in Europe, and are spreading in populations previously considered to be at low risk [42]. Rifaximin is highly active against this pathogen and has a distribution in the body appropriate for a specific therapy. In a recent study, a 2-week course of rifaximin following a 10–14-day course of vancomycin was effective in most patients with recurrent disease [43].
7.13 Summary
CH3
CH3 H3C
O OH
O H3C
CH3
CH3 O
OH
OH O N
H3C
CH3 O
O
O O
O
N
CH3 HO
N
CH3 N CH3
Figure 7.5 Rifalazil.
7.12 Trials for Other Therapeutic Indications
Rifalazil (Figure 7.5) is a rifamycin particularly active against Chlamydophila pneumoniae, including rifamycin-resistant strains [44]. It has been investigated for treatment of atherosclerosis. This pathology has been associated [45] with chronic inflammatory processes putatively caused by C. pneumoniae. However, a phase III study performed on patients with intermittent claudication failed to demonstrate clinically relevant results [46]. Further activities have been investigated for several rifamycins. Extensive studies have been focused on the inhibition of various polymerizing enzymes, such as eukaryotic DNA and RNApols and viral reverse transcriptase, but without any success [6]. Rifampicin, for instance, inhibits in vitro vaccinia viruses, but eventually it was shown to interfere with virus capsid assembly. Rifabutin has been reported to inhibit the replication of human immunodeficiency virus 1 (HIV1) in concentrations (10 mg/ml) that are not toxic to lymphoid cells, but no efficacy on HIV infections has been demonstrated. Several rifamycins have also shown some immunosuppressive effect in animals, but the clinical significance is not clear. There is also anecdotal evidence of the efficacy of topical applications of rifamycin SV in curing wounds, particularly bedsores.
7.13 Summary
The rifamycins are a family of antibacterial antibiotics acting on bacterial RNA polymerase and structurally characterized by an aromatic ring spanned by an
j183
j 7 Rifamycins, Antibacterial Antibiotics and Their New Applications
184
aliphatic bridge (ansa). The core structure of the rifamycins used in therapy derives from rifamycin B, a fermentation product from an actinomycete first isolated in 1957. Although its antimicrobial activity was moderate, it was soon observed that oxidation followed by mild hydrolysis generated rifamycin S, a quinone molecule with potent antimicrobial activity but poor tolerability. Subsequent reduction of rifamycin S to the hydroquinone form rifamycin SV resulted in good potency and efficacy against infections by Gram-positive pathogens, and tolerability appropriate for clinical development. It was marketed for parenteral administration with the name Rifocine. A wider therapeutic window was obtained with rifamide, an amide of rifamycin B. Clinical use of these molecules was limited by lack of efficacy by oral administration and unsatisfactory pharmacokinetics. Analysis of the activity of various derivatives substituted on different regions of the molecule demonstrated that modifications of the aliphatic bridge led to inactivity. On the contrary, modifications at carbons 3 or 4 of the aromatic ring maintained or improved activity and positively modified pharmacokinetics to give oral efficacy. Several series of derivatives were then synthesized. Among them 3-[[(4-methyl-1-piperazinyl)imino] methyl]rifamycin SV, named rifampicin (INN) or rifampin (USAN) had the desired properties and was marketed worldwide. The antibiotic has unique therapeutic properties against tuberculosis and leprosy and is used in combination with unrelated antibiotics to prevent the emergence of resistant strains. Subsequently, two more analogues have been developed. Rifapentine (Priftin) that permits intermittent therapy for tuberculosis because it provides lasting blood levels. Rifabutin (Mycobutin) is targeted at infections caused by the M. avium complex and shows an appropriate organ and cellular distribution. It is approved for the prevention of mycobacterial infections in AIDS patients. In addition to tuberculosis, rifampicin is recommended for the prophylaxis of meningitis in persons exposed to patients with this infection. Because of their high antimicrobial activity and distinct mode of action (inhibition of RNA polymerase), the rifamycins may be effective in a variety of severe bacterial infections. For instance, rifaximin, which is poorly absorbed from the gut and is targeted at gastrointestinal infections, may provide a therapeutic option to treat infections caused by C. difficile, a high toxin producer, which represents an emerging medical problem.
References 1 Sensi, P., Margalith, P., and Timbal, M.T.
(1959) Rifomycin a new antibiotic: preliminary report. Farmaco, 14, 146–147. 2 Sensi, P., Ballotta, R., Greco, A.M., Gallo, G.G., and Rifomycin, X.V. (1961) Activation of rifomycin B and rifomycin O. Production and properties of rifomycin S and rifomycin SV. Farmaco, 16, 165–180. 3 Oppolzer, W., Prelog, V., and Sensi, P. (1964) The composition of rifamycin B and
related rifamycins. Experientia, 20, 336–339. 4 Brufani, M., Fedeli, W., Giacomello, G., and Vaciago, A. (1964) The X-ray analysis of the structure of rifamycin B. Experientia, 20, 339–342. 5 Gallo, G.G., Martinelli, E., Pagani, V., and Sensi, P. (1974) The conformation of rifamycin S in solution by 1 H NMR spectroscopy. Tetrahedron, 30, 3093–3097.
References 6 Lancini, G.C. and Zanichelli, W. (1977)
7
8
9
10
11
12
13
14
15
16
17
Structure–activity relationship in rifamycin, in Structure–Activity Relationships Among the Semisynthetic Antibiotics (ed. D. Perlman), Academic Press, San Francisco, pp. 531–600. Brufani, M., Cerrini, S., Fedeli, W., and Vaciago, A. (1974) Rifamycins: an insight into biological activity based on structural investigation. J. Mol. Biol., 87, 409–443. Hartmann, G., Onikel, K.O., Knusel, F., and Nuesch, J. (1967) The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim. Biophys. Acta, 145, 843–844. Hartmann, G.R., Heinrich, P., Kollenda, M.C., Skrobranek, B., Tropshung, M., and Weiss, W. (1985) Molecular mechanism of action of the antibiotic rifampicin. Angew. Chem. Int. Ed. Engl., 24, 1009–1014. Campbell, E.A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., and Darst, S.A. (2001) Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell, 104, 901–912. White, R.J. and Lancini, G.C. (1971) Uptake and binding of [3 H]rifampicin byEscherichia coli and Staphylococcus aureus. Biochim. Biophys. Acta, 240, 429–434. Pelizza, G., Lancini, G.C., Allievi, G.C., and Gallo, G.G. (1973) The influence of lipophilicity on the antibacterial activity of rifamycins. Farmaco, 28, 298–315. Bergamini, N., Fowst, G., and Rifamycin, S.V. (1965) A review. Arzneim.-Forsch., 15 (Suppl.), 951–1002. Sensi, P., Maggi, N., Furesz, S., and Maffii, G. (1966) Chemical modifications and biological properties of rifamycins. Antimicrob. Agents Chemother., 6, 699–714. Arioli, V., Pallanza, R., Furesz, S., and Carniti, G. (1967) Rifampicin: a new rifamycin. I. Bacteriological studies. Arzneim.-Forsch., 17, 523–529. Kucers, A., Crowe, S.M., Grayson, M.L., and Hoy, J.F. (1997) The Use of Antibiotics. A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs, 5th edn, Butterworth, Einemann, Oxford, UK, pp. 676–708. Parenti, F. and Lancini, G.C. (2003) Rifamycins, in Antibiotics and
18
19
20
21
22
23
24
25 26
27
Chemotherapy, 8th edn (eds R.G. Finch, D. Greenwood, S.R. Norrby, and R.J. Whitley), Churchill-Livingstone, London, pp. 374–381. Lester, W. (1972) Rifampin: a semisynthetic derivative of rifamycin – a prototype for the future. Ann. Rev. Microbiol., 26, 85–102. Ormerod, L.P. (2003) Other mycobacterial infections, in Antibiotic and Chemotherapy, 8th edn (eds R.G. Finch, D. Greenwood, S.R. Norrby, and R.J. Whitley), ChurchillLivingstone, London, pp. 817–832. Ellard, G.A. and Fourie, P.B. (1999) Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int. J. Tuberc. Lung Dis., 3 (3 Suppl.), 301S–308S. Morris, A.B., Brown, R.B., and Sands, M. (1993) Use of rifampin in nonstaphylococcal, non-mycobacterial disease. Antimicrob. Agents Chemother., 37, 1–7. Loeffler, A.M. (1999) Uses of rifampin for infections other than tuberculosis. Pediatr. Infect. Dis. J., 18, 631–632. Heifets, L.B., Lindholm-Levy, P., and Flory, M. (1990) Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis., 141, 626–630. Keung, A.C., Owens, R.C., Jr., Eller, M.G., Weir, S.J., Nicolau, D.P., and Nightingale, C.H. (1999) Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase 1 study. Antimicrob. Agents Chemother., 43, 1230–1233. Jarvis, B. and Lamb, M.M. (1998) Rifapentine. Drugs, 56, 607–616. Mor, N., Simon, B., Mezo, N., and Heifets, L.B. (1995) Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother., 39, 2073–2077. Saito, H., Sato, K., and Tomioka, H. (1988) Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle, 69, 187–192.
j185
j 7 Rifamycins, Antibacterial Antibiotics and Their New Applications
186
28 Heifets, L.B. and Iseman, M.D. (1985)
29
30
31
32
33
34
35
36
Determination of in vitro susceptibility of mycobacteria to ansamycin. Am. Rev. Respir. Dis., 132, 710–711. Tsukamura, M. (1987) Two groups of Mycobacterium avium complex strains determined according to the susceptibility to rifampicin and ansamycin. Microbiol. Immunol., 31, 615–623. William, J., Burman, W.J., Gallicano, K., and Peloquin, C. (2001) Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet., 40, 327–341. OBrien, R.J., Lyle, M.A., and Snider, D.E., Jr. (1987) Rifabutin (ansamycin LM 427): a new rifamycin S derivative for the treatment of mycobacterial diseases. Rev. Infect. Dis., 9, 519–530. Nightingale, S.D., Cameron, D.W., Gordin, F.M., Sullam, P.M., Cohn, D.L., Chaisson, R.E. et al. (1993) Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N. Engl. J. Med., 329, 828–833. Kuper, J.J. and DAprile, M. (2000) Drug–drug interactions of clinical significance in the treatment of patients with Mycobacterium avium disease. Clin. Farmacokinet., 39, 203–204. Pallanza, R., F€ uresz, S., Timbal, M.T., and Carniti, G. (1965) In vitro bacteriological studies on rifamycin B diethylamide (rifamide). Arzneim.-Forsch., 15, 800–802. Khan, G.A. and Scott, A.G. (1967) The place of rifamycin B diethylamide in the treatment of cholangitis complicating biliary obstructions. Br. J. Pharmacol. Chemother., 31, 506–512. Corazza, G.R., Ventrucci, M., Strocchi, A., Sorge, M., Pranzo, L., Pezzilli, R. et al. (1988) Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J. Intern. Med. Res., 16, 312–316.
37 Fumi, A.L. and Trexler, K. (2008)
38
39
40
41
42
43
44
45
46
Rifaximin treatment for symptoms of irritable bowel syndrome. Ann. Pharmacother., 42, 408–412. DuPont, H.L. (2005) Travelers diarrhea: antimicrobial therapy and chemoprevention. Nat. Clin. Pract. Gastroenterol. Hepatol., 2, 191–198. Papi, C., Koch, M., and Capurso, L. (2005) Management of diverticular disease: is there room for rifaximin? Chemotherapy, 51 (Suppl. 1), 110–114. Festi, D., Mazzella, G., Orsini, M., Sottili, S., Sangermano, A., Li Bassi, S. et al. (1993) Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr. Ther. Res., 54, 598–609. Pelosini, I. and Scarpignato, C. (2005) Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. Chemotherapy, 51 (Suppl. 1), 122–130. Loo, V.G., Poirier, L. et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med., 353, 2442–2449. Johnson, S., Schriever, C., Galang, M., Kelly, C.P., and Gerding, D.N. (2007) Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis., 44, 846–848. Rothstein, D.M., Suchland, R.J., Xia, M., Murphy, C.K., and Stamm, W.E. (2008) Rifalazil retains activity against rifampinresistant mutants of Chlamydia pneumoniae. J. Antibiot., 61, 489–495. Becker, A.E., De Boer, O.J., and Van Der Wal, A.C. (2001) The role of inflammation and infection in coronary artery disease. Annu. Rev. Med., 52, 289–297. Powell, J.T. (2008) Three drug indications for patients with peripheral arterial disease bite the dust. Eur. J. Vasc. Endovasc. Surg., 35, 49–50.
References
Giancarlo Lancini
University of Varese, FIIRV, Via Lepetit 34, Gerenzanon (VA), Italy Giancarlo Lancini graduated in chemistry in 1956. In 1957, he joined Lepetit, where in 1966 he became Head of the Department of Antibiotics and in 1974 Director of the research laboratories. His research spans several aspects of the antibiotic screening, biosynthesis, mechanisms of action, and synthesis. He contributed to the discovery of rifamycins and teicoplanin. He taught courses on biotechnology of fermentations at the University of Pavia (1971–1982), at the University of Milan (2000–2005), and Varese (2006–present). He has authored over 100 scientific papers, and two books of which Antibiotics: An Integrated View had several editions in Italian and English and has been translated into Russian and Chinese.
Enrico Selva
University of Pavia, via Di Vittorio 23, 27027 Gropello Cairoli (PV), Italy Enrico Selva has worked on R&D of bioactive microbial products in major pharmaceutical companies and in a biotech start-up he contributed to set up and manage. His work on microbial product chemistry, screening, isolation of environmental microorganisms, fermentation, strain development, and medical microbiology contributed to the discoveries of the glycopeptide A40926 (precursor of Dalbavancin), Ramoplanin, and original antibiotics acting on bacterial protein synthesis, RNA polymerase, and cell wall biosynthesis. Four molecules are in clinical development. He is a lecturer of industrial biotechnology at the University of Pavia, Italy.
j187
j189
8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs Andras Nemes
8.1 Introduction
The monoterpenoid indole alkaloids are secondary metabolites of certain flowering plants. More than 2500 isolated representatives of them are formed mainly in three plant families Apocynaceae, Loganiaceae, and Rubiaceae from two building blocks tryptamine 1 and secologanin 2 through a single precursor strictosidine 3 (Figure 8.1) [1]. Different biosynthetic pathways lead from unrearranged coryanthean-type alkaloids to the rearranged classes ibogaine and vincamine and further to bisalkaloids such as vinblastine. Quinine-type and camptothecin (CPT)-type quinoline alkaloids are also biosynthesized via strictosidine. Although the role of monoterpenoid indole alkaloids in plant biochemistry is unclear, in animals and humans they have revealed a wide spectrum of pharmacological activity that suggests considerable potential for clinical application. At present, monoterpenoid indole alkaloids are used as neuromuscular blocking agents (curare alkaloids: toxiferine 4, alcuronium 5), for the treatment of hypertension (yohimbine alkaloids: reserpine 6), addiction (ibogamine alkaloids: ibogaine 7), cerebral insufficiencies (vinca alkaloids: vincamine 8), malaria, cardiac arrhythmia (cinchona alkaloids: quinine 9, quinidine 10), and various malignancies (dimeric vinca alkaloids: vinblastine 11, vincristine 12, and Camptotheca alkaloids: camptothecin 13) (Figure 8.2). Like many other natural compounds, monoterpenoid indole alkaloids have been the subject of analogue-based drug research. No compounds with better activity have been found among the antihypertensive reserpine 6 stereoisomers, derivatives, and related molecules. The same holds in respect of the enantiomer pair quinine 9 and quinidine 10. Alcuronium 5 is the only semisynthetic derivative of active curare alkaloid toxiferine 4, which has been used clinically and marketed in Europe. Only one active analogue, the metabolite noribogaine 7, R ¼ H, is known for the antiaddictive ibogaine 7, R ¼ Me. By contrast, vincamine 8, vinblastine 11, and camptothecin 13 have all served as lead compounds for more potent or specific agents in
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
190
CHO H
N H 1 Tryptamine
NH2
+
H
OGlu
O
CH3O2C
NH
N H H
H H
CH3O2C 2 Secologanin
OGlu
O
3 Strictosidine
Figure 8.1 Biosynthesis of monoterpenoid alkaloid precursor.
the appointed range of activity. The numbering system of alkaloids reported throughout this chapter follows the biogenetic numbering [2].
8.2 Vincamine and Derivatives: Cerebrovascular and Neuroprotective Agents 8.2.1 Medicinal Chemistry of Vincamine Derivatives
Vincamine 8, an alkaloid of Vinca minor, was investigated by several research groups in the 1960s. Szasz and coworkers, for example, considered the molecule to be a potential analogue of reserpine 5 [3]. After extensive investigation, it was found, however, that 8 improved cerebral functions, rather than blood pressure. Vincamine was subsequently introduced for the treatment of cerebral insufficiencies in Europe. Research then focused on the mechanism of action of these compounds in an effort to find more potent derivatives by structural modification of the lead alkaloid molecule. Of the several thousand derivatives prepared, only three reached the market, based on their beneficial effect on brain circulation and neuronal homeostasis. A common structural feature of these molecules is the retention of the cis-fused ring system of vincamine, and an ester or carbonyl function at C-16 (Figure 8.3). Vinburnine 14, a degradation product of vincamine, which also occurs in some species of Apocynaceae as minor alkaloid, was launched in 1977 by SmithKline Beecham. The following year, it was followed by Richters vinpocetine 15. For vinburnine 14, demethoxycarbonylation affords a simple entry from the parent compound 8 [4]. Replacement of the hydroxy and methoxycarbonyl groups with a single carbonyl group improved the cerebral metabolic and hemodynamic effects [5]. Vinpocetine 15, produced from vincamine 8 by dehydration and transesterification [3], was significantly more active than the lead molecule in cognitive activating ability, both in preventing hypoxia-induced deficits in step-through passive avoidance retention in rats [6] and in protecting against the lethal effects of hypoxia in mice [7]. In the latter test, vinburnine 14 was almost as effective as vinpocetine. Brovincamine 16, the 11-brominated derivative of vincamine 8, was developed in the next decade and subsequently launched in Japan (1986, Sandoz) for its ability to
8.2 Vincamine and Derivatives: Cerebrovascular and Neuroprotective Agents
Figure 8.2 Structures of clinically used monoterpenoid indole alkaloids.
selectively increase cranial and coronary blood flow [8]. Brovincamine 16 also markedly increases the blood flow in the optic nerve head of albino rabbits [9] and is recommended for the treatment of ophthalmologic insufficiencies such as glaucoma (Figure 8.3).
j191
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
192
Structural formula
H N
N
Name
Synonymes
(-)-Eburnamonine
Vinburnine Cervoxane Vincamone
Launched (Company)
1977 (Beecham)
O 14 6
H 11
N
N 21
16
Ethyl apovincaminate
Vinpocetine Cavinton
1978 (Richter)
11-Bromovincamine
Brovincamine Sabromine
1986 (Sandoz)
20
H5C2O2C 15
H N
Br HO
N
H3CO2C 16 Figure 8.3 Structures of clinically used vincamine derivatives.
8.2.1.1 Structure–Activity Relationships In a study, performed with all possible stereoisomers of vincamine 8, vinburnine 14, and vinpocetine 15, it was established that the cerebrovascular activity strongly depends on the natural cis-(20S,21S)-eburnane skeleton [10]. 20-Epi derivatives, such as trans-(20R,21S)-vinpocetine 17, and (20R,21S)-dihydroeburnamenine-16-methanol 18 or its dinor-derivative (1S,12bS)-octahydroindoloquinolizinyl-1-methanol 19 (Vintoperol, RGH-2981) exhibit significant peripheral vasodilator effects [10, 11]. No vascular effects were found with trans-(20S, 21R) derivatives. The pharmacological profile of vindeburnol (trans-desethyl-(20S,21S,16R)-dihydroeburnamenine-16-ol, RU 24722) 20 differs from that of vincamine. In addition to improved cerebral blood flow (CBF), this compound markedly suppressed the cerebral metabolic rate during decapitation ischemia, increased the EEG resistance time, and decreased the EEG recovery time in rats under asphyxic anoxia [12]. (20S,21S)-(Nitrooxy)ethyl apovincaminate (VA-045) 21 was tested for cerebrovascular ischemia and cognitive disorders [13], while (20S,21R)-hydroxyethyl apovincaminate (RGH-10885) 22 was identified as an antioxidant and cognitive enhancer [14] (Figure 8.4).
8.2 Vincamine and Derivatives: Cerebrovascular and Neuroprotective Agents 6
9 8
10
7
5
H
1
11 12
13
N
ROOC 16
20 17 19
N
4
21
H 3
N
14 15 18
17 20S,21R R = C 2H5 21 20S,21S R = NO 2OC2H4 22 20S,21S R = HOC 2H4
H
N
R1
R2 18 20S,21R R 1 = CH2OH, R2 = C2H5 20 20S,21S R 1 = OH R2 = H
N 12b H 1 HO
N
19
Figure 8.4 Structures of pharmacologically active vincamine derivatives.
8.2.2 Synthesis of Vincamine Derivatives
As isolation of vincamine from natural sources is both expensive and limited, an efficient synthesis was needed. The biomimetic transformation of dihydrotabersonine to vincamine [15, 16] is one possible approach since tabersonine, the biogenetic precursor of vincamine 8, constitutes around 4% in the seeds of Vocanga africana. The clinical use of vincamine derivatives initiated numerous dia- and enantioselective total syntheses of this type of alkaloid [17]. The synthetic route reported in Ref. [18] affords vincamine, vinburnine, and vinpocetine from a common intermediate and was accomplished in industrial scale [18, 19]. 8.2.3 Pharmacological Properties of Vincamine Derivatives 8.2.3.1 Mechanism of Action The beneficial effect of vincamine derivatives on cerebral circulation disorders was first explained by dilatation of cerebral vessels [20], which was deduced from the common structural elements of reserpine 5 and vincamine 8. Subsequent studies, however, established that the mechanisms of action of reserpine and vincamine are different. Reserpine appears to act by inhibition of the active transport of neurohormonal amines into tissue storage sites, consequently decreasing peripheral vascular resistance to evoke a fall in blood pressure [21]. The mechanism of action of vincamine derivatives proved to be more complex. The molecular targets are the phosphodiesterase-1 (PDE-1) enzyme, voltage-dependent Na þ channels, voltageoperated Ca2 þ channels and glutamate receptors. Phosphodiesterase-1 Vinpocetine 15 noncompetitively inhibits Ca2 þ /calmodulinedependent cGMP-PDE [22] and is now considered to be a selective inhibitor of this (PDE-1) isoenzyme [23]. Inhibition of PDE-1 and increase in cAMP and cGMP levels are presumably responsible for the positive vascular effects, for the improvement in cerebral circulation, and for the beneficial effect on platelets [24].
j193
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
194
Na þ Channels Vinpocetine 15 inhibited Na þ currents in cortical neurons with a 44 mM K50 value [25] and reduced the Na þ load induced by toxic doses of veratridine [26]. Vinpocetine 15 selectively inhibits neurotransmitter release triggered by sodium channel activation [27]. Accumulation of Na þ in neurons during anoxia, and then oxidative stress during reperfusion, has deleterious effect, so pharmacological blockade of Na þ channels is beneficial against oxidative stress and might have a particular importance in neuroprotection [28, 29]. Ca2 þ Channels The vasodilative effects of bromovincamine 16 seem to involve inhibition of depolarization-dependent Ca2 þ slow channel [30]. Vinpocetine 15 inhibited the Ca-uptake on guinea pig forebrain synaptosomes [31] and inhibited veratridine-induced Ca influx in rat hippocampal CA1 pyramidal cells [32]. Glutamate Receptors Vipocetine 15 was able to protect neurons against the cytotoxic effect of glutamate [33] or N-methyl D-aspartate [34]. 8.2.3.2 Clinical Pharmacology Pharmacokinetics The absorption of vincamine and derivatives following oral administration is rapid. Peak plasma concentrations are reached within 1–2 h after dosing [35, 36]. A biphasic clearance with half-lives of 1 and 5 h was observed for plasma pharmacokinetics of bromovincamine 16 in humans [36]. Vinpocetine 15 acts similarly with the corresponding half-life values of 0.3 and 4.8 h [35]. The parent compound vincamine 8 can be oxidatively metabolized (CYP enzymes) to 6-hydroxy and 6-keto-vincamines and hydrolytically (hydrolase enzymes) to vincaminic acid. The latter metabolite transforms further to eburnamonine 14, by a decarboxylation–oxidation process [35]. The 6-hydroxy derivative is the main metabolite of vinburnine 14 [37]. For the ester derivatives 15 and 16, the main metabolites are apovicaminic acid [35] and bromovincaminic acid [36], respectively. Clinical Results with Vincamine Derivatives Double-blind placebo-controlled studies were accomplished to establish the effectiveness of vinburnine 14. It improved 22 of the 25 parameters measured to assess brain functions for 129 patients treated with geriatric complaints [38]. In a 12-week trial, a 60 mg daily dose vinburnine improved more frequently the symptoms of cerebrovascular disorders compared to placebo [39]. Vinburnine (40 mg i.v.) exhibited beneficial effects on blood rheology, oxygen transport, and regional circulation under normal conditions, and hypoxemia in two groups of patients (with low hemoglobin oxygen affinity and with normal values, respectively) [40]. Double-blind placebo-controlled, randomized trials have been carried out to confirm that vinpocetine is effective in the treatment of chronic cerebral diseases in the 15–30 mg/day dose range [41–44]. Positron emission tomography (PET) studies were performed on chronic ischemic stroke patients to study the pharmacological and physiological effects of vinpocetine 15. Single-dose intravenous infusion resulted in positive changes in regional
8.3 Antitumor Dimeric Vinca Alkaloids
cerebral blood flow and metabolism in both peri-stroke regions and healthy brain tissue [44]. A two-week long intravenous vinpocetine treatment increased global CBF. The highest CBF changes were observed in regions, in which the highest regional uptake of labeled vinpocetine was measured in other PETstudies. The global cerebral metabolic rate of glucose (CMRglc) did not change markedly, whereas regional CMRglc values markedly improved [45]. PET scans with brovincamine in patients with misery perfusion syndrome confirmed improved CBF but gave no evidence of favorable effects on metabolic state [46]. Oral brovincamine 16 treatments (3 20 mg daily) may retard further visual field deterioration in patients with normal-tension glaucoma, as established in a study performed with 52 patients and followed for 2 years [47]. Antitumor Monoterpenoid Indole Alkaloids A wide range of complex natural products exert antitumor activity [48], but the utility of these cytotoxic compounds in the host organism is disputed. One argument is that they are defensive agents against the hostile environment, while a more feasible argument is that they are cellular growth regulators that interfere with the cell cycle. The fact that the primary target of the most effective natural antitumor agents is DNA or tubulin makes this latter hypothesis more likely. The dimeric vinca alkaloids interfere with tubulin polymerization, while camptothecin inhibits the DNA processing topoisomerase I enzyme.
8.3 Antitumor Dimeric Vinca Alkaloids
Catharanthus roseus (formerly Vinca rosea), a Madagascan periwinkle, is a rich source of indole and bisindole alkaloids. Vinblastine 11 was first discovered in 1958 as potent cytotoxic compound by Noble et al. at the University of Western Ontario [49] and independently by Svoboda et al. at Lilly Research Laboratories [50]. Further isolations from the leaf extracts led to vincristine 12 and a series of other derivatives of vinblastine 11 [51]. Of these, 11 and 12 became clinically important antitumor agents and marketed as Velban in 1960 and Oncovin in 1963, respectively. 8.3.1 Medicinal Chemistry of Dimeric Vinca Alkaloid Derivatives
The antitumor vinca alkaloids are dimerized from a tetracyclic ibogan (upper part) and pentacyclic aspidosperman (lower part) unit. The antiproliferative activity is related to their specific interaction with tubulin, disrupting the cell division process, by destabilizing the structure of microtubules [52]. Minor structural differences between the molecules led to major differences in potency and utility. Vinblastine 11 and Vincristine 12, despite their chemical similarities, display significantly different clinical effects. Thus, vinblastine is used in the treatment of Hodgkins disease and metastatic testicular tumors, while vincristine is applied in combination with other antitumor drugs for the treatment of acute
j195
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
196
lymphocytic leukemia in children [53]. The toxicity profile of 11 and 12 is also different. Vinblastine causes severe tissue necrosis upon extravasation, while mild neurotoxicity and myelosuppression also occur. Beside the tissue necrosis, neurotoxicity is a significant potential problem with vincristine. Myelosuppression occurs to a lesser extent. Vinblastine 11 was chosen as the lead molecule to solve problems of limited therapeutic spectrum and severe toxicity associated with dimeric vinca drugs. The aspidosperman part of the molecule provides more opportunities for semisynthetic modifications. Vindesine 23, desacetyl vinblastine amide, which was selected from the modified derivatives by Lillys researchers, differs from the lead molecule only by deacetylation and replacing the C-16 ester group by an amide group [54]. The antitumor spectrum of 23 resembles vincristine 12, while the toxicity profile appears to be less neurotoxic. Phase I clinical trials commenced in 1977 and 23 has been used for the treatment of non-small cell lung cancer (NSCLC), lymphoblastic leukemia, and non-Hodgkins lymphomas. The compound was marketed in the United Kingdom, Germany, France, and Ireland as Eldisine for the treatment of acute lymphoblastic leukemia of childhood, blastic crises of chronic myeloid leukemia, and malignant melanoma in 1980 [55] (Figure 8.5). Modification of the ibogan part led to the second successful antitumor analogue of vinblastine to reach the marketplace. Navelbine or vinorelbine 24, R0 ¼ R00 ¼ H, was synthesized by Polonovsky–Potier reaction from anhydrovinblastine 25 and has become one of the most prescribed anticancer products. It has been found effective against NSCLC and less neurotoxic than vincristine. Vinorelbine 24 was discovered by Potier in 1978 at CNRS, developed and licensed to Borroughs Wellcome by Pierre Fabre (1988). First approved for NSCLC treatment in1989 in France [56], launched in the United Sates of America in 1995 (Figure 8.5). 8.3.1.1 Structure–Activity Relationships The (160 S,140 S) configuration of the ibogan part proved to be critical for anticancer activity. Structural modifications on the aspidosperman part are better tolerated. Several hundred new congeners have been synthesized in order to exploit the presence of various functional groups in the aspidosperman moiety. Some of them were selected for phase I and II clinical trials. Vindesine 23 N-alkylated analogues showed reduced antitumor activity [57]. Deacetylation at C-17, as well as acetylation of the free hydroxyl groups, inactivates the molecule. The C-17 acetoxy group of 11 was substituted by the N,N-dimethylglycinoyl group in vinglycinate 26 [56]. As a vinblastine prodrug, 26 showed improved absorption but no improvements in efficacy or toxicity [58]. Vintriptol 27, a vinblastine-23-oyl tryptophan ethyl ester, was selected from among 21 amino acid derivatives of 11 for its good antileukemic activity and diminished toxicity [59]. New spiro-fused derivatives were produced by forming an oxazolidine ring from the two substituents on C-16 with alkyl isocyanates. Vinzolidine, N-chloroethyl spirooxazolidinyl vinblastine 28 was tested in clinical studies due to its excellent activity and oral absorption [60]. No further developments were reported on the clinical use of vinblastine analogues 26–28 (Figure 8.6).
8.3 Antitumor Dimeric Vinca Alkaloids Structural formula 6'
Desacetyl vinblastine-16 carboxamide
Vindesine Eldisine
Launched (Company)
OH 18'
20'
14'
19'
15'
16' CO2CH3 5
14
N
6
20
10
CH3O 11
Synonymes
5'
N N H
Name
15 18
H
17 19
1
16
N H CH3
OH OH CO2NH2
23
1980 (Ely Lilly)
6'
N 14'
N H
18'
15' R'
R''
16' CO2CH3 5
14
N
6
20
10
CH3O 11
19' 20'
H
15 18
17 19
1
16
N H CH3
OAc OH CO2CH3
24
R' = R" = H
15',20'-Anhydro 5'-norvinblastine
j197
1989 Vinorelbine Navelbine (Pierre Fabre)
Figure 8.5 Structures of clinically used vinblastine derivatives.
Naturally occurring vinblastine 11 congeners such as leurosidine (200 -epivinblastine), leurosine (200 -deoxy-150 ,200 -epoxyvinblastine), and other 200 -deoxy derivatives possess active antitumor properties [61]. Vincristine 12 derivatives, modified on the ibogan part as vinepidine, 200 -deoxy-200 -epivincristine 29 [62], and vinformide, 200 deoxy-150 ,200 -epoxy-200 -epivincristine 30 [63] (Figure 8.6) were more effective against lymphosarcoma and leukemia. However, neuromuscular and cardiac toxicity hindered their further clinical development. Vinflunine 24, R0 ¼ R00 ¼ F (Figure 8.5), 190 ,190 -difluoro-vinorelbine, exerted the highest level of activity against the numerous in vivo antitumor models compared to presently used vinca dimer alkaloids [64]. Clinically significant activity has been seen in phase II studies, mainly in the treatment of transitional cell carcinoma of the urothelial tract, NSCLC, and breast carcinoma [65].
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
198
Figure 8.6 Structures of vinblastine derivatives.
8.3.2 Synthesis of Dimeric Vinca Alkaloid Derivatives
The occurrence of vinblastine 11 in the plant is rare, and the scarcity of vincristine 12 is as low as 0.03 g/kg dried material. The biological precursors catharanthine and vindoline are more frequent alkaloidal components of Catharanthus roseus. The Potier synthesis of anhydrovinblastine 25 from pentacyclic ibogan and aspidosperman halves follows a biomimetic pathway [66]. When the C16–C-21 skeletal fragmentation of the ibogan skeleton induced by the Polonovsky–Potier reaction occurs conjointly with the attack of the nucleophile vindoline, the resulting 25 bis-indole alkaloid has the natural (160 S) configuration. A considerable amount of effort has been directed toward other methods both to couple the two parts of the molecule and transform 25 to oxygenated derivatives 11 and 12 [67, 68]. The oxidation of vinblastine 11 to the less accessible vincristine 12 was established by chromic acid or sodium dichromate [69, 70]. Ammonolysis or
8.3 Antitumor Dimeric Vinca Alkaloids
hydrazinolysis of vinblastine 11 produces vindesine 18 [54]. A second Polonovsky– Potierreactionofanhydrovinblastine 25furnished C0 ring-contractednavelbine 24[71]. 8.3.3 Pharmacological Properties of Dimeric Vinca Alkaloid Derivatives 8.3.3.1 Mechanism of Action Formation of the mitotic spindle is an essential step for accurate chromosome segregation. During mitosis, the microtubules search and capture chromosomes by establishing stable connections with the kinetochore, a macromolecular complex that is assembled onto the centromere at the onset of mitosis. The microtubules are constructed by the controlled polymerization of monomeric tubulin proteins [72]. The dimeric vinca alkaloids interfere with polymerization, thus preventing cell division by preventing the formation of new microtubules. Inhibition of microtubule polymerization perturbs spindle formation, interferes with chromosome alignment, and invariably blocks cell regulators from progressing through mitosis, blocking cells in M-phase. Cancer cells proliferate more rapidly than normal cells, so disruption of cell division affects more widely the growth of the diseased cells. The parent compound vinblastine binds to the b-subunit of tubulin in its dimer in a one-to-one complex, thus preventing polymerization into microtubules. The preformed tubulin depolymerizes and the complex with vinblastine crystallizes [73]. The C-200 position appears to be particularly critical for interaction with tubulin [74]. In a study comparing the actions of vinblastine 11, vincristine 12, and vinorelbine 24 on the axonal and mitotic microtubules in mouse embryos, all three drugs produced depolymerization of mytotic interpolar microtubules and cell metaphase block at the same concentration, but only 24 gave complete depolymerization. In contrast, 24 was less active on axonal microtubules than 11 or 12 [75]. Detailed investigations evaluating microtubule dynamics have shown that vinorelbine 24, together with its difluoro derivative vinflunine, has a mode of action qualitatively different from 11 [76]. 8.3.3.2 Clinical Pharmacology Pharmacokinetics The pharmacokinetic profiles of the dimeric vinca alkaloids are remarkably similar both across species and among individual compounds; they are characterized by high plasma clearance, a large volume of distribution, and a long terminal half-life, with very limited urinary excretion [77]. A triphasic clearance curve has been observed after intravenous administration to humans with a very short distribution phase and a prolonged terminal phase with half-lives in the range 24–70 h. Urinary excretion in unchanged form is about 15%, the bulk of excretion occurs via the liver and bile after metabolism [78]. The metabolites are excreted as conjugates. Oxidative degradation by action of myeloperoxidase occurs by cleavage between C-200 and C-210 and is facilitated by the presence of a C-200 hydroxyl moiety [79]. In comparison to vinblastine or vincristine, vinorelbine has a higher clearance and a larger volume of distribution [80].
j199
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
200
Adverse Effects Microtubules are also major components of other cellular structures, as cilia and flagella, which are present especially in the axons of nerve cells. The inhibition of microtubule dynamics disrupts crucial physiological processes such as vesicle transport and cell shape, interphase, and axonal transport. The adverse peripheral neurological effects, such as neuropathies, as well as cardiotoxic and neuromuscular actions, can be attributed to undesirable impacts of dimeric vinca drugs on microtubules [81]. The most notable toxic side effects of vinblastine 11 are myelosuppression and tissue necrosis. Vincristine 12 causes severe neurotoxicity and tissue necrosis. Neuromuscular actions can be observed to a lesser extent for vindesine 23 and minimal for vinorelbine 24 [82]. Only mild neurotoxicity and myelosuppression occur with vinorelbine, where the most notable side effects appear to be granulocytopenia and neutropenia. Other side effects of dimeric vinca drugs are common to antitumor agents (alopecia, ulceration, nausea, and diarrhea). Resistance Acquisition of drug-resistance is a major problem for cancer patients undergoing chemotherapy. Resistance to the vinca alkaloids develops rapidly in vitro in the presence of agents. Members of the human multidrug resistance-associated protein (MRP) family are membrane proteins able to transport a wide range of anticancer drugs out of the cells. Their presence in many tumors makes them prime suspects in unexplained cases of drug resistance. MRPs are organic anion transporters, transporting anionic drugs and neutral drugs conjugated to acidic ligands, such as glutathione, glucuronate, or sulfate [83]. The permeability glycoprotein (P-gp) is an ATP binding cassette (ABC) transporter protein. The multidrug resistanceassociated proteins belong to the ABC family. In vitro, the MRP/ABC transporters can collectively confer resistance to natural product anticancer drugs and their conjugated metabolites [84]. The cross-resistance includes not only the dimeric vinca alkaloids but also, for varying degrees, other bulky natural antitumor agents such as taxanes, anthracyclines, or epipodophyllotoxins [85]. Clinical Results with Dimeric Vinca Alkaloid Derivatives Vindesine New perspectives of combined therapies with vindesine 18 as component of antitumor cocktails in treating NSCLC were examined. The concurrent and sequential treatment with radiotherapy and chemotherapy consisting of cisplatin, vindesine, and mitomycin was compared in a phase III study, performed on 320 patients, suffering from unresectable stage III NSCLC. The concurrent approach yielded a significantly increased response rate and enhanced median survival duration [86]. The neoadjuvant (preoperative) chemotherapy can significantly improve long-term survival in stage III NSCLC [87]. The results of a randomized trial with a total of 132 patients suggested the survival advantage of the three-drug regimen of vindesine, ifosfamide, and cisplatin over the two-drug combination of cisplatin and vindesine for inoperable NSCLC [88]. Vinorelbine In a large multicenter European trial for NSCLC patients, single-agent vinorelbine was compared with vinorelbine/cisplatine and vindesine/cisplatine. With regard to response rate and median survival, the vinorelbine/cisplatin
8.4 Antitumor Camptothecin Derivatives
combination was superior to the other treatment regimen. Single-agent vinorelbine was equivalent to the European standard of cisplatin/vindesine and was much less toxic [89]. Neoadjuvant vinorelbine/cisplatin therapy has improved the survival of NSCLC patients with resectable stage IIIa disease compared to surgery alone [90]. In a phase II study, performed with 50 NSCLC patients in stage IIIB/IV, a threedrug combination of gemcitabine, ifosfamide, and vinorelbine showed promising activity against NSCLC [91]. In a randomized phase III trial, two-drug vinorelbine/doxorubicin therapy gave an overall response rate of 74% in the treatment of advanced breast carcinoma [92]. Phase II studies with vinorelbine plus epirubicin [93], vinorelbine plus epirubicin and paclitaxel [94], or vinorelbine plus docetaxel [95] have yielded pathological complete remission rates of 4–20% in women with stage II/III breast cancer.
8.4 Antitumor Camptothecin Derivatives 8.4.1 Medicinal Chemistry of Camptothecin Derivatives
Camptothecin 13 was isolated from the bark of Camptotheca acuminata (Nyssaceae) by Wall and Wani in 1966 [96]. It was also found in Ervatamia heyneana (Apocynaceae) and Ophiorrhiza pumila (Rubiaceae) [97]. Camptothecin and congeners such as 10-hydroxycamptothecin 31 [98] were found potent cytotoxic agents against a wide range of experimental mammalian tumor systems. CPT itself is very insoluble; the early clinical trials were performed in the form of a water-soluble sodium salt. The trials were, however, suspended [99, 100] due to the severe toxic events. Only later was it realized that the E-ring opened form is about one-tenth as active as 13 [101]. Renewed interest occurred 15 years later, with the discovery of the unique mode of action of CPT by inhibiting nuclear mammalian topoisomerase I. Thousands of CPT derivatives have been subsequently prepared with the goal of finding a clinically useful anticancer drug, to overcome the drawbacks of CPT, notably its poor water solubility, ease of hydrolytic lactone opening to the undesirable acid form, and high serum protein binding. These analogues were obtained by the modification of the lead molecule and by total synthesis [102]. Two molecules, topotecan (Hycamtin, 32) and irinotecan (Camptosar, CPT-11, 33), gained clinical approval. Both are derivatives of 10-hydroxy-CPT 31, more stable, much more soluble in water, and less serum protein-bound than CPT (Figure 8.7). Topotecan (TPT, 32), (S)-9-dimethylaminomethyl-10-hydroxy-CPT is produced from the parent compound [103]. Compared to 13, TPT is twice less active against L1210 leukemia cells in vitro but more active in treating leukemic mice bearing L1210 and P388 leukemias. TPT 32 is also active against a number of experimental solid tumors. In vivo, it has demonstrated superior activity against Lewis lung cancer, and melanoma B16 compared to CPT [104]. TPT was launched by SmithKline Beecham for small-cell lung cancer (SCLC) treatment in 1998 in Switzerland.
j201
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
202
Structural formula
9
HO 10 11
7
8
A
B
12
13 N 1
O
5
6
Name
4
3
31
14
H3C
Launched (Company)
17
16
N 22 C D 2
Synonymes
E O 20
10-Hydroxycamptothecin
21
O
15
OH 19
18
N(CH3)2
O
HO
N N
RO
OH
H3C
CH3
O N
O
N
O OH
H3C
R=
C O
34,
R=
1998 (SmithKline Beecham)
O 32
33,
9-DimethylaminoethylTopotecan 10-hydroxycamptothecin Hycamtin
O
H
N
N
7-Ethyl-10-[4-(1-piperidyl)1-piperidyl]carbonyloxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Irinotecan Topotecin CP-11
1994 (Daiichi Yakult Honsha)
SN-38
Figure 8.7 Structures of camptothecin derivatives.
TPT 32 has gained approval by the FDA for treatment SCLC and ovarian cancers (OC) [105]. Irinotecan (Camptosar, CPT-11 33), 7-ethyl-10-[4-(1-piperidyl)-1-piperidyl] carbonyloxycamptothecin [106] is a prodrug; its active metabolite (SN-38, 34) is 7-ethyl-10hydroxycamptothecin (Figure 8.5). Irinotecan was launched in Japan in 1994 by Daiichi and Yakult Honsha for treatment of lung, cervix, and ovarian cancers. In France, 33 was launched by Rhône-Poulenc Rorer in 1996 for the treatment of advanced colorectal cancer (CRC) refractory to standard chemotherapy. Irinotecan was approved by the FDA in 2000 as first-line treatment for advanced CRC [107]. 8.4.1.1 Structure–Activity Relationships The main structural features influencing the activity of CPT derivatives are 20(S)hydroxyl, pyridone moiety (D-ring), lactone moiety (E-ring), and planarity of the
8.4 Antitumor Camptothecin Derivatives
pentacyclic ring system. The C–D–E rings cannot be altered [97, 108]. The modifications of quinoline ring (9, 10, and 11-position of the A-ring and 7-position of the B-ring) enhance the potency of the CPT derivatives in both in vivo and in vitro studies [97, 109]. Monosubstitution at 9, 10, or 11 positions by NH2 or OH group increases the antitumor activity, while the 12-substitution greatly reduces it. Disubstitutions at 10 and 11 are unpreferable, exceptions are the 10,11-methylenedioxy and 10,11-ethylenedioxy derivatives [110]. Substitution at the C-10 position with a hydroxyl group contributes to the increased activity of TPT 32 and SN-38 34. The 11-fluoro or 11-cyano substitution increases the DNA topoisomerase inhibition [111]. Substitution at the 7-position of the B-ring resulted in an increase in water solubility [112]. The 7-ethyl position is also important for stabilizing the CPT-topoisomerase I-DNA adduct [113]. The four oxygen atoms of the D/E ring are involved in hydrogen bonding with the topo I–DNA complex. The only favorable alteration of this part of the molecule was the replacement of the a-hydroxylactone moiety with b-hydroxylactone to obtain homoCPT derivatives [114]. Several second-generation CPT derivatives are in various stages of clinical trials [115]. Rubitecan 35, a 9-nitro derivative [102], was tested for the treatment of locally advanced or metastatic pancreatic cancer [116]. 35 is metabolically converted in vivo into the equally or more potent 9-amino derivative IDEC-132 36 [117]. Lurtotecan 37, a water-soluble 7(N-methyl piperidinyl) methyl)-10,11-ethylenedioxy analogue [110] was three times more potent in vivo, compared to TPT. It has been tested for advanced or metastatic solid tumors in liposomal formulation [118]. Exatecan 38, a 10-methyl-11-fluoro derivative with an additional amino-substituted hexane ring fused on 7, 8, 9 position [119], was tested for NSCLC, CRC, and hepatocellular cancers [120]. A 7(N-methylpiperidinyl) methyl)-10-methyl-11-chloro homoCPT derivative, BN 80927 39 [121], inhibits both topoisomerase I- and topoisomerase II-mediated DNA relaxation and shows pronounced cytotoxicity against human tumor cell lines [122] (Figure 8.8). A recently published excellent SAR/QSAR study on CPT analogues helps in understanding the requirements of physicochemical properties of the substituents in key locations as well as molecules as a whole [123]. The analysis of QSAR models reveals the two most important descriptors, the hydrophobicity and molecular refractivity; the optimal log P and MR values are given. 8.4.2 Synthesis of Camptothecin Derivatives
The clinically used CPT derivatives have been obtained semisynthetically. The reduction of CPT 13, followed by oxidative acylation and hydrolysis, led to 10hydroxy-CPT 31, which was transformed to TPT 32 by Mannich reaction [102]. The reaction of CPT with propionaldehyde gives 7-ethyl-CPT. H2O2 oxidation to N-oxide and then isomerization with UV light affords 7-ethyl-10-hydroxy-CPT 40. Treatment with pyperidinopiperidine carbamoyl chloride led to CPT-11 33 [104]. Numerous convergent synthetic strategies were reported utilizing the possibilities of versatile approach of CPT [101, 124]. Comins and Nolans short asymmetric synthesis involves the formation of the C-ring by connecting the A/B- and D/E-
j203
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
204
R4
R3 R2 10 11
R1
8 7
9
5
13
N
4
16
N
B
A 12
O 6
22
E O 21
17
20 2
3
14
1
O
15
H3C
OH 19
18
R1
R2
R3
R4
E-ring
Compound
H
H
NO2
H
normal
35 Rubitecan
H
H
NH2
H
normal
36 IDEC 132
O
O
H
normal
37 Lurtotecan
F
CH 3
normal
38 Exatecan
Cl
CH 3
20-homo
39 BN 80927
CH2 N
N CH3
NH2 H
H
Figure 8.8 Selected A, B, and E ring-modified camptothecin derivatives.
fragments via N-alkylation and ring closure in an intramolecular Heck reaction [125]. Starting from commercially available materials, this method is suitable for industrial production of CPT. 8.4.3 Pharmacological Properties of Camptothecin Derivatives 8.4.3.1 Mechanism of Action The primary cellular target of CPTs is DNA topoisomerase I (topo I). The topoisomerases play an essential role in the key cellular processes of replication and transcription. DNA topoisomerases are classified into type I and type II subclasses. Type I topoisomerases change the topological state of DNA via transient enzymelinked single-strand breaks. In contrast, type II topoisomerases catalyze the strand passing reaction by transiently breaking both strands of duplex DNA [126]. The primary function of topo I is to remove both excessive positive supercoils and negative supercoils arising during DNA replication and transcription. Topo I removes the supercoils by introducing transient breaks into the DNA helix. In this reaction, DNA topo I binds noncovalently to superhelical DNA and cleaves one of the DNA strands via a nucleophilic attack of the phosphodiester bond in DNA, forming
8.4 Antitumor Camptothecin Derivatives
a covalent linkage between a tyrosine group at the active site of topo I and a 30 phosphate group along the DNA backbone [127]. The covalent intermediate is reversed when the 50 -OH of the broken strand reattacks the phosphotyrosine intermediate. Topo I dissociates from the DNA molecule and undergoes another catalytic cycle, the replication fork serves as a template for the synthesis of a new strand of DNA [128]. The rate of religation is much faster than the rate of cleavage, and the concentration of covalent binary complex remains low. CPTs bind to the normally transient cleavable DNA–topo I complex and form an enzyme–drug–DNA ternary cleavable complex. As a consequence of the formation of a cleavable complex, both the initial cleavage reaction and the religation steps are inhibited, causing collision of the replication fork, double-strand DNA breakage, and conversion of reversible cleavable complex into an irreversible complex [129]. One or more of these events generate other cellular responses that can lead to the cell cycle arrest in the G2 and S phase and to cell death [130]. Several structural models have been suggested for the interaction of CPTs with the covalent binary complex [125]. The computation models used the reported crystal structure of the binary human topo I–DNA cleavable complex [125] and made much account of hydrogen bonding. Recently, X-ray crystal structures of the ternary complexes of TPT and CPT bound to human topo I covalently joined to a DNA duplex were reported [131, 132]. The crystal structures reveal that CPTs intercalate at the site of DNA cleavage and mimic a DNA base pair. Comparing the two ternary complexes, there is a slight twist in the orientation of CPT relative to TPT. The difference can be attributed to the 7-C substituent of TPT. The increased activity of 7-, 9-, and 10-substituted CPTderivatives is also in agreement with the steric position of CPTs in the crystalline ternary complex. 8.4.3.2 Clinical Pharmacology Pharmacokinetics The different pharmacokinetics of the two clinically used CPT derivatives can be explained by their different structures and by the fact that CPT11 33, unlike TPT 32, acts as a prodrug. The terminal half-life of TPT is 3 h, while that of CPT-11 is 6.3 h, and for its active metabolite SN-38 34 11.5 h [133]. TPT is subject to alteration by esterases and the products are glucuronidated or oxidized by CYP3A4 [134]. The conversion of CPT-11 into SN-38 is accompanied with glucuronidation in the liver. The glucuronide is excreted into the bile and further deconjugated in the intestinal microflora to SN-38. CPT-11 can also undergo CYP3A4-mediated oxidative process to form a metabolite in which the first piperazine ring is oxidatively opened to an acid analogue [135]. Biliary clearance is the major route of excretion for SN-38 and CPT-11, while TPT is mainly excreted in urine. Adverse Effects The longer exposure time and higher cellular accumulation of CPT11 and its active metabolite SN-38 explain the gastrointestinal toxicities, the development of diarrhea, which is troublesome and dose limiting [136]. Myelosuppression is also a serious problem with CPTs. For TPT, neutropenia was the principal
j205
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
206
dose-limiting toxicity, gastrointestinal adverse effects such as diarrhea, nausea, and vomiting were successfully controlled with standard supportive care measures [137]. Resistance Resistance to CPTs has been attributed to enhanced drug efflux by ABC transporters, as breast cancer resistance protein BCRP/MXR/ABCG2 [138]. Another possible mechanism of resistance is the alteration in the structure of topo I. Crystal structures of two CPT-resistant forms of human topo I in ternary complexes with DNA and TPT were reported [139]. The alteration of Asn722 to Ser leads to elimination of a water-mediated contact between the enzyme and the TPT. A clear relationship between the carboxylesterase level and the chemosensitivity of human small-cell and non-small-cell lung cancer cell lines has been demonstrated in vitro where CPT-11 resistance was encountered in cell lines with low carboxylesterase expression. Furthermore, as SN-38 34 is inactivated to SN-38 glucuronate by glucuronidation by UDP-glucuronosyltransferase 1A1 (UGT 1A1), overexpression of UGT at the protein and mRNA levels was found to account for SN-38 resistance in a human lung cancer cell line. In addition, ABC transmembrane transporters such as P-gp and MRP also mediate resistance to CPTs and play an important role in the efflux and active excretion of CPT-11 [140]. Clinical Results with CPT Derivatives Vinca Dimer Derivatives and CPTs A critical phase III randomized trial comparing CPT-11, either alone or in combination with cisplatin, to vindesine/cisplatin demonstrated superior survival for stage IV NSCLC patients receiving irinotecan [141]. In a phase III trial, a total of 398 patients with previously untreated NSCLC were randomized to receive cisplatin þ CPT-11, cisplatin þ vindesine, or cisplatin alone. CPT-11 monotherapy is not inferior to vindesine–cisplatin in terms of survival, while the CPT-11-containing regimen is one of the most efficacious and well tolerated in the treatment of advanced NSCLC [142]. The cytotoxic interactions between vinorelbine and SN-38 on human NSCLC lines were studied in vitro. On simultaneous exposure, additive effects were observed, while sequential administrations generated antagonistic effects [143]. Vinorelbine strongly inhibits CPT-11 catabolism by CYP3A4 at clinically relevant concentrations [144]. Irinotecan (CPT-11) The combination of irinotecan/5-fluorouracil (5-FU)/leucovorin (LV) is superior to 5-FU/LV alone as first-line therapy for patients with metastatic CRC, as emerged from two prospective phase III randomized, controlled, multicenter, and multinational clinical trials [145]. A phase III study in extensive-disease SCLC compared irinotecan/cisplatin and standard etoposide/cisplatin regimens and demonstrated a significant difference in survival in the irinotecan-containing regimen [146]. A large North American phase III trial failed to confirm the abovementioned survival benefit observed with irinotecan in Japanese patients [147]. Weekly combined administration of irinotecan and cisplatin achieved a promising overall response rate, median time to tumor progression, and median survival in patients with stage IIIB/IV NSCLC [148].
References
Topotecan In an open, multicenter, randomized, and stratified phase III study in 226 advanced epithelial OC patients who had failed prior platinum-based therapy, TPT compared to paclitaxel showed a better response rate, a longer duration response, and a significant difference in median time to progression [149]. In phase III studies, TPT was shown to be equivalent in efficacy to both paclitaxel and liposomal doxorubicin as second-line therapy in patients with relapsed OC. Furthermore, non-cross-resistance between TPT and paclitaxel was demonstrated in a third-line phase III crossover study. Hematological toxicities are usually short lived, noncumulative, and manageable with dose modifications, while nonhematologic toxicities are usually mild to moderate in severity [150]. A phase II study of TPT combined with gemcitabine in the treatment of relapsed OC patients demonstrated favorable toxicity profile and efficacy of this novel combination regimen [151].
8.5 Summary and Conclusions
A wide range of pharmacologically active compounds can be found among the monoterpenoid indole alkaloids. Relatively few of them are used in clinical practice, and only three have proved as lead molecules for ABDD. To date, seven monoterpenoid indole analogues have gained clinical approval in different countries. Typically, these new drugs are direct natural product analogues. Their common structural feature is the retained natural configuration, 20S,21S for vincamine analogues, 160 S,140 S for vinblastine analogues, and 20S for camptothecins. Three of them are analogues of vincamine and used in several countries for the treatment of cerebral insufficiencies. Analogues of vinca dimer alkaloids and the modified monoterpenoid indole camptothecin are of greater importance. The spectrum of drugs, origined from ABDD of the two anticancer monoterpenoid alkaloid groups, covers the most fatal tumor species, and their share in the US$ 10 billion cytotoxic market can be estimated at more than 20%. New information obtained from studies on the molecular modes of action and the results of SAR helped to gain a better understanding of important biological processes such as cell cycle or ion transport in neurons. The discovery of analogues of the Cataranthus and Camptotheca family will continue. With regard to the next generation of cytotoxic monoterpenoid indole derivatives, members of which are in various stages of clinical trials, the future of anticancer monoterpenoid indole research is open.
References 1 Herbert, R.B. (1994) The biosynthesis of
terpenoid indole alkaloids, in The Monoterpenoid Indole Alkaloids, Supplement to Indoles, Part 4 (ed. J.E. Saxton), Wiley-InterScience, Chichester, pp. 1–13.
2 Le Men, J. and Taylor, W.I. (1965)
Uniform numbering system for indole alkaloids. Experientia, 21, 508–510. rincz, C., Szasz, K., and Kisfaludy, L. 3 Lo (1976) The synthesis of ethyl
j207
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
208
4
5
6
7
8
9
10
11
12
apovincaminate. Arzneim.-Forsch., 26, 1905–1908. (1975) Levorotatory, dextrorotatory and racemic eburnamonines, Fr. Patent 2 268 016, Omnium Chimique S.A. Lacroix, P., Quiniou, M.J., Linee, P., and Le Polles, J.B. (1979) Cerebral metabolic and hemodynamic activities of 1eburnamonine in the anesthetized dog. A comparison with vincamine. Arzneim.Forsch., 29, 1094–1101. De Noble, V.J., Repetti, S.J., Gelpke, L.W., Wood, L.M., and Keim, K.L. (1986) Vinpocetine: nootropic effects of a stepthrough passive-avoidance response in rats. Pharmacol. Biochem. Behav., 24, 1123–1128. King, G.A. (1987) Protective effects of vinpocetine and structurally related drugs on the lethal consequences of hypoxia in mice. Arch. Int. Pharmacodyn. Ther., 286, 299–307. Kushiku, K., Katsuragi, T., Mori, R., Morishita, H., and Furukawa, T. (1985) Cardiovascular effects of brovincamine and possible mechanisms. Clin. Exp. Pharmacol. Physiol., 12, 121–130. Tonomoto, M., Hatta, S., Nagata, M., Takahashi, Y., and Tamai, A. (1998) Blood flow changes in optic nerve head of albino rabbits following intravenous administration of brovincamine fumarate. Yonago Acta Med., 41, 89–97. Czibula, L., Nemes, A., Visky, G., Farkas, M., Szombathelyi, Z., Karpati, E., Sohar, P., Kessel, M., and Kreidl, J. (1993) Syntheses and cardiovascular activity of stereoisomers and derivatives of eburnane alkaloids. Liebigs. Ann. Chem., 221–229. Szombathelyi, Z., Karpati, E., Kalaus, G., Szabó, L., and Szantay, C. (1991) Vasodilator and angioprotective activity of 1-ethyl-1-hydroxyalkyloctahydroindolo[2,3-a]quinolizine derivatives. Arzneim.-Forsch., 41, 621–625. Barzaghi, F., Dragonetti, M., Formento, M.L., Gueniau, C., Nencioni, A., and Mantegazza, P. (1986) A comparison of some of the pharmacological properties of vindeburnol with those of vincamine, vinburnine, dihydroergotoxine and
13
14
15
16 17
18
19
20
21
nicergoline. Arznneim.-Forsch., 36, 1442–1448. Kawasima, Y., Ikemoto, T., Horiguchi, A., Hayashi, M., Matsumoto, K., Kawarasaki, K., Yamazaki, R., Okuyama, R., and Hatayama, K. (1993) Synthesis and pharmacological evaluation of (nitrooxy) alkyl apovincaminate. J. Med. Chem., 36, 815–819. Nemes, A., Czibula, L., Szantay, C., Jr., Gere, A., Laszy, J., Gyertyan, I., Szombathelyi, Z., and Szantay, C. (2008) Synthesis and evaluation of 2hydroxyethyl-trans-apovincaminate derivatives as antioxidant and cognitive enhancer agents. J. Med. Chem., 51, 479–486. Hugel, G., Massiot, G., Levy, J., and Le Men, J. (1981) Methylene-indolines, indolenines et indoleniums – XIII: Lhydroxy-16-dehydro-1 vincadifformine, intermediaire dans le rearrangement biomimetique de la vincadifformine en vincamine. Tetrahedron, 37, 1369–1375. Bernardelli, G. (1986) Vincamine, Ger. Offen. 3606665, Arysearch Arylan AG. Szantay, C. and Nemes, A. (1994) The eburnamine-vincamine group, in The Monoterpenoid Indole Alkaloids, Supplement to Indoles, Part 4 (ed. J.E. Saxton), Wiley-InterScience, Chichester, pp. 437–486. Nemes, A., Czibula, L., Visky, G., Farkas, M., and Kreidl, J. (1991) Alternative routes to vincamine. Heterocycles, 32, 2329–2338. Nemes, A., Kreidl, J., Czibula, L., Nógradi, K., Farkas, M., Szantay, C., Jr., Tarkanyi, G., Juhasz, I., Kalman, A., and Parkany, L. (2000) Synthesis of pentacyclic ring systems, indolo[2,3-a] [1,2]oxazino[5,6-i]quinolizine and indolo [2,3-a] pyrano[3,2-i]quinolizine, and their application for the synthesis of eburnamine-vincamine alkaloids. Heterocycles, 53, 1697–1711. Wotchal, B.E.and Tschapidze, G.E. (1965) Das Verhalten der peripheren Gef€asse bei der hypertoniekrankheit. Ther. Hung., 13, 3–6. Schlittler, E.and Bein, H.J. (1967) Antihypertensive Agents (ed. E. Schlittler), Academic Press, New York, pp. 191–221.
References 22 Hagiwara, M., Endo, T., and Hidaka, H.
32 Zelles, T., Franklin, L., Koncz, I., Lendvai,
(1984) Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol., 33, 453–457. Beavo, J.A. (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 75, 725–748. Hayakawa, M. (1992) Comparative efficacy of vinpocetine, pentoxyfilline and nicergoline on red blood cell deformability. Arzneim.-Forsch., 42, 108–111. , S.L. (1995) Molnar, P.and Erdo Vinpocetine is as potent as phentoin to block voltage-gated Na þ channels in rat cortical neurons. Eur. J. Pharmacol., 273, 303–306. Tretter, L.and Adam-Vizi, V. (1998) The neuroprotective drug vinpocetine prevents veratridine-induced [Na þ ]i and [Ca2 þ ]i rise in synaptosomes. Neuroreport, 9, 1849–1853. Sitges, M.and Nekrassov, V. (1999) Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation. Neurochem. Res., 24, 1585–1591. Chinopoulos, C., Tretter, L., Rozsa, A., and Adam-Vizi, V. (2000) Exacerbated responses to oxidative stress by an Na( þ ) load in isolated nerve terminals. The role of ATP depletion and rise of [Ca(2 þ )]i. J. Neurosci., 20, 2094–2103. B€ on€ ock, P., Gulyas, B., Adam-Vizi, V., Nemes, A., Karpati, E., Kiss, B., Kapas, M., Szantay, C., Koncz, I., Zelles, T., and Vas, Á. (2000) Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull., 53, 245–254. Tanaka, Y., Morimoto, K., Ishii, K., and Nakayama, K. (1994) Calcium antagonistic vasodilator mechanisms of brovincamine fumarate studied in canine cerebral artery. Arzneim.-Forsch., 44, 803–808. Kaneko, S., Takahashi, H., and Satoh, M. (1990) The use of Xenopus oocytes to evaluate drugs affecting brain Ca2 þ channels: effect of bifemelane and several nootropic agents. Eur. J. Pharmacol., 189, 51–58.
B., and Zsilla, G. (2001) The nootropic drug vinpocetine inhibits veratridine induced [Ca2 þ ]i increase in rat hippocampal CA1 pyramidal cells. Neurochem. Res., 26, 1095–1100. Miyamoto, M., Murphy, T.H., Schnaar, R.L., and Coyle, J.T. (1989) Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J. Pharmacol. Exp. Ther., 250, 1132–1140. , S.L., Cai, N.S., Wolff, J.R., and Kiss, Erdo B. (1990) Vinpocetine protects against excitotoxic cell death in primary cultures of rat cerebral cortex. Eur. J. Pharmacol., 187, 551–553. Vereczkey, L. (1985) Pharmacokinetics and metabolism of vincamine and related compounds. Eur. J. Drug Metab. Pharmacokinet., 10, 89–103. Mayo, B.C., Biggs, S.R., Hawkins, D.R., Chasseaud, L.F., Darragh, A., and Leaf, F.C. (1985) The metabolic fate of 11bromo[15 3 H]vincamine in man. Eur. J. Drug Metab. Pharmacokinet., 10, 189–196. Sado, P.A., Gibassier, D., LeVerge, R., Acerbi, D., and Schiantelli, P. (1985) Biodisponsibilite relative de la vinburnine chez lhomme. J. Pharm. Belg., 40, 308–322. Bargheon, J., Durocher, A.M., and Lagrannge, M. (1984) Treatment of cerebrovascular deficiencies. Therapeutic evaluation from 129 cases using the double-blind method against placebo. Sem. Hop., 60, 169–174. Jansen, W., OConnolly, M., Lehmann, E., and Mayer, M. (1986) Experimental clinical studies on the effect of eburnamonine in cerebrovascular disorders. Pharmacopsychiatry, 19, 389–394. Domini, L., Acciavatti, A., Caligani, C., Saletti, M., De Franco, V., Pecchi, S., Auteri, A., and Di Perri, T. (1990) The effect of the acute administration of vinburnine on blood rheology, oxygen transport and regional circulation under normal conditions and in hypoxemia. In vivo research. Recent Prog. Med., 81, 716–723.
23
24
25
26
27
28
29
30
31
33
34
35
36
37
38
39
40
j209
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
210
41 Manconi, E., Binaghi, E., and Pitzus, F.
42
43
44
45
46
47
48
(1986) A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr. Ther. Res., 40, 702–709. Ballesteri, R., Fontana, L., and Astengo, F. (1987) A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with cronic vascular senile cerebral dysfuntion. J. Am. Geriatr. Soc., 35, 425–430. Blaha, L., Erzigkeit, H., Adamczyk, A., and Freytag, S. (1989) Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Hum. Psychopharmacol., 4, 103–111. Szakall, S., Boros, I., Balkay, L., Emri, M., Fekete, I., Kerenyi, L., Lehel, S., Marian, T., Molnar, T., Varga, J., Galuska, L., Trón, L., Bereczky, D., Csiba, L., and Gulyas, B. (1998) Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J. Neuroimaging, 8, 197–204. Vas, Á., Gulyas, B., Szabó, Z., B€on€oczk, P., Csiba, L., Kiss, B., Karpati, E., Panczel, G., and Nagy, Z. (2002) Clinical and nonclinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. J. Neurol. Sci., 203–204, 259–262. Yamaguchi, S., Fukuyama, H., Yonekura, K., and Konishi, J. (1992) Effect of brovincamine on cerebral circulation and metabolism in internal carotid artery occlusion examined by positron emission tomography. Eur. Neurol., 32, 314–317. Koseki, N., Araie, M., Yamagami, J., Shirato, S., and Yamamoto, S. (1999) Effects of oral brovincamine on visual field damage in patients with normal tension glaucoma with low-normal intraocular pressure. J. Glaucoma, 8, 117–123. da Rocha, A.B., Lopes, R.M., and Schwartsmann, G. (2001) Natural products in anticancer therapy. Curr. Opin. Pharmacol., 1, 364–369.
49 Noble, R.L., Beer, C.T., and Cutts, J.H.
50
51
52
53
54
55 56 57
58
59
(1958) Further biological activities of vincaleukoblastine – an alkaloid isolated from Vinca rosea (L.). Biochem. Pharmacol., 1, 347–348. Johnson, I.S., Wright, H.F., Svoboda, G.H., and Vlantis, J. (1960) Antitumor principles derived from Vinca rosea Linn. I. Cancer Res., 20, 1016–1022. Svoboda, G.H., Johnson, I.S., Gorman, M., and Neuss, N. (1962) Current status of research on the alkaloids of Vinca rosea. J. Pharm. Sci., 51, 707–720. Sartorelli, A.C.and Creasey, W.A. (1969) Cancer chemotherapy. Annu. Rev. Pharmacol., 9, 51–72. Noble, R.L. (1990) The discovery of the vinca alkaloids – chemotherapeutic agents against cancer. Biochem. Cell. Biol., 68, 1344–1351. Barnett, C.J., Cullinan, G.J., Gerzon, K., Hoying, R.C., Jones, W.E., Newlon, W.M., Poore, G.A., Robison, R.L., and Sweeney, J.M. (1978) Structure–activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate. J. Med. Chem., 21, 88–96. Owen, R.T. (1980) Vindesine. Med. Actual/Drugs Today, 16, 196–201. Prous, J.R. (1990) The years new drugs. Drug News Perspect., 3, 19–29. Conrad, R.A., Cullinan, G.J., Gerzon, K., and Poore, G.A. (1979) Structure–activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates. J. Med. Chem., 22, 391–400. Johnson, I.S., Hargrove, W.W., Harris, P.N., Wright, H.F., and Boder, G.B. (1966) Preclinical studies with vinglycinate, one of a series of chemically derived analogs of vinblastine. Cancer Res., 26, 2431–2436. Bhushana Rao, K.S.P., Collard, M.P.M., Dejonghe, J.P., Atassi, G., Hannart, J.A., and Trouet, A. (1985) Vinblastin-23-oyl amino acid derivatives: chemistry, physico-chemical data, toxicity and antitumor activities against P338 and L1210 leukemias. J. Med. Chem., 28, 1079–1088.
References 60 Miller, J.C.and Gutowski, G.E. (1978).
61
62
63
64
65
66
67
68
69
70 71
Vinca alkaloid derivatives, Ger. Offen. 2753791, Eli Lilly and Co. Miller, J.C., Gutowski, G.E., Poore, G.A., and Boder, G.B. (1977) Alkaloids of Vinca rosea, L. (Catharanthus roseus G. Don). 38. 40 -Dehydrated derivatives. J. Med. Chem., 20, 409–413. Johnson, I.S., Cullinan, G.J., Boder, G.B., Grindey, C.B., and Laguzza, B.C. (1987) Structural modification of the vinca alkaloids. Cancer Treat. Rev., 14, 407–410. Conrad, R.A. (1983). Method of preparing vincristine, US Patent 4,375,432, Ely Lilli and Co. Hill, B.T., Fiebig, H.H., Waud, W.R., Poupon, M.-F., Colpaert, F., and Kruczynsky, A. (1999) Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur. J. Cancer, 35, 512–520. Bennouna, J., Delard, J.-P., Campone, M., and Nguyen, L. (2008) Vinflunine: a new microtubule inhibitor agent. Clin. Cancer Res., 14, 1625–1632. Langlois, N., Gueritte, F., Langlois, Y., and Potier, P. (1976) Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloids. J. Am. Chem. Soc., 98, 7017–7024. Brossi, A.and Suffness, M.(eds) (1990) Antitumor bisindole alkaloids from Catharanthus roseus (L.), in The Alkaloids, vol. 37, Academic Press, Inc., San Diego. Sapi, J.and Massiot, G. (1994) Bisindole alkaloids, in The Monoterpenoid Indole Alkaloids, Supplement to Indoles, Part 4 (ed J.E. Saxton), Wiley-InterScience, Chichester, pp. 523–646. Jovanovics, K., Szasz, K., Fekete G., Bittner, E., Dezseri, E., and Éles, J. (1975) Chromic oxidation of vinblastine sulfate to form vincristine, US Patent 3,899,493, G. Richter Ltd Conrad, R.A. (1982) Vinca dimer, EP37 290, Eli Lilly Co. Mangeney, P., Andrimialisoa, R.Z., Lallemand, J.Y., Langlois, N., Langlois, Y., and Potier, P. (1979) 50 Noranhydrovinblastine. Tetrahedron, 35, 2175–2179.
72 Sudakin, V.and Yen, T.J. (2007) Targeting
73
74
75
76
77
78
79
80
81
82
83
mitosis for anti-cancer therapy. Biodrugs, 21, 225–233. Sackett, D.L. (1995) Vinca site agents induce structural changes induced in tubulin different from and antagonistic to changes induced by colchicine site agents. Biochemistry, 34, 7010–7019. Borman, L.S.and Kuehne, M.E. (1987) Proc. Annu. Meet. Assoc. Cancer Res., 28, 331–339. Binet, S., Chaineau, E., Fellous, A., Lataste, H., Krikorian, A., Couzinier, J.P., and Meininger, V. (1990) Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubles. Int. J. Cancer, 46, 262–266. Ngan, V.K., Bellman, K., Panda, D., Hill, B.T., Jordan, M.A., and Wilson, L. (2000) Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res., 60, 5045–5051. van Tellingen, O., Beinen, J.H., Nooijen, W.J., and Bult, A. (1993) Plasma pharmacokinetics of vinblastine and the investigational vinca alkaloid N-(deacetylO-4-vinblastoyl-23)-L-ethyl isoleucinate in mice. Cancer Res., 53, 2061–2065. Rahmani, R.and Zhou, X.J. (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv., 17, 269–281. Schlaifer, D., Cooper, M.R., Attal, M. et al. (1993) Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia. Blood, 81, 482–489. Wargin, W.A.and Lucas, V.S. (1994) The clinical pharmacokinetics of vinorelbine. Semin. Oncol., 21, 21–27. Lampidis, T.J., Kolonias, D., Savaraj, N., and Rubin, R.W. (1992) Cardiostimulatory and antiarrhytmic activity of tubulin-binding agents. Proc. Natl. Acad. Sci. USA, 89, 1256–1260. Hacker, M.P. (1992) The Toxicity of Anticancer Drugs (eds G. Powisand M.P. Hacker), Pergamon Press, New York, p. 152. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (2000) A family of drug transporters: the multidrug
j211
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
212
84
85
86
87
88
89
90
91
resistance-associated proteins. J. Natl. Cancer Inst., 16, 1295–1302. Zhou, S.F., Wang, L.L., Di, Y.M., Xue, C.C., Duan, W., Li, C.G., and Li, Y. (2008) Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem., 15, 1981–2039. Luker, K.E., Pica, C.M., Schreiber, R.D., and Piwnica-Worms, D. (2001) Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res., 61, 6540–6547. Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., and Ariyoshi, Y. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol., 17, 2692–2699. Friedel, G., Hruska, D., Budach, W., Wolf, M., Kyriss, T., Hurtgen, M., Eulenbruch, H.-P., Dierkesmann, R., and Toomes, H. (2000) Neoadjuvant chemo-radiotherapy of stage III non-small-cell lung cancer. Lung Cancer, 30, 175–185. Kodani, T., Ueoka, H., Kiura, K., Tabata, M., Takigawa, N., Segawa, J., Moritaka, T., Hiraki, S., Harada, M., and Tanimoto, M. (2002) A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer, 36, 316–319. Wozniak, A.J. (1999) Single-agent vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol., 26 (62–66), 71–72. Greco, F.A.and Hainsworth, J.D. (1997) Multidisciplinary approach to potentially curable non-small cell carcinoma of the lung. Oncology (Huntingt), 11 (27–36), 41, 49. Baldini, E., Ardizzoni, A., Prochilo, T., Cafferata, M.A., Boni, L., and Tibaldi, C. (2002) Gemcitabine, ifosfamide and navelbine (GIN): a platinum-free combination in advanced non-small-cell
92
93
94
95
96
97
98
99
100
lung cancer (NSCLC). Cancer Chemother. Pharmacol., 49, S25–S28. Blajman, C., Balbiani, I., Block, J. et al. (1999) A prospective randomized Phase III trial comparing combination therapy with cyclophosphamide, doxorubicine and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer, 12, 108–112. Nistico, C., De Matteis, A., Rossi, E. et al. (2005) Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer. Anticancer Res., 25 (2B), 1343–1348. Abriel, C., Van Praagh, I., Delue, R. et al. (2005) Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. Oncologist, 10, 242–249. Limetani, S.A., Brufsky, A.M., Erban, J.K. et al. (2006) Phase II study of neoadjuvant docetaxel/vinorelbine followed by surgery and adjuvant doxorubicin/ cyclophosphamide in women with stage II/III breast cancer. Clin. Breast Cancer, 6, 511–517. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, K.H., McPhail, A.T., and Sim, G.A. (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca accuminata. J. Am. Chem. Soc., 88, 3888–3890. Lorence, A.and Nessler, C.L. (2004) Camptothecin, over four decades of surprising findings. Phytochemistry, 65, 2735–2749. Wani, M.C.and Wall, M.E. (1969) Plant antitumor agents. II. Structure of two new alkaloids from Camptotheca accuminata. J. Org. Chem., 34, 1364–1367. Moertel, C.G., Schutt, A.J., Reitemeier, R.J., and Hahn, R.G. (1972) Phase II study of camptothecin (NSC-100880) in the treatment of gastrointestinal cancer. Cancer Chemother. Rep., 56, 95–102. Gottlieb, J.A. and Luce, J.K. (1972) Treatment of malignant melanoma with camptothecin (NSC-100880) Cancer Chemother Rep., 56, 103.
References 101 Wani, M.C., Ronman, P.E., Lindley, J.T.,
102
103
104
105
106
107
108
109
110
and Wall, M.E. (1980) Plant antitumor agents 18. Synthesis and biological activity of camptothecin analogs. J. Med. Chem., 23, 554–560. Wall, M.E.and Wani, M.C. (1994) Camptothecin, in The Monoterpenoid Indole Alkaloids, Supplement to Indoles, Part 4 (ed. J.E. Saxton), WileyInterScience, Chichester, pp. 689–713. Kingsbury, W.D., Boehm, J.C., Jakas, D.R., Holden, K.G., Hecht, S.M., Gallagher, G., Caranfa, F.J., McCabe, F.L., Faucette, L.R., Johnson, R.K., and Hertzberg, R.P. (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogs: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34, 98–107. Johnson, R.K., Hertzberg, R.P., and Kingsbury, W.D. (1989) Preclinical profile of SK&F 104864, a water soluble analog of camptothecin. Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Abst. 301. Takimoto, C.H.and Arbuck, S.G. (1997) Clinical status and optimal use of topotecan. Oncology (Huntingt), 11, 1635–1646. Sawada, S., Okajima, S., Aiyama, R., Nokata, K., Furuta, T., Yokokura, T., Sugino, E., Yamaguchi, K., and Miyasaka, T. (1991) Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem. Pharm. Bull., 39, 1446–1454. FDA (2000) FDA approves irinotecan as first-line therapy for colorectal cancer. Oncology (Huntingt), 14, 652–654. Wang, X., Zhou, X., and Hecht, S.M. (1999) Role of the 20-hydroxyl group in camptothecin binding by topoisomerase I–DNA binary complex. Biochemistry, 38, 4374–4381. Redinbo, M.R., Stewart, L., Kuhn, P., Champoux, J.J., and Hol, W.G.J. (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science, 279, 1504–1513. Wall, M.E., Wani, M.C., Nicholas, A.W., Manikumar, G., Tele, C., Moore, L., Truesdale, A., Leitner, P., and Besterman,
111
112
113
114
115
116
117
118
J.M. (1993) Plant antitumor agents 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem., 36, 2689–2700. Yaegashi, T., Sawada, S., Nagata, H., Furota, T., Yokokura, T., and Miyasaka, T. (1994) Synthesis and antitumor activity of 20(S)-camptothecin derivatives. A-ringsubstituted 7-ethylcamptothecins and their E-ring-modified water-soluble derivatives. Chem. Pharm. Bull., 42, 2518–2525. Carrigan, S.W., Fox, P.C., Wall, M.E., Wani, M.C., and Bowen, J.P. (1997) Comparative molecular field analysis and molecular modeling studies of 20-(S)camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/ antitumor agents. J. Comput.-Aided Mol. Design, 11, 71–78. Tanizawa, A., Kohn, K.W., Kohlhagen, G., Leteurtre, F., and Pommier, Y. (1995) Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry, 34, 7200–7206. Lavergne, O., Demarquay, D., Bailly, C., Lanco, C., Rolland, A., Huchet, M., Coulomb, H., Muller, N., Baroggi, N., Camara, J., Le Breton, C., Manginot, E., Cazaux, J.-B., and Bigg, D.C.H. (2000) Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J. Med. Chem., 43, 2285–2289. Ulukan, H.and Swaan, P.W. (2002) Camptothecins. A review of their chemotherapeutic potential. Drugs, 62, 2039–2057. Burris, H.A., Rivkin, S., Reynolds, R., Harris, J., Wax, A., Gerstein, H., Karl, L., Mettinger, K.L., and Staddon, A. (2005) Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist, 10, 183–190. Pantazis, P. (1995) The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies. Leuk. Res., 19, 775–788. Emerson, D.L., Bendele, R., Brown, E. et al. (2000) Antitumor efficacy, pharmacokinetics, and biodistribution
j213
j 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
214
119
120
121
122
123
124
125
126
127
128
129
of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin. Cancer Res., 6, 2903–2912. Jew, S.-S., Kim, H.-J., Kim, M.G., Roh, E.Y., Hong, C., Kim, J.-K., Lee, J.-H., Lee, H., and Park, H.-G. (1999) Synthesis and in vitro toxicity of hexacyclic camptothecin analogues. Bioorg. Med. Chem. Lett., 9, 3203–3206. Zunino, F.and Pratesi, G. (2004) Camptothecins in clinical development. Exp. Opin. Invest. Drugs, 13, 269–284. Lavergne, O., Harnett, J., Rolland, A., Lanco, C., Lesueur-Ginot, L., Demarquay, D., Huchet, M., Coulomb, H., and Bigg, D.C.H. (1999) BN 80927: a novel camptothecin with inhibitory activities on both topoisomerase I and topoisomerase II. Biorg. Med. Chem. Lett., 9, 2599–2602. Demarquay, D., Huchet, M., Coulomb, H., Leseur-Ginot, L., Lavergne, O., Camara, J., Kasprzik, P.G., Prevost, G., and Bigg, D.H. (2004) BN 80927. A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Cancer Res., 64, 4942–4949. Verma, R.P.and Hansch, C. (2009) Camptothecins: A SAR/QSAR study. Chem. Rev., 109, 213–235. Li, Q.-Y., Zu, Y.-G., Shi, R.-Z., and Yao, L.P. (2006) Review camptothecin: current perspectives. Curr. Med. Chem., 13, 2021–2039. Comins, D.L.and Nolan, J.M. (2001) A practical six-step synthesis of (S)camptothecin. Org Lett., 3, 4255–4257. Liu, L.F. (1983) DNA topoisomerases: enzymes that catalyse the breaking and rejoining of DNA. CRC Crit. Rev. Biochem., 15, 1–24. Eng, W.K., Pandit, S.D., and Sternglanz, R. (1989) Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I. J. Biol. Chem., 264, 13373–13376. Stewart, L., Redinbo, M.R., Qiu, X. et al. (1998) A model for the mechanism of human topoisomerase I. Science, 279, 1534–1541. Kjeldsen, E., Svejstrup, J.Q., Gromova, I.I. et al. (1992) Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J. Mol. Biol., 228, 1025–1030.
130 Hsiang, Y.H., Lihou, M.G., and Liu, L.F.
131
132
133
134
135
136
137
138
139
(1989) Arrest of replication forks by drugstabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49, 5077–5082. Staker, B.L., Hjerrild, K., Feese, M.D., Behnke, C.A., Burgin, A.B., and Stewart, L. (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Sci. USA, 99, 15387–15392. Staker, B.L., Feese, M.D., Cushman, M., Pommier, Y., Zembower, D., Stewart, L., and Burgin, A.B. (2005) Structures of three classes of anticancer agents bound to the human topoisomerase I–DNA covalent complex. J. Med. Chem., 48, 2336–2345. Potmesil, M. (1994) Camptothecins: from bench research to hospital wards. Cancer Res., 54, 1431–1439. Mathijssen, R.H., van Alphen, R.J., Verweij, J., Loos, W.J., Nooter, K., Stoter, G., and Sparreboom, A. (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer. Res., 7, 2182–2194. Takasuna, K., Hagiwara, T., Hirohashi, M. et al. (1996) Involvement of betaglucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res., 56, 3752–3757. Negoro, S., Fukuoka, M., Masuda, N. et al. (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 83, 1164–1168. Costin, D.and Potmesil, M. (1994) Preclinical and clinical development of camptothecins. Adv. Pharmacol., 29B, 51–72. Meng, L.-H., Liao, Z.-Y., and Pommier, Y. (2003) Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy. Curr. Top. Med. Chem., 3, 305–320. Chrencik, J.E., Staker, B.L., Burgin, A.B., Pourquier, P., Pommier, Y., Stewart, L., and Redinbo, M.L. (2004) Mechanisms of camptothecin resistance by human
References
140
141
142
143
144
145
146
topoisomerase I mutations. J. Mol. Biol., 339, 773–784. Xu, Y.and Villalona-Calero, M.A. (2002) Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol., 13, 1841–1851. Langer, C.J. (2001) The emerging role of irinotecan in lung cancer. Oncology (Huntingt), 15, 15–21. Negoro, S., Masuda, N., Takada, Y., Sugiura, T., Kudoh, S., Katakami, N., Arioshi, Y., Ohashi, Y., Niitani, H., and Fukuoka, M. (2003) Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer, 88, 335–341. Gauvin, A., Bressolle, F., Martineau, P., Astre, C., and Pinguet, F. (2002) In vitro schedule-dependent interaction between irinotecan and vinorelbine in NCI H460 non-small cell lung cancer line. Anticancer Res., 22, 905–912. Charasson, V., Haaz, M.C., and Robert, J. (2002) Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab. Dispos., 30, 731–733. Saltz, L.B., Douillard, J.Y., Pirotta, N., Alakl, M., Gruia, G., Awad, L., Elfring, G.L., Locker, P.K., and Miller, L.L. (2001) Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist, 6, 81–89. Tamura, T. (2001) New state of the art in small-cell lung cancer. Oncology (Huntingt), 15, 8–10.
147 Lara, P.N., Jr., Natale, R., Crowley, J., Lenz,
148
149
150
151
H.J., Redman, M.W., Carleton, J.E., Jett, J., Langer, C.J., Kuebler, P., Dakhi, S.R., Chansky, K., and Gandara, D.R. (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol., 27, 2530–2535. Jagasia, M.N., Langer, C.J., Johnson, D.H., Yunus, F., Rodgers, J.S., Schlabach, L.L., Cohen, A.G., Shyr, Y., Carbone, D.P., and Devore, R.F. (2001) Weekly irinotecan and cisplatin in advanced nonsmall cell lung cancer: a multicenter phase II study. Clin. Cancer Res., 7, 68–73. Carmichel, J., Gordon, A., Malfetano, J. et al. (1996) Topotecan, a new active drug, vs paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group Trial. Proc. Am. Soc. Clin. Oncol., 15, Abst. 765. Herzog, T.J. (2002) Update on role of topotecan in the treatment of recurrent ovarian cancer. Oncologist, 7 (Suppl.5), 3–10. Sehouli, J., Sttengel, D., Oskay, G., Camara, O., Hindenburg, H.J., Klare, P., Blohmer, J., Heinrich, G., Elling, D., Ledwon, P., and Lichtenegger, W. (2002) A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line therapy. Ann. Oncol., 13, 1749–1755.
Andras Nemes
Gedeon Richter Plc., Gyömro˝i u. 19-21, 1103 Budapest, Hungary Andras Nemes received his undergraduate education at E€ ov€ os Lórand University, Budapest, and his PhD degree in medicinal chemistry from the Technical University in 1966. After working at the Research Institute for Medicinal Chemistry, Budapest, he joined Gedon Richter Ltd. in 1975, where his main activity was elaboration of processes for preparing heterocyclic and alkaloid origin drug substances. He won Prominent Inventor Award in 1970 and 1982 and Zemplen Geza Academic Award in 2008. He is the author of some 80 patents and scientific publications.
j215
j217
9 Anthracyclines, Optimizing Anticancer Analogues Federico-Maria Arcamone
9.1 Introduction: Biosynthetic Antitumor Anthracyclines
The anthracyclines are glycosides belonging to the large family of the polyketidederived natural products that display a considerable molecular diversity [1]. In 1959, it was found that red pigments produced in the cultures of a Streptomyces spp. were active against Ehrlich carcinoma and sarcoma 180 in mice [2]. The pigments were found to be similar in structure to anthracyclines previously studied and described by different authors, notably among them Hans Brockmann [3]. A typical representative of these anthracyclines is rhodomycin A (1). Shortly afterward, an active principle that is distinctly more active in different laboratory tests for antitumor activity was independently discovered at Farmitalia Research Laboratories, Italy, in the cultures of S. peucetius [4, 5], and at Rhone-Poulenc, France, in the cultures of S. coeruleorubidus [6], and the generic name daunorubicin was attributed to the compound [7]. Characteristic structural features of the components of the fermentation broth of S. peucetius are the novel aminosugar, L-daunosamine, the 4-methoxy group in the tetracyclic aglycone, and the C-9 side chain, represented by an acetyl group in daunomycinone or a hydroxyacetyl group in adriamycinone [8]. These compounds include daunorubicin (2a), doxorubicin (2b) (originally named adriamycin) 13dihydrodaunorubicin (3), and the disaccharide derivative 4-O-a,L-daunosaminyldaunorubicin. Daunorubicin is clinically useful as an antileukemic agent [9, 10]. On the other hand, doxorubicin (since its registration as AdriamycinÒ in the United States in the early 1970s) is a component of many frequently used drug combinations in the medical treatment of lymphomas, sarcomas, breast and ovarian cancer, and other solid tumors [11]. A practical method for the industrial preparation of doxorubicin (2b) is the conversion of 2a to the 14-bromo derivative and subsequent nucleophilic substitution of the halogen atom with base [8]. Antitumor activity has been associated also with other biosynthetic anthracyclines [12].
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 9 Anthracyclines, Optimizing Anticancer Analogues
218
O 1 4
12 5
OH OH 10 7
11 6
O
13 OH
1 D 4
C
OH
O
O
OH
R A 9 OH 14 7
B
OH OH
7
OH O
OH O
OH
OMe O
OH O
O
O
NEt2
NH2
1
OH
2a: R=H 2b: R=OH
OMe O
OH O O OH
NH2
3
Soon after the discovery of the pharmacological properties of daunorubicin, Di Marco and coworkers drew attention to the affinity of the compound for calf-thymus DNA [13] and its inhibitory properties against the reactions of DNA and RNA polymerases in cell-free systems and in cultured cells [14, 15]. The high affinity was attributed to the formation of an intercalation complex of the type already known to be formed by a number of dyes such as the acridines and other planar polycyclic aromatic molecules [16]. It was also anticipated that this type of interaction would be at the basis of the biological properties of the new compounds. The structural features of the anthracyclines, namely, the presence of a planar electron-poor chromophore and of a cationic appendage, well explained the formation of an intercalation complex. Although the micromolar range value of the association constants of the binding is inconsistent with this interaction being the sole explanation of the biological effects, since these are observed at nanomolar concentrations of the drugs, a generally accepted concept is that DNA binding is a necessary, albeit nonsufficient, requirement for bioactivity [17]. The quinone function, would, on the other hand, allow participation in redox reactions vis-a-vis appropriate electron donors or acceptors. Despite these simple chemical properties being common to all antitumor anthracyclines, it seems unlikely that it could completely explain the specific biological properties of the S. peucetius metabolites. Inhibition of the subsequently discovered mammalian topoisomerase II and its sensitivity to anthracyclines is now considered to be their main mode of action whereas intercalation and a number of other cellular disturbances brought about by these drugs is considered to be contributory. A study using cultured HeLa cells showed that daunorubicin and doxorubicin were indistinguishable in their effect both on cell mitosis and on protein and RNA synthesis, and that low doses of 50–100 ng/ml were markedly active antimitotically but had only a slight effect on RNA synthesis [18a]. On the other hand, doxorubicin is invariably more effective than daunorubicin against the growth of experimental tumors in mice [18b]. It was also demonstrated that both daunorubicin and doxorubicin reached a plasma level of around 1 mg/ml 20 min after the i.v. administration of a 10 mg/kg dose in rats, the former showing a significantly higher excretion rate and the latter a greater concentration in the
9.2 Analogues with Modification of the Aminosugar Moiety
tissues with time. Daunorubicin was extensively converted to a major metabolite (13-dihydrodaunorubicin or daunorubicinol 3) but no doxorubicin metabolite was found [18c]. These and other results suggested the importance of metabolism– tissue distribution–elimination factors for the exhibition of antitumor properties in vivo. A major dose-limiting toxic side effect of doxorubicin is the development of cardiotoxicity. This is observed at cumulative clinical dosages higher than 400 mg/m2 of body surface area. In the laboratory, the myocardium of mice treated with repeated doxorubicin administrations exhibited an increased reactivity of the sarcoplasmic reticulum with zinc iodide-osmium tetroxide reagent that allows detection of disulfide bonds derived from the oxidation of cell constituents containing sulfhydryl groups such as polypeptides, cysteine, and glutathione [19]. This might be the consequence of an oxidative stress caused by a higher than normal oxygen tension in the heart tissue [20, 21]. Excess oxygen could be related to the reduction of metabolic consumption of oxygen, a consequence of the long lasting inhibition of nucleic acid synthesis in the heart [22]. Inhibition of mitochondrial DNA transcription by doxorubicin would also lead to a diminished ATP production and consequently to cell damage in the high-energy demanding heart tissue [23]. The role of free radicals in the biological actions of the anthracyclines has been discussed [24]. With the aim of improving the pharmacological properties, synthesis of antitumor anthracyclines analogues has been carried out [8, 25a–d, 26].
9.2 Analogues with Modification of the Aminosugar Moiety
Different stereochemical variants containing 3-amino-2,3,6-trideoxy-L-hexopyranosides have been prepared and tested. The first study was concerned with the 40 epimer of 2a and 2b, involved replacement of L-daunosamine with 3-amino-2,3,6trideoxy-L-arabino-hexose, that is, L-acosamine, an aminosugar constituent, together with its 4-O-methyl derivative actinosamine, of the antibiotic actinoidin [27]. 7-O-a,LAcosaminyldaunomycinone (4a) was obtained by Koenigs Knorr coupling of daunomycinone with 3-trifluoroacetamido-4-O-trifluoroacetyl-a-L-acosaminyl chloride (5) and subsequent methanolysis, chromatographic separation, and deprotection of the resulting N,O-ditrifluoroacetylated anomeric aminoglycosides. When the coupling reaction was performed on 9-deacetyl-9-(2,20 -dimethyl-40 -methoxydioxolan-40 yl)-daunomycinone 6, chromatographic separation after methanolysis of the reaction products afforded two compounds that were treated with aqueous HCl and then with 0.1 NaOH to give, respectively, the a-anomer 4b and the b-anomer of 40 -epidoxorubicin. Compounds 4a and 4b, with an a-anomeric configuration at C-10 , are as cytotoxic as 2a and 2b in cultured cells in vitro and display antitumor effects in vivo in experimental tumors in mice at comparable doses [28], but anomers with the b configuration at C-10 show a markedly lower bioactivity. Following demonstration of a
j219
j 9 Anthracyclines, Optimizing Anticancer Analogues
220
lower toxicity, including cardiotoxicity, when compared to 2b in vivo, compound 4b was developed, under the generic name epirubicin, to the clinical stage. A more practical process for the preparation of epirubicin (4b) was eventually developed starting from N-trifluoroacetyldaunorubicin that was oxidized at C-40 and then stereoselectively reduced with sodium borohydride. Removal or the N-trifluoroacetyl group with base and introduction of the 14-OH as described above for the conversion of 2a to 2b produced 4b [29]
O
OH
O R Cl
OH OMe O
OH O
4' NH2 4a: R=H 4b: R=OH
OH
MeO
O F3CCOO
O O OH
NHCOCF3
O HO
O
OMe O 5
OH OH 6
A quite different case was that of 30 ,40 -diepidaunorubicin 7a and of 30 ,40 -diepidoxorubicin 7b, in which the sugar moiety was L-ristosamine, the aminosugar component of the ristocetins [30], and of 7c, containing the opposite configuration at C-30 compared to the natural compounds. For the synthesis of 7a, 4-O-pnitrobenzoyl-3-N-trifluoroacetyl-ristosaminyl chloride (8a) and daunomycinone were allowed to react in the presence of silver triflate to give, after removal of the trifluoroacetyl groups, 7a that was then converted to doxorubicin stereoisomer 7b [31]. Condensation of 8b with daunomycinone and deprotection afforded L-xylo analogue 30 -epi-daunorubicin 7c [32]. Configurational analogues 7a, 7b, and 7c display lower affinity toward calf-thymus DNA and lower antitumor activity against L1210 leukemia in mice even at a 10 times higher dosage compared to the corresponding L-lyxo isomers daunorubicin (2a) and doxorubicin (2b) [25a–c]. The study was extended to include the related glycosides containing a hydroxyl group at C-60 . The new sugar moieties were obtained from intermediates 9a and 9b, by standard procedures [33]. Analogues 10a,c and 11a,c were obtained upon glycosidation of daunomycinone with the activated derivatives of the Ntrifluoroacetylated appropriate aminosugars and subsequent hydrolytic removal of the protecting groups. Doxorubicin analogues 10b, 11b, and 11d were prepared by bromination at C-14 and substitution of the halogen with base. Although 60 hydroxy analogues 10a–c display significant affinity toward calf-thymus DNA and activity in the inhibition of DNA-dependent polymerases in vitro, they are distinctly less active, on a weight basis, compared to 2a and 2b both in cultured cells and in in vivo antitumor tests. The more than one order of magnitude lower cytotoxicity exhibited in cultured cells leads to the conclusion that introduction of the additional hydroxyl group and the consequent enhanced hydrophilicity strongly
9.2 Analogues with Modification of the Aminosugar Moiety
j221
disfavors cellular uptake of these analogues. An even greater loss of bioactivity is observed both with compounds 11a–d and with (20 R)-hydroxydaunorubicin [25b, 34, 35].
O
OH
CF3CO Cl
O R OH
OMe O
OH
HO 4'
OH
O
4 8a: R=OpNBz 8b: as 8a, epi at C-4 8c: R=H OMe
NH2 O 3'
O Ph
O O
R 9a: R=OH 9b: R=NH2
O
OH
O
R
R
OH
R
O
7a: R=H 7b: R=OH 7c: R=OH, epi at 4'
O
NH O OMe O
OH
HO
O
O
R1 2
R
NH2
10a: R=H, R1=OH, R2=H 10b: R= R1=OH, R2=H 10c: R=R1=H, R2=OH
OH OMe O HO R1
OH O NH2 O
R2 11a: R=R2=H, R1=OH 11b: R= R1=OH, R2=H 11c: R=R1=H, R2=OH 11d: R=R2=OH, R1=H
A higher lipophilicity was expected for the analogues bearing deoxy or O-methyl modifications in the aminosugar moiety. The 40 -deoxy derivative 12a of daunorubicin was obtained starting from 4-deoxy derivative 8c that was converted to the 1chlorosugar used for the glycosidation of daunomycinone followed by standard transformations. Alternatively, the compound was prepared by deoxygenation of 4a at C-40 [29]. Glycoside 12a and related doxorubicin analogue 12b display similar behavior as regard to calf-thymus DNA complexation and the DNA-dependent polymerase reactions, but they appear one order of magnitude more potent than the natural compounds in inhibiting the colony-forming ability of cultured HeLa cells [36]. Because of a comparable or even higher in vivo activity in different experimental cancers, especially colon tumors in mice, and a lower cardiotoxicity in the animal models than doxorubicin (2b) [25b], compound 12b was submitted to phase 1 and 2 clinical trials with the generic name esorubicin. Along this line, 40 -O-methyl derivatives of daunorubicin (2a), doxorubicin (2b), and of their 40 -epimers (the actinosaminides) were also synthesized and tested. The new aminoglycosides exhibit antitumor activity in murine transplantable leukemias comparable to that of the parent compounds, with 40 -O-methyldoxorubicin 13a being the most effective [37]. Analogues bearing a 40 -C-methyl substitution of the 0 L-lyxo and L-arabino series together with the corresponding 4 -O-methyl ethers were also prepared [38]. The different analogues display 50% inhibition of HeLa cells at a concentration close to 10 nM, compounds with an equatorial C-methyl such as 13b displaying higher activity than those in which this substituent was axial. A general trend of correlation of affinity for calf-thymus DNA versus cytotoxicity was recorded. Although the C-methyl analogues exhibit antitumor activity in vivo, none shows a higher activity at the optimal doses compared to the parent compounds [39a]. However, berubicin, a 40 -O-benzyl derivative, has been recently shown to cross the blood–brain barrier, thus showing potential in the medical treatment of glioblastomas [39b].
j 9 Anthracyclines, Optimizing Anticancer Analogues
222
O
OH
O
O
OH
O OH
OH OMe O
OH
O
O NH2 12a: R=H 12b: R=OH
O
OH
O
OH
R
OMe O R2
OH
O
O NH2 R1
13a: R1=OMe, R2=H 13b: R1=OH, R2=Me 13c: R1=I, R2=H
OH
4 OMe O
OH
O
O R 14a: R=OH NH2 14b: R=H 14c: R=NH2 (demethoxy at C-4)
The pharmacological properties of epirubicin (4b) and esorubicin (12b) prompted the synthesis of other C-40 derivatives. 40 -Iodo-40 -deoxydoxorubicin (iodorubicin, 13c) was designed to improve lipophilicity at physiological pH and consequently uptake, transport, and tissue distribution of the drug by reducing the basicity of the amino group at C-30 while keeping the same group in place. The synthesis was achieved starting from N-trifluoroacetyl-40 epidaunorubicin that was converted to 13c upon treatment of the 40 -O-trifluoromethanesulfonyl derivative with tetra-n-butylammonium iodide, removal of the N-trifluoroacetyl group with base followed by the introduction of the 14-hydroxyl via the standard methodology. The compound shows a pKa value of 6.4 (2b: pKa ¼ 8.2) and a high apparent partition coefficient (Papp ¼ 31.4 between octanol and aqueous pH 7 phosphate buffer). Iodorubicin (13c) is superior to doxorubicin in terms of antitumor efficacy, particularly striking results have been obtained in doxorubicin-resistant leukemias and in metastatic Lewis lung carcinoma. It also appears devoid of cardiotoxicity as no atrial or ventricular lesions are observed in mice at dosages and schedules at which doxorubicin treatment affects 100% of the treated animals [40]. Antitumor activity of selected compounds differing in the aminosugar moiety is shown in Table 9.1. Displacement of the amino group to position 40 was carried out with the synthesis of 40 -amino derivatives 14a and 14b from which the corresponding doxorubicin analogues were also obtained [41, 42]. On the basis of their significant bioactivity, the 4-demethoxy analogues of 2a and 2b possessing an amino group in place of the hydroxyl at C-40 , that is, two amino groups on the sugar moiety, were prepared starting from 4-demethoxydaunomycinone and 2,3,4,6-tetradeoxy-3,4-ditrifluoroacetamido-L-lyxo-hexopyranosyl chloride to give 14c, from which the corresponding 14-hydroxylated compound was also obtained. The compounds did not show superior antitumor activity in the laboratory tests, but are distinctly more cytotoxic than doxorubicin on resistant cells in vitro [43]. In conclusion, epirubicin (4b), esorubicin (12b), and iodorubicin (13b) entered in this temporal succession in preclinical development and clinical evaluation. The first was demonstrated to exhibit a practically equivalent antitumor activity in different solid cancers, but a better tolerability compared to doxorubicin [44a,b]. The metabolism of epirubicin in human patients is characterized by extensive biotransformation
9.3 Analogues with Modifications in the Anthraquinone Moiety Table 9.1 Cytotoxicity in vitro on HeLa cells (LD50, ng/ml after 24 h exposure) and antitumor activity (AST%)a) against L1210 murine transplantable leukemia at optimal nontoxic doses (O.D., mg/kg body weight, treatment by the intraperitoneal route on day 1) of analogues modified in the sugar moiety.
Compound
Cytotoxicity LD50
Daunorubicin (2a) Daunorubicin, 30 ,40 -diepi- (9a) Doxorubicin (2b) Doxorubicin (2b) Doxorubicin, 40 -O-methyl- (13a) Doxorubicin, 40 -C-methyl- (13b) Epirubicin (4b) Doxorubicin, 60 -hydroxy- (10b) Iodorubicin (13b)
6.8 90 18 110b) 5.0 16.5 8.5 1000b) 2
Antitumor activity
References
O.D.
AST%
References
[31b] [31b] [40] [34] [39] [39] [39] [34] [40]
4 50 5 19c) 4.4 7.7c) 5 40 6.6c)
150 137 166 320 312 172 150 137 300
[25a] [25b] [25a] [40] [39] [39] [25a] [25b] [40]
a) Average survival time of treated animals as percentage of untreated controls. b) After 8 h exposure. c) Murine transplantable P388 leukemia, intraperitoneal treatment on day 1.
to partially or totally inactive metabolites, including a 13-dihydro derivative, epirubicinol, two 40 -glucuronides, and four aglycones. This metabolic transformation (not observed in experimental animals) might be responsible for better tolerability of this drug by patients compared to doxorubicin [45]. Epirubicin is available in oncology as PharmorubicinÒ or, in the United States, as EllenceÒ [25d]. On the other hand, esorubicin did not show, at the clinical level, the lower cardiotoxicity suggested from the results recorded in the animal experiments [46]. In the case of iodorubicin, the unexpectedly extensive metabolic transformation in the human body impaired the expression of useful pharmacological properties [47], whereas recently developed berubicin is undergoing clinical trials as a potential agent for the clinical treatment of brain tumors [39b].
9.3 Analogues with Modifications in the Anthraquinone Moiety
The first total synthesis of daunorubicin analogues provided 4-demethoxydaunorubicin (idarubicin, 15a), obtained together with the (7R),(9R) diastereomer upon glycosidation of racemic 4-demethoxydaunomycinone prepared by substantially following the procedure of Wong et al. [48]. The compound soon appeared of interest owing to its potency and antitumor activity, especially against experimental leukemia in mice, and reduced cardiotoxicity in animal models. In a subsequent study, the synthesis was carried out starting from phthalic anhydride or an appropriate derivative thereof that was allowed to react with the (R)() stereoisomer of 6acetyl-6-hydroxy-1,4-dimethoxytetralin to give, with a concomitant O-demethylation,
j223
j 9 Anthracyclines, Optimizing Anticancer Analogues
224
7-deoxy-4-demethoxy-daunomycinone 16a. The introduction of the 7-hydroxyl group in the corresponding 13-ethylenedioxyketal derivative was performed by radical bromination followed by hydrolysis. Deprotection yielded 4-demethoxydaunomycinone (idarubicinone, 16b). Glycosidation was carried out using N,O-ditrifluoroacetyla-L-daunosaminyl chloride and silver triflate as the chloride acceptor [8]. Doxorubicin analogue 15b displays high cytotoxic potency but is not superior to doxorubicin in terms of antitumor activity at the optimal, nontoxic doses, in vivo. Other analogues displaying 1,4 or 2,3 substitution with methyl groups or chlorine atoms or (2,3-a)benzo-derivatives with an extended aromatic ring system are less potent and less effective than 15a. The 40 -epi, 40 -deoxy, and 40 -O-methyl derivatives of 15b were also prepared [49]. The enantiomer 15d of idarubicin has been synthesized by a similar procedure and found devoid of significant bioactivity, in agreement with the stereochemical requirements for bioactivity of antitumor anthracyclines [50a]. However, enantiomeric daunorubicin shows, interestingly, unprecedented structural selectivity as it can discriminate and selectively recognize right- and left-handed DNA [50b]. A method of idarubicinone synthesis from biosynthetic daunomycinone has also been developed for industrial purposes [51]. A study concerning the relevance of the peri substitution in the anthraquinone chromophore for antitumor activity has involved both synthetic work and isolation of novel biosynthetic compounds. It was therefore of interest to assess the role of the anthraquinone chromophoric system as a simple electron-deficient planar system responsible for the formation of intercalation complexes with suitable electron-rich acceptors or, alternatively, as a redox reagent intervening in a catalytic mechanism leading to the generation of toxic oxygen radicals [25b]. Substitution of the 6-OH or of the 11-OH or both in 2a with a methoxyl strongly reduced or abolished bioactivity and stability of the DNA intercalation complex [52, 53]. The biosynthetic analogue 4-O-demethyldaunorubicin (carminomycin, 17a), showing three hydroxyl groups peri to the quinone carbonyls, is endowed with higher cytotoxicity than 2a and exhibits comparable activity in laboratory tests at significantly lower dosages [54]. In the 4-hydroxylated series, the daunorubicin isomer with a methoxy group at C-6 shows low affinity for calf thymus DNA but still significant activity in the mouse L1210 leukemia test, whereas the corresponding 11-methylated isomer is only marginally active [55]. 4-Demethyl-6-O-methyl-doxorubicin analogue 17b is of interest because of the exhibition of activity against experimental murine tumors comparable to doxorubicin (2b), notwithstanding a lower DNA binding affinity, and because of a reduced cardiotoxicity in vivo. The presence of the methoxy group at position 6 is thought to modify the geometry of the DNA complex albeit in a way that does not affect the molecular interaction determining the tumor-inhibiting properties [56]. 11-Deoxy analogues of antitumor anthracyclines were isolated from the cultures of different Streptomyces strains related to S. peucetius. These compounds are 10 times less potent on a weight basis in vivo, but the activity of 11-deoxydaunorubicin (18a) and of 11-deoxydoxorubicin (18b) at optimal doses in the P388 mouse leukemia system is comparable to that of doxorubicin [57, 58a,b]. In the 4-demethoxy series, 11-deoxy idarubicin was prepared by Umezawa et al. [59]. Activity in vitro and in vivo of the corresponding 14-hydroxylated compound is comparable to that exhibited by
9.3 Analogues with Modifications in the Anthraquinone Moiety
j225
doxorubicin. As for the 6-deoxy analogues, the condensation of 1,4-dimethoxy-2bromonaphthalene in the presence of butyl lithium with 19, itself obtained in six reaction steps from dimethyl cyclohexenedicarboxylate, afforded 6,7-deoxyidarubicinone that was converted to 6-deoxyidarubicin 15c through the same reaction steps as used in the synthesis of 15a. The compound shows a much higher IC50 value in HeLa cells compared to idarubicin (15a) [60a]. An improved regiospecific procedure allowed preparation of 6-deoxycarminomycin 17c [60b]. O
OH
O
O
OH
O
O
4
7 O
9 OH
1
R
O O
NH2 OH 15a: R =OH, R2=H 15b: R1=OH, R2=OH 15c: R1=R2=H 15d: as 15a, epi at C-7 and C-9 1
OH O
11 6
4
R
16a: R=H 16b: R=OH
S
MeO2C
S
OHC 19
O R2
OH
4 R1
1
OH O
OH R
O
O
OH
R2
R2
OH
O
7 O
OH O
O
O
NH2
NH2
1
17a: R =OH, R2=H 17b: R1=OMe. R2=OH 17c: R1=R2=H 17d: R1=H, R2=OH
OH 18a: R1=OMe, R2=H 1 18b: R =OMe, R2=OH 18c: R1=R2=H 18d: R1=OH, R2=OH
In conclusion, modification of the anthracenequinone chromophore has produced compounds that retain the bioactivity of the parent biosynthetic compounds (Table 9.2). Compound 15 (idarubicin) was selected for further development as a useful agent for the treatment of acute leukemias. It has been registered worldwide Table 9.2 Cytotoxicity in vitro on HeLa cells (LD50, ng/ml after 24 h exposure) and antitumor activity (AST%)a) against L1210 murine transplantable leukemia at optimal nontoxic doses (O.D., mg/kg body weight, treatment by the intraperitoneal route on day 1) of analogues modified in the chromophore moiety.
Compound
Daunorubicin (2a) Daunorubicin, 11-deoxy- (18a) Daunorubicin, 4-demethyl- (27a)b) Daunorubicin, 4-demethyl-11-deoxy- (18c) Idarubicin (15a)c) Idarubicin, 7,9-diepi- (15d)d) Idarubicin, 6-deoxy- (17c) Doxorubicin (2b) Doxorubicin, 11-deoxy- (18b) Doxorubicin, 4-demethyl-6-O-methyl- (17b) Doxorubicin, 4-demethyl-11-deoxy- (18d) a) b) c) d) e) f)
Cytotoxicity
Antitumor activity
LD50
References
O.D.
AST%
References
10 70 3 14 0.15 >200 17 7 100 16 6.5
[49] [57] [54b] [58] [49] [25c] [62b] [56] [57] [56] [57]
2.9 44 0.4 1.9 1 8.0 —e) 6.6f) 66f) 4.4f) 3.4f)
144 142 133 122 150 100 —e) 190 232 177 190
[49] [57] [54b] [58] [49] [25c] —e) [56] [57] [56] [57]
Average survival time of treated animals as percentage of untreated controls. Carminomycin. 4-Demethoxydaunorubicin. Idarubicin diasteromer. Not available. Murine transplantable P388 leukemia.
9 OH
j 9 Anthracyclines, Optimizing Anticancer Analogues
226
with the trademark ZavedosÒ [61]. Unlike the other clinically useful anthracyclines, idarubicin has significant oral bioavailability (in average 28%). The oral formulation has demonstrated efficacy in advanced breast cancer, non-Hodgkins lymphoma, myelodysplastic syndromes, and as first-line induction therapy of acute myelogenous leukemia [25e]. Methylation or deoxygenation of the peri phenolic groups afforded compounds with reduced activity in terms of efficacy and/or of potency in respect to the respective parent compounds. However, compound 17b deserves attention as it is endowed with a distinct and potentially advantageous biochemical and pharmacological behavior. A correlation has been established between cytotoxicity and DNA breaks induced in cultured cells by the related 6-deoxy-4-demethyldoxorubicin 17d, which shows a behavior similar to doxorubicin, in agreement with the role of topoisomerase II as the target of this class of antitumor agents [62a,b].
9.4 Analogues Modified on Ring A of the Aglycone
Esterification of doxorubicin (2b) at position 14 afforded compounds exhibiting bioactivity compatible with a role as prodrugs of 2b. However, doxorubicin octanoate appeared of interest because of its reduced cardiotoxicity in the rat [8]. A prodrug behavior was also demonstrated for some derivatives at the 13-carbonyl function, such as daunorubicin benzoylhydrazone (rubidazone), which was introduced in oncology as an alternative medication to daunorubicin because of lower cardiotoxicity [63]. O
OH
O
O
OH
O
O
OH
OMe O
R OH F
H OMeO
R
OH O
O
OH
OMe O O
OMe O
OH 23
OMe O
O
OH
22
NH2
20a: R=H 20b: R=OH O
OH OH
21a: R=H 21b: R=OMe
O OH
O
O
OH
O
OMe O
OH
OH F
O R OMe O
OH OMe
O
R
O
OH O
24a: R=OH 24b: R=F
O OH
NH2
25a: R=H 25b: R=OMe
9-Deoxy derivatives 20a and 20b [64], although able to form stable intercalation complexes with DNA, display only marginal antitumor activity [65]. One good reason for this behavior is destabilization, because of the absence of a hydrogen bond between OH-7 and OH-9, of the a conformation of ring A, a specific requirement of all bioactive anthracyclines. Moreover, according to the molecular model of the
9.4 Analogues Modified on Ring A of the Aglycone
daunorubicin–DNA complex, the 9-hydroxyl group points outside the double helix and might be involved in a specific interaction such as the one determining the stabilization of the topoisomerase II–DNA–drug ternary complex [66, 67]. The introduction of a fluorine at the a-position to the said hydroxyl as a substituent on ring A at C-8 and at C-10 and at C-14 was thought of interest in order to enhance the acidity of the 9-OH (or of the 14-OH). Racemic trans-fluoridrin 21a was obtained by total synthesis whereas, more expeditiously, (8S)-fluorodaunomycinone (21b) was obtained starting from 22, the product of the reaction of daunomycinone with 2,20 -dimethoxypropane in boiling benzene in the presence of p-toluenesulfonic acid, followed by epoxidation to 23. Opening of the epoxide ring to give 24a, then fluorination to 24b, and hydrolysis afforded 21b. Glycosidation of 21a with N-trifluoroacetyl-1,4-di-O-p-nitrobenzoyl-Ldaunosaminyl chloride in the presence of trimethylsilyl triflate allowed, after separation of the diasteromeric mixture and deprotection, to obtain (8S)-fluoroidarubicin 25a, whereas 8(S)-fluorodaunorubicin 25b was obtained from 21b. Both 25a and 25b exhibit antiproliferative properties against cultured tumor cells inferior to those of the nonfluorinated parent aminoglycosides. Compound 25b was eventually converted to (8S)-fluorodoxorubicin, albeit in low yields because of low reactivity of 25b toward electrophilic bromination at C-14 [68, 69]. The significantly lower cytotoxic potency exhibited by 25a compared to unsubstituted idarubicin is consistent with the b-conformation of ring A predominating the solution of 25a over the a-conformation typical of idarubicin and the other antitumor anthracyclines [69]. This is not the case with cis-fluoridrin (8R)-fluoroidarubicin (26), the epimer of 25a, as it keeps the same conformation in solution as the biosynthetic compounds. Compound 26 was obtained starting from the product of the Diels– Alder condensation of quinizarine with 2-(1-hydroxyethyl)-1,3-butadiene and this was tautomerized and was treated with N-bromosuccinimide and tetrabutylammonium dihydrogentrifluoride to give the desired trans 8-fluoro-9-bromo derivative 27 together with the 8-bromo-9-fluoro regioisomer. Compound 27 was then converted to 9,13-epoxide 28 with base. Acid treatment of 28 and oxidation at C-13 of the resulting 9,13-diol gave ketone 29a and this was converted to 29b by protection as a 13ethylidene ketal and bromination at C-7 followed by hydrolysis. Glycosylation of 29b followed by separation of the diastereomeric glycosides and deprotection produced 26.This compound shows inhibition of the growth of cultured tumor cell lines with ID50 close to the value shown by idarubicin [69]. Moreover, (8R)-fluoroidarubicin (26) displays a significantly greater activity than that of idarubicin against doxorubicin-resistant cell lines (Table 9.3) and is more efficacious than doxorubicin and markedly more so than idarubicin in inhibiting the growth of human ovarian carcinoma xenografts in immunodepressed mice. Interestingly, the compound displays a particularly high activity in stimulating topoisomerase II DNA cleavage in vitro [70]. The compound is a candidate for further preclinical development. The synthesis of 10-fluoroderivatives was carried out from the 9,10-epoxides of 40 epidaunorubicin or 40 -epiidarubicin, which were treated with triethylamine/hydrogen fluoride to give the approximately (1 : 1) mixture of, respectively, 30a and 30c, or 30b and 30d. As deduced from the activity data against different cultured tumor cell lines
j227
j 9 Anthracyclines, Optimizing Anticancer Analogues
228
Table 9.3 Inhibition (IC50, ng/ml) of in vitro cultured tumor cells by idarubicin (IDR) and epimeric fluoro derivatives after 24 h exposure to the drug [70].
Tumor
Compound IDR (15a)
IDR, (8S)fluoro- (25a)
IDR, (8R)fluoro- (26)
5.3 3.0 2.8 10
35 22 14 60
3.5 1.8 5.0 9.0
Cervical carcinoma A431 Lung carcinoma H480 Ovarian carcinoma A2780 Ovarian Carcinoma A2780a) a) Doxorubicin resistant cell line.
recorded at the US National Cancer Institute, compounds 30b and 30d display similar antiproliferative spectrum and potency, but both were less potent than doxorubicin [70]. O
OH
O
O
OH
OH
O
OH O
OH
OH
O
O
OH
O OH F
F O
27
O 26
OH
Br F
OH F O
O
OH
O
28
OH R
29a: R=H 29b: R=OH
NH2
Synthesis of 14-fluorodoxorubicin started from 14-bromodaunomycinone by treatment with AgBF4 and dimethylsulfoxide to give fluoroderivative 31a. This compound was brominated to 31b whose reaction with AgBF4 afforded 31c. Glycosylation of 31c with 1-p-nitrobenzoyl-3,4-N,O-diallyloxycarbonyldaunosamine and trimethylsilyltriflate and treatment of the resulting protected glycoside with the AgBF4-DMSO reagent, followed by removal of the protecting groups, produced the two epimeric forms of 14-fluorodoxorubicin 32 [71]. O
OH F 10
R
O
OH
O
O
O
O
O
OH
O
R1 OH
F OH
OH R2 OMe O
O HO
OH
NH2
30a: R=OMe 30b: R=H 30c: R=OMe, epi at C-10 30d: R=H, epi at C-10
OH OH 1 31a: R =F, R2=H 31b: R1=F, R2=Br 31c: R1=F, R2=OH
OMe O
OH
OH O O
32 OH
NH2
In conclusion, synthetic work leading to modification of alicyclic ring A of antitumor anthracyclines has established the importance of this portion of the
9.5 Disaccharide Analogues
molecule as a scaffold projecting the C-9 side chain and the C-7 sugar moiety outside the putative DNA intercalation site to interact with the topoisomerase protein, thus stabilizing the binding of the enzyme to its substrate with the consequent formation of the DNA breaks that stimulate apoptotic cell death. Reducing the stability of the a-conformation of ring A, as in the 9-deoxy derivatives 20a,b or in the (8S)-fluoro compounds 25a,b, is strongly detrimental to bioactivity. On the other hand, although no advantage has been demonstrated for the presence of the electron-withdrawing fluorine at C-10, in vicinal position to the 9-hydroxyl group at C-9 as in compounds with structure 30b or 30d, (8R)-fluoroidarubicin (26) should be considered a lead compound for the synthesis of new pharmacologically improved anthracycline analogues.
9.5 Disaccharide Analogues
The synthesis of disaccharide analogues of the antitumor anthracyclines was justified because additional stabilization of the DNA–drug–topoisomerase complex, responsible for the DNA damage leading to the apoptotic response, might be obtained through a functional enrichment of the portion of the anthracycline molecule possibly involved in the said molecular interactions [72, 73]. On the other hand, compounds not possessing an amino group in the carbohydrate moiety directly linked to the aglycon are still active, even more active than the parent compounds, albeit at much higher dosages and the addition of a daunosamine residue could bring the active dose to more reasonable values by enhancing the stability of the corresponding DNA complex. Synthesis of disaccharide derivatives of daunomycinone and of idarubicinone in which the first sugar moiety linked to the aglycon was 2-deoxy-L-fucose or 2-deoxy-Lrhamnose and the second moiety was daunosamine or a related aminosugar was achieved by glycosylation of the aglycon with the appropriate protected and activated disaccharide [74]. Disaccharide intermediate 33a, obtained upon glycosidation of pmethoxybenzyl 3-O-p-nitrobenzoyl-L-fucoside with 1-thiophenyl-3-N-trifluoroacetyl4-O-p-nitrobenzoyl-L-daunosamine in the presence of iodonium dicollidine perchlorate (IDCP) was converted to 33b with ceric ammonium nitrate and finally esterified with p-nitrobenzoyl chloride to give 33c. Reaction of the latter with the appropriate aglycon in the presence of trimethylsilyl triflate and removal of the protecting groups gave desired 34a and 34b. Similarly, intermediate 35a, obtained from p-methoxybenzyl 3-O-p-nitrobenzoyl-L-fucoside, 1,4-di-O-p-nitrobenzoyl-3-N-trifluoroacetyl-Ldaunosamine, and trimethylsilyl triflate, was converted to 35b and this to 35c as above. Finally, glycosidation of daunomycinone or idarubicinone with 35c and deacylation of the products afforded, respectively, new aminodisaccharide derivatives 36a and 36b. According to biological tests, 34b was the most interesting compound in this series [75], and therefore the synthesis of the corresponding doxorubicin analogue was carried out by reacting 14-acetoxyidarubicinone with activated disaccharide 37 according to the standard procedures, followed by removal
j229
j 9 Anthracyclines, Optimizing Anticancer Analogues
230
of protecting groups to afford 34c, the first disaccharide analogue of doxorubicin ever obtained. Compound 34c gave rise, especially at selected DNA sites, to a more marked topoisomerase II-mediated cleavage and a very significant activity against a spectrum of human tumors, such as breast, ovary, and lung cancer; xenografted in immunodepressed mice, the compound was found markedly superior to doxorubicin in terms of tumor growth inhibition and the number of disease-free survivors among treated animals. The high activity of 34c was tentatively related to the activation of p53independent apoptosis [76]. In tumor cell cultures, 34c and doxorubicin show similar cytotoxicity notwithstanding a significantly reduced rate of cell uptake of the former. When tested on an enlarged number of experimental tumors, 34c inhibited proliferation of 11 of 16 tumor types xenografted in nude mice. This result was found superior to that of doxorubicin (doxorubicin 5/16) when directly compared for 110 days after the first treatment in two different schedules of administration. Compound 34c induced phosphorylation, and therefore inactivation, of the antiapoptotic factor bcl-2 [76]. The generic name selected for 34c by the WHO is sabarubicin [77]. Comparative in vivo activity of sabarubicin and doxorubicin is presented in Table 9.4. O
OR
O
OH
O OpNBz O O NHCOCF3 pNBzO
33a: R=pMeOBn 33b: R=OH 33c: R=pNBz
O R2
OH R
O
OH
O
O
OH
OpNBz
O
R
O
4' OH pNBzO O 35a: R=pMeOBn 35b: R=OH 35c: R=pNBz OpNBz 4'' NH 2 O OH 1 2 OCO2All 34a: R =OMe, R =H O 34b: R1=R2=H O
OH
O
O
NHCOCF3
34c: R1=H, R2=OH
O
O O
1
OH
OR
O
NH2 OH
4' OH 36a: R=OMe 36b: R=H
37
NHCO2All
pNBzO
Stability of DNA complexes formed by sabarubicin (34c) in solution is similar to those of doxorubicin [78]. X-ray diffraction data of the sabarubicin–d(CGATCG) complex indicated, similar to other antitumor anthracyclines, intercalation of two molecules at each end of the DNA duplex in the CpG steps albeit with different conformations at each of the two binding sites. Interestingly, in one of the two sites a tight interaction takes place between the amino group and a guanine residue of a second DNA molecule determining a unique crystal structure [79]. Elongation of the glycosidic moiety has therefore determined the possibility, for the daunosamine residue, to exert productive interactions with other molecular targets in close proximity with DNA.
9.5 Disaccharide Analogues Table 9.4 Activity of anthracycline drugs on human tumors xenografted in nude mice.
Tumor
Schedule
Compound Doxorubicin (2b)
MX-1 (breast) A2780 (ovary) NCI-H460 (lung)
q7d 3b) q3/4d 5d) q7d 3 q3/4d 5 q7d 3 q3/4d 5
Sabarubicin (34c)
Dose
LCKa)
Dose
LCK
10 7 7 7 8.4 5.8
1.4 1.2 2.3 2.1 0.9 1.8
5 2c) 6 5 2c) 7.2 6 2c) 6
2.3 2.4 2.1 3.1 1.4 2.4
Inhibition of in vivo tumor cell proliferation by doxorubicin (2b) and by sabarubicin (34c) given at the indicated doses (mg/kg body weight) according to two different schedules of intravenous administration [76a]. a) Drug efficacy was assessed as the logarithm of cell kill (LCK) achieved in consequence of drug treatment according to the formula LCK ¼ (T C)/DT 3.32 where T is the mean time (days) required for the treated tumors and C for the control untreated tumors to reach an established weight, and DT is the doubling time of control tumors. b) Treatment on days 1, 8, and 15. c) Two injections with a 1 h interval. d) Treatment on days 3, 4, 10, 11, 17, 18, 24, 25, 31, and 32.
Sabarubicin (34c) shows important deviations from doxorubicin in pharmacokinetic properties. A study in human patients indicated higher plasma levels and a much smaller volume of distribution compared to doxorubicin [80]. Also, binding to serum albumin, the value of the corresponding binding constant having been measured spectrophotometrically as 1.1 105 M1, is much stronger than that shown by doxorubicin [81]. Sabarubicin induced less severe myocyte lesions than doxorubicin when repeated equimyelotoxic doses of the two compounds where given to rats and, interestingly, functional and histological effects did not progress after the end of treatment, as is the case with doxorubicin [82]. Phase I clinical studies in patients with solid tumors, who were administered sabarubicin by a short intravenous infusion given every 3 weeks or using a weekly schedule, indicated a better tolerability of sabarubicin compared to doxorubicin [83]. Phase II studies in non-small-cell lung cancer patients with advanced disease revealed two partial responses and eight minor responses in 22 evaluable patients [84]. Seven partial responses and one stable disease were recorded in a group of 10 patients with small-cell lung cancer [85]. Sabarubicin showed significant response rates in patients with advanced resistant ovarian cancer [86] and in hormone refractory prostate cancer [87]. Following substantially similar reaction sequences, the 400 -epimer of sabarubicin, 30 -deoxy disaccharides, and a trisaccharide have also been prepared [88]. The disaccharides showed cytotoxic activity comparable to that of sabarubicin, whereas the trisaccharide, although endowed with topoisomerase II-poisoning properties in
j231
j 9 Anthracyclines, Optimizing Anticancer Analogues
232
the cell-free enzyme test, was less active, presumably because of a lower cell uptake rate. A similar pharmacological profile is shown by nonaminated disaccharide analogues that have been synthesized more recently following the chemistry already outlined for the disaccharide derivatives reported above [89].
9.6 Other Compounds
Annamycin, 30 -deamino-4-demethoxy-30 -hydroxy-20 (R)-iodo-40 -epidoxorubicin (38), has been synthesized and has demonstrated significant activity against the proliferation of resistant human tumors implanted in mice showing that analogues of antitumor anthracyclines in which the basic amino group was substituted with a hydroxyl group were active. These compounds were equally cytotoxic as doxorubicin in cultured cells, but when tested in tumor-bearing mice the optimal dose was found to be approximately one order of magnitude higher. Their interest resided, however, in their activity against doxorubicin-resistant cell lines and in the apparently reduced cardiotoxic effects at equitoxic doses compared to 2b. Annamycin has been developed for clinical trials as a third-generation anthracycline with a liposomal formulation in order to overcome the problem of its low solubility and also to obtain more favorable access to the target tumor tissue [90]. Amrubicin (39) is a totally synthetic idarubicin analogue in which an hydroxyl group replaces the amino group at C-30 and an amino group replaces the C-9 hydroxyl [91]. The compound, as well as the 13-dihydro metabolite, stabilized topoisomerase II–DNA complex [92] and exhibited high potency in in vitro and in vivo laboratory experiments [93, 94]. Amrubicin is registered in Japan and has been proved to be a clinically useful agent in the treatment of small-cell lung cancer [95]. The semisynthetic 30 -morpholino analogues represented by structures 40a,b belong to a definitely different class of anthracycline derivatives [96]. Compounds 40a,b and related derivatives exhibit significant cytotoxicity against both doxorubicinsensitive and -resistant cell lines. Most interesting, however, is the high potency shown by these derivatives, especially by 40b, that inhibits growth of cultured cells at picomolar concentrations and whose active dose in laboratory animals is in the order of a few nanomoles per kilogram of body weight. The results of biochemical investigations have led to the conclusion that the high cytotoxicity should be related to the conversion to reactive species able to form covalent bonds with cellular DNA and to induce the formation of cross-links [97]. It was then found that when the morpholino substitution was performed on the 40 -amino derivatives such as 14a–c, the 40 -morpholino analogues did not show the intense potency of the 30 derivatives, irrespective of the stereochemistry at C-40 [98]. Among the interesting variants of 30 (2-alkoxy-4-morpholino) analogues, the methoxy derivative 40c (nemorubicin) is the most potent in P388 leukemia-bearing mice, exhibits practically the same activity when the animals are inoculated with the doxorubicin-resistant P388 tumor line, and is under clinical investigation [99, 100].
9.7 Summary and Final Remarks O
OH
O
OH
O
OH
O
OH O HO
OH
O
OH
O OH OH
NH2 O
OH
O
O
O
OHI
OH
38
O
OH
OMe O
OH O O
HO
39 1
N
R1
O
R2
2
40a: R =R =H 40b: R1=CN, R2=H 40c: R1=H, R2=OMe
Mitoxantrone is an anthracenedione derivative often referred to as a pharmacological analogue of the anthracyclines. It is used in medical oncology for the treatment of breast cancer [101]. Finally, mention should be made of the bisanthracyclines, a novel structural type characterized by improved sequence specificity and high affinity toward DNA [102].
9.7 Summary and Final Remarks
Notwithstanding the addition, in the past 30 years, of a variety chemical entities to the oncological market, the original biosynthetic anthracyclines, especially doxorubicin, are still present in many drug combinations employed in established modalities of cancer treatment. In fact, doxorubicin is still one of the most widely used drugs in cancer chemotherapy. The successful therapeutic application of doxorubicin, despite its dose-limiting cardiotoxicity and the occurrence of resistance, has stimulated a considerable effort aimed at the development of better analogues by chemical modification of the parent drug or by total synthesis of new structurally related compounds. One early approach to new analogues consisted in the synthesis of related aminosugars, differing in the stereochemistry or in the structure from daunosamine, and coupling the same to the aglycone moiety, with the aim of modifying the pharmacokinetics and/or the metabolism of the natural glycosides. This approach afforded a number of compounds with a wide variation in bioactivity, out of which epirubicin (40 -epidoxorubicin) exhibited a significantly higher chemotherapeutic index when compared to doxorubicin at the clinical level and berubicin (40 -O-benzydoxorubicin) displays activity against brain tumors. A second approach was based on totally synthetic analogues. Idarubicin (4-demethoxydaunorubicin) is an important drug that was developed to the clinical stage because of its powerful activity in experimental leukemia models and reduced cardiotoxicity. Epirubicin is characterized by the detoxification to a glucuronide, whereas idarubicin is extensively reduced to a 13-dihydro derivative showing significant antitumor activity. These drugs are characterized as the second-generation anthracyclines.
j233
j 9 Anthracyclines, Optimizing Anticancer Analogues
234
The search for the third-generation analogues with improved activity and lower side effects has been focused on selected modifications of the aglycone moiety (deoxy and fluoro derivatives), of the sugar moiety (deoxy and iodo derivatives), or to the elongation of the latter (disaccharide derivatives). (8R)-Fluoroidarubicin was found to be as potent as idarubicin in the inhibition of the growth of tumor cell lines in vitro. Interestingly, it displayed a marked cytotoxic activity against doxorubicin-resistant cell lines. It might become the first representative of new pharmacologically important 8R-fluoro anthracycline analogues. Totally synthetic sabarubicin has gone through full preclinical development and is undergoing phase II/III clinical trials in human tumor diseases such as lung, prostate, and breast cancer. Amrubicin is a new synthetic anthracycline so successfully designed that the compound has already been on the market in Japan for a number of years and is employed in the treatment of lung cancer. Alkylating anthracyclines such as nemorubicin, characterized by a (supposedly) completely different molecular mode of action, high potency, and practically an absence of cardiotoxicity at tolerated dosages, await a final assessment as potentially manageable drugs in a field in search of medications conjugating a better tolerability with improved selectivity in terms of biochemical targets.
References 1 OHagan, D. (1991) The Polyketide
2
3
4
5
6
Metabolites, Ellis Horwood, Chichester, UK. Arcamone, F., Di Marco, A., Gaetani, M., and Scotti, T. (1961) Isolamento ed attivita antitumorale di un antibiotico da Streptomyces sp. Giorn. Microbiol., 9, 83–90. Brockmann, H. (1963) Anthracyclinone und anthracycline (rhodomycinone, pyrromycinone und ihre glycoside), in Fortschritte der Chemie Organischer Naturstoffe, vol. 21 (ed. L. Zechmeister), Springer, Vienna, pp. 121–182. Di Marco, A., Gaetani, M., Orezzi, P.G., Scarpinati, B., Silvestrini, R., Soldati, M., Dasdia, T., and Valentini, L. (1964) Daunomycin, a new antibiotic of the rhodomycin group. Nature, 201, 706–707. Di Marco, A., Gaetani, M., Dorigotti, L., Soldati, M., and Bellini, O. (1963) Studi sperimentali sullattivita antineoplastica del nuovo antibiotico daunomicina. Tumori, 49, 203–217. Dubost, M., Ganter, P., Maral, R., Ninet, L., Preudhomme, J., and Werner, G.H. (1964) Un nouvel antibiotique a
7
8
9
10
11
12
13
proprietes antitumorales. Compt. Rend., 257, 1813–1818. Rhone-Poulenc and Farmitalia (1967) Daunomycin und Rubidomycin. Artzneim.-Forsch., 17 1338. Arcamone, F. (1981) Doxorubicin Anticancer Antibiotics (ed. G. De Stevens), Academic Press, New York. Bernard, J., Paul, R., Boiron, M., Jacquillat, C., and Maral, R. (eds) (1969) Recent Results in Cancer Research: Rubidomycin, Springer Verlag, Berlin. Gale, R.P. and Foon, K.A. (1987) Therapy of acute myelogenous leukaemia. Semin. Hematol., 24, 40–54. Carter, S.K. (1975) Adriamycin: a review. J. Nat. Cancer Inst., 55, 1265–1274. Arcamone, F. and Cassinelli, G. (1998) Biosynthetic anthracyclines. Curr. Med. Chem., 5, 391–419. Calendi, E., Di Marco, A., Reggiani, M., Scarpinato, M., and Valentini, L. (1965) On physico-chemical interactions of daunomycin with nucleic acids. Biochim. Biophys. Acta, 103, 25–49.
References 14 Zunino, F., Gambetta, R., Di Marco, A.,
15
16
17
18
19
and Zaccara, A. (1972) Interaction of daunomycin and its derivatives with DNA. Biochim. Biophys. Acta, 277, 489–498. Di Marco, A., Arcamone, F., and Zunino, F. (1975) Daunomycin (daunorubicin) and adriamycin and structural analogues: biological activity and mechanism of action, Mechanism of Action of Antimicrobial and Antitumor Agents (eds J.W. Corcoran and F.E. Hahn), Springer Verlag, Berlin, pp. 101–128. Di Marco, A. and Arcamone, F. (1975) DNA complexing antibiotics: daunomycin, adriamycin and their derivatives. Artzneim.-Forsch., 25, 368–375. Chaires, J.B. (1995) Molecular recognition of DNA by daunorubicin, in Anthracycline Antibiotics, New Analogues, Methods of Delivery and Mechanism of Action, ACS Symposium Series 574 (ed. W. Priebe), American Chemical Society, Washington DC, USA, pp. 156–167. (a) Wheatley, D.N. (1972) Action of adriamycin on HeLa cells. Evidence of a G2 inhibition, in International Symposium on Adriamycin (eds S.K. Carter, A. Di Marco, M. Ghione, I.H. Krakoff, and G. Mathe), Springer Verlag, Berlin, pp. 47–52; (b) Di Marco, A. (1972) Adriamycin: the therapeutic activity in experimental tumors, in International Symposium on Adriamycin (eds S.K. Carter, A. Di Marco, M. Ghione, I.H. Krakoff, and G. Mathe), Springer Verlag, Berlin, pp. 53–63; (c) Yesair, D.W., Asbell, M.A., Bruni, R., Bullock, F.J., and Schwartzbach, E. (1972) Pharmacokinetics and metabolism of adriamycin and daunomycin, in International Symposium on Adriamycin (eds S.K. Carter, A. Di Marco, M. Ghione, I.H. Krakoff, and G. Mathe), Springer Verlag, Berlin, pp. 117–123. Bellini, O. and Solcia, E. (1985) Early and late sarcoplasmic reticulum changes in doxorubicin cardiomyopathy. Virchows Arch. (Cell Pathol.), 49, 137–152.
20 Ishikawa, T. and Sies, H. (1984)
21
22
23
24
25
26
Cardiac transport of glutathione disulfide and S-conjugates. Studies with isolated perfused rat heart during hydroperoxide metabolism. J. Biol. Chem., 239, 3838–3843. Olson, R.D., Mac Donald, J.S., Von Boxtel, C.J., Boerth, R.C., Harbison, R.D., Slonim, A.E., Freman, R.W., and Oates, J. (1980) Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. J. Pharmacol. Exp. Ther., 215, 450–454. Formelli, F., Zedeck, M.S., Sternberg, S.S., and Plilips, F.S. (1978) Effect of adriamycin on DNA synthesis in mouse and rat heart. Cancer Res., 38, 3286–3292. Ellis, C.N., Ellis, M.B., and Blakemore, W.S. (1987) Effect of adriamycin on heart mitochondrial DNA. Biochem. J., 245, 309–312. Gerwitz, D.A. (1992) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracyclines antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 57, 727–741. (a) Arcamone, F. (1977) New antitumor anthracyclines. Lloydia, 40, 45–66; (b) Arcamone, F., Di Marco, A., and Casazza, A.M. (1978) Chemistry and pharmacology of new antitumor anthracyclines, in Advances in Cancer Chemotherapy (eds H. Umezawa et al.), Japan Sci. Soc. Press, Tokyo University Park Press, Baltimore, pp. 297–312; (c) Arcamone, F. (1980) The development of new antitumor anthracyclines, in Antitumor Agents Based on Natural Product Models (eds J. Cassady and J. Douros), Academic Press, New York, pp. 1–41; (d) Arcamone, F. (1984) Antitumor anthracyclines: recent developments, in Medicinal Research Reviews, vol. 4 (ed. G. de Stevens), Wiley and Sons New York, pp. 153–188. Arcamone, F. (2005) Anthracyclines, in Anticancer Agents from Natural Products (eds G.M. Cragg, D.G.I. Kingston, and D.J. Newman), CRC Press, Taylor & Francis Group, Boca Raton, pp. 299–320.
j235
j 9 Anthracyclines, Optimizing Anticancer Analogues
236
27 Lomakina, N.N., Spiridonova, I.A.,
28
29
30
31
32
33
34
Shenker, Y.U.N., and Vlasova, T.F. (1973) The structure of the amino sugars from the antibiotic actinoidin. Chem. Nat. Compd., 9, 90–94. Arcamone, F., Penco, S., Vigevani, A., Redaelli, S., Franchi, G., Di Marco, A., Casazza, A.M., Dasdia, T., Formelli, F., Necco, A., and Soranzo, C. (1975) Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J. Med. Chem., 18, 703–707. Suarato, A., Penco, S., Vigevani, A., and Arcamone, F. (1981) Anthracycline chemistry: direct conversion of daunorubicin into the L-arabino, L-ribo, and L-lyxo analogues and selective deoxygenation at C-40 . Carbohyd. Res., 98, C1–C3. Bognar, R., Sztaricskai, F., Munk, M.E., and Tamas, J. (1974) Structure and stereochemistry of ristosamine. J. Org. Chem., 39, 2971–2974. Arcamone, F., Bargiotti, A., Cassinelli, G., Penco, S., and Hanessian, S. (1976) Synthesis of a configurational analog of daunorubicin. Carbohyd. Res., 46, C3–C5. Bargiotti, A., Cassinelli, G., and Arcamone, F. (1978) Antitumorglycoside und Verfahren zu deren Herstellung, Ger. Offen. 2,752,115, Filed November 22, 1977 and published June 1. Bargiotti, A., Cassinelli, G., Franchi, G., Gioia, B., Lazzati, E., Redaelli, S., Vigevani, A., Arcamone, F., and Hanessian, S. (1977) Synthesis of derivatives of 3-amino-2,3-dideoxy-Lhexose related to daunosamine (3-amino-2,3, 6-trideoxy-L-lyxo-hexose). Carbohyd. Res., 58, 353–361. Arcamone, F., Bargiotti, A., Cassinelli, G., Redaelli, S., Hanessian, S., Di Marco, A., Casazza, A.M., Dasdia, T., Necco, A., Reggiani, P., and Supino, R. (1976) Stereocontrolled glycosidation of daunomycinone. Synthesis and biological evaluation of 6-hydroxy-Larabino analogues of antitumor anthracyclines. J. Med. Chem., 19, 733–734.
35 Penco, S., Angelucci, F., and
36
37
38
39
40
41
Arcamone, F. (1978) Daunomycinderivate, Verfahren zu ihrer Herstellung und ihrer Verwendung, Ger. Offen. 2,757,057, Filed December 21, 1977 and issued July 6. Arcamone, F., Penco, S., Redaelli, S., and Hanessian, S. (1976) Synthesis and antitumor activity of 40 deoxydaunorubicin and 40 deoxyadriamycin. J. Med. Chem., 19, 1424–1425. Cassinelli, G., Ruggeri, D., and Arcamone, F. (1979) Synthesis and antitumor activity of 40 -Omethyldaunorubicin, 40 -Omethyladriamycin, and their 40 -epianalogues. J. Med. Chem., 22, 121–123. Bargiotti, A., Cassinelli, G., Penco, S., Vigevani, A., and Arcamone, F. (1982) Synthesis of branched-chain aminodeoxyhexoses related to daunosamine (3-amino-2,3,6-trideoxy-Llyxo-hexose). Carbohyd. Res., 100, 273–281. (a) Bargiotti, A., Casazza, A.M., Cassinelli, G., Di Marco, A., Penco, S., Pratesi, G., Supino, R., Zaccara, A., Zunino, F., and Arcamone, F. (1983) Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety. Cancer Chemother. Pharmacol., 10, 84–89; (b) Kazerooni, R., Conrad, C., Johansen, M.J., Sakamoto, M., Fokt, I., Schroeder, C., Thapar, N., Meyer, C., Priebe, W., and Madden, T. (2008) Hematologic pharmacodynamics linked to the pharmacokinetics of berubicin, a blood–brain barrier penetrating anthracycline active against high grade glioma, in phase I/II clinical trials. Eur. J. Cancer, 6 (12 Suppl.), 187. Barbieri, B., Giuliani, F.C., Bordoni, T., Casazza, A.M., Geroni, C., Bellini, O., Suarato, A., Gioia, B., Penco, S., and Arcamone, F. (1987) Chemical and biological characterization of 40 -iodo-40 deoxy-doxorubicin. Cancer Res., 47, 4001–4006. Bargiotti, A., Caruso, M., Suarato, A., and Giuliani, F. (1987) 30 -Deamino-30 -
References
42
43
44
45
46
47
48
49
hydroxy-40 -deoxy-40 -amino doxorubicin and related daunorubicin, US Patent 4,684,629, Filed March 24, 1986 and published August 4. Bargiotti, A., Suarato, A., Zini, P., Grandi, M., and Pezzoni, G. (1991) 30 -Deamino40 -deoxy-40 -amino anthracyclines, US Patent 4,987,126, Filed January 9, 1989 and issued January 22. Bargiotti, A., Grandi, M., Suarato, A., and Giuliani, F. (1991) 4-Demethoxy-40 amino-40 -deoxy-anthracycline derivatives, US Patent 5,045,534, Filed March 30, 1990 and issued September 3. (a) Ganzina, F. (1983) 40 -Epidoxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev., 10, 1–22; (b) Plosker, G.L. and Fauld, D. (1993) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs, 45, 788–856. Robert, J. (1994) Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet., 26, 428–438. Ringenberg, Q.S., Propert, K.J., Muss, H.M., Weis, R.B., Schilsky, R.L., Modeas, C., Perry, M.C., Norton, L., and Green, M. (1990) Clinical cardiotoxicity of esorubicin (40 -deoxydoxorubicin, DxDx): prospective studies with serial gated heart scans and reports of selected cases. A cancer and leukemia group B report. Invest. New Drugs, 8, 221–226. Sessa, C., Calabresi, F., Cavalli, F., Cerny, T., Liati, P., Skovsgaard, T., Sorio, R., and Kaye, S.B. (1991) Phase II studies of 40 iodo-40 -deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. Ann. Oncol., 2, 727–731. Wong, C.M., Schwenk, R., Popien, D., and Ho, T.L. (1973) The total synthesis of daunomycinone. Can. J. Chem., 51, 466–473. Penco, S., Casazza, A.M., Franchi, G., Barbieri, B., Bellini, O., Podesta, A., Savi, G., Pratesi, G., Geroni, C., Di Marco, A., and Arcamone, F. (1983) Synthesis, antitumor activity and cardiac toxicity of
50
51
52
53
54
55
56
new 4-demetoxyanthracyclines. Cancer Treat. Rep., 67, 665–674. (a) Arcamone, F., Cassinelli, G., and Penco, S. (1982) Recent developments in the chemistry of doxorubicin-related anthracycline glycosides, in Anthracycline Antibiotics (ed. H.S. El Khadem), Academic Press, New York, pp. 59–73; (b) Qu, X., Trent, J.O., Fokt, I., Priebe, W., and Chaires, J.B. (2000) Allosteric, chiral-selective drug binding to DNA. Proc. Natl. Acad. Sci. USA, 97 (22), 12032–12037. Cabri, W., De Bernardinis, S., Francalanci, F., and Penco, S. (1990) A novel synthesis of ( þ )4demethoxydaunomycinone. J. Chem. Soc., Perkin Trans. 1, 428–429. Zunino, F., Casazza, A.M., Pratesi, G., Formelli, G., and Di Marco, A. (1981) Effect of the methylation of aglycone hydroxyl groups on the biological and biochemical properties of daunorubicin. Biochem. Pharmacol., 13, 1856–1858. Valentini, L., Nicolella, V., Vannini, E., Menozzi, M., Penco, S., and Arcamone, F. (1985) Association of anthracycline derivatives with DNA: a fluorescence study. Farmaco Ed. Sci., 40, 377–390. Cassinelli, G., Grein, A., Masi, P., Suarato, A., Bernardi, L., Arcamone, F., Di Marco, A., Casazza, A.M., Pratesi, G., and Soranzo, C. (1978) Preparation and biological evaluation of 4-Odemethyldaunorubicin (carminomycin I) and its 13-dihydroderivative. J. Antibiot., 31, 178–184. Masi, P., Suarato, A., Giardino, P., Iraci, G., Bernardi, L., and Arcamone, F. (1980) 4-Demethoxy-4-hydroxydaaunorubicin 6-methyl ether and 11methyl ether, two active isomers of daunorubicin. Farmaco Ed. Sci., 35, 347–356. Zunino, F., Barbieri, B., Bellini, O., Casazza, A.M., Geroni, C., Giuliani, F., Ciana, A., Mancini, G., and Quadrifoglio, F. (1986) Biochemical and biological activity of the anthracycline analog, 4-demethyl-6-Omethyl-doxorubicin. Invest. New Drugs, 4, 17–23.
j237
j 9 Anthracyclines, Optimizing Anticancer Analogues
238
57 Cassinelli, G., Di Matteo, F., Forenza, S.,
58
59
60
61
62
Ripamonti, M.C., Rivola, G., Arcamone, F., Di Marco, A., Casazza, A.M., Soranzo, C., and Pratesi, G. (1980) New anthracycline glycosides from Micromonospora. II. Isolation, characterization and biological properties. J. Antibiot., 33, 1468–1473. (a) Arcamone, F., Cassinelli, G., Di Matteo, F., Forenza, S., Ripamonti, M.C., Rivola, G., Vigevani, A., Clardy, J., and McCabe, T. (1980) Structures of novel anthracycline antitumor antibiotics from Micromonospora peucetica. J. Am. Chem. Soc., 102, 1462–1463;(b) Cassinelli, G., Rivola, G., Ripamonti, D., Arcamone, F., Grein, A., Merli, S., Spalla, C., Casazza, A.M., Di Marco, A., and Pratesi, G. (1982) New anthracycline glycosides: 4-O-demethyl-11deoxydoxorubicin and analogues from Streptomyces peucetius var. aureus. J. Antibiot., 35, 175–183. Umezawa, H., Takahashi, Y., Naganawa, H., Tatsuta, K., and Takeuchi, T. (1980) Synthesis of 4-demethoxy-11-deoxy analogs of daunomycin and adriamycin. J. Antibiot., 33, 1581–1985. (a) Penco, S., Angelucci, F., Arcamone, F., Ballabio, M., Barchielli, G., Franceschi, G., Suarato, A., and Vanotti, E. (1983) Regiospecific total synthesis of 6-deoxyanthracyclines: 4-demethoxy-6deoxy-daunorubicin. J. Org. Chem., 48, 405–406; (b) Angelucci, F., Arcamone, F., Barchielli, G., Suarato, A., Vanotti, E., and Penco, S. (1984) Regiospecific total synthesis of 6-deoxyanthracyclines: 6deoxycarminomycin. Chem. Commun., 530–531. (a) Cersosimo, R.J. (1992) Idarubicin: an anthracycline antineoplastic agent. Clin Pharm., 11, 152–167; (b) Buckley, M.M. and Lamb, H.M. (1997) Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Drugs Aging, 11, 61–86. (a) Capranico, G., De Isabella, P., Penco, S., Tinelli, S., and Zunino, F. (1989) Role of DNA breakage in cytotoxicity of
63
64
65
66
67
68
69
70
doxorubicin, 6-deoxydoxorubicin, and 4demethyl-6-deoxydoxorubicin in murine leukemia P388 cells. Cancer Res., 49, 2022–2027; (b) Arcamone, F. and Penco, S. (1989) Relationship of structure to anticancer activity and toxicity in anthracyclines. Gann Monogr. Cancer Res., 36, 81–94. Pavlovsky, S., Fernandez, I., Palau, V., Santarelli, M.T., De Bellis, R., RuizArguelles, G., Brandalise, S., and Jimenez-Fonseca, E. (1991) Short report: combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukaemia. Ann. Oncol., 2, 441–442. Penco, S., Franchi, G., and Arcamone, F. (1980) Antitumor deoxy-anthracyclines and use thereof, US Patent 4,218,440, Filed September 13, 1978 and issued August 19. Arcamone, F. and Penco, S. (1987) Molecular mechanisms of carcinogenic and antitumor activity, in Pontificiae Academiae Scientiarium, Scripta Varia, vol. 70 (eds C. Chagas and B. Pullman), Adenine Press Schenectady, pp. 225–241. Penco, S., Vigevani, A., Tosi, C., Fusco, R., Borghi, D., and Arcamone, F. (1986) Conformational flexibility of ring A in a series of substituted anthracyclines: 1 H-n.m.r. and quantum mechanical studies. Anticancer Drug Des., 1, 161–165. Gresh, N., Pullman, B., Arcamone, F., Menozzi, M., and Tonani, R. (1989) Joint experimental and theoretical investigation of the comparative DNA binding affinities of intercalative anthracycline derivatives. Mol. Pharmacol., 35, 251–258. Pasqui, F., Canfarini, F., Giolitti, A., Guidi, A., Pestellini, V., and Arcamone, F. (1996) Synthesis of ring A fluorinated anthracyclines. Tetrahedron, 52, 185–198. Lombardi, P., Animati, F., Cipollone, A., Giannini, G., Monteagudo, E., and Arcamone, F. (1995) Synthesis and conformational preference of novel 8-fluoroanthracyclines. Acta Biochim. Polonica, 42, 433–444. Animati, F., Arcamone, F., Bigioni, M., Capranico, G., Caserini, C., De Cesare,
References
71
72
73
74
75
76
M., Lombardi, P., Pratesi, G., Salvatore, C., Supino, R., and Zunino, F. (1996) Biochemical pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation. Mol. Pharmacol., 50, 603–609. Berrettoni, M., Cipollone, A., Olivieri, L., Palomba, D., Arcamone, F., Maggi, C.A., and Animati, F. (2002) Synthesis of 14-fluorodoxorubicin. Tetrahedron Lett., 43, 2867–2871. Moro, S., Beretta, G.L., Dal Ben, D., Nitiss, J., Palumbo, M., and Capranico, G. (2004) Interaction model for anthracycline activity against DNA topoisomerase II. Biochemistry, 43, 7503–7513. Arcamone, F. (1985) Properties of antitumor anthracyclines and new developments in their application, Cain Memorial Award Lecture. Cancer Res., 45, 5995–5999. Animati, F., Arcamone, F., Berettoni, M., Cipollone, A., Franciotti, M., and Lombardi, P. (1996) New anthracycline disaccharides. Synthesis of Ldaunosaminyl-a(1-4)-2-deoxy-Lrhamnosyl and of L-daunosaminyla(1-4)-2-deoxy-L-fucosyl daunorubicin analogues. J. Chem. Soc., Perkin Trans. I, 1327–1329. Arcamone, F., Animati, F., Bigioni, M., Capranico, G., Caserini, C., Cipollone, A., De Cesare, M., Ettorre, A., Guano, F., Manzini, S., Monteagudo, E., Pratesi, G., Salvatore, C., Supino, R., and Zunino, F. (1999) Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides. Biochem. Pharmacol., 57, 1133–1139. Arcamone, F., Animati, F., Berettoni, M., Bigioni, M., Capranico, G., Casazza, A.M., Caserini, C., Cipollone, A., De Cesare, M., Franciotti, M., Lombardi, P., Madami, A., Mancini, S., Monteagudo, E., Polizzi, D., Pratesi, G., Righetti, S.C., Salvatore, C., Supino, R., and Zunino, F. (1997) Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J. Nat. Cancer Inst., 89, 1217–1223.
77 Arcamone, F. (2008) Sabarubicin, in
78
79
80
81
82
83
Anthracycline Chemistry and Biology II, Topics in Current Chemistry, vol. 283 (ed. K. Krohn), Springer, Berlin, pp. 171–189. Messori, L., Temperini, C., Piccioli, F., Orioli, P., Di Bugno, C., and Animati, F. (2001) Solution chemistry and DNA binding properties of MEN 10755, a novel disaccharide analogue of doxorubicin. Bioorg. Med. Chem., 9, 938–941. Temperini, C., Messori, L., Orioli, P., Di Bugno, C., Animati, F., and Ughetto, G. (2003) The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d (CGATCG) reveals two different binding sites involving two DNA duplexes. Nucleic Acids Res., 31, 1464–1469. Bos, A.M.E., De Vries, E.G.E., Dombernovsky, P., Aamdal, S., Uge, D.R.A., Shuijvers, D., Wanders, J., Roelwink, M.W.J., Hanauske, A.R., Bortini, S., Capriati, A., Crea, A.E.G., and Vermorken, J.B. (2001) Pharmacokinetics of Men 10755, a novel anthracycline disaccharide analogue in two phase I studies in adults with advanced solid tumours. Cancer Chemother. Pharmacol., 48, 361–369. Messori, L., Piccioli, F., Gabrielli, S., Orioli, P., Angeloni, L., and Di Bugno, C. (2002) The disaccharide anthracycline MEN 10755 binds human serum albumin to a non-classical drug binding site. Bioorg. Med. Chem., 10, 3425–3432. Cirillo, R., Sacco, G., Venturella, S., Brightwell, J., Giachetti, A., and Mancini, S. (2000) Comparison of doxorubicin and MEN 10755-induced long term progressive cardiotoxicity in the rat. Cardiovasc. Pharmacol., 35, 100–108. Schrivers, D., Bos, A.M.E., Dyck, J., De Vries, E.G.E., Wanders, J., Roelvik, M., Fumoleau, P., Bortini, S., and Vermorke, J.B. (2002) Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European
j239
j 9 Anthracyclines, Optimizing Anticancer Analogues
240
84
85
86
87
88
89
Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Ann. Oncol., 13, 385–391. Tjan-Heijnen, V.C.G., Gerritsen, A., ten Valde, G.P.M., Giaccone, G., Gamucci, T., Comandini, A., Capriati, A., Mordiva, A., Nurmohamed, S., and Ruland-Adank, S. (2002) A phase II study with MEN 10755 as second line therapy in advanced non small cell lung cancer (NSCLC). Ann. Oncol., 13 (Suppl. 5), 148. Dickgreber, N.J., Welte, T., Gillissen, A., Dunlop, D., Eberhardt, W., Wagner, T., Swinson, D., Capriati, A., and OByrne, K. (2003) Phase II open-label study of MEN-10755 in patients with small cell lung cancer extensive disease. Proc. Am. Soc. Clin. Oncol., 22, 703. Caponigro, F., Willems, P., Sorio, R., Floquet, A., van Belle, S., Demol, J., Tambaro, R., Comandini, A., Capriati, A., Adank, S., and Wanders, J. (2005) A phase II study of sabarubicin (MEN10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Invest. New Drugs, 23, 85–89. Fiedler, W., Tchen, N., Bloch, J., Fargeot, P., Sorio, R., Vermorken, J.B., Collette, L., Lacombe, D., and Twelves, C. (2006) A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN10755) in patients with progressive hormone refractory prostate cancer. Eur. J. Cancer, 42, 200–204. Cipollone, A., Berettoni, M., Bigioni, M., Binaschi, M., Cermele, C., Monteagudo, E., Olivieri, L., Palomba, D., Animati, F., Goso, C., and Maggi, C.A. (2002) Novel anthracycline oligosaccharides: influence of chemical modifications of the carbohydrate moiety on biological activity. Bioorg. Med. Chem., 10, 1459–1470. Bigioni, M., Salvatore, C., Cipollone, A., Berrettoni, M., Maggi, C.A., and Binaschi, M. (2005) Pharmacological profile of new deamino analogues of sabarubicin. Lett. Drug Design Disc., 2, 65–73.
90 Priebe, W., Skibicki, P., Varela, O.,
91
92
93
94
95
96
Neamati, N., Sznaidman, M., Dziewiszek, K., Grynkiewicz, G., Horton, D., Zou, Y., Ling, Y.-H., and Perez Soler, R. (1995) Non-cross-resistant anthracyclines with reduced basicity and increased stability of the glycoside bond, in Anthracycline Antibiotics. New Analogues, Methods of Delivery and Mechanisms of Action, ACS Symposium Series 574 (ed. W. Priebe), American Chemical Society, Washington, DC, pp. 14–46. Ishizumi, K., Ohashi, N., and Tanno, N. (1987) Stereospecific total synthesis of 9-aminoanthracyclines: ( þ )-9-amino-9deoxydaunomycin and related compounds. J. Org. Chem., 52, 4477–4485. Hanada, M., Mizuno, S., Fukushima, A., Yoshikazu, S., Noguchi, T., and Yamaoka, T. (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II–DNA complex. Jpn. J. Cancer Res., 89, 1229–1238. Yamaoka, T., Hanada, M., Ichii, S., Morisada, S., Noguchi, T., and Yanagi, Y. (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumour cells. Jpn. J. Cancer Res., 89, 1067–1073. Morisada, S., Yanagi, Y., and Noguchi, T. (1989) Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn. J. Cancer Res., 80, 69–76. Yana, T., Negoro, S., Takada, M., Yokota, S., Takada, Y., Sugiura, T., Yamamoto, H., Sawa, T., Kawahara, M., Katakami, N., Ariyoshi, Y., and Fukuoka, M. (2007) Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group study. Invest. New Drug., 25, 253–258. Acton, E.M., Tong, G.L., Mosher, G.W., and Wolgemuth, R.L. (1984) Intensely potent morpholinyl anthracyclines. J. Med. Chem., 27, 638–645.
References 97 Acton, E.M., Wasserman, K., and
Newman, R.A. (1988) Morpholinyl anthracyclines, in Anthracycline and Anthracenedione-Based Anticancer Agents (ed W. Lown), Elsevier, Amsterdam, pp. 55–101. 98 Suarato, A., Angelucci, F., Bargiotti, A., Caruso, M., Faiardi, D., Capolongo, L., Geroni, C., Ripamonti, M., and Grandi, M. (1995) Synthesis and study of structure–activity relationships of new classes of anthracyclines, in Anthracycline Antibiotics. New Analogues, Methods of Delivery and Mechanisms of Action, ACS Symposium Series 574 (ed. W. Priebe), American Chemical Society, Washington, DC, pp. 142–155. 99 Bakker, M., Droz, J.P., Hanauske, A.R., Verweij, J., van Oosterom, A.T., Groen, H.J., Pacciarini, M.A., Domenigoni, L., van Weissenbruch, F., Pianezzola, E., and De Vries, E.G.E. (1998) Broad phase II
and pharmacokinetic study of methoxymorpholino doxorubicin (FCE 23762MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. Br. J. Cancer, 77, 139–146. 100 Broggini, M. (2008) Nemorubicin, in Anthracycline Chemistry and Biology II, Topics in Current Chemistry, vol. 283 (ed. K. Krohn), Springer, Berlin pp. 191–206. 101 Durr, F.E. (1988) Biochemical pharmacology and tumor biology of mitoxantrone and ametantrone, in Anthracycline and AnthracenedioneBased Anticancer Agents (ed. W. Lown), Elsevier, Amsterdam, pp. 163–200. 102 Portugal, J., Cashman, D.J., Trent, J.O., Ferrer-Miralles, N., Przewloka, T., Fokt, I., Priebe, W., and Chaires, J.B. (2005) A new bisintercalating anthracycline with picomolar DNA binding affinity. J. Med. Chem., 48, 8209–8219.
Federico-Maria Arcamone
Professor Dott., Naxospharma, 70 Via Giuseppe Di Vittorio, 20026 Novate (Milano), Italy Federico-Maria Arcamone, a Scuola Normale Superiore di Pisa chemistry licentiate, has been active in the field of natural product chemistry and antibiotic research, becoming Head of Chemical Research at Farmitalia, Milan, in 1973. He is the author of over 200 research papers and over 100 patents, and has been an active lecturer in different countries, especially in the United States as well as in Italy. He has been honored with, among others, the gold medal of the Accademia dei XL, the Bruce Cain Award of the American Association for Cancer Research, the Musajo Award of the Italian Chemical Society, and the gold medal of the Italian Federation of Chemical Industries.
j241
j243
10 Paclitaxel and Epothilone Analogues, Anticancer Drugs Paul W. Erhardt and Mohammad El-Dakdouki
10.1 Introduction
As described within the first volume of this series, analogue-based drug discovery (ABDD) represents a long-standing strategy that can contribute to the generation of new chemical entities (NCE), as well as play a lead role in the continued chemical and pharmacological evolution of clinically validated therapeutic paradigms [1]. It was further noted that ABDD represents a particularly useful approach toward ligandbased drug design by virtue of the inherent drug-like properties that already are present when a successfully marketed drug is deployed as a template for elaboration into new compounds [2]. Alternatively, as summarized in a recent review article [3], the even longer standing field of small molecule natural products (NPs) offers a different type of contribution that also remains highly important for modern drug discovery. Constituting the initial source for numerous of todays medicines [3, 4], the seemingly limitless structural [diversity of NPs] coupled with their novel biological properties [continues to] provide enormous inspiration [5] to medicinal chemists during the pursuit of new drugs. It has thus become a logical extension to further elaborate new NP pioneer drugs by undertaking tandem ABDD strategies. Indeed, of about 1000 NCEs approved in the United States between 1981 and 2006, nearly 50 were unaltered NPs and nearly another 250 were second-generation NP derivatives primarily created to improve clinically relevant properties such as solubility and pharmacokinetic (PK) profile [4, 6]. The present chapter will highlight just one of such NP-prompted ABDD areas, namely, that associated with the pursuit of compounds that can overstabilize microtubules and thereby cause apoptosis of human cancer cells.
10.2 Discovery and Development of Paclitaxel
Several texts and reviews have provided excellent discussions about the fascinating historical aspects that eventually led to paclitaxels present status as an NP pioneer
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
244
HO
O
AcO
OH
(a)
O
OTES
(b) HO
HO
O
O AcO
HO
AcO
HO OBz
OBz O
10-DAB
O
Ph N
(c)
Ph O
AcO O
NH
Ph
O
OTES
O
OH
10
(d)
7
AcO NH
Ph
O
OTES
O
2'
O
Ph
13
O
OH
AcO
HO
O
Ph
O
OTES HO
OBz
1 Scheme 10.1 Semisynthetic route ultimately used to prepare commercial quantities of paclitaxel shown as 1 from 10-deacetyl-baccatin III shown as 10-DAB [18]. A similar semisynthetic route can be used to prepare docetaxel (shown later) by deploying the t-
AcO OBz
butoxycarbonyl version of the benzyloxy b-lactam and by utilizing other C-13 side-chain synthons. Conditions and yields: (a) Et3SiCl/ pyridine, 86%; (b) AcCl/pyridine, 86%; (c) nBuLi/THF then b-lactam/THF, 98%; (d) HF/ pyridine, 98%.
drug [7–10]. The following account offers just a quick backdrop for our subsequent ABDD-related discussions while paying tribute to at least some of the notable scientists who played key roles in that story. First obtained from the bark of the Pacific yew about 40 years ago by Wall and Wani [11] under an NP screening program being conducted by the US National Cancer Institute, the development of paclitaxel (1 in Scheme 10.1) initially was delayed by its low yield after a tedious isolation process coupled with the misconception that its anticancer properties stemmed from a common and thus rather ordinary biological mechanism. It was not until nearly 15 years later, after Horwitz and coworkers [12] demonstrated that 1 had a unique mechanism of action derived from an overstabilization of microtubules, when excitement about this compound began to mount. The rush to then move 1 into the clinic as rapidly as possible, and the need to provide huge supplies to accommodate its immediate success, quickly led to considerable concern about the future supply of 1 because removal of a yews bark leads to destruction of the tree. Amid extraordinary efforts by several investigators to synthesize 1 [7–10], it was eventually demonstrated by Potier et al. that 10-deacetyl-baccatin III (10-DAB in Scheme 10.1) that is obtained from the needles of both the Pacific and the European yew in a manner that is not destructive to the source, constitutes a key intermediate for a practical semisynthesis of what had by then become an extremely precious NP [13]. Although many notable chemists, as well as a modest effort in our labs
10.3 Clinical Success and Shortcomings of Paclitaxel
j245
O O Ph
OH OCH3
a
O
Br
2
Ph
OCH3
3
NH
c Ph
OH
Scheme 10.2 Acyl migration route developed and confirmed in our labs [14] to produce the C-13 side chain via a Sharpless dihydroxylation procedure [15]. (a) AD-a mixture, t-BuOH/H2O; (b) i. PhC(OCH3)3, cat. p-TsOH; ii. AcBr, 15 C; (c) i. NaN3, DMF; ii.
Ph
O
b OCH3 OCOPh
O
Ph
OCH3 OH
H2, 10% Pd/C; overall yield ¼ 25%. Although never progressing to a competitive commercial process, this chemical strategy has recently drawn interest in the design of prodrugs having increased selectivity for cancer cells [19].
(Scheme 10.2) [14] using a Sharpless dihydroxylation procedure [15], contributed significantly to this chemistry arena, Holtons patented semisynthesis that takes advantage of a lithium alkoxide [16, 17] eventually was adopted for converting 10-DAB to 1 via reaction with the indicated b-lactam on a commercial scale according to Scheme 10.1 [18]. Today, the production of paclitaxel can be said to have gone green with its principal manufacturer Bristol-Meyers Squibb having recently been recognized by the US EPA for its development of a plant cell fermentation (PCF) method that has completely replaced chemical synthesis [20]. In the PCF process, calluses of a specific taxus cell line are propagated in an aqueous medium in large fermentation tanks under ambient temperature and pressure. The final product 1 is harvested as a crude extract from the plant cell cultures, purified by column chromatography and isolated by crystallization. Compared to the semisynthetic route across a period of 5 years of commercialization, the PCF process is estimated to have avoided the concomitant production of 71 000 pounds of hazardous by-product chemicals while eliminating 10 solvents and 6 drying steps that also equates to saving a significant amount of energy [20].
10.3 Clinical Success and Shortcomings of Paclitaxel
Initially studied for the treatment of ovarian cancer [21] and shortly thereafter for the treatment of breast tumors [22], paclitaxel quickly became regarded as one of the major breakthroughs in cancer therapy during the 1990s. Since that hugely successful introduction, 1 has maintained the status of being one of the most important anticancer drugs today wherein its use in other cancers and in combination with other agents is still being optimized. As with many other drugs and for cancer chemotherapeutic agents in general, however, 1 does have some significant shortcomings relative to its deployment in the clinic. The first of these to be noted was its extremely poor aqueous solubility. Because 1 is not orally bioavailable, it must be administered by intravenous infusion (i.v.) wherein the low aqueous solubility becomes problematic. To address the solubility issue, the most widely used formulation of 1 contains 50% CremophorÒ EL and 50% dehydrated ethanol [23].
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
246
Unfortunately, the presence of such a high level of CremophorÒ EL can frequently trigger acute hypersensitivity reactions [24], and it likely contributes to the less than ideal, nonlinear pharmacokinetic behavior of 1 observed in both mice and humans [25, 26]. A second shortcoming pertains to a very common issue among many cancer chemotherapeutic compounds. Like most agents that rely upon the rapid division of cancer cells to achieve selective toxicity relative to healthy cells, the therapeutic margin for 1 is not as large as would be desired. Thus, side-effect toxicity, particularly associated with rapidly dividing normal cells, becomes dose limiting. Finally, it was noted that upon prolonged treatment, breast cancer cells can develop resistance to the effects of 1. When this last phenomenon couples with an already small window for safe (side-effect free) therapy, further treatment at higher doses essentially becomes precluded. One of the predominant mechanisms for this resistance stems from the overexpression of the P-glycoprotein (Pgp) efflux transporter. The significance of these last two shortcomings is further exemplified by the plots displayed in Figure 10.1 that conveys data generated from our laboratories. The narrow safety margin between paclitaxels effects on cancer cells and its effects on rapidly dividing healthy cells is reflected by the very close proximity of the first two log dose–response curves for causing growth inhibition (GI) of cell cultures. Likewise, the profound effect that Pgp-derived resistance can have upon paclitaxels effects is illustrated by the third curve that has shifted to the right in such a manner that it now requires nearly three orders of magnitude higher drug concentration to cause 50% inhibition of cell growth (GI50 value). Although 1 and its related taxanes appear to be 1.2 Paclitaxel Fraction of Control Growth
1.0 0.8
NCI/ADR-RES (Pgp+/ER-)
MCF12A (Normal)
MCF7 (Pgp-/ER+)
0.6 0.4 0.2 0.0
N = 130 for most concentrations N = 5-24 for two highest and two lowest concentrations
-0.2 10-11
10-10
10-9
10-8 10-7 Concentration (M)
Figure 10.1 Log dose–response curves for the action of paclitaxel on three different human cell lines grown in cell culture. Control cultures did not receive drug. MCF-7 (red curve with circled data points) is a nonresistant breast cancer. MCF-12A (green curve with square data points) is a healthy breast epithelial cell line that is
10-6
10-5
10-4
noncancerous and nonresistant. NCI/ADR-RES (blue curve with triangular data points) is a drugresistant ovarian cancer. Pgp refers to Pglycoprotein that is either absent () or overexpressed ( þ ) and ER refers to estrogen receptor responsiveness ( þ ) or absence ().
10.4 ABDD Leading to Docetaxel
exceptional substrates for Pgp [27], the far from ideal profile of activity conveyed in Figure 10.1 is a common shortcoming that is displayed by many cancer chemotherapeutic agents in general. Underscoring this situation is the fact that the Pgp component is so prevalent and is so promiscuous in its substrate structural requirements that its overexpression leads to the broadly applicable phenomenon known as multidrug resistance or MDR.
10.4 ABDD Leading to Docetaxel
In addition to the compound supply aspects that became so critical for 1s development and progression into the clinic, the subsequently huge success of paclitaxel fueled even further by its noted shortcomings, prompted a surge in basic research on several fronts. These fronts encompassed (i) pursuit of 1s binding site in response to the finding that its interactionwith microtubules had been shown tobe stoichiometric [28]; (ii) elaboration of classical medicinal chemistry structure–activity relationships (SARs) including detailed assessments of 1s conformational behavior in different environments as well as production of photoaffinity label derivatives for use as receptor probes [29]; (iii) numerous efforts directed toward addressing the specific shortcomings present in its clinical profile as discussed in the previous section; and (iv) pursuit of entirely new structures that might still act via 1s unique mechanism when it was eventually shown that an overstabilization of microtubules prompts apoptosis at the G2 to M transition stage of the cell cycle during attempted replication. While (i)–(iii) largely represent areas directed toward structural analogues that preserve the desired biological effect (the so-called structural and pharmacological analogues), area (iv) represents a distinct case of pursuing pharmacological analogues [1] wherein the latter derive from a different molecular scaffold and different three-dimensional display of pertinent functional groups, that is, the pursuit of nonobvious molecular systems even beyond scaffold-hopping according to the patent terminology and jargon of today. Aspects of some of these areas will be further discussed in the following sections after using the remainder of this section to highlight the developments leading to 1s first clinically successful analogue derived from ABDD, namely, docetaxel. The latter is shown immediately below as 2 wherein it should be apparent that 2 is both a close structural and pharmacological analogue of 1. O
HO O
NH
O
O
OH
10 7
2'
O
Ph
2 Docetaxel
13
O
OH
AcO
HO OBz
j247
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
248
Responding to the critical issues associated with producing and maintaining adequate supplies of 1, Potier et al. [30–32] had become immersed in the semisynthetic methods that can take advantage of 10-DAB (Scheme 10.1) including the possibilities that this route additionally affords for the preparation of analogues modified on the C-13 position side chain. Thus, this chemistry initially was explored via the Sharpless hydroxyamination procedure [33] while utilizing tertiary-butyl-Nchloro-N-sodiocarbamate. By this approach, the resulting t-butoxycarbonyl (BOC) group can be gently removed from what becomes the 30 -nitrogen atom then poised for further derivatization, including that of acylation with benzoylchloride so as to produce the paclitaxel form of the C-13 side chain. Presumably practicing a fundamental strategy of medicinal chemistry to test both synthetic intermediates and final target compounds, Potier et al. found that their BOC version of the C-13 side chain exhibited nearly twice the potency as 1s original benzoyl version when coupled to 10-DAB and tested in a microtubule stabilization assay [34]. This fortuitous observation occurred whether or not the C-10 position hydroxyl group was acetylated, the latter alteration in itself having little effect on 1s activity. Further exploration of other types of groups at this position did not show any added benefit over that seen with BOC, although a para-fluorobenzoyl seemingly came the closest upon reviewing the composite of their data. Capping these initial SAR studies, the increase in potency provided by the BOC group was then demonstrated even more convincingly during cell culture and especially during in vivo studies [35, 36]. Together, these results led to the selection of this analogue, namely, 2, for further study as a preclinical development candidate [37]. As studies progressed, the enhanced potency of 2 compared to 1 was maintained and even greater differences potentially related to additional mechanisms that could contribute toward overall efficacy were uncovered, such as 2 having about 100-times greater potency than 1 toward phosphorylation of bcl-2. The latter, in turn, may lead to inactivation of this oncoprotein and a concomitant release of its braking effect upon apoptosis [38]. Although these differences in inherent potency are real and apparently served as the main incentive to complete the drive of 2 toward the clinic, they should also be viewed amid the underlying fact that 1 already had more than enough potency to serve quite well in the clinic. Thus, the more practical attribute of docetaxel over paclitaxel was yet to be fully realized and it encompasses an important alteration at another site on these molecules, namely, that at the 10-position wherein 2 no longer bears an acetyl, ester-forming moiety on the common scaffolds hydroxyl group. Beyond producing an increase in localized hydrophilicity, it is understandable why this effect was not readily discernible within the context of the overall molecular system that remains highly lipophilic and, seemingly just like 1, essentially water insoluble upon gross experimental observation. Ultimately, however, the formulations for 2 during early clinical studies were able to use 100% polysorbate 80 and thereby avoided the undesirable CremophorÒ EL altogether [23]. Thus, this initially subtle difference in solubility between 1 and 2 became a very real and practical improvement in the overall profile that again can be regarded as being quite fortuitous. Not so much for the increased potency but because of these later findings, we would agree with an assessment suggested at a much earlier point in this story by
10.5 Additional Structural Analogues Table 10.1 Clinical comparison of paclitaxel (1) and docetaxel (2) [10, 23, 38, 40].
Property Formulation Administrationa) Dosing protocol Frequency PK profile Disposition Term. Half-life Excretion Metabolism Toxicityb) MDR liabilityc)
1
2
50% CremophorÒ EL þ 50% anhydrous ethanol
100% Polysorbate 80
175 mg/m2 over 3 h Repeated every 3 weeks
60–100 mg/m2 over 1 h Repeated every 3 weeks
Nonlinear with dose 20 h, highly variable Hepatic about 80% unchanged C6 and C30 -p-phenyl hydroxylation, saturable >200 mg/m2 Yes
Linear with dose 12 h, highly variable Hepatic about 80% metab. Various metabolites, nonsaturable >150 mg/m2 Yes
a) As typically deployed for treating breast carcinoma by intravenous infusion. b) Typically observed as neutropenia. c) MDR is multidrug resistance, in this case resulting largely from overexpression of Pgp transporter to the extent that treatment becomes compromised.
some of the actual players, that paclitaxel and docetaxel are not simply two of a kind [23]. The precisely determined solubilities of 1 and 2 in water are 0.25 and 6–7 mg/ml, respectively [39]. Some of the other clinically relevant properties for these two drugs are compared in Table 10.1 that has been collated from several sources [10, 23, 38, 40]. Perhaps as a fitting summary to the docetaxel story, it can be offered that this unique example of NP ABDD, initiated by chemical supply issues and then conducted by practicing the venerable strategy to examine chemical intermediates for both SAR purposes and the distinct possibility of serendipity, did indeed produce a clinically relevant structural and pharmacological analogue. For in the end, no two pharmacological analogues are ever truly quite the same. And moving forward from that particular period in time, the latter certainly can be restated relative to todays pharmacogenomic trend wherein personalized medicine approaches are being pursued to improve individual therapies. Within this context, however, the variability and metabolic differences between 1 and 2 that can be noted from Table 10.1 further emphasize the need to have even more of these types of otherwise seemingly very similar compounds available to the practitioner.
10.5 Additional Structural Analogues
An intense ABDD effort has occurred over the past 15 years using the initial knowledge afforded by the discoveries of both 1 and 2 as a starting point for further design strategies. In addition to enhancing our knowledge about SAR and the
j249
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
250
conformational details associated with how the taxanes interact with microtubules, numerous structural analogues have been obtained for which some have improved aqueous solubility, others have less problems with multiple drug resistance, and still others exhibit increased selectivity for cancer cells compared to healthy cells. In many cases, these ABDD efforts have encompassed prodrug strategies [41] into their final structural motifs. However, even though several of these promising compounds have progressed into various stages of clinical study, none has made it to the marketplace as of this writing. Thus, their further discussion is beyond the scope of this chapter. Readers interested in this huge body of research are encouraged to see the previously cited reviews [7–10] and a broader perspective highlighted within the context of ABDD that we will be publishing elsewhere [42].
10.6 The Pursuit of Microtubule-Stabilizing Pharmacological Analogues
ABDD aimed at discovering completely different structures that have the same mechanism of action as a marketed drug generally involve a random structural survey that deploys a high-throughput screen (HTS) to serve as an effective assay for that mechanism. This approach proceeds in a truly unbiased manner with regard to structural considerations and thus precludes any hint of overlap with structure-driven ABDD. Alternatively, a detailed knowledge about the receptor or enzyme-active site associated with the desired mechanism can be used as a blueprint for the ab initio design of another series of distinctly unique structures that can also reside in such a pocket while associating with a different array of contact amino acids. Finally, it is also possible to engage an allosteric site or some other dynamic aspect inherent in the desired mechanism at the molecular level that is different from the parent drugs interaction, providing that the same consequence then occurs within that system so as to ultimately bestow the same pharmacological end point. Note, however, that even in these less frequent strategies, the pharmacological analogue would still be working within the immediate system and it would not be working at some separate step that is upstream or downstream along the same signaling pathway. By definition, the latter would lead to a new class of drugs rather than to an analogue even if the net pharmacological end points were still essentially the same. For the taxanes, we shall see that all pharmacological analogues to date have been discovered by the more common, random screening pathway. Perhaps ironic to the semantics of the categorizations just laid out, however, whenever one or more of such analogues are discovered in this manner, it immediately becomes a challenge for a medicinal chemist to work-in-reverse in an attempt to discern how such pharmacological analogues may be overlapping at the molecular level with the original agents distinct structure that was responsible for prompting the screening campaign in the first place. Thus, after reviewing the only marketed pharmacological analogue of 1 discovered to date, this section will discuss the ongoing attempts being made to discern their common interactions with microtubules.
10.6 The Pursuit of Microtubule-Stabilizing Pharmacological Analogues
The chemotherapeutic success of 1 coupled with its unique mechanism of action prompted researchers around the world to discover new cytotoxic natural products that can promote microtubule assembly and stabilization leading to apoptosis. Recent reviews reflect the high interest in both microtubule inhibitors and stabilizers [43–46], although we will focus herein upon only stabilizers [47]. In 1993, Reinchenbach and H€ofle isolated a new class of cytotoxic compounds as secondary metabolites from the fermentations of myxobacterium Sorangium cellulosum [48]. Based on their molecular structure, they named these molecules epothilones. In 1995, a group at Merck Research Laboratories confirmed that the newly discovered class of molecules possesses a paclitaxel-like mechanism of action [49]. Thereafter, the rush was on and several other natural compounds were subsequently found to stabilize microtubules such as discodermolide 3 [50–59], eleutherobin 4 [60, 61], laulimalide 5 [62–68], and peloruside A 6 [69, 70]. These last four agents are depicted in Figure 10.2. At this point, however, only an epothilone has made it to the actual marketplace, and so only their family is further discussed in the next section.
O O
N
H O
O
OH
N
OH O
NH2
OMe
H
HO
O OAc
HO
OH O
O
OH O
4 Eleutherobin
3 Discodermolide
H HO
O H
O H
O
H
OH
H
O
O O
O
HO
HO
OCH3
HO O HO OCH3
H3CO OH
5 Laulimalide
6 Peloruside A
Figure 10.2 Chemical structures of several pharmacological analogues discovered by HTS assays designed to uncover paclitaxel-like activity.
j251
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
252
10.7 The Epothilones
Of all the new paclitaxel-like microtubule stabilizers, the epothilone family has excited the most interest and is the only one to have sent a member to the marketplace. Although epothilones A (7) and B (8) initially were described as antifungal agents [48], these 16-membered macrolides later were shown to mimic all the biological effects of 1 both biochemically and in cell culture [49]. A variety of other epothilone-related structures, such as epothilones C 9, D 10, E 11, and F 12, were also isolated from the fermentations as minor components [71–75]. In general, these compounds are reported to be 30–50 times more soluble than paclitaxel (Figure 10.3) [76]. Compounds 7 and 8 promoted microtubule polymerization, hyperstabilized polymerized microtubules, and induced microtubule bundling. Competitive studies revealed that the macrolides acted as competitive inhibitors for [3 H]1 binding to microtubules. This is consistent with the interpretation that 7 and 8 compete for the same binding site as 1. These pharmacological analogues were roughly one order of magnitude more potent in cell culture models than was 1 with IC50 values in the suband low nanomolar range. The cytotoxicities of epothilones A, B, and D, and 1 in human cancer cell lines are summarized in Table 10.2. In key contrast to 1, 7 and 8 were active both on MDR cell lines and on paclitaxel-resistant cell lines [77, 78]. The promising anticancer activity of the epothilones prompted medicinal chemists to design and synthesize hundreds of epothilone analogues with improved cytotoxic and pharmacological properties. Such syntheses led to the SAR summarized in
R
O S N
S
13 12
22
OH 15 O 1
3
O
7 R= H 8 R= CH3
OH
OH
N
7
O
5
O
O
Epothilone A Epothilone B
OH
O
9 Epothilone C
O
R
S
S OH
N
HO
OH
N O
O O
OH
O
10 Epothilone D Figure 10.3 Various epothilone natural product family members.
O
OH
O
11 R= H Epothilone E 12 R= CH3 Epothilone F
10.7 The Epothilones
j253
Cytotoxicity (IC50) in nM of epothilones in comparison to paclitaxel (1) in human tumor cell lines (adapted from Ref. [72]).
Table 10.2
Cell line
Epothilone A
HCT116 (colon) SW620 (colon) SW620AD (PAC-resistant colon carcinoma subline) PC-3M (prostate) A549 (lung) MCF-7 (breast) MCF-7/ADR (breast) KB-31 (epidermoid) CCRF-CEM (leukemia)
2.51 NA NA 4.27 2.67 1.49 27.50 2.10 NA
Epothilone B
Epothilone D
Paclitaxel
0.32 0.1 0.3
NA NA NA
2.79 0.2 250
0.52 0.23 0.18 2.92 0.19 0.35
NA NA 2.90 NA 2.70 9.5
4.77 3.19 1.80 9105 2.31 NA
a) NA: Data not available.
Figure 10.4. SAR studies showed that the C-1-C-8 region is highly sensitive to structural modifications where even modest changes led to diminished activity. In contrast, the C-9-C-17 portion tolerated modifications and offered greater degrees of flexibility. The C-13 and C-15 stereochemistry must be S, while that of C-12 can be R or S. Binding affinity was enhanced when the epoxide ring was replaced by a cyclopropane ring or by a double bond, and when the C-21 methyl was replaced by a thiomethyl moiety. Based on extensive SAR studies of epothilones, a remarkable seven analogues, both natural and synthetic, have made their way to human clinical trials. Some of these analogues are still in phase I trials, while others have advanced to phase III and, just recently, one has now made it all the way to the market place (see discussion in next section). Figure 10.5 depicts the structures undergoing clinical study [79]. As mentioned above, the epothilones are competitive inhibitors of 1 in terms of binding to microtubules. Several investigators have tried to identify structural overlap
- Replacement of epoxide with a cyclopropyl group INCREASES binding affinity - Replacement of epoxide with a cyclobutyl group greatly DECREASES binding affinity - The C-12 stereochemistry can be R or S, while C-13 stereochemistry MUST be S - A methyl group at C-12 ENHANCES activity
O
- Aryl analogues ACTIVE - Replacement of C-21 methyl with thiomethyl INCREASES binding when the ring is thiazole
R
S OH
N O O
OH
C-15 stereochemistry MUST be S for maximum binding affinity
Figure 10.4 Epothilones SAR. (Adapted from Refs [44] and [80].)
O
Modest structural changes DIMINISH/ABOLISH activity
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
254
O
O S
S OH
N
S OH
N
OH
N
O
O O
OH
HN O
O
Epothilone B (Patupilone, EPO906)
OH
O
O
OH
O
Aza-epothilone B (Ixabepilone, BMS-247550)
Epothilone D (KOS-862)
O S
O
S S OH
N
N
H2N
OH
N
O
O
O
OH
O O
OH
O O
Sagopilone (ZK-epo, ZK 219477)
OH
O
OH
Amino-epothilone B (BMS-310705)
O
Dehydelone (KOS-1584)
O S S
OH
N O O
OH
O
Methylthioepothilone B (ABJ879)
Figure 10.5 Epothilone analogues that were entered into clinical trials. (Adapted from Ref. [79].) Note that aza-epothilone B has already progressed to a market launch (also see further discussion in Section 10.8).
with 1 by developing a common pharmacophore, but different conclusions were drawn [81]. One of the first attempts to find a common pharmacophore was reported by Winkler and Axelsen in 1996 when no structural information about the drug binding site was yet available [82]. In their attempt to overlap both structures, the authors relied on the SAR available for 1 and the epothilones, and used molecular mechanics software to find regions of steric and functional similarities in the conformational space of the two molecules. They developed a 3D model (Figure 10.6) that superimposed 13 of the 15 ring carbon atoms of epothilone A and most of the side chain atoms onto corresponding atoms in paclitaxel. The C-1-C-3 and C-8-C-12 fragments and the thiazole ring in epothilone A were superimposed with the C-10 -C30 , C-2 benzoyl, and C-10 acetate of 1, respectively. The authors cautioned that other plausible conformations of both molecules could be superimposed and that the steric complementarity between 1 and epothilone was not ideal. Ojima et al. proposed a pharmacophore common for 1, nonataxel, the epothilones, eleutherobin, and discodermolide [83]. Nonataxel (13 in Figure 10.7) is a paclitaxel analogue that exhibits two- to eightfold higher activity against various cancer cell lines. The authors expected that the nonaromatic groups in nonataxel would allow
10.7 The Epothilones
j255
Figure 10.6 Schematic 2D representation of the model proposed by Winkler and Axelsen to define the structural similarity between 1 and the epothilones. (Adapted from Ref. [82].)
better mapping of the rings of epothilones. Comparing the 3D structure of nonataxel derived from limited 2D NMR studies and restrained molecular dynamics (rMD), with that of the template-fitted epothilone B, revealed excellent topological homology between the two structures. The C-1-C-6 portion of epothilone B corresponded to the southern hydrophobic surface of nonataxel, while the thiazole side chain overlapped with the BOC group at the C-30 -N of nonataxel. These relationships are depicted in Figure 10.7. The authors claimed that the proposed model accounts for a vast SAR data associated with the structural modifications of epothilone B such as the diminished/abolished activity observed upon epimerization at the C-3 position, reduction of the C-5 carbonyl group, or deletion of any moiety in the C-3-C-8 region. Moreover, the SAR studies indicated that the C-12-C-13 epoxide is not crucial for epothilone binding to microtubules based on the fact that analogues such as 12,13desoxyepothilone B (E and Z isomers) retained excellent tubulin binding activity. In the model proposed by Ojima et al., the epoxide oxygen pointed away from the overlapping structural terrain and is thus not essential for binding. He et al. proposed an alternative common pharmacophore for 1 and the epothilones based on SAR indicating that 2-m-azidotaxol had greater activity than paclitaxel, O
A
O O O
O
OH
O
NH O
A O O
OH HO O
13 Nonataxel
AcO O
R
S OH
N O O
OH
B
O
B
Figure 10.7 Labeled boxed regions represent areas of common overlap between nonataxel and the epothilones. (Adapted from Ref. [83].)
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
256
and that even 2-m-azidobaccatin III (shown immediately below as 14) surprisingly exhibited paclitaxel-like activity, while Baccatin III and 2-p-azidobaccatin III did not [84]. These observations highlight the specificity and significance of the m-azido substitution in enhancing biological activity. 2-m-Azidobaccatin III was cytotoxic to different cancer cell lines although the cytotoxicity was 25–45-fold less than that of 1. AcO
O
OH
HO O AcO
HO O
O
N3
14 2-m-Azidobaccatin III
Analogue 14 induced all the morphological changes in microtubules typical for paclitaxel. It promoted tubulin polymerization in the absence of GTP, stabilized the polymerized microtubules against depolymerization by cold treatments, induced microtubule bundle formation in cultured cells, and caused cell cycle arrest at mitosis. Neither baccatin III nor 2-p-azidobaccatin III demonstrated such activity. More important, 14 competitively inhibited the binding of [3 H]1 to microtubules. This observation demonstrated that 14 and 1 bind to the same or overlapping sites on the microtubules, although the binding affinity of 14 was reduced compared to that of 1. The authors conducted molecular modeling studies to rationalize the significance of the m-azido substitution. In the proposed model, the C-2 benzoyl ring was positioned into a pocket formed by His-227 and Asp-224. Placing the azido group at the meta-position kept it in close proximity to the carboxylate of Asp-224, thus forming a new salt bridge as a consequence of the electrostatic interactions and resulting in enhanced binding of the molecule to the b-tubulin. Although the C-13 side chain is normally thought to be a requisite for 1 binding, the presence of the mazido group on the C-2 benzoyl ring of baccatin III apparently can compensate for the loss of the C-13 side chain and reestablish the binding affinity of the molecule. In contrast, a repositioning of the taxane ring would be required to fit the p-azido into the binding pocket formed by His-227 and Asp-224, thus inhibiting the interaction of 1 with the microtubules. Based on the observation that the C-13 side chain is not an absolute requirement for biological activity, the authors proposed a common pharmacophore for 1 and the epothilones in which the thiazole chain of the epothilones corresponded to the C-2 side chain of 1 and the macrocyclic ring of the epothilones overlaid with the taxane core. The proposed model is distinctly
10.7 The Epothilones
j257
O O
O NH
O
O
OH
S
O
OH
N
O O
OH HO
O
O OBz
O
OH
O
Figure 10.8 Common overlap of 1 and epothilone B as proposed by Giannakakou et al. (Adapted from Ref. [85].)
different from the one proposed by Ojima et al. where the thiazole side chain of the epothilones was superimposed with the C-13 side chain of 1. Giannakakou et al. have proposed a common pharmacophore for 1 and the epothilones based on the data collected from molecular modeling, mutations, and cytotoxicity assays [85]. To identify tubulin residues important for epothilone binding, two epothilone-resistant human ovarian carcinoma cell lines were isolated, each with a different point mutation: 1A9/A8 (b274Thr ! Ile) and 1A9/ B10 (b282Arg ! Gln). Of the two originally proposed pharmacophores, the one in which the methylthiazole side chain of epothilone B superimposed with the C-30 phenyl ring of 1 was more clearly discernible. This result is highlighted in Figure 10.8. Mutating Thr-b-274 to Ile in clone 1A/A8 had a greater impact on the binding of epothilone than 1. The hydrogen bond that existed between the C-7 OH of epothilone B and the Thr-b-274 was disrupted, while the hydrogen bond donors or acceptors at the C-7, C-10, and C-19 positions of 1 can form alternate hydrogen bonds to compensate for the disrupted hydrogen bond. This rationale is in agreement with the cross-resistance data and the in vivo polymerization studies. In addition, the b282Arg ! Gln mutation, sitting on the M-loop, directly affected the binding of taxanes and epothilones, and disrupted the lateral contacts between protofilaments. The data collected from drug sensitivity assays against a resistant paclitaxel-selected cell line containing a b270Phe ! Val mutation provided evidence for the preference of the proposed model. In this model, the thiazole side chain was placed in close proximity to Phe-270. As expected, the pyridine-containing epothilone experienced a 10-fold change in sensitivity compared to a threefold change observed with thiazole-containing epothilone B. The proposed pharmacophore accounted for a significant amount of SAR developed for epothilones and taxanes. The oxygen atoms of the oxetane ring of 1 and the epoxide of epothilones overlapped, and are located near a cluster of polar tubulin residues (273, 275, and 276) with the Thr-274 hydroxyl group in this hydrophilic area. It is known that epothilone B, 8, is 14-fold more potent than epothilone A, 7, with the only structural difference between the two molecules being the presence of a methyl group at C-12 of epothilone B. The proposed model positioned this methyl group in the vicinity of the hydrophobic side chains of Leu-273, Leu-215, Leu-228, and Phe-270, thus stabilizing favorable hydrophobic
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
258
interactions and accounting for the enhanced potency. Such hydrophobic interactions also accounted for the fact that replacing the epothilones epoxide ring by a double bond enhanced in vitro tubulin polymerization because the electron-rich p cloud of the double bond can also act as a hydrogen-bond acceptor for a nearby water molecule. Capping this effort to equate paclitaxel and the epothilones, however, the most recent report by Downing and coworkers [86] ultimately concludes that the longstanding expectation of a common pharmacophore is not met, because each ligand exploits the tubulin-binding pocket in a unique and independent manner [86]. These investigators combined NMR, electron crystallography, and molecular modeling across a series of analogues. In the resulting model, the epothilones occupy the same binding site as paclitaxel, but this pocket is quite expansive and displays promiscuous binding with various ligands by exploiting contacts with different residues. For example, of the five oxygen-containing polar groups present on the epothilone macrocycle, only the C7-OH falls near the similar C7-OH of paclitaxel, making this center the only notable common non-bonded contact for the two molecules [86]. These authors further suggest that the observed promiscuity afforded by this pocket will likely apply to the binding of other ligands that occupy the taxane site on microtubules such as the discodermolide, eleutherobin, and sarcodictyin NPs. In summary, we find it interesting to note that the studies highlighted in this section of the chapter truly come full-circle with the intended theme for the overall text, namely, that there is a very special relationship between natural product chemistry and analogue-based drug design that simply cannot be denied. Initially serving as an inspiration for medicinal chemists in their quest for novel structures having new biological properties, such NP activities are typically followed with extensive ABDD campaigns directed toward both the practical improvement of an NP-derived pioneer drug and the generation of basic medicinal chemistry principles that can be ascertained from the composite of ongoing investigations. Furthermore, when there are significant clinical benefits from these efforts, this seamless continuum of ABDD research and development activities often returns to NPs in the pursuit of additional pharmacological analogues having diverse molecular templates, exactly as is the case with our paclitaxel discourse wherein all of the next-generation pharmacological analogues can be seen to have come from new NP surveys.
10.8 ABDD and Development Leading to Ixabepilone
As previously discussed, epothilones A and B are novel cytotoxic macrolides obtained from bacterial fermentation that represent pharmacological analogues of 1 by virtue of having deployed an assay for the latters microtubule-stabilizing properties to identify their interesting biological properties. Their mechanism is essentially the same as that of 1 except that they seem to interact with microtubules at different
10.8 ABDD and Development Leading to Ixabepilone O
O
O
S
S OH
N
a
S OH
N N3
O O
OH
j259
O
8 Scheme 10.3 Synthesis of ixabepilone (15) from epothilone B (8) [86]. (a) Pd(PPh3)4, 10 mol%, NaN3, degassed THF-H2O, 45 C, 1 h, 65–70%; (b) PPh3, THF, 45 C for 14 h, then 28% NH4OH, H2O, 45 C for 4 h, or H2, EtOH,
OH
COOH
b
c
OH
N NH
O
O
OH
15 PtO2, 50 wt%, 10 h, then an additional 25 wt% of PtO2, 10 h, or PMe3, THF-H2O, 25 C, 2 h, 53–89%; (c) DPPA, NaHCO3, DMF (2.5 mM), 4 C, 24 h or EDCl, HOBt, MeCN (0.03 M), 25–65%.
contact sites within what appears to be a rather promiscuous receptor for the taxanes and various other ligands. In contrast to 1, the epothilones are subject to different drug-induced resistance mechanisms including sensitivity to b-tubulin mutations. However, while they exhibit potent in vitro activity including action against MDR cancer cells, their in vivo activity was disappointing because of pharmacokinetic related issues. The latter involved poor metabolic stability and a short half-life due in part to the presence of the lactone moiety within the parent NP scaffold. Ixabepilone, 15, is an analogue of epothilone B, 8, wherein the lactone has been replaced by a lactam that is much less susceptible to hydrolytic metabolic pathways. As shown in Scheme 10.3, this ABDD-related transformation can be accomplished via a semisynthesis in three steps [87]. Compound 15 is comparable to 8 in all biochemical and in vitro tests including activity against three different MDR cancer cell lines. Like 1 and 2 (Table 10.1), it is a parenteral agent with a recommended dosage protocol of 40 mg/m2 administered via intravenous infusion over 3 h every 3 weeks [88]. Although its PK profile was considerably improved, 15 is subject to gradual metabolism primarily by CYP3A that can potentially lead to drug–drug interactions. It is mostly eliminated as various metabolites in the feces (65%) and urine (21%) after a terminal elimination half-life of 52 h [88]. Compound 15 is used to treat metastatic or locally advanced breast cancer. It is specifically indicated either for use in combination with capecitabine in patients who have failed treatment with an anthracycline such as doxorubicin and a taxane such as 1 or 2, or for use as a monotherapy in patients whose tumors are refractory (resistant) to anthracyclines, taxanes, and capecitabine. The most common adverse reactions (20% or higher) are peripheral neuropathy, myalgia, alopecia, and several other related conditions. The most common hematologic abnormalities (40% or higher) are neutropenia, anemia, and so on. Thus, the side-effect toxicity profile is not too dissimilar from that of 1 and 2 (Table 10.1). In summary for this section, it can be offered that ixabepilone (15) appears to stand out most over paclitaxel and docetaxel (1 and 2) by its ability to be deployed in MDR tumors, thus supplying another very useful weapon to the armamentarium that is needed to combat cancer, particularly in the latters advanced onslaughts. Interestingly, 15s development reflects a case where an NP pioneer drug (namely,
O
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
260
paclitaxel) served to prompt a pharmacological-ABDD campaign that eventually led to another NP family (namely, the epothilones) that then required additional ligandbased drug design to address a significant PK issue.
10.9 Conclusions
Figure 10.9 attempts to capture the breadth of ABDD activities and their associated contributions that have stemmed from the initial discovery of paclitaxel, 1. Starting with the US National Cancer Institute (NCI) Plant Programs survey wherein Taxus brevifolia was first collected in 1962 and from which 1 was isolated by Wall and Wani at the Research Triangle Institute (RTI) in 1966, it was Horwitz et al.s later demonstration in 1979 showing 1 to possess a unique mechanism of action involving stabilization of microtubules that finally ignited the preclinical development of this compound that, in turn, led to an approved US Investigational New Drug (IND) application/phase I clinical study in 1984 and an eventual market launch in 1993. Contributing to this flow of events was Potier et al.s key finding that 10-deacetyl-baccatin III could be isolated from natural sources without the latters depletion and then used in an effective semisynthesis strategy so as to meet the critical supply issues associated with taxane compounds. A similar contribution came from Holton et al. for coupling a b-lactam version of the C-13-position side chain to 10-DAB in high yield by deploying a specific lithium salt form of the latter. Potiers contributions also went on to produce the first ABDD-derived analogue of 1 to reach the market, namely, docetaxel, 2, after a European phase I study in 1990 that quickly led to a successful launch in 1995. Although 2 essentially has the same pharmacological profile as 1 with a bit more potency, it does have enough of an increase in aqueous solubility so that a less toxic formulation can be advantageously deployed in the clinic. Importantly and as also shown in Figure 10.9 across the middle of the panel, all aforementioned events came together during the 1990s to inspire a barrage of ABDD campaigns that, even today, are still contributing very significantly to the evolution of basic medicinal chemistry principles across several drug design constructs. The latter encompass contemporary topics such as (i) altering a drug candidates lipophilicity so as to provide a better PK profile or formulation partner, particularly by taking advantage of highly polar prodrug strategies; (ii) the interdisciplinary pursuit of efficacy-related SAR and ligand-receptor (active site) binding details using a composite of medicinal chemistry, molecular biology, computational chemistry, and X-ray and NMR spectroscopy approaches; (iii) delineation of these same types of details for Pgp using the same composite of interdisciplinary approaches, particularly with practical end points that can be directed toward improving a drug candidates oral bioavailability and distribution profile wherein the latter includes avoidance of Pgpderived MDR during chemotherapy and modulation for or against passage across the blood–brain barrier (BBB) depending upon what is desired; and (iv) enhancing a drug
1962 NCI 1966 Wall et al. 1979 Horwitz et al.
HO
O OH
O Ph
N Ph
O
HO HO
OTES
O
AcO OBz
1989, 1992 Holton et al. semisynthesis
1980 Potier et al. semisynthesis O
AcO
O OH
O
NH
Ph
O
O
Ph OH
HO
AcO
O
OBz
HO
O
Ph OH
Paclitaxel 1984 IND/ Phase I 1993 Market Launch
O OH
O
NH
O
HO
AcO OBz
Docetaxel 1990 Eur./ Phase I 1995 Market Launch
(i) Water Solubilizing Prodrug Principles
(ii) SAR & Microtubule Binding Studies
(iii) Pgp SAR
Pharmacological Analog Studies
Improved Clinical Candidates
Improved Clinical Candidates
Novel Chemosensitizers
(iv) Selectivity Targeting Principles
Improved Clinical Candidates
O S OH
N HN O
OH
O
Ixabepilone 2007 Market launch
Figure 10.9 Summary of significant events leading to the discovery of paclitaxel and for the subsequent ABDD activities that led to the immediate discovery of docetaxel and eventual discovery of ixabepilone. Also highlighted are the significant contributions from the ABDD efforts toward establishing general principles associated with (i) designing water soluble
prodrug moieties; (ii) understanding SAR and ligand binding that causes stabilization of microtubules; (iii) understanding SAR and substrate binding that causes inhibition or avoidance of Pgp; and (iv) designing simple and increasingly complex prodrug systems that can be used to achieve selectivity.
O
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
262
candidates selectivity of actions and reducing side-effect toxicity by again using a composite of interdisciplinary approaches for which the derived molecular constructs are rapidly growing in sophistication and complexity as a workable knowledge about such things is expanded and again by particularly taking advantage of prodrug (conjugate) strategies. Despite this enormous amount of impressive efforts in basic research activities that have resulted in numerous clinical candidates, as well as in ongoing clinical trials for several selected agents, it becomes disappointing to discern that there is an already significant and still growing gap in time for the second-generation taxoids to truly arrive. We reserve this phrase to mean the next round of compounds that actually become launched into the marketplace after the arrival of the first-generation compounds, rather than using it for what we instead refer to as still being drug wannabes [89] wherein no matter how impressive their perceived attributes may be, the latter are only on route to the market. In this same context, we prefer to consider both 1 and 2 to represent a pair of first-generation agents with 1 constituting the true pioneer drug and first-in-its-class. Alternatively, given the theme of NP-derived ABDD for this book, it is certainly worthwhile to note that the emphasis placed upon screening for microtubule stabilizing agents as an integral part of the ABDD activities directly stemming from 1 has next led to yet another structurally novel NP that has indeed been entered into the marketplace. In our view, the latter is shown appropriately in Figure 10.9 as flowing directly from the ABDD-driven receptor binding studies (ii) so as to lead to what can be called a pharmacological analogue. From such a prestigious lineage it has ultimately taken the form of 15 and gone on to successfully achieve a market launch in 2007. Nevertheless, while considering 15 to thus represent a second-generation microtubule stabilizer (for which there could soon be additional NP arrivals also flowing down this same pathway of activities) and without purposefully trying to further confuse the semantics of this situation, we still very much look forward to seeing the arrival of the second structural generation taxoids into the marketplace (and perhaps a third and maybe even a fourth as well).
Acknowledgments
We thank Dr. Laurie Mauro, RPh, PharmD, for her assistance in obtaining the clinical related data, particularly the up-to-date information pertaining to the most recently marketed agent. We likewise thank both of the editors and the several reviewers for their useful comments that eventually led to the present, abbreviated version of our submission, particularly Drs. K.-H. Lee (University of North Carolina, USA) and Jo€elle Dubois (ISCN-CNRS, France). Finally, we thank the technical assistance of Mrs. Nicole R. Bearss, during the culling of this huge body of literature and, in particular, for her efforts during the assembly of the reference section.
References
References 1 Fischer, J. and Ganellin, C.R. (eds) (2006)
2
3
4
5
6
7
8
9 10
11
12
13
Analogue-Based Drug Discovery, WileyVCH Verlag GmbH, Weinheim. Erhardt, P.W. and Matos, L. (2006) Selective beta-adrenergic receptorblocking agents, in Analogue-Based Drug Discovery (eds J. Fischer and C.R. Ganellin), Wiley-VHC Verlag GmbH, Weinheim, pp. 193–232. Ganesan, A. (2008) The impact of natural products upon modern drug discovery. Chem. Biol., 12, 306–317. Newman, D.J. and Cragg, G.M. (2007) Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 70, 461–477. Ghosh, A.K. (2009) Harnessing natures insight: design of aspartyl protease inhibitors from treatment of drugresistant HIV to Alzheimers disease. J. Med. Chem., 52, 2163–2176. McCullagh, M. (2008/2009) Natural product pharmaceuticals: the third generation. Drug Discov. World, Winter, 69–73. Wall, M.E. (1993) Camptothecin and taxol, in Chronicles of Drug Discovery, vol. 3 (ed. D. Lednicer), American Chemical Society, Washington, DC, pp. 327–348. George, G.I., Chen, T.T., Ojima, I., and Vyas, D.M. (eds) (1995) Taxane Anticancer Agents: Basic Science and Current Status, American Chemical Society, Washington, DC. Suffness, M. (ed.) (1995) TaxolÒ : Science and Applications, CRC Press, New York. Itokawa, H. and Lee, K.H. (eds) (2003) Taxus: The Genus Taxus, Taylor & Francis Group, New York. Wall, M.E. and Wani, M.C. (1967) Abstracts of Papers, 153rd National Meeting of the American Chemical Society, Maimi Beach, FL, No. M-006. Schiff, P.B., Fant, J., and Horwitz, S.B. (1979) Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665–667. Chauviere, G., Guenard, D., Picot, F., Senilh, V., and Potier, P. (1981) Analyse structurale et etude biochimique de produits isoles de llf: Taxus baccata L
14
15
16 17
18
19
20 21
22
23
(Taxacees). C.R. Acad. Sci. Paris II, 293, 501–507. Hu, Z. and Erhardt, P.W. (1997) Utilization of a benzoyl migration to effect an expeditious synthesis of the paclitaxel side chain. Org. Process Res. Dev., 1, 387–390. Wang, Z.M., Kolb, H.C., and Sharpless, K.B. (1994) Large-scale and highly enantioselective synthesis of the taxol C-13 side chain through asymmetric dihydroxylation. J. Org. Chem., 59, 5104–5105. Holton, R.A. (1993) Metal alkoxides, US Patent 5,229,526 and 5,274,124 Holton, R.A. and Biediger, R.J. (1993) Certain alkoxy substituted taxanes and pharmaceutical compositions containing them, US Patent 5,243,045. Other patents pending. Holton, R.A., Biediger, R.J., and Boatman, P.D. (1995) Synthesis of taxol and taxotere, in TaxolÒ : Science and Applications (ed. M. Suffness), CRC Press, New York, pp. 97–121. Skwarczynski, M., Sohma, Y., Noguchi, M., Kimura, M., Hayashi, Y., Hamada, Y., Kimura, T., and Kiso, Y. (2005) No auxiliary, no byproduct strategy for watersoluble prodrugs of taxoids: scope and limitation of O–N intramolecular acyl and acyloxy migration reactions. J. Med. Chem., 48, 2655–2666. http://www.epa.gov/greenchemistry/ pubs/pgcc/winners/gspa04.html(2004). McGuire, W.P., Rowinsky, E.K., Rosenshein, N.B., Grumbine, F.C., Ettinger, D.S., Armstrong, D.K., and Donehower, R.C. (1989) Taxol: a unique antineoplasticagentwithsignificantactivity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111, 273–279. Holmes, F.A., Walters, R.S., Theriault, R.L., Raber, M.N., Bazdar, A.U., Frye, D.K., and Hortobagyi, G.N. (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83, 1797–1805. Verweij, J., Clavel, M., and Chevalier, B. (1994) Paclitaxel (TaxolÔ) and docetaxel (TaxotereÔ): not simply two of a kind. Ann. Oncol., 5, 495–505.
j263
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
264
24 Weiss, R.B., Donehover, R.C., Wiernik,
25
26
27
28
29
30
31
32
33
P.H., Ohnuma, T., Gralla, R.J., Trump, D.L., Baker, J., Jr., Van Echo, D.A., Von Hoff, D.D., and Leyland-Jones, B. (1990) Hypersensitivity reactions from taxol. J. Clin. Oncol., 8, 1263–1268. Sparreboom, A., Van Tellingen, O., Nooijen, W.J., and Beijnen, J.H. (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle cremophor EL. Cancer Res., 56, 2112–2115. Lee, E., Lee, J., Lee, I.H., Yu, M., Kim, H., Chae, S.Y., and Jon, S. (2008) Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J. Med. Chem., 51, 6442–6449. Sarver, J.G., Klis, W., Byers, J., and Erhardt, P.W. (2002) Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in multidrug resistant breast cancer cells. J. Biomol. Screen., 7, 29–34. Erhardt, P.W. (1997) The biochemical mechanism of paclitaxel: in pursuit of a microtubule binding site. Taxane J., 3, 36–42. George, G.I., Boge, T.C., Cheruvallath, Z.S., Clowers, J.S., Harriman, G.C.B., Hepperle, M., and Park, H. (1995) The medicinal chemistry of taxol, in TaxolÒ : Science and Applications (ed. M. Suffness), CRC Press, New York, pp. 317–375. Denis, J.N., Greene, A.E., Guenard, D., Gueritte-Voegelein, F., Mangatal, L., and Potier, P. (1988) A highly efficient, practical approach to natural taxol. J. Am. Chem. Soc., 110, 5917–5919. Mangatal, L., Adeline, M.T., Guenard, D., Gueritte-Voegelein, F., and Potier, P. (1989) Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron, 45, 4177–4190. Guenard, D., Gueritte-Voegelein, F., and Potier, P. (1993) Taxol and taxotere: discovery, chemistry, and structure–activity relationships. Acc. Chem. Res., 26, 160–167. Herranz, E., Biller, S.A., and Sharpless, K.B. (1978) Osmium-catalized vicinal
34
35
36
37
38
39
40 41
42
oxyamination of olefins by N-chloro-Nargentocarbamates. J. Am. Chem. Soc., 100, 3596–3598. Gueritte-Voegelein, F., Guenard, D., Lavelle, F., Le Goff, M.T., Mangatal, L., and Potier, P. (1991) Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem., 34, 992–998. Lavelle, F., Fizames, C., GueritteVoegelein, F., Guenard, D., and Potier, P. (1989) Experimental properties of RP 56976, a taxol derivative. Proc. Am. Assoc. Cancer Res., 30, 2254. Bissery, M.C., Guenard, D., GueritteVoegelein, F., and Lavelle, F. (1991) Experimental antitumor activity of taxotere (RP, 56976, NCS 628503), a taxol analogue. Cancer Res., 51, 4845–4852. Gueritte-Voegelein, F., Guenard, D., Dubois, J., Wahl, A., Marder, R., M€ uller, R., Lund, M., Bricard, L., and Potier, P. (1995) Chemistry and structure–activity relationships of taxoids and modified skeletons, in Taxane Anticancer Agents: Basic Science and Current Status (eds G.I. George, T.T. Chen, I. Ojima, and D.M. Vyas), American Chemical Society, Washington, DC. Figgitt, D.P. and Wiseman, L.R. (2000) Docetaxel: an update of its use in advanced breast cancer. Drugs, 59, 621–651. Vyas, D.M., Wong, H., Crosswell, A.R., Casazza, A.M., Knipe, J.O., Mamber, S.W., and Doyle, T.W. (1993) Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorg. Med. Chem. Lett., 3, 1357–1361. www.thomsonhc.com; Drugs; Paclitaxel; Comparison Information (2009). Erhardt, P.W., Khupse, R., Sarver, J.G., and Trendel, J.A., Prodrugs: strategic deployment, metabolic considerations and chemical design principles, in Burgers Medicinal Chemistry, Drug Discovery and Development (ed. D. Abraham), John Wiley & Sons, Inc., Hoboken, NJ, Vol. 3, p. 103, (2010). Erhardt, P.W. and El-Dakdouki, M., The multiple benefits of analog based drug discovery (ABDD): microtubule stabilizers as a case in point. J. Pure Appl. Chem., submitted.
References 43 Jordan, M.A. and Wilson, L. (2004)
44
45
46
47
48
49
50
51
52
53
Microtubules as a target for anticancer drugs. Nature reviews. Cancer, 4, 253–265. Hearn, B.R., Shaw, S.J., and Myles, D.C. (2006) Microtubule targeting agents. Comp. Med. Chem. II., 7, 81–110. Feyen, F., Cachoux, F., Gertsch, J., Wartmann, M., and Altmann, K.H. (2008) Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc. Chem. Res., 41, 21–31. Kingston, D.G.I. (2009) Tubulininteractive natural products as anticancer agents. J. Nat. Prod., 72, 507–515. Myles, D.C. (2002) Emerging stabilizing agents for cancer chemotherapy. Ann. Rep. Med. Chem., 37, 125–132. Gerth, K., Bedorf, N., Hoefle, G., Irschik, H., and Reichenbach, H. (1996) Antibiotics from gliding bacteria. 74. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria): production, physico-chemical and biological properties. J. Antibiot., 49, 560–563. Bollag, D.M., McQueney, P.A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Goetz, M., Lazarides, E., and Woods, C.M. (1995) Epothilones, a new class of microtubulestabilizing agents with a taxol-like mechanism of action. Cancer Res., 55, 2325–2333. Gunasekera, S.P., Gunasekera, M., Longley, R.E., and Schulte, G.K. (1990) Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissolute. J. Org. Chem., 55, 4912–4915;Correction: J. Org. Chem., 1991, 56, 1346. Longley, R.E., Caddigan, D., Harmody, D., Gunasekera, M., and Gunasekera, S.P. (1991) Discodermolide: a new, marinederived immunosuppressive compound. I. In vitro studies. Transplantation, 52, 650–656. Longley, R.E., Caddigan, D., Harmody, D., Gunasekera, M., and Gunasekera, S.P. (1991) Discodermolide: a new, marinederived immunosuppressive compound. II. In vivo studies. Transplantation, 52, 656–661. Longley, R.E., Gunasekera, S.P., Faherty, D., Mclane, J., and Dumont, F. (1993)
54
55
56
57
58
59
60
61
62
63
Immunosuppression by discodermolide. Ann. N.Y. Acad. Sci., 696, 94–107. Hung, D.T., Nerenberg, J.B., and Schreiber, S.L. (1994) Distinct binding and cellular properties of synthetic ( þ )- and ()-discodermolides. Chem. Biol., 1, 67–71. ter Haar, E., Kowalski, R.J., Hamel, E., Lin, C.M., Longley, R.E., Gunasekera, S.P., Rosenkranz, H.S., and Day, B.W. (1996) Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry, 35, 243–250. Kalesse, M. (2000) The chemistry and biology of discodermolide. ChemBioChem, 1, 171–175. Nerenberg, J.B., Hung, D.T., Somers, P.K., and Schreiber, S.L. (1993) Total synthesis of the immunosuppressive agent ()-discodermolide. J. Am. Chem. Soc., 115, 12621–12622. Smith, A.B., III, Kaufman, M.D., Beauchamp, T.J., LaMarche, M., and Arimoto, H. (1999) Gram-scale synthesis of ( þ )-discodermolide. Org. Lett., 1, 1823–1826. Mickel, S.J. (2004) Toward a commercial synthesis of ( þ )-discodermolide. Curr. Opin. Drug Discov. Dev., 7, 869–881. Lindel, T., Jensen, P.R., Fenical, W., Long, B.H., Casazza, A.M., Carboni, J., and Fairchild, C.R. (1997) Eleutherobin, a new cytotoxin that mimics paclitaxel (taxol) by stabilizing microtubules. J. Am. Chem. Soc., 119, 8744–8745. Long, B.H., Carboni, J.M., Wasserman, A.J., Cornell, L.A., Casazza, A.M., Jensen, P.R., Lindel, T., Fenical, W., and Fairchild, C.R. (1998) Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res., 58, 1111–1115. Corley, D.G., Herb, R., Moore, R.E., Scheuer, P.J., and Paul, V.J. (1988) Laulimalides. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator. J. Org. Chem., 53, 644–646. Jefford, C.W., Bernardinelli, G., Tanaka, J.I., and Higa, T. (1996) Structures and absolute configurations of the marine toxins, latrunculin A and laulimalide. Tetrahedron Lett., 37, 159–162.
j265
j 10 Paclitaxel and Epothilone Analogues, Anticancer Drugs
266
64 Mooberry, S.L., Tien, G., Hernandez, A.H.,
65
66
67
68
69
70
71
72
73
74
Plubrukarn, A., and Davidson, B.S. (1999) Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res., 59, 653–660. Pryor, D.E., OBrate, A., Bilcer, G., Diaz, J.F., Wang, Y., Wang, Y., Kabaki, M., Jung, M.K., Andreu, J.M., Ghosh, A.K., Giannakakou, P., and Hamel, E. (2002) The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry, 41, 9109–9115. Mulzer, J. and Ohler, E. (2001) An intramolecular case of Sharpless kinetic resolution: total synthesis of laulimalide. Angew. Chem. Int. Ed., 40, 3842–3846. Paterson, I., De Savi, C., and Tudge, M. (2001) Total synthesis of the microtubulestabilizing agent ()-laulimalide. Org. Lett., 3, 3149–3152. Ghosh, A.K. and Wang, Y. (2000) Total synthesis of ()-laulimalide. J. Am. Chem. Soc., 122, 11027–11028. West, L.M., Northcote, P.T., and Battershill, C.N. (2000) Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J. Org. Chem., 65, 445–449. Hood, K.A., West, L.M., Rouwe, B., Northcote, P.T., Berridge, M.V., Wakefield, S.J., and Miller, J.H. (2002) Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res., 62, 3356–3360. Nicolaou, K.C., Roschangar, F., and Vourloumis, D. (1998) Chemical biology of epothilones. Angew. Chem. Int. Ed., 37, 2014–2045. Harris, C.R. and Danishefsky, S.J. (1999) Complex target-oriented synthesis in the drug discovery process: a case history in the dEpoB series. J. Org. Chem., 64, 8434–8456. Altmann, K.H., Bold, G., Caravatti, G., Florsheimer, A., Guagnano, V., and Wartmann, M. (2000) Synthesis and biological evaluation of highly potent analogues of epothilones B and D. Bioorg. Med. Chem. Lett., 10, 2765–2768. Wartmann, M. and Altmann, K.H. (2002) The biology and medicinal chemistry of
75
76
77
78
79
80 81
82
83
84
85
epothilones. Curr. Med. Chem. Anticancer Agents, 2, 123–148. Altmann, K.H. (2003) Epothilone B and its analogs: a new family of anticancer agents. Mini Rev. Med. Chem., 3, 149–158. Stachel, S.J., Biswas, K., and Danishefsky, S.J. (2001) The epothilones, eleutherobins, and related types of molecules. Curr. Pharm. Des., 7, 1277–1290. Fumoleau, P., Coudert, B., Isambert, N., and Ferrant, E. (2007) Novel tubulintargeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann. Oncol., 18, 9–15. Altmann, K.H. (2005) Recent developments in the chemical biology of epothilones. Curr. Pharm. Des., 11, 1595–1613. Goodin, S., Kane, M.P., and Rubin, E.H. (2004) Epothilones: mechanism of action and biologic activity. J. Clin. Oncol., 22, 2015–2025. Kingston, D.G.I. (2004) What makes epothilones stick? Chem. Biol., 11, 153–155. Jimenez-Barbero, J., Amat-Guerri, F., and Snyder, J.P. (2002) The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr. Med. Chem. Anticancer Agents, 2, 91–122. Winkler, J.D. and Axelsen, P.H. (1996) A model for the taxol (paclitaxel)/epothilone pharmacophore. Bioorg. Med. Chem. Lett., 6, 2963–2966. Ojima, I., Chakravarty, S., Inoue, T., Lin, S., He, L., Horwitz, S.B., Kuduk, S.D., and Danishefsky, S.J. (1999) A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl. Acad. Sci. USA, 96, 4256–4261. He, L., Jagtap, P.G., Kingston, D.G.I., Shen, H.J., Orr, G.A., and Horwitz, S.B. (2000) A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain. Biochemistry, 39, 3972–3978. Giannakakou, P., Gussio, R., Nogales, E., Downing, K.H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K.C., and Fojo, T. (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by
References tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA, 97, 2904–2909. 86 Nettles, J.H., Li, H., Cornett, B., Krahn, J.M., Snyder, J.P., and Downing, K.H. (2004) The binding mode of epothilone A on a,b-tubulin by electron crystallography. Science, 305, 866–869. 87 Borzilleri, R.M., Zheng, Z., Schmidt, R.J., Johnson, J.A., Kim, S.H., DiMarco, J.D., Fairchild, C.R., Gougoutas, J.Z., Lee, F.Y.F., Long, B.H., and Vite, G.D. (2000) A novel application of a Pd(0)-catalyzed
nucleophilic substitution reaction to the regio- and stereoselective synthesis of lactam analogues of the epothilone natural products. J. Am. Chem. Soc., 122, 8890–8897. 88 Hegde, S. and Schmidt, M. (2008) To market, to market-2007. Ann. Rep. Med. Chem., 43, 455–497. 89 Erhardt, P.W., Drug discovery, in Advanced Pharmacology (eds K.A. Bachmann, M. Hacker, and W. Messer), Elsevier, Oxford, UK, p. 175, (2009).
Mohammad El-Dakdouki
The University of Toledo College of Pharmacy, Center for Drug Design and Development, 2801 West Bancroft Street, Toledo, OH 43606-3390, USA and Research Associate, Michigan State University, Department of Chemistry, East Lansing, MI 48824-1322, USA Mohammad El-Dakdouki obtained a BS in chemistry from the Lebanese University in 2001 and an MS in chemistry from the American University of Beirut (AUB) in 2004. He then joined the Center for Drug Design and Development at the University of Toledo where he acquired a PhD in medicinal chemistry in 2009 for his work on the synthesis of agents targeting cancer cells while reducing MDR liability. At present, he is working as a Research Associate in the Department of Chemistry at the Michigan State University where his main interest is in the development of carbohydrate-based cancer vaccines. Paul W. Erhardt
Professor Medicinal Chemistry, Director, The University of Toledo College of Pharmacy, Center for Drug Design and Development, 2801 West Bancroft Street, Toledo, OH 43606-3390, USA Paul W. Erhardt received a PhD in medicinal chemistry from the University of Minnesota and did postdoctoral research at the University of Texas at Austin. He then worked for nearly 20 years in the pharmaceutical industry where he is credited with the discovery of esmolol. For the past 15 years, he has been at the University of Toledo where he is a Professor of Medicinal Chemistry in the College of Pharmacy and is serving as Director of the Center for Drug Design and Development.
j267
j269
11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression Wayne E. Childers Jr. and David P. Rotella
11.1 Introduction
Selective serotonin reuptake inhibitors (SSRIs) are most widely used for the treatment of depression. Approved agents in this class include fluoxetine (1, ProzacÒ ), sertraline (2, ZoloftÒ ), paroxetine (3, PaxilÒ ), escitalopram (4, LexaproÒ ), the active isomer of racemic citalopram that was approved initially (see Section 11.3.2), and fluvoxamine (5, LuvoxÒ , approved in the EU only) (Figure 11.1). These compounds act by elevating levels of the neurotransmitter serotonin in regions of the brain that influence mood and represent a potentially useful symptomatic approach for the treatment of depression. Compounds in this class were introduced to clinical practice in the late 1980s and have remained important tools for pharmacological treatment of depression. SSRIs are recognized to have an improved side-effect profile compared to tricyclic antidepressants such as imipramine or amitriptyline [1]. SSRIs act by binding to the serotonin reuptake transporter on neurons to prevent the reuptake of serotonin from the synapse. This elevates levels of serotonin and produces beneficial effects on mood, among other actions. Even though all these compounds share a common mechanism of action, there are features about specific members of the group that allow researchers and clinicians distinguish between them. Paroxetine, fluvoxamine, and fluoxetine are relatively more potent inhibitors of the important drug-metabolizing enzyme CYP2D6, compared to escitalopram [2]. The potency and secondary receptor selectivity profiles of these agents are also different and can play a role in efficacy and adverse event profiles. Clinical studies have shown that patients who do not respond to the maximally tolerated dose of fluoxetine may respond to citalopram [3]. The array of different serotonin receptors, their role in the expression of SSRI activity, and the selectivity profile of each SSRI at these receptors differ [4]. Paroxetine and fluoxetine have activity at the norepinephrine transporter, and sertraline shows some dopamine transporter activity. In contrast, escitalopram has negligible affinity for other transporters. The affinity of SSRIs for other receptors, such as histamine, muscarinic, and 5-HT2C, is known to differ and may be expressed in the adverse event profile of the drug [4].
Analogue-based Drug Discovery II. Edited by János Fischer and C. Robin Ganellin Copyright Ó 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32549-8
j 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression
270
NHCH3
O
NHCH3
F3C Cl Cl 1 fluoxetine O
2 sertraline
NC
O
O
NH
F 3 paroxetine
O N(CH3)2
F 4 escitalopram
N
O
F3C
NH2
OCH3 5 fluvoxamine
Figure 11.1 Approved SSRIs.
The serotonin reuptake transporter is a protein with a comparatively broad tolerance for structural variation of inhibitors, as evidenced by the structural diversity of compounds in this class. As a result, and as shown in Figure 11.1, a wide range of structures show activity at this site. The opportunity for wide structural variation, coupled with the unmet medical need in the treatment of depression, has stimulated a substantial medicinal chemistry effort to discover compounds with this activity, as well as novel organic chemistry approaches to these important molecules. This chapter will summarize the published structure–activity relationships for each of the commercially available SSRIs, mechanism of action studies, preclinical and clinical pharmacology, and a survey of other potential uses for SSRIs.
11.2 Neurochemistry and Mechanism of Action
The exact mechanism of action for the antidepressant activity seen with SSRIs remains somewhat uncertain, but a number of biochemical events associated with SSRI treatment have been demonstrated [5]. As described above, SSRIs bind competitively to the 5-HT transporter and prevent the reuptake of 5-HT from the synapse. The acute result is an increase in synaptic 5-HT, which would be expected to exert beneficial effects in depression where there is significant evidence for serotonergic deficiencies. However, the increase in serotonin results in enhanced stimulation of presynaptic 5-HT autoreceptors and an acute decrease in the firing rate of serotonergic neurons, thus leading to a reduction in the secretion of 5-HT from presynaptic terminals. Ultimately, these presynaptic autoreceptors become
11.3 Preclinical Pharmacology
desensitized. Desensitization of terminal 5-HT1B/5-HT1D autoreceptors causes a greater amount of 5-HT to be released per impulse, while desensitization of somatodendritic 5-HT1A autoreceptors on the cell body leads to an enhanced firing rate by the neuron in general. Long-term administration of SSRIs also causes downregulation of the 5-HT transporter (but not the norepinephrine transporter). All these compensatory responses contribute to an eventual enhancement in serotonergic activity. The time needed for these compensatory responses to manifest themselves may, in part, explain the delayed onset of action in the clinical efficacy seen with SSRIs [6].
11.3 Preclinical Pharmacology 11.3.1 Sertraline
In the seminal paper describing preclinical characterization of sertraline, Koe and colleagues showed that the compound has an IC50 value of 58 nM as an inhibitor of serotonin reuptake in rat brain synaptosomal preparations and shows approximately 20-fold selectivity versus dopamine and norepinephrine transporters [7]. Dosedependent antagonism of the 5-HT depleting activity of p-chloroamphetamine (PCA), a compound that requires uptake into serotinergic neurons for activity, was demonstrated with an ED50 of 0.68 mmol/kg. This activity is six times more potent than chlorimipramine and 60-fold more active than amitriptyline. When 2 was acutely administered to rats at a dose of 32 mmol/kg subcutaneously (s.c.), brain levels of 5-HT were unchanged after 1 and 4 h, and a small increase in 5-HIAA (5-hydroxyindole acetic acid) levels was measured. Elevation of this serotonin metabolite suggested a decrease in 5-HT turnover as a result of inhibition of serotonin reuptake. Sertraline was 3–10 times more potent (depending on the end point) than fluoxetine or fluvoxamine in a serotonin potentiation model, and was much more potent than chlorimipramine. The magnitude of these effects was time dependent. At a dose of 5.6 mg/kg orally, maximal activity was observed at 1–3 h, with less of an effect using a 30 min pretreatment period, and no activity was observed with a 4 h pretreatment protocol. In a mouse forced swim test, sertraline demonstrated dosedependent reduction in immobility over a dose range of 3.2–56 mg/kg (s.c.). For comparison, in the same assay, fluvoxamine was inactive over a dose range of 3.2–100 mg/kg s.c. and fluoxetine reduced immobility at a dose of 56 mg/kg s.c. Lower doses of fluoxetine (down to 10 mg/kg) and doses up to 100 mg/kg were inactive. Sertraline did not reverse reserpine-induced hypothermia in mice. This activity is associated with norepinephrine and is consistent with monoaminergic reuptake selectivity exhibited by sertraline and some other SSRIs. In addition, at doses up to 32 mg/kg s.c., sertraline did not prevent oxotremorine-induced symptoms in mice. Some tricyclic antidepressants, such as amitriptyline, do ameliorate
j271
j 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression
272
tremors, salivation, and diarrhea, consistent with known anticholinergic properties of the compound. Later work showed that over 4 days, sertraline downregulates b-receptors in rat brain, lowering receptor expression without changing affinity [8]. This property has been investigated as a preclinical biomarker for antidepressant activity [9]. 11.3.2 Escitalopram
The initial characterization of escitalopram was carried out on the racemic compound, citalopram [10, 11]. In a rabbit blood platelet model of serotonin reuptake inhibition, citalopram gave an IC50 of 14 nM and reversed serotonin depletion in rat brain with an ED50 (s.c.) of 0.8 mg/kg. It was essentially inactive as an inhibitor of norepinephrine uptake in vitro and in vivo. Like sertraline, citalopram was active in a mouse 5-hydroxytryptophan (5-HTP) potentiation model, with an oral ED50 of 1.2 mg/kg. In rats, citalopram potentiated tryptophan activity in the presence of an MAO inhibitor, at doses as low as 0.5 mg/kg orally. In this model, the tricyclic antidepressant chlorimipramine was less potent. Citalopram administration to MAO inhibitor-treated rabbits and dogs resulted in a dose-dependent, rapid, and substantial increase in body temperature. Serotonin-induced contraction of isolated rat fundus strips was potentiated, as shown by leftward shift in dose–response curves in the presence of a fixed concentration of the SSRI. Compared to several tricyclic antidepressants, citalopram showed significantly less potent anticholinergic and antihistaminergic activity in isolated guinea pig ileum tissue strips. For example, chlorimipramine showed an IC50 of 0.62 mM for anticholinergic activity, while citalopram showed an IC50 of 7.2 mM. When the separate enantiomers of citalopram were studied, it was observed that the (S)-enantiomer possessed essentially all of the serotonin reuptake inhibition activity of the racemate [12]. The (S)-isomer has an IC50 of 1.5 nM and the (R)-isomer shows an IC50 of 250 nM for SSRI activity in vitro using a rat brain synaptosome preparation, and the (S)-isomer (eutomer) retained the selective monoamine transporter profile observed with the racemate. In this same assay, the racemate has an IC50 of 1.8 nM. In a 5-HTP model, the (R)-isomer (distomer) was inactive and escitalopram showed an ED50 (s.c.) of 0.55 mg/kg in mice. This value is within twofold of the oral ED50 of the racemate in the same assay (vide supra). Subsequently, it was shown that the racemate and (S)-enantiomer show approximate